

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 May 2001 (31.05.2001)

PCT

(10) International Publication Number  
**WO 01/38564 A3**

- (51) International Patent Classification<sup>7</sup>: **C12Q 1/68**,  
A61P 43/00, C07K 14/705
- (21) International Application Number: **PCT/CA00/01404**
- (22) International Filing Date:  
24 November 2000 (24.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/167,623 26 November 1999 (26.11.1999) US
- (71) Applicant (for all designated States except US): **MCGILL UNIVERSITY [CA/CA]**; 3550 University Street, Montreal, Quebec H3A 3V9 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ROULEAU, Guy, A.** [CA/CA]; Appartement 7, 4850 Côte Saint-Luc, Montréal, Québec H3W 2H2 (CA). **LAFRENIERE, Ronald, G.** [CA/CA]; 1264 Osborne Avenue, Verdun, Quebec H4H 1X5 (CA). **ROCHEFORT, Daniel** [CA/CA]; 2134 de Calmar, Laval, Quebec H7M 5T1 (CA). **COSSETTE, Patrick** [CA/CA]; 3550 University Street, Montreal, Quebec H3A 3V9 (CA). **RAGSDALE, David** [CA/CA]; 3550 University Street, Montreal, Quebec H3A 3V9 (CA).
- (54) Agents: **DUBUC, Jean, H. et al.**; Goudreau Gage Dubuc, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
8 November 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY**

(57) Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognosis or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders. In a particular embodiment, the invention provides a method for identifying, from a library of compounds, a compound with therapeutic effect on epilepsy or other neurological disorders comprising: providing a screening assay comprising a measurable biological activity of SCN1A, SCN2A or SCN3A protein or gene; contacting this screening assay with a test compound; and detecting if the test compound modulates the biological activity of SCN1A, SCN2A or SCN3A protein or gene; wherein a test compound which modulates the biological activity thereof is a compound with the desired therapeutic effect.

WO 01/38564 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01404

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q1/68 A61P43/00 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data, STRAND

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MOULARD BRUNO ET AL: "Identification of a new locus for generalized epilepsy with febrile seizures plus (GEFS+) on chromosome 2q24-q33." AMERICAN JOURNAL OF HUMAN GENETICS, vol. 65, no. 5, November 1999 (1999-11), pages 1396-1400, XP002170644 ISSN: 0002-9297 the whole document	1-13
X	BAULAC S ET AL: "A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33." AMERICAN JOURNAL OF HUMAN GENETICS, (1999 OCT) 65 (4) 1078-85. , XP002170645 the whole document	1-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"G" document member of the same patent family

Date of the actual completion of the international search

27 June 2001

Date of mailing of the international search report

11/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Reuter, U



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01404

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PUGSLEY MICHAEL K ET AL: "Effects of bisaramil, a novel class I antiarrhythmic agent, on heart, skeletal muscle and brain Na<sup>+</sup> channels."</p> <p>EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 342, no. 1, 19 January 1998 (1998-01-19), pages 93-104, XP001009949</p> <p>ISSN: 0014-2999</p> <p>the whole document</p>	12,13
A	<p>WALLACE ROBYN H ET AL: "Febrile seizures and generalized epilepsy associated with a mutation in the Na<sup>+</sup>-channel beta1 subunit gene SCN1B."</p> <p>NATURE GENETICS, vol. 19, no. 4, August 1998 (1998-08), pages 366-370, XP001009923</p> <p>ISSN: 1061-4036</p> <p>cited in the application</p> <p>the whole document</p>	1-13
A	<p>MALO M S ET AL: "TARGETED GENE WALKING BY LOW STRINGENCY POLYMERASE CHAIN REACTION: ASSIGNMENT OF A PUTATIVE HUMAN BRAIN SODIUM CHANNEL GENE (SCN3A) TO CHROMOSOME 2Q24-31"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 91, no. 8, 12 April 1994 (1994-04-12), pages 2975-2979, XP002051362</p> <p>ISSN: 0027-8424</p> <p>the whole document</p>	1-13
A	<p>MALO M S ET AL: "LOCALIZATION OF A PUTATIVE HUMAN BRAIN SODIUM CHANNEL GENE (SCN1A) TO CHROMOSOME BAND 2Q24"</p> <p>CYTOGENETICS AND CELL GENETICS,CH,BASEL, vol. 67, no. 3, 1994, pages 178-186, XP000603748</p> <p>ISSN: 0301-0171</p> <p>the whole document</p>	1-13
A	<p>PLUMMER NICHOLAS W ET AL: "Evolution and diversity of mammalian sodium channel genes."</p> <p>GENOMICS, vol. 57, no. 2, 15 April 1999 (1999-04-15), pages 323-331, XP002170646</p> <p>ISSN: 0888-7543</p> <p>the whole document</p>	1-13
	-/--	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01404

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 21875 A (UNIV UTAH RES FOUND) 6 May 1999 (1999-05-06) the whole document ---	1-13
P,X	ESCAYG ANDREW ET AL: "Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2." NATURE GENETICS, vol. 24, no. 4, April 2000 (2000-04), pages 343-345, XP001009967 ISSN: 1061-4036 cited in the application the whole document -----	1-13

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01404

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9921875 A	06-05-1999	EP 1037900 A	27-09-2000



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 May 2001 (31.05.2001)

PCT

(10) International Publication Number  
**WO 01/38564 A2**

- (51) International Patent Classification<sup>7</sup>: **C12Q 1/68**; 3V9 (CA). **RAGSDALE, David** [CA/CA]; 3550 University Street, Montreal, Quebec H3A 3V9 (CA).  
A61P 43/00
- (21) International Application Number: **PCT/CA00/01404**
- (22) International Filing Date:  
24 November 2000 (24.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/167,623 26 November 1999 (26.11.1999) US
- (71) Applicant (for all designated States except US): **MCGILL UNIVERSITY** [CA/CA]; 3550 University Street, Montreal, Quebec H3A 3V9 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ROULEAU, Guy, A.** [CA/CA]; Appartement 7, 4850 Côte Saint-Luc, Montréal, Québec H3W 2H2 (CA). **LAFRENIERE, Ronald, G.** [CA/CA]; 1264 Osborne Avenue, Verdun, Quebec H4H 1X5 (CA). **ROCHEFORT, Daniel** [CA/CA]; 2134 de Calmar, Laval, Quebec H7M 5T1 (CA). **COSSETTE, Patrick** [CA/CA]; 3550 University Street, Montreal, Quebec H3A
- (74) Agents: **DUBUC, Jean, H.** et al.; Goudreau Gage Dubuc, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY**

(57) Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognosis or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders. In a particular embodiment, the invention provides a method for identifying, from a library of compounds, a compound with therapeutic effect on epilepsy or other neurological disorders comprising: providing a screening assay comprising a measurable biological activity of SCN1A, SCN2A or SCN3A protein or gene; contacting this screening assay with a test compound; and detecting if the test compound modulates the biological activity of SCN1A, SCN2A or SCN3A protein or gene; wherein a test compound which modulates the biological activity thereof is a compound with the desired therapeutic effect.

WO 01/38564 A2

**TITLE OF THE INVENTION**

LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY,  
MUTATIONS THEREOF AND METHOD USING SAME TO ASSESS,  
DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY

**5    FIELD OF THE INVENTION**

The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three loci mapping to chromosome 2, which show a linkage with epilepsy in patients. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA), to variations and mutations in these sequences and to the use thereof to assess, diagnose, prognosis or treat epilepsy. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.

**BACKGROUND OF THE INVENTION**

Epilepsy is one of the most common neurological conditions, occurring in about 1.0% of the general population. The disease is characterised by paroxysmal abnormal electrical discharges in the brain, which lead to transient cerebral dysfunction in the form of a seizure. A seizure is considered partial when the epileptic discharge is limited to part of one brain hemisphere, or generalised when it involves both cerebral hemispheres at the onset. The current classification of the epileptic syndromes rests on two criteria: 1) seizure type which may be generalised or partial at the onset, according to clinical and EEG features; and 2) etiology, which may be idiopathic, cryptogenic and symptomatic. Symptomatic epilepsies have multiple and heterogeneous causes including

brain injury, CNS infection, migrational and metabolic disorders. In the majority (65%) of the patients with either generalised or partial epilepsy, there is no underlying cause (idiopathic) or the cause is thought to be hidden or occult (cryptogenic). Also, in the idiopathic epileptic syndromes, there is no evidence of cerebral dysfunction other than the seizure, and the neurological examination is normal. There is now increasing evidence that in this latter group, genetic factors are important, especially for the idiopathic generalised epilepsy (IGE). In a recent study, Berkovic et al (1998) showed a 62% concordance rate in monozygotic twins overall for epilepsy. In this study, a higher concordance rate has been found in the generalised compared to the partial epilepsies, with 76% concordance rate for IGE. Recent studies using molecular genetic approaches have shown that many susceptibility genes for the epilepsies in human involve membrane ion channel and related proteins. These studies include the syndrome of benign familial neonatal convulsions where two loci have been identified [EBN1 on chromosome 20, the KCNQ2 gene (a potassium channel); and EBN2 on chromosome 8, the KCNQ3 gene (also a potassium channel)] (Bievert et al, 1998; Charlier et al, 1998; Singh et al, 1998), as well as autosomal dominant nocturnal frontal lobe epilepsy [ADNFLE - chromosome 20, and the CHRNA4 gene (the neuronal nicotinic acetylcholine receptor alpha 4 subunit)] (Steinlein et al, 1995). More recently, there was a clinical description of a new syndrome (GEFS), which consisted of generalised epilepsy with febrile seizures. According to the current classification of epileptic syndrome, this syndrome would fall in the category of IGE, based on the seizure and electroencephalographic features. However, febrile seizures were present in all probands with GEFS, and the pattern of inheritance was clearly autosomal dominant, which are not part of the usual IGE phenotype. This unique GEFS syndrome has been shown to be associated with a mutation on the beta-1 subunit of brain voltage-gated sodium channel (SCN1B) gene (Wallac et

al, 1998). In addition, three different groups, including the group of the present inventors, have identified another locus on chromosome 2 in large kindred with this specific syndrome (GEFS). This region contains many candidate genes, including a cluster of alpha subunits of sodium channels (SCNA). Voltage-gated sodium channels play an important role in the generation of action potential in nerve cells and muscle. The alpha subunit (SCNA) is the main component of the channel, and would be sufficient to generate an efficient channel when expressed in cells *in vitro*. In turn, the beta-1 and 2 subunits need an alpha subunit to give an effective channel. The role of these subunits would be to modify the kinetic properties of the channel, mainly by fast inactivation of the sodium currents. The mutation found in the GEFS syndrome on the SCN1B gene was shown to reduce the fast inactivation of the sodium channels as compared to a normal SCNB1, when co-expressed with an alpha subunit. It is probable that this could be the mechanism by which the mutation induce an hyperexcitability state in the brain, leading to seizure in humans. Interestingly, the mechanism of action of most of the anticonvulsant drugs is through a reduction of the repetitive firing of neurons, which is also known to be dependent on fast inactivation. These finding make it likely that additional epilepsy genes will be identified by mutations in ion channels.

There thus remains a need to identify whether IGE is caused by a mutation in a sodium channel (SCNA). There also remains a need to assess whether a mutation(s) in SCNA is associated with GEFS. There also remains a need to determine whether a mutation that affects the fast inactivation of a sodium channel, given the particular phenotype of GEFS or IGE, could be linked to a region which includes SCNA genes.

The present invention seeks to meet these and other needs.



The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.

## 5 SUMMARY OF THE INVENTION

In one embodiment, the present invention relates to a genetic assay for determining predisposition to epilepsy.

In another embodiment, the present invention relates to a use of at least one of the loci of the present invention or an equivalent thereof (e.g. a loci in linkage disequilibrium therewith) as a marker for  
10 epilepsy and to determine the optimal treatment thereof (e.g. to guide the treatment modalities, thereby optimizing treatment to a particular clinical situation).

Yet in another embodiment, the present invention  
15 relates to an assay to screen for drugs for the treatment and/or prevention of epilepsy. In a particular embodiment, such assays can be designed using cells from patients having a known genotype at one of the loci of the present invention. These cells harboring recombinant vectors can enable an assessment of the functionality of the SCN1A, and/or SCN2A and/or  
20 SCN3A and a combination thereof. Non-limiting examples of assays that could be used in accordance with the present invention include *cis-trans* assays similar to those described in U.S.P. 4,981,784.

It shall be understood that the determination of allelic variations in at least one of the loci of the present invention can be  
25 combined to the determination of allelic variation in other gene/markers linked to a predisposition to epilepsy. This combination of genotype analyses could lead to better diagnosis programs and/or treatment of epilepsy. Non-limiting examples of such markers include SCN1B, EBN1, KCNQ2, EBN2, KCNQ3, ADFLE and CHRNA4.

In accordance with the present invention, there is therefore provided a method of determining an individual's predisposition to epilepsy, which comprises determining the genotype of at least one locus selected from the group consisting of SCN1A, SCN2A and SCN3A.

5 In one particular embodiment, the present invention provides a method of determining an individual's predisposition to epilepsy, which comprises determining a polymorphism (directly or indirectly by linkage disequilibrium) in a biological sample of an individual and analyzing the allelic variation in at least one of the loci selected from SCN1A, SCN2A  
10 and SCN3A, thereby determining an individual's predisposition to epilepsy.

In accordance with the present invention, there is also provided a method for identifying, from a library of compounds, a compound with therapeutic effect on epilepsy or other neurological  
15 disorders comprising providing a screening assay comprising a measurable biological activity of SCN1A, SCN2A or SCN3A protein or gene; contacting the screening assay with a test compound; and detecting if the test compound modulates the biological activity of SCN1A, SCN2A or SCN3A protein or gene; wherein a test compound which modulates the  
20 biological activity is a compound with this therapeutic effect.

Also provided within the present invention is a compound having therapeutic effect on epilepsy or other neurological disorders, identified by a method comprising: providing a screening assay comprising a measurable biological activity of SCN1A, SCN2A or SCN3A  
25 protein or gene; contacting the screening assay with a test compound; and detecting if the test compound modulates the biological activity of SCN1A, SCN2A or SCN3A protein or gene, wherein a test compound which modulates the biological activity is a compound with this therapeutic effect.

SCN1A, SCN2A and SCN3A refers to genes and proteins for Sodium Channel, Neuronal Type I, Alpha Subunit isoforms, and are described at OMIM # 182389 (Online Mendelian Inheritance in Man). These genes are structurally distinct sodium channel alpha-subunit  
5 isoforms in brain, also known as brain types I, II and III, respectively. Gene, cDNA and protein sequences for the various isoforms are shown in SEQ ID NOS:1-98.

Numerous methods for determining a genotype are known and available to the skilled artisan. All these genotype  
10 determination methods are within the scope of the present invention. In a particular embodiment of a method of the present invention, the determination of the genotype comprises an amplification of a segment of one of the loci selected from the group consisting of SCN1A, SCN2A and SCN3A and in a particularly preferred embodiment, the amplification is  
15 carried out using polymerase chain reaction.

In a particular embodiment, a pair of primers is designed to specifically amplify a segment of one of the markers of the present invention. This pair of primers is preferably derived from a nucleic acid sequence of SCN1A, SCN2A or SCN3A or from sequences flanking  
20 these genes, to amplify a segment of SCN1A, SCN2A or SCN3A (or to amplify a segment of a loci in linkage disequilibrium with at least one of the loci of the present invention). While a number of primers are exemplified herein, other primer pairs can be designed, using the sequences of the SCN1A, SCN2A and SCN3A nucleic acids molecules  
25 described hereinbelow. The same would apply to primer pairs from loci in linkage disequilibrium with the markers of the present invention.

Restriction fragment length polymorphisms can be used to determine polymorphisms at the SCN1A, SCN2A and SCN3A loci (and equivalent loci).

While human SCN1A, SCN2A and SCN3A are preferred sequences (nucleic acid and proteins) in accordance with the present invention, the invention should not be so limited. Indeed, in view of the significant conservation of these genes throughout evolution, sequences from different species, and preferably mammalian species, could be used in the assays of the present invention. One non-limiting example is the rat SCN1A ortholog gene which shows 95% identity with the human SCN1A gene. The significant conservation of the mouse SCN1A gene can also be observed in OMIM (see above).

10 In order to provide a clear and consistent understanding of terms used in the present description, a number of definitions are provided hereinbelow.

As used herein the term "RFLP" refers to restriction fragment length polymorphism.

15 The terms "polymorphism", "DNA polymorphism" and the like, refer to any sequence in the human genome which exists in more than one version or variant in the population.

The term "linkage disequilibrium" refers to any degree of non-random genetic association between one or more allele(s) of two different polymorphic DNA sequences, that is due to the physical proximity of the two loci. Linkage disequilibrium is present when two DNA segments that are very close to each other on a given chromosome will tend to remain unseparated for several generations with the consequence that alleles of a DNA polymorphism (or marker) in one segment will show a non-random association with the alleles of a different DNA polymorphism (or marker) located in the other DNA segment nearby. Hence, testing of a marker in linkage disequilibrium with the polymorphisms of the present invention at the SCN1A, SCN2A and/or SCN3A genes (indirect testing), will give almost the same information as

testing for the SCN1A, SCN2A and SCN3A polymorphisms directly. This situation is encountered throughout the human genome when two DNA polymorphisms that are very close to each other are studied. Linkage disequilibriums are well known in the art and various degrees of linkage  
5 disequilibrium can be encountered between two genetic markers so that some are more closely associated than others.

It shall be recognized by the person skilled in the art to which the present invention pertains, that since some of the polymorphisms or mutations herein identified in the SCN1A, SCN2A  
10 and/or SCN3A genes can be within the coding region of the genes and therefore expressed, that the present invention should not be limited to the identification of the polymorphisms/mutations at the DNA level (whether on genomic DNA, amplified DNA, cDNA, or the like). Indeed, the herein-identified polymorphisms and/or mutations could be detected at  
15 the mRNA or protein level. Such detections of polymorphism identification on mRNA or protein are known in the art. Non-limiting examples include detection based on oligos designed to hybridize to mRNA or ligands such as antibodies which are specific to the encoded polymorphism (i.e. specific to the protein fragment encoded by the distinct polymorphisms).

20 Nucleotide sequences are presented herein by single strand, in the 5' to 3' direction, from left to right, using the one letter nucleotide symbols as commonly used in the art and in accordance with the recommendations of the IUPAC-IUB Biochemical Nomenclature Commission.

25 Unless defined otherwise, the scientific and technological terms and nomenclature used herein have the same meaning as commonly understood by a person of ordinary skill to which this invention pertains. Generally, the procedures for cell cultures, infection, molecular biology methods and the like are common methods

used in the art. Such standard techniques can be found in reference manuals such as for example Sambrook et al. (1989, Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratories) and Ausubel et al. (1994, Current Protocols in Molecular Biology, Wiley, New York).

5                   The present description refers to a number of routinely used recombinant DNA (rDNA) technology terms. Nevertheless, definitions of selected examples of such rDNA terms are provided for clarity and consistency.

10                   As used herein, "nucleic acid molecule", refers to a polymer of nucleotides. Non-limiting examples thereof include DNA (i.e. genomic DNA, cDNA, RNA molecules (i.e. mRNA) and chimeras of DNA and RNA. The nucleic acid molecule can be obtained by cloning techniques or synthesized. DNA can be double-stranded or single-stranded (coding strand or non-coding strand [antisense]).

15                   The term "recombinant DNA" as known in the art refers to a DNA molecule resulting from the joining of DNA segments. This is often referred to as genetic engineering.

20                   The term "DNA segment", is used herein, to refer to a DNA molecule comprising a linear stretch or sequence of nucleotides. This sequence when read in accordance with the genetic code, can encode a linear stretch or sequence of amino acids which can be referred to as a polypeptide, protein, protein fragment and the like.

25                   The terminology "amplification pair" refers herein to a pair of oligonucleotides (oligos) of the present invention, which are selected to be used together in amplifying a selected nucleic acid sequence by one of a number of types of amplification processes, preferably a polymerase chain reaction. Other types of amplification processes include ligase chain reaction, strand displacement amplification, or nucleic acid sequence-based amplification, as explained

in greater detail below. As commonly known in the art, the oligos are designed to bind to a complementary sequence under selected conditions.

The nucleic acid (i.e. DNA, RNA or chimeras thereof)  
5 for practicing the present invention may be obtained according to well known methods.

Oligonucleotide probes or primers of the present invention may be of any suitable length, depending on the particular assay format and the particular needs and targeted genomes employed.  
10 In general, the oligonucleotide probes or primers are at least 12 nucleotides in length, preferably between 15 and 24 molecules, and they may be adapted to be especially suited to a chosen nucleic acid amplification system. As commonly known in the art, the oligonucleotide probes and primers can be designed by taking into consideration the  
15 melting point of hybridization thereof with its targeted sequence (see below and in Sambrook et al., 1989, Molecular Cloning -A Laboratory Manual, 2nd Edition, CSH Laboratories; Ausubel et al., 1989, in Current Protocols in Molecular Biology, John Wiley & Sons Inc., N.Y.).

The term "DNA" molecule or sequence (as well as  
20 sometimes the term "oligonucleotide") refers to a molecule comprised of the deoxyribonucleotides adenine (A), guanine (G), thymine (T) and/or cytosine (C). Sometimes, in a double-stranded form, it can comprise or include a "regulatory element" according to the present invention, as the term is defined herein. The term "oligonucleotide" or "DNA" can be found  
25 in linear DNA molecules or fragments, viruses, plasmids, vectors, chromosomes or synthetically derived DNA. As used herein, particular double-stranded DNA sequences may be described according to the normal convention of giving only the sequence in the 5' to 3' direction. Of

course, as very well-known, DNA molecules or sequences are often in single stranded form.

“Nucleic acid hybridization” refers generally to the hybridization of two single-stranded nucleic acid molecules having complementary base sequences, which under appropriate conditions will form a thermodynamically favored double-stranded structure. Examples of hybridization conditions can be found in the two laboratory manuals referred to above (Sambrook et al., 1989, *supra* and Ausubel et al., 1989, *supra*) and are commonly known in the art. In the case of a hybridization to a nitrocellulose filter, as for example in the well known Southern blotting procedure, a nitrocellulose filter can be incubated overnight at 65°C with a labeled probe in a solution containing 50% formamide, high salt (5 x SSC or 5 x SSPE), 5 x Denhardt's solution, 1% SDS, and 100 µg/ml denatured carrier DNA (i.e. salmon sperm DNA). The non-specifically binding probe can then be washed off the filter by several washes in 0.2 x SSC/0.1% SDS at a temperature which is selected in view of the desired stringency: room temperature (low stringency), 42°C (moderate stringency) or 65°C (high stringency). The selected temperature is based on the melting temperature ( $T_m$ ) of the DNA hybrid. Of course, RNA-DNA hybrids can also be formed and detected. In such cases, the conditions of hybridization and washing can be adapted according to well known methods by the person of ordinary skill. Stringent conditions will be preferably used (Sambrook et al., 1989, *supra*).

Probes of the invention can be utilized with naturally occurring sugar-phosphate backbones as well as modified backbones including phosphorothioates, dithionates, alkyl phosphonates and  $\alpha$ -nucleotides and the like. Modified sugar-phosphate backbones are generally taught by Miller, 1988, Ann. Reports Med. Chem. 23:295 and Moran et al., 1987, Nucleic Acids Res., 14:5019. Probes of the invention



can be constructed of either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), and preferably of DNA.

The types of detection methods in which probes can be used include Southern blots (DNA detection), dot or slot blots (DNA, RNA), and Northern blots (RNA detection). Although less preferred, labeled proteins could also be used to detect a particular nucleic acid sequence to which it binds. More recently, PNAs have been described (Nielsen et al. 1999, Current Opin. Biotechnol. 10:71-75). PNAs could also be used to detect the polymorphisms of the present invention. Other detection methods include kits containing probes on a dipstick setup and the like.

Although the present invention is not specifically dependent on the use of a label for the detection of a particular nucleic acid sequence, such a label might be beneficial, by increasing the sensitivity of the detection. Furthermore, it enables automation. Probes can be labeled according to numerous well known methods (Sambrook et al., 1989, supra). Non-limiting examples of labels include  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ , and  $^{35}\text{S}$ . Non-limiting examples of detectable markers include ligands, fluorophores, chemiluminescent agents, enzymes, and antibodies. Other detectable markers for use with probes, which can enable an increase in sensitivity of the method of the invention, include biotin and radionucleotides. It will become evident to the person of ordinary skill that the choice of a particular label dictates the manner in which it is bound to the probe.

As commonly known, radioactive nucleotides can be incorporated into probes of the invention by several methods. Non-limiting examples thereof include kinasing the 5' ends of the probes using gamma  $^{32}\text{P}$  ATP and polynucleotide kinase, using the Klenow fragment of Pol I of *E. coli* in the presence of radioactive dNTP (i.e. uniformly labeled DNA

probe using random oligonucleotide primers in low-melt gels), using the SP6/T7 system to transcribe a DNA segment in the presence of one or more radioactive NTP, and the like.

As used herein, "oligonucleotides" or "oligos" define a molecule having two or more nucleotides (ribo or deoxyribonucleotides). The size of the oligo will be dictated by the particular situation and ultimately on the particular use thereof and adapted accordingly by the person of ordinary skill. An oligonucleotide can be synthesised chemically or derived by cloning according to well known methods.

As used herein, a "primer" defines an oligonucleotide which is capable of annealing to a target sequence, thereby creating a double stranded region which can serve as an initiation point for nucleic acid synthesis under suitable conditions.

Amplification of a selected, or target, nucleic acid sequence may be carried out by a number of suitable methods. See generally Kwoh et al., 1990, Am. Biotechnol. Lab. 8:14-25. Numerous amplification techniques have been described and can be readily adapted to suit particular needs of a person of ordinary skill. Non-limiting examples of amplification techniques include polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), transcription-based amplification, the Q-beta replicase system and NASBA (Kwoh et al., 1989, Proc. Natl. Acad. Sci. USA 86, 1173-1177; Lizardi et al., 1988, BioTechnology 6:1197-1202; Malek et al., 1994, Methods Mol. Biol., 28:253-260; and Sambrook et al., 1989, *supra*). Preferably, amplification will be carried out using PCR.

Polymerase chain reaction (PCR) is carried out in accordance with known techniques. See, e.g., U.S. Pat. Nos. 4,683,195; 4,683,202; 4,800,159; and 4,965,188 (the disclosures of all three U.S. Patent are incorporated herein by reference). In general, PCR involves, a

treatment of a nucleic acid sample (e.g., in the presence of a heat stable DNA polymerase) under hybridizing conditions, with one oligonucleotide primer for each strand of the specific sequence to be detected. An extension product of each primer which is synthesized is complementary to each of the two nucleic acid strands, with the primers sufficiently complementary to each strand of the specific sequence to hybridize therewith. The extension product synthesized from each primer can also serve as a template for further synthesis of extension products using the same primers. Following a sufficient number of rounds of synthesis of extension products, the sample is analysed to assess whether the sequence or sequences to be detected are present. Detection of the amplified sequence may be carried out by visualization following EtBr staining of the DNA following gel electrophores, or using a detectable label in accordance with known techniques, and the like. For a review on PCR techniques (see PCR Protocols, A Guide to Methods and Amplifications, Michael et al. Eds, Acad. Press, 1990).

Ligase chain reaction (LCR) is carried out in accordance with known techniques (Weiss, 1991, Science 254:1292). Adaptation of the protocol to meet the desired needs can be carried out by a person of ordinary skill. Strand displacement amplification (SDA) is also carried out in accordance with known techniques or adaptations thereof to meet the particular needs (Walker et al., 1992, Proc. Natl. Acad. Sci. USA 89:392-396; and *ibid.*, 1992, Nucleic Acids Res. 20:1691-1696).

As used herein, the term "gene" is well known in the art and relates to a nucleic acid sequence defining a single protein or polypeptide. A "structural gene" defines a DNA sequence which is transcribed into RNA and translated into a protein having a specific amino acid sequence thereby giving rise to a specific polypeptide or protein. It will be readily recognized by the person of ordinary skill, that the nucleic

acid sequence of the present invention can be incorporated into anyone of numerous established kit formats which are well known in the art.

5 A "heterologous" (i.e. a heterologous gene) region of a DNA molecule is a subsegment of DNA within a larger segment that is not found in association therewith in nature. The term "heterologous" can be similarly used to define two polypeptidic segments not joined together in nature. Non-limiting examples of heterologous genes include reporter genes such as luciferase, chloramphenicol acetyl transferase, beta-galactosidase, and the like which can be juxtaposed or joined to  
10 heterologous control regions or to heterologous polypeptides.

The term "vector" is commonly known in the art and defines a plasmid DNA, phage DNA, viral DNA and the like, which can serve as a DNA vehicle into which DNA of the present invention can be cloned. Numerous types of vectors exist and are well known in the art.

15 The term "expression" defines the process by which a gene is transcribed into mRNA (transcription), the mRNA is then being translated (translation) into one polypeptide (or protein) or more.

The terminology "expression vector" defines a vector or vehicle as described above but designed to enable the expression of an  
20 inserted sequence following transformation into a host. The cloned gene (inserted sequence) is usually placed under the control of control element sequences such as promoter sequences. The placing of a cloned gene under such control sequences is often referred to as being operably linked to control elements or sequences.

25 Operably linked sequences may also include two segments that are transcribed onto the same RNA transcript. Thus, two sequences, such as a promoter and a "reporter sequence" are operably linked if transcription commencing in the promoter will produce an RNA transcript of the reporter sequence. In order to be "operably linked" it is

not necessary that two sequences be immediately adjacent to one another.

Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a  
5 prokaryotic or eukaryotic host or both (shuttle vectors) and can additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.

Prokaryotic expressions are useful for the preparation  
10 of large quantities of the protein encoded by the DNA sequence of interest. This protein can be purified according to standard protocols that take advantage of the intrinsic properties thereof, such as size and charge (i.e. SDS gel electrophoresis, gel filtration, centrifugation, ion exchange chromatography...). In addition, the protein of interest can be purified via  
15 affinity chromatography using polyclonal or monoclonal antibodies. The purified protein can be used for therapeutic applications.

The DNA construct can be a vector comprising a promoter that is operably linked to an oligonucleotide sequence of the present invention, which is in turn, operably linked to a heterologous gene,  
20 such as the gene for the luciferase reporter molecule. "Promoter" refers to a DNA regulatory region capable of binding directly or indirectly to RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of the present invention, the promoter is bound at its 3' terminus by the transcription initiation site and  
25 extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter will be found a transcription initiation site (conveniently defined by mapping with S1 nuclease), as well as protein binding domains (consensus sequences) responsible for the

binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CCAT" boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.

5                   In accordance with one embodiment of the present invention, an expression vector can be constructed to assess the functionality of specific alleles of the SCN1A, SCN2A and SCN3A sodium channels. Non-limiting examples of such expression vectors include a vector comprising the nucleic acid sequence encoding one of the sodium  
10 channels (or part thereof) according to the present invention. These vectors can be transfected in cells. The sequences of the alpha subunit of the sodium channels in accordance with the present invention and their structure-function relationship could be assessed by a number of methods known to the skilled artisan. One non-limiting example includes the use of  
15 cells expressing the  $\beta$ -1 and  $\beta$ -2 subunits and the sequence of an alpha subunit in accordance with the present invention. For example, an alpha subunit having a mutation, which is linked to epilepsy, could be compared to a sequence devoid of that mutation, as a control. In such cells, the functionality of the sodium channel could be tested as known to the skilled  
20 artisan and these cells could be used to screen for agents which could modulate the activity of the sodium channel. For example, agents could be tested and selected, which would reduce the hyperexcitability state of the sodium channel (e.g. their reduction in fast inactivation). Agents known to the person of ordinary skill as affecting other sodium channels  
25 could be tested, for example, separately or in batches. Of course, it will be understood that the SCN1A, SCN2A and/or SCN3A genes expressed by these cells can be modified at will (e.g. by *in vitro* mutagenesis or the like).

As used herein, the designation "functional derivative" denotes, in the context of a functional derivative of a sequence whether a

nucleic acid or amino acid sequence, a molecule that retains a biological activity (either function or structural; e.g. sodium channel function or structure) that is substantially similar to that of the original sequence. This functional derivative or equivalent may be a natural derivative or may be prepared synthetically. Such derivatives include amino acid sequences having substitutions, deletions, or additions of one or more amino acids, provided that the biological activity of the protein is conserved. The same applies to derivatives of nucleic acid sequences which can have substitutions, deletions, or additions of one or more nucleotides, provided that the biological activity of the sequence is generally maintained. When relating to a protein sequence, the substituting amino acid generally has chemico-physical properties which are similar to that of the substituted amino acid. The similar chemico-physical properties include, similarities in charge, bulkiness, hydrophobicity, hydrophylicity and the like. The term "functional derivatives" is intended to include "fragments", "segments", "variants", "analogs" or "chemical derivatives" of the subject matter of the present invention. The genetic code, the chemico-physical characteristics of amino acids and teachings relating to conservative vs. non-conservative mutations are well-known in the art. Non-limiting examples of textbooks teaching such information are Stryer, Biochemistry, 3rd ed.; and Lehninger, Biochemistry, 3rd ed. The functional derivatives of the present invention can be synthesized chemically or produced through recombinant DNA technology. all these methods are well known in the art.

The term "variant" refers herein to a protein or nucleic acid molecule which is substantially similar in structure and biological activity to the protein or nucleic acid of the present invention.

As used herein, "chemical derivatives" is meant to cover additional chemical moieties not normally part of the subject matter of the invention. Such moieties could affect the physico-chemical

characteristic of the derivative (i.e. solubility, absorption, half life, decrease of toxicity and the like). Such moieties are exemplified in Remington's Pharmaceutical Sciences (1980). Methods of coupling these chemical-physical moieties to a polypeptide or nucleic acid sequence are well known in the art.

The term "allele" defines an alternative form of a gene which occupies a given locus on a chromosome.

As commonly known, a "mutation" is a detectable change in the genetic material which can be transmitted to a daughter cell. As well known, a mutation can be, for example, a detectable change in one or more deoxyribonucleotide. For example, nucleotides can be added, deleted, substituted for, inverted, or transposed to a new position. Spontaneous mutations and experimentally induced mutations exist. The result of a mutations of nucleic acid molecule is a mutant nucleic acid molecule. A mutant polypeptide can be encoded from this mutant nucleic acid molecule.

As used herein, the term "purified" refers to a molecule having been separated from a cellular component. Thus, for example, a "purified protein" has been purified to a level not found in nature. A "substantially pure" molecule is a molecule that is lacking in all other cellular components.

As used herein, "SCNA biological activity" refers to any detectable biological activity of SCN1A, SCN2A or SCN3A gene or protein (herein sometimes collectively called SCNA genes or SCNA proteins). This includes any physiological function attributable to an SCNA gene or protein. It can include the specific biological activity of SCNA proteins which is efflux of sodium or related ions. This includes measurement of channel properties such as, but not limited to: 1) the voltage-dependence of activation, a measure of the strength of membrane depolarization



necessary to open the channels, 2) the voltage-dependence of steady state inactivation, a measure of the fraction of channels available to open at the resting membrane potential; and 3) the time course of inactivation. At a larger scale, SCNA biological activity includes transmission of impulses through cells, wherein changes in transmission characteristics caused by modulators of SCNA proteins can be identified. Non-limiting examples of such measurements of these biological activities may be made directly or indirectly, such as through the transient accumulation of ions in a cell, dynamics of membrane depolarization, etc. SCNA biological activity is not limited, however, to these most important biological activities herein identified. Biological activities may also include simple binding or pKa analysis of SCNA with compounds, substrates, interacting proteins, and the like. For example, by measuring the effect of a test compound on its ability to increase or inhibit such SCNA binding or interaction is measuring a biological activity of SCNA according to this invention. SCNA biological activity includes any standard biochemical measurement of SCNA such as conformational changes, phosphorylation status or any other feature of the protein that can be measured with techniques known in the art. Finally, SCNA biological activity also includes activities related to SCNA gene transcription or translation, or any biological activities of such transcripts or translation products.

As used herein, the terms "molecule", "compound", "agent" or "ligand" are used interchangeably and broadly to refer to natural, synthetic or semi-synthetic molecules or compounds. The term "molecule" therefore denotes for example chemicals, macromolecules, cell or tissue extracts (from plants or animals) and the like. Non limiting examples of molecules include nucleic acid molecules, peptides, ligands (including, for example, antibodies and carbohydrates) and pharmaceutical agents. The agents can be selected and screened by a

variety of means including random screening, rational selection and by rational design using for example protein or ligand modelling methods such as computer modelling. The terms "rationally selected" or "rationally designed" are meant to define compounds which have been chosen  
5 based on the configuration of the interacting domains of the present invention. As will be understood by the person of ordinary skill, macromolecules having non-naturally occurring modifications are also within the scope of the term "molecule". For example, peptidomimetics, well known in the pharmaceutical industry and generally referred to as  
10 peptide analogs can be generated by modelling as mentioned above. Similarly, in a preferred embodiment, the polypeptides of the present invention are modified to enhance their stability. It should be understood that in most cases this modification should not alter the biological activity of the protein. The molecules identified in accordance with the teachings  
15 of the present invention have a therapeutic value in diseases or conditions in which sodium transport through the sodium channels is compromised by a mutation (or combination thereof) in one of the genes identified in accordance with the present invention. Alternatively, the molecules identified in accordance with the teachings of the present invention find  
20 utility in the development of compounds which can modulate the activity of the alpha subunit sodium channels and/or the action potential in nerve cells and muscles cells (e.g. restore the fast inactivation of the sodium channel to normal levels).

As used herein, agonists and antagonists also include  
25 potentiators of known compounds with such agonist or antagonist properties. In one embodiment, modulators of the fast inactivation of the sodium channel in accordance with the present invention can be identified and selected by contacting the indicator cell with a compound or mixture or library of molecules for a fixed period of time.

As used herein the recitation "indicator cells" refers to cells that express at least one sodium channel  $\alpha$  subunit (SCNA) according to the present invention. As alluded to above, such indicator cells can be used in the screening assays of the present invention. In  
5 certain embodiments, the indicator cells have been engineered so as to express a chosen derivative, fragment, homolog, or mutant of the combination of genotypes of the present invention. The cells can be yeast cells or higher eukaryotic cells such as mammalian cells. In one particular embodiment, the indicator cell would be a yeast cell harboring vectors  
10 enabling the use of the two hybrid system technology, as well known in the art (Ausubel et al., 1994, *supra*) and can be used to test a compound or a library thereof. In another embodiment, the *cis-trans* assay as described in USP 4,981,784, can be adapted and used in accordance with the present invention. Such an indicator cell could be used to rapidly  
15 screen at high-throughput a vast array of test molecules. In a particular embodiment, the reporter gene is luciferase or beta-Gal.

It shall be understood that the "*in vivo*" experimental model can also be used to carry out an "*in vitro*" assay. For example, cellular extracts from the indicator cells can be prepared and used in an  
20 "*in vitro*" test. A non-limiting example thereof include binding assays.

In some embodiments, it might be beneficial to express a fusion protein. The design of constructs therefor and the expression and production of fusion proteins and are well known in the art (Sambrook et al., 1989, *supra*; and Ausubel et al., 1994, *supra*).

25 Non-limiting examples of such fusion proteins include hemagglutinin fusions and Gluthione-S-transferase (GST) fusions and Maltose binding protein (MBP) fusions. In certain embodiments, it might be beneficial to introduce a protease cleavage site between the two polypeptide sequences which have been fused. Such protease cleavage

sites between two heterologously fused polypeptides are well known in the art.

In certain embodiments, it might also be beneficial to fuse the protein of the present invention to signal peptide sequences enabling a secretion of the fusion protein from the host cell. Signal peptides from diverse organisms are well known in the art. Bacterial OmpA and yeast Suc2 are two non-limiting examples of proteins containing signal sequences. In certain embodiments, it might also be beneficial to introduce a linker (commonly known) between the interaction domain and the heterologous polypeptide portion. Such fusion protein find utility in the assays of the present invention as well as for purification purposes, detection purposes and the like.

For certainty, the sequences and polypeptides useful to practice the invention include without being limited thereto mutants, homologs, subtypes, alleles and the like. It shall be understood that generally, the sequences of the present invention should encode a functional (albeit defective) alpha subunit of sodium channels (SCNA). It will be clear to the person of ordinary skill that whether the SCNA sequence of the present invention, variant, derivative, or fragment thereof retains its function, can be determined by using the teachings and assays of the present invention and the general teachings of the art.

It should be understood that the SCNA protein of the present invention can be modified, for example by *in vitro* mutagenesis, to dissect the structure-function relationship thereof and permit a better design and identification of modulating compounds. However, some derivative or analogs having lost their biological function may still find utility, for example for raising antibodies. These antibodies could be used for detection or purification purposes. In addition, these antibodies could

also act as competitive or non-competitive inhibitor and be found to be modulators of the activity of the SCNA proteins of the present invention.

A host cell or indicator cell has been "transfected" by exogenous or heterologous DNA (e.g. a DNA construct) when such DNA  
5 has been introduced inside the cell. The transfecting DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transfecting DNA may be maintained on a episomal element such as a plasmid. With respect to eukaryotic cells, a stably transfected  
10 cell is one in which the transfecting DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transfecting DNA. Transfection methods are well  
15 known in the art (Sambrook et al., 1989, *supra*; Ausubel et al., 1994 *supra*). The use of a mammalian cell as indicator can provide the advantage of furnishing an intermediate factor, which permits for example the interaction of two polypeptides which are tested, that might not be present in lower eukaryotes or prokaryotes. It will be understood that  
20 extracts from mammalian cells for example could be used in certain embodiments, to compensate for the lack of certain factors.

In general, techniques for preparing antibodies (including monoclonal antibodies and hybridomas) and for detecting antigens using antibodies are well known in the art (Campbell, 1984, In  
25 "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology", Elsevier Science Publisher, Amsterdam, The Netherlands) and in Harlow et al., 1988 (in: Antibody-A Laboratory Manual, CSH Laboratories). The present invention also provides polyclonal, monoclonal antibodies, or humanized versions

thereof, chimeric antibodies and the like which inhibit or neutralize their respective interaction domains and/or are specific thereto.

From the specification and appended claims, the term therapeutic agent should be taken in a broad sense so as to also include  
5 a combination of at least two such therapeutic agents. Further, the DNA segments or proteins according to the present invention could be introduced into individuals in a number of ways. For example, cells can be isolated from the afflicted individual, transformed with a DNA construct according to the invention and reintroduced to the afflicted individual in a  
10 number of ways. Alternatively, the DNA construct can be administered directly to the afflicted individual. The DNA construct can also be delivered through a vehicle such as a liposome, which can be designed to be targeted to a specific cell type, and engineered to be administered through different routes.

15 For administration to humans, the prescribing medical professional will ultimately determine the appropriate form and dosage for a given patient, and this can be expected to vary according to the chosen therapeutic regimen (i.e. DNA construct, protein, cells), the response and condition of the patient as well as the severity of the disease.

20 Composition within the scope of the present invention should contain the active agent (i.e. molecule, hormone) in an amount effective to achieve the desired therapeutic effect while avoiding adverse side effects. Typically, the nucleic acids in accordance with the present invention can be administered to mammals (i.e. humans) in doses ranging  
25 from 0.005 to 1 mg per kg of body weight per day of the mammal which is treated. Pharmaceutically acceptable preparations and salts of the active agent are within the scope of the present invention and are well known in the art (Remington's Pharmaceutical Science, 16th Ed., Mack Ed.). For the administration of polypeptides, antagonists, agonists and the like, the

amount administered should be chosen so as to avoid adverse side effects. The dosage will be adapted by the clinician in accordance with conventional factors such as the extent of the disease and different parameters from the patient. Typically, 0.001 to 50 mg/kg/day will be  
5 administered to the mammal.

The present invention also relates to a kit for diagnosing and/or prognosing epilepsy, and/or predicting response to a medication comprising an assessment of a genotype at SCNA loci of the present invention (or loci in linkage disequilibrium therewith) using a  
10 nucleic acid fragment, a protein or a ligand, a restriction enzyme or the like, in accordance with the present invention. For example, a compartmentalized kit in accordance with the present invention includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of  
15 plastic or paper. Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include in one particular  
20 embodiment a container which will accept the test sample (DNA protein or cells), a container which contains the primers used in the assay, containers which contain enzymes, containers which contain wash reagents, and containers which contain the reagents used to detect the extension products.

## 25 BRIEF DESCRIPTION OF THE DRAWINGS

Having thus generally described the invention, reference will now be made to the accompanying drawings, showing by way of illustration a preferred embodiment thereof, and in which:

Figure 1 shows the IGE candidate region on ch 2q23-q31. Order and distance between markers are according to Gyapay et al., 1994.

Figure 2 shows the PCR primers used for genomic  
5 PCR-SSCP of SCN1A;

Figure 3 shows the sequence of the SCN1A mutations found in epilepsy patients;

Figure 4 shows the PCR primers used for genomic  
PCR-SSCP of SCN2A;

10 Figure 5 shows the mutation found in epilepsy patients in SCN2A;

Figure 6 shows the PCR primers used for genomic  
PCR-SSCP of SCN3A; and

15 Figure 7 shows the mutation found in epilepsy patients in SCN3A.

Sequences are also shown in the Sequence Listing. For example, SEQ ID NO.:1 shows the nucleic acid sequence of the adult form of SCN1A; SEQ ID NO.:2 shows the nucleic acid sequence of the neonatal form of SCN1A; SEQ ID NO.:3 shows the protein sequence of  
20 the adult form of SCN1A; SEQ ID NO.:4 shows the protein sequence of the neonatal form of SCN1A; SEQ ID NOS.:5-32 show the genomic sequence of SCN1A; SEQ ID NO.:33 shows the cDNA sequence of the adult form of SCN2A; SEQ ID NO.:34 shows the cDNA sequence of the neonatal form of SCN2A; SEQ ID NO.:35 shows the protein sequence of  
25 the adult form of SCN2A; SEQ ID NO.:36 shows the protein sequence of the neonatal form of SCN2A; SEQ ID NOS.:37-64 show the genomic sequence of SCN2A; SEQ ID NO.:65 shows the cDNA sequence of the adult form of SCN3A; SEQ ID NO.:66 shows the cDNA sequence of the neonatal form of SCN3A; SEQ ID NO.:67 shows the protein sequence of



the adult form of SCN3A; SEQ ID NO.:68 shows the protein sequence of the neonatal form of SCN3A; and SEQ ID NOS.:69-98 show the genomic sequence of SCN3A. Rat SCNA1 sequences can be found in GenBank under accession numbers M22253 and X03638.

5                   Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of preferred embodiments with reference to the accompanying drawing which is exemplary and should not be interpreted as limiting the scope of the present invention.

#### 10    **DESCRIPTION OF THE PREFERRED EMBODIMENT**

Epilepsy is one of the most common neurological conditions, affecting 1-2% of the general population. Familial aggregation studies have shown an increased risk for epilepsy in relatives of probands with different types of epilepsy, and especially for the idiopathic  
15    generalized epilepsies (IGEs). The epilepsy genes identified to date account for a very small proportion of all the epilepsies. In addition, they have been identified in rare syndromes where the pattern of inheritance was clearly Mendelian. This is not the case for the vast majority of epileptic patients, however, where the pattern of inheritance is not  
20    compatible with a simple Mendelian model. In fact, most authors consider epilepsy to be the result of a combination of many different genetic and environmental factors, features of a complex trait. While the pattern of inheritance is not mendelian, sporadic IGE cases may be caused by specific mutations in the same genes. Based on this assumption, a large  
25    cohort of IGE patients was tested for mutation in the SCNA genes.

In order to localize the gene causing epilepsy in a large family segregating an autosomal dominant form of IGE, 41 family members, including 21 affected individuals, were genotyped. A detailed clinical description of this family has been reported elsewhere (Scheffer

and Berkovic 1997). The majority of patients in this family present a benign epilepsy syndrome occurring in childhood and characterized by frequent generalized tonic-clonic seizures not always associated with fever: a syndrome called febrile seizures plus (FS+). However, several  
5 patients presented other types of generalized seizures (GTCS) as well, such as myoclonic seizures and absences (Scheffer and Berkovic 1997). Mean age at onset was 2.2 years and offset was 11.7 years. Neurological examination and intellect were normal in all individuals except one, who  
10 had moderate intellectual disability. EEG recordings were normal in most patients. However, in three individuals generalized epileptiform activity was found and four patients had mild or moderate diffuse background slowing. Table 1 shows the different types of seizures found in the 21 patients included in this study.

**Table 1.** Different types of generalized seizures found in the 21 patients included in the linkage analysis.

Type of seizures	n
Febrile convulsions alone	9
GTCSs <sup>a</sup> + absence seizures	4
GTCSs + myoclonic seizures	1
GTCSs + atonic seizures	1
Solitary afebril GTCS	1
Secondary epilepsy + mental retardation	1
Unwitnessed events	4

<sup>a</sup> GTCS: generalized tonic clonic seizure

5

A genome wide search examining 190 markers identified linkage of IGE to chromosome (ch) 2 based on an initial positive lod score for marker D2S294 ( $Z=4.4$ ,  $(=0)$ ). A total of 24 markers were tested on ch 2q in order to define the smallest IGE candidate region. Table 2 shows the two-point lod scores for 17 markers spanning the IGE candidate region. The highest lod score ( $Z_{\max}=5.29$ ;  $(=0)$ ) was obtained with marker D2S324. Critical recombination events mapped the IGE gene to a 29cM region flanked by markers D2S156 and D2S311, assigning the IGE locus to ch 2q23-q31 (Figure 1). Although the relationship of FS+ with other IGE phenotypes remains unclear, the observation that in this family, several affected individuals have different types of generalized seizures, suggests that seizure predisposition determined by the ch 2q-IGE gene could be modified by other genes and/or environmental factors, to produce different seizure types.

20

**Table 2.** Two-point lod-scores for 17 markers localized  
on ch 2q23-q31.

Locus	Recombination fractions							Zmax	max
	0	0.05	0.1	0.15	0.2	0.3	0.4		
D2S142	0.99	1.94	1.97	1.85	1.68	1.22	0.66	1.98	0.078
D2S284	1.3	1.18	1.06	0.94	0.82	0.57	0.3	1.3	0
D2S306	1.9	2.82	2.74	2.52	2.25	1.6	0.85	2.82	0.057
D2S156	2.15	3.05	2.96	2.73	2.43	1.73	0.93	3.05	0.056
D2S354	4.72	4.26	3.82	3.4	2.97	2.1	1.13	4.72	0
D2S111	5.15	4.71	4.26	3.78	3.29	2.26	1.17	5.15	0
D2S124	3.5	3.2	2.89	2.58	2.26	1.58	0.84	3.5	0
D2S382	4.31	3.93	3.54	3.14	2.74	1.91	1.02	4.31	0
D2S399	0.48	0.4	0.33	0.27	0.22	0.14	0.08	0.48	0
D2S294	4.4	4.04	3.65	3.25	2.84	2	1.07	4.4	0
D2S335	4.76	4.32	3.91	3.51	3.1	2.22	1.21	4.76	0
D2S333	1.42	1.23	1.04	0.87	0.72	0.45	0.22	1.4	0
D2S324	5.29	4.72	4.16	3.63	3.13	2.15	1.14	5.29	0
D2S384	3.85	3.52	3.17	2.82	2.45	1.69	0.89	3.85	0
D2S152	1.9	1.7	1.52	1.36	1.2	0.87	0.48	1.9	0
D2S311	-0.81	1.62	1.66	1.58	1.46	1.11	0.63	1.66	0.085
D2S155	-5.21	0.57	1.12	1.29	1.29	1.04	0.59	1.3	0.17

Haplotypes using 17 markers spanning the IGE candidate region were constructed (data not shown). The centromeric boundary was defined by a recombination event between the markers D2S156 and D2S354; whereas a recombination between the markers  
5 D2S152 and D2S311 set the telomeric boundary. These critical recombination events localized the IGE gene to a 29cM region flanked by markers D2S156 and D2S311 (Figure 1).

Over the last four decades, family studies provided two important pieces of evidence supporting the role of genetic factors in  
10 determining susceptibility to seizures: 1) familial aggregation studies have shown evidence for an increased risk for epilepsy in relatives of probands with different types of epilepsy. In two studies standardized morbidity ratios for unprovoked seizures in relatives of individuals with idiopathic childhood-onset epilepsy varied from 2.5 to 3.4 in siblings and 6.7 in  
15 offspring (Anneger et al. 1982; Ottman et al. 1989); and 2) the presence of higher concordance rates for epilepsy in monozygotic than in dizygotic twins. Different studies showed concordance rates varying from 54 to 11 % in monozygotic twins and 10 to 5% in dizygotic pairs (Inouye 1960; Lennox, 1960; Harvald and Hauge 1965; Corey et al. 1991; Silanpaa et al  
20 1991).

It is now generally accepted that seizure susceptibility probably reflects complex interactions of multiple factors affecting neuronal excitability and that most common genetic epilepsies display familial aggregation patterns that are not explained by segregation of a  
25 single autosomal gene (Andermann 1982; Ottman et al. 1995). This of course significantly makes more complex one's ability to isolate genes which predispose or induce epilepsy. However, some specific epileptic syndromes, which aggregate in families, may result from definable monogenic abnormalities. These families present a unique opportunity to

rapidly map genes that play a role in determining predisposition to seizures.

To date, there are a total of six loci (Greenberg et al. 1988; Leppert et al 1989; Lewis et al. 1993; Elmslie et al. 1997; Guipponi et al. 1997; Wallace et al. 1998), for which three genes have been identified in specific IGE syndromes (Bievert et al. 1998; Singh et al. 1998; Wallace et al. 1998). Interestingly, all three genes are ion channels, including a mutation found in the Na<sup>+</sup>-channel (1 in a Tasmania family with febrile seizures and generalized epilepsy (Wallace et al. 1998). While the candidate interval identified in our kindred remains large, a number of interesting genes map to the region. These include a cluster of Na<sup>+</sup> channel genes and K<sup>+</sup> channel genes (electronic data base search), as well as the GAD1 gene, which encodes for glutamate decarboxylase, an enzyme involved in the syntheses of  $\gamma$ -aminobutyric acid (GABA) (Bu and Tobin 1994). GABA is one of the major neurotransmitters involved in synaptic inhibition in the central nervous system (Barnard et al. 1987). However, the large size of the candidate interval will require further refinement of the locus prior to the identification of the gene responsible for IGE in the kindred studied herein.

Fifty-three % (9/17) of affected individuals in the large IGE family described herein, who had their seizures classified, had only febrile convulsions. However, 41 % of patients (7/17) presented with different types of generalized seizures. These findings may indicate that, although the predisposition to IGE in this family is determined by a single gene localized on ch2q23-q31, the different types of generalized seizures occurring in the same family may have resulted from interactions among genetic and/or environmental modifiers.

In conclusion, a locus for IGE was mapped on ch 2q23-q31. This locus seems to be associated with a specific IGE syndrome, FS

+. However, the relationship of FS+ with other IGE phenotypes, and the role of the ch 2q locus in other FS+ families and in other forms of IGE are still undetermined.

Having identified a locus for IGE on chromosome 2q23-q31, it was next verified whether mutations and/or polymorphisms could be linked to epilepsy. Public data bases were screened to identify potential genes in that chromosome region. The blasts of the data bases were also oriented to identify more specifically, membrane channels since seizures in mice and human are known to be associated with membrane channels. Having identified membrane channel coding sequences or parts thereof by the computer searches, the candidate genes, potentially involved in epilepsy, had to be validated as susceptibility genes for the disease. Two approaches were used. The first one was to test the candidate genes for mutations in a family comprising members having the disease (data not shown). The second approach was as follows. Since it is known that epilepsy results from a lower seizure threshold, and that generalized epilepsy results, in many instances, from a generalized lowering of the seizure threshold, the following hypothesis was formulated. The gene which results in epilepsy in the large family (that enabled the focusing chromosome 2q23-q31) should have other, less severe, mutations that would cause epilepsy in people who have only a weak family history of epilepsy. The sodium channel genes were chosen because they are involved in key electrical functions and could thus be good candidates. To formally test the hypothesis, many (60 to 70) unrelated cases of epilepsy were tested for mutations in these candidate genes. Surprisingly, mutations were found in all three candidate genes.

In order to assess whether mutations/polymorphisms could be identified and correlated to epilepsy, a panel of 70 to 80 epileptic patients (IGE) were tested for mutations in SCN1A, SCN2A and SCN3A,

using Single-strand conformation polymorphism (SSCP). SSCP analysis enables the detection of mutations as small as single-base substitutions. Indeed, such substitutions, by altering the conformations of single-strand DNA molecules, affect the electrophoretic mobilities thereof in non-denaturing gels. Thus, one can distinguish among sequences by comparing the mobilities of wild type (wt), mutant DNA, or different alleles of a given locus. The identification of single base substitutions of genes using SSCP is well known in the art, and numerous protocols are available therefor. A non-limiting example thereof includes fluorescence-based SSCP analysis, following PCR carried out using fluorescent-labeled primers specific for the DNA regions one wishes to amplify.

Upon the identification of differences between normal and epileptic mobilities for one of the SCNA loci of the present invention, the amplified fragments were sequenced and the nucleic acid sequences between a normal patient and an epileptic patient (IGE) compared. This comparison enabled the identification of mutations in SCN1A, SCN2A, and SCN3A. To assess, whether this difference in sequence or mutation was significantly associated with the disease, SSCP analysis was performed once again using a large cohort of normal patients. This analysis enabled to show that the mutations identified by SSCP and confirmed by sequence analysis were not present in the large cohort of normal patients tested, thereby showing that the mutations identified correlated with IGE, for the population tested.

Taken together, these results show that SCN1A, SCN2A and SCN3A are validated genes associated with epilepsy and more specifically with IGE.

This invention now establishes, for the first time, that SCN1A, SCN2A, and SCN3A, is directly responsible for idiopathic generalized epilepsy (IGE) in certain human populations. Further, this



discovery suggests that compounds which modulate the activity of SCN1A, SCN2A and SCN3A may have application far beyond the small groups of families with IGE, and may have applicability for treating many or all forms of epilepsy and related neurological disorders. It is therefore  
5 an object of this invention to provide screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders. This invention also claims those compounds, the use of these compounds in treating epilepsy and related neurological disorders, and any use of any  
10 compounds identified using such a screening assay in treating epilepsy and related neurological disorders.

Generally, high throughput screens for one or more SCN1A, SCN2A or SCN3A (herein collectively called SCNA) sodium channels modulators i.e. candidate or test compounds or agents (e.g.,  
15 peptides, peptidomimetics, small molecules or other drugs) may be based on assays which measure biological activity of SCNA. The invention therefore provides a method (also referred to herein as a "screening assay") for identifying modulators, which have a stimulatory or inhibitory effect on, for example, SCNA biological activity or expression, or which  
20 bind to or interact with SCNA proteins, or which have a stimulatory or inhibitory effect on, for example, the expression or activity of SCNA interacting proteins (targets) or substrates.

Examples of methods available for cell-based assays and instrumentation for screening ion-channel targets are described in the  
25 review by Gonzalez et al. (Drug Discov. Today 4:431-439, 1999), and high-throughput screens for ion-channel drugs are described in review by Denyer et al. (Drug Discov. Today 3:323-332, 1998). Such assays include efflux of sodium or related ions that can be measured in a cell line (recombinant or non-recombinant) using fluorescence-based assays using

both sodium indicator dyes and voltage sensing dyes. Preferred assays employ  $^{14}\text{C}$  guanidine flux and/or sodium indicator dyes such as SBFI and voltage sensing dyes such as DiBAC. Oxonal dyes such as DiBAC<sub>4</sub> are responsive to membrane depolarization. Hyper-polarization results in removal of the dye from the cell by passive diffusion, while depolarization results in concentration of the dye within the cell.

In one embodiment, the invention provides assays for screening candidate or test compounds which interact with substrates of a SCNA protein or biologically active portion thereof.

10 In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a SCNA protein or polypeptide or biologically active portion thereof.

In one embodiment, an assay is a cell-based assay in which a cell which expresses a SCNA protein or biologically active portion thereof, either natural or recombinant in origin, is contacted with a test compound and the ability of the test compound to modulate SCNA biological activity, e.g., modulation of sodium efflux activity, or binding to a sodium channel or a portion thereof, or any other measurable biological activity of SCNA is determined. Determining the ability of the test compound to modulate SCNA activity can be accomplished by monitoring, for example, the release of a neurotransmitter or other compound, from a cell which expresses SCNA such as a neuronal cell, e.g. a substantia nigra neuronal cell, or a cardiac cell upon exposure of the test compound to the cell. Furthermore, determining the ability of the test compound to modulate SCNA activity can be accomplished by monitoring, for example, the change in current or the change in release of a neurotransmitter from a cell which expresses SCNA upon exposure to a test compound. Currents in cells can be measured using the patch-clamp technique as

described in the Examples below using the techniques described in, for example, Hamill et al. 1981 Pfluegers Arch. 391:85-100. Alternatively, changes in current can be measured by dye based fluorescence assays described below.

- 5                   Determining the ability of the test compound to modulate binding of SCNA to a substrate can be accomplished, for example, by coupling the SCNA agent or substrate with a radioisotope or enzymatic label such that binding of the SCNA substrate to SCNA can be determined by detecting the labeled SCNA substrate in a complex. For  
10                   example, compounds (e.g., SCNA agents or substrates) can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting radio-emission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase or alkaline phosphatase. In these assays,  
15                   compounds which inhibit or increase substrate binding to SCNA are useful for the therapeutic objectives of the invention.

- It is also within the scope of this invention to determine the ability of a compound (e.g. SCNA substrate) to interact with SCNA without the labeling of any of the interactants. For example, a  
20                   microphysiometer can be used to detect the interaction of a compound with SCNA without the labeling of either the compound or the SCNA (McConnell H.M.et al. (1992), Science 257:1906-1912). As used herein, a "microphysiometer" (e.g., Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-  
25                   addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and SCNA.

                  Modulators of SCNA can also be identified through the changes they induce in membrane potential. A suitable instrument for

measuring such changes is the VIPR™ (voltage ion probe reader) from Aurora Biosciences. This instrument works together with a series of voltage-sensing ion probe assays. The probes sense changes in transmembrane electrical potential through a voltage-sensitive FRET  
5 mechanism for which the ratio donor fluorescence emission to acceptor fluorescence emission reveals the extent of cell depolarization for both sodium and potassium channels. Depolarization results from transport of a quencher across the membrane and far enough away from a membrane-bound fluorescence emitter to relieve the initial quenching and  
10 produce light at the emission wavelength of the emitter. The system follows fluorescence at two wavelengths, both the intensities and ratios change during cell depolarization. The reader permits detection of sub-second, real-time optical signals from living cells in a microplate format. The system is amenable to manual operation for assay development or  
15 automation via robots for high-throughput screening.

In another embodiment, the assay is a cell-based assay comprising a contacting of a cell containing a target molecule (e.g. another molecule, substrate or protein that interacts with or binds to SCNA) with a test compound and determining the ability of the test  
20 compound to indirectly modulate (e.g. stimulate or inhibit) the biological activity of SCNA by binding or interacting with the target molecule. Determining the ability of the test compound to indirectly modulate the activity of SCNA can be accomplished, for example, by determining the ability of the test compound to bind to or interact with the target molecule  
25 and thereby to indirectly modulate SCNA, to modulate sodium efflux, or to modulate other biological activities of SCNA. Determining the ability of the SCNA protein or a biologically active fragment thereof, to bind to or interact with the target molecule can be accomplished by one of the methods described above or known in the art for determining direct

binding. In a preferred embodiment, determining the ability of the test compound's ability to bind to or interact with the target molecule and thereby to modulate the SCNA protein can be accomplished by determining a secondary activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g. intracellular  $\text{Ca}^{2+}$ , diacylglycerol,  $\text{IP}_3$ , and the like), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (comprising a target -responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, such as luciferase), or detecting a target-regulated cellular response such as the release of a neurotransmitter. Alternatively, recombinant cell lines may employ recombinant reporter proteins which respond, either directly or indirectly to sodium efflux or secondary messengers all as known in the art.

In yet another embodiment, an assay of the present invention is a cell-free assay in which a SCNA protein or biologically active portion thereof, either naturally occurring or recombinant in origin, is contacted with a test compound and the ability of the test compound to bind to, or otherwise modulate the biological activity of, the SCNA protein or biologically active portion thereof is determined. Preferred biologically active portions of the SCNA proteins to be used in assays of the present invention include fragments which participate in interactions with non-SCNA molecules, (e.g. other channels for sodium, potassium or  $\text{Ca}^{2+}$  or fragments thereof, or fragments with high surface probability scores for protein-protein or protein-substrate interactions). Binding of the test compound to the SCNA protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the SCNA protein or biologically active portion thereof

with a known compound which binds SCNA to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a SCNA protein, wherein determining the ability of the test compound to interact with a SCNA  
5 protein comprises determining the ability of the test compound to preferentially bind to SCNA or biologically active portion thereof as compared to the known compound.

In another embodiment, the assay is a cell-free assay in which a SCNA protein or biologically active portion thereof is contacted  
10 with a test compound and the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the SCNA protein or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of a SCNA protein can be accomplished, for example, by determining the ability of the SCNA protein  
15 to bind to a SCNA target molecule by one of the methods described above for determining direct binding. Determining the ability of the SCNA protein to bind to a SCNA target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA, Sjolander, S. and Urbaniczky, C. (1991) Anal. Chem. 63:2338-2345  
20 and Szabo et al. (1995) Curr. Opin. Struct. Biol. 5:699- 705). As used herein, "BIA" refers to a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g. BIA core). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological  
25 molecules.

In an alternative embodiment, determining the ability of the test compound to modulate the activity of a SCNA protein can be accomplished by determining the ability of the test compound to modulate the activity of an upstream or downstream effector of a SCNA target

molecule. For example, the activity of the test compound on the effector molecule can be determined or the binding of the effector to SCNA can be determined as previously described.

The cell-free assays of the present invention are  
5 amenable to use of both soluble and/or membrane-bound forms of isolated proteins. In the case of cell-free assays in which a membrane-bound form of an isolated protein is used (e.g. a sodium channel) it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the isolated protein is maintained in solution. Examples of such  
10 solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)n. 3-[(3-cholamidopropyl)dimethylamino]-l-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamino  
15 ]-2-hydroxy-l-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-l-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either SCNA or its target molecule to facilitate separation of complexed from  
20 uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a SCNA protein or interaction of a SCNA protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants.  
25 Examples of such vessels include microtitre plates, test tubes and micro-centrifuge tubes. In one embodiment a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/SCNA fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto

glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or SCNA protein and the mixture incubated under conditions conducive to complex formation (e.g. at physiological conditions for salt and pH). Following incubation the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of SCNA binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices (and well-known in the art) can also be used in the screening assays of the invention. For example, either a SCNA protein or a SCNA target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated SCNA protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with SCNA protein or target molecules but which do not interfere with binding of the SCNA protein to its target molecule can be derivatized to the wells of the plate, and unbound target or SCNA protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST -immobilized complexes, include immunodetection of complexes using antibodies reactive with the SCNA protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the SCNA protein or target molecule.



In a preferred embodiment, candidate or test compounds or agents are tested for their ability to inhibit or stimulate a SCNA molecule's ability to modulate vesicular traffic and protein transport in a cell, e.g. a neuronal or cardiac cell using the assays described in for example Komada M. et al. (1999) Genes Dev.13(11):1475-85, and Roth M.G. et al. (1999) Chem. Phys. Lipids. 98(12):141-52.

In another preferred embodiment candidate, or test compounds or agents are tested for their ability to inhibit or stimulate or regulate the phosphorylation state of a SCNA channel protein or portion thereof, or an upstream or downstream target protein, using for example an *in vitro* kinase assay. Briefly, a SCNA target molecule (e.g. an immunoprecipitated sodium channel from a cell line expressing such a molecule), can be incubated with radioactive ATP, e.g., [ $\gamma$ -<sup>32</sup>P] - ATP, in a buffer containing MgCl<sub>2</sub> and MnCl<sub>2</sub>, e.g., 10 mM MgCl<sub>2</sub> and 5 mM MnCl<sub>2</sub>. Following the incubation, the immunoprecipitated SCNA target molecule (e.g. the sodium channel), can be separated by SDS-polyacrylamide gel electrophoresis under reducing conditions, transferred to a membrane, e.g., a PVDF membrane, and autoradiographed. The appearance of detectable bands on the auto radiograph indicates that the SCNA substrate, e.g., the sodium channel, has been phosphorylated. Phosphoaminoacid analysis of the phosphorylated substrate can also be performed in order to determine which residues on the SCNA substrate are phosphorylated. Briefly, the radiophosphorylated protein band can be excised from the SDS gel and subjected to partial acid hydrolysis. The products can then be separated by one-dimensional electrophoresis and analyzed on, for example, a phosphoimager and compared to ninhydrin-stained phosphoaminoacid standards. Assays such as those described in, for example, Tamaskovic R. et al. (1999) Biol. Chem. 380(5):569-78.

In another preferred embodiment, candidate or test compounds or agents are tested for their ability to inhibit or stimulate a SCNA molecule's ability to associate with (e.g. bind) calcium, using for example, the assays described in Liu L. ( 1999) Cell Signal. 11(5):317-24  
5 and Kawai T. et al. (1999) Oncogene 18(23):3471-80.

In another preferred embodiment, candidate or test compounds or agents are tested for their ability to inhibit or stimulate a SCNA molecule's ability to modulate chromatin formation in a cell using for example the assays described in Okuwaki M. et al. (1998) J. Biol.  
10 Chem. 273(51):34511-8 and Miyaji- Yamaguchi M. (1999) J. Mol. Biol. 290(2): 547-557.

In yet another preferred embodiment candidate or test compounds or agents are tested for their ability to inhibit or stimulate a SCNA molecule's ability to modulate cellular proliferation, using for  
15 example, the assays described in Baker F.L. et al. (1995) Cell Prolif. 28(1):1-15, Cheviron N. et al. ( 1996) Cell Prolif. 29(8):437-46. Hu Z. W. et al. (1999) J: Pharmacol. Exp. Ther. 290(1):28-37 and Elliott K. et al. (1999) Oncogene 18(24):3564-73.

In a preferred embodiment, candidate or test  
20 compounds or agents are tested for their ability to inhibit or stimulate a SCNA molecule's ability to regulate it's association with the cellular cytoskeleton. Using for example, the assays similar to those described in Gonzalez C. et al. (1998) Cell Mol. Biol. 44(7):1117-27 and Chia C.P. et al. (1998) Exp. Cell Res. 244(1):340-8.

25 In another preferred embodiment, candidate or test compounds or agents are tested for their ability to inhibit or stimulate a SCNA molecule's ability to modulate membrane excitability, using for example, the assays described in Bar-Sagi D. et al. (1985) J. Biol. Chem. 260(8):4740-4 and Barker J.L. et al. (1984) Neurosci. Lett. 47(3):313-8.

In another preferred embodiment, candidate or test compounds or agents are tested for their ability to inhibit or stimulate a SCNA molecule's ability to modulate cytokine signaling in a cell, (e.g., a neuronal or cardiac cell), the assays described in Nakashima Y. et al. (1999)J: Bone Joint Surg. Am. 81 (5):603-15.

In another embodiment, modulators of SCNA expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of SCNA mRNA or protein in the cell is determined. The level of expression of SCNA mRNA or protein in the presence of the candidate compound is compared to the level of expression of SCNA mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of SCNA expression based on this comparison. For example, when expression of SCNA mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of SCNA mRNA or protein expression. Alternatively, when expression of SCNA mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of SCNA mRNA or protein expression. The level of SCNA mRNA or protein expression in the cells can be determined by methods described herein or other methods known in the art for detecting SCNA mRNA or protein.

The assays described above may be used as initial or primary screens to detect promising lead compounds for further development. Often, lead compounds will be further assessed in additional, different screens. Therefore, this invention also includes secondary SCNA screens which may involve electrophysiological assays utilizing mammalian cell lines expressing the SCNA channels such as

patch clamp technology or two electrode voltage clamp and FRET-based voltage sensor. Standard patch clamp assays express wild type and mutant channels in *Xenopus* oocytes, and examine their properties using voltage-clamp electrophysiological recording. Wild type sodium channels are closed at hyperpolarized membrane potentials. In response to membrane depolarization the channels open within a few hundred microseconds, resulting in an inward sodium flux, which is terminated within a few milliseconds by channel inactivation. In whole cell recordings, rapid activation and inactivation of thousands of sodium channels distributed throughout the cell membrane results in a transient inward sodium current that rises rapidly to peak amplitude and then decays to baseline within a few milliseconds.

Tertiary screens may involve the study of the identified modulators in rat and mouse models for epilepsy. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, a test compound identified as described herein (e.g., a SCNA modulating agent, an antisense SCNA nucleic acid molecule, a SCNA-specific antibody, or a SCNA-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatment (e.g. treatments of different types of epilepsy or CNS disorders), as described herein.

The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic

library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, Anticancer Drug Des. 12: 145, 1997). Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. USA. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994), J. Med. Chem. 37:2678; Cho et al. (1993) Science 261 :1303; Carrell et al. (1994) Angew. Chem, Int. Ed Engl. 33:2059; Carell et al. (1994) Angew. Chem. Jnl. Ed. Engl. 33:2061; and in Gallop et al. (1994). Med Chem. 37:1233. Libraries of compounds may be presented in solution (e.g., Houghten (1992) Biotechniques 13:412-421 ), or on beads (Lam (1999) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull et al.(1992) Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith (1990); Science 249:386-390). Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. USA. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91: 11422; Zuckermann et al. (1994), J. Med. Chem. 37:2678; Cho et al. (1993), Science 261 :1303; Carrell et al. (1994) Angew. Chem Int. Ed. Engl. 33:2059, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

It is recognized by the inventors that certain therapeutic agents have been identified for cardiac, muscular, chronic pain, acute pain and other disorders, and analgesics and anesthetics that are modulators of sodium channels. Use of these sodium channel modulators

for treating epilepsy and related neurological disorders also falls within the scope of this invention. In one embodiment of this invention, sodium channel blockers are modified to achieve improved transport across the blood brain barrier in order to have direct effect on neuronal SCNA proteins and genes. Descriptions of such compounds are found at Hunter, JC et al. Current Opinion in CPNS Invest. Drugs. 1999 1(1):72-81; Muir KW et al. 2000. Cerebrovasc. Disc. 10(6):431-436; Winterer, G. 2000. Pharmacopsychiatry 33(5):182-8; Clare et al. 2000. Drug. Discov. Today 5(11):506-520; Taylor CP et al. 2000. Adv. Pharmacol. 39:47-98, and Pugsley MK et al. 1998. Eur. J. Pharmacol. 342(1)93-104.

It is also recognized by the inventors that compounds which modulate (i.e. either upregulate or downregulate) transcription and translation of SCNA genes are useful for treating epilepsy or related neurological disorders. According to this invention, test compounds which modulate the activity of promoter elements and regulatory elements of sodium channel genes are useful for treating these disorders.

In summary, based on the disclosure herein, those skilled in the art can develop SCNA screening assays which are useful for identifying compounds which are useful for treating epilepsy and other disorders which relate to potentiation of SCNA expressing cells. The assays of this invention may be developed for low-throughput, high-throughput, or ultra-high throughput screening formats.

The assays of this invention employ either natural or recombinant SCNA protein. Cell fraction or cell free screening assays for modulators of SCNA biological activity can use *in situ*, purified, or purified recombinant SCNA proteins. Cell based assays can employ cells which express SCNA protein naturally, or which contain recombinant SCNA gene constructs, which constructs may optionally include inducible promoter sequences. In all cases, the biological activity of SCNA can be

directly or indirectly measured; thus modulators of SCNA biological activity can be identified. The modulators themselves may be further modified by standard combinatorial chemistry techniques to provide improved analogs of the originally identified compounds.

5                   Finally, portions or fragments of the SCNA cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome and thus, locate gene regions associated with  
10                   genetic disease (mutations/polymorphisms) related to epilepsy or CNS disorders that involve SCNA directly or indirectly; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample.

                  The present invention is illustrated in further detail by  
15                   the following non-limiting examples.

### **EXAMPLE 1**

#### **Molecular analysis**

                  Genomic DNA was extracted from blood samples  
20                   (Sambrook et al. 1989) or lymphoblastoid cell lines (Anderson and Gusella 1984) from each individual. A panel of 210 dinucleotide (CA)<sub>n</sub> repeat polymorphic markers with high heterozygosity (75%) were chosen from the 1993-94 Généthon map (Gyapay et al. 1994). Dinucleotide markers were spaced an average of 20 cM from each other throughout  
25                   the 22 autosomes.

                  Genotyping of microsatellite markers was accomplished by polymerase chain reaction (PCR). The reaction mixture was prepared in a total volume of 13 $\mu$ l, using 80ng genomic DNA; 1.25 $\mu$ l 10x buffer with 1.5mM MgCl<sub>2</sub>; 0.65 $\mu$ l BSA (2.0mg/ml); 100ng of each

oligonucleotide primer; 200mM dCTP, dGTP and dTTP; 25mM dATP; 1.5mCi [35S] dATP; and 0.5units Taq DNA polymerase (Perkin-Elmer). Reaction samples were transferred to 96 well plates and were subjected to: 35 cycles of denaturation for 30 seconds at 94°C, annealing for 30  
5 seconds at temperatures varying from 55°C to 57°C depending on the specificity of the oligonucleotide primers, and elongation for 30 seconds at 72°C. PCR reaction products were electrophoresed on 6% denaturing polyacrylamide sequencing gels.

10

### EXAMPLE 2

#### **Genetic analysis**

Two-point linkage analysis was carried out using the MLINK program version 5.1 from the LINKAGE computer package (Lathrop et al. 1984). Precise values for Zmax were calculated with the ILINK program from the  
15 same computer package. Lod scores were generated based on an autosomal dominant mode of inheritance, 80% penetrance, disease gene frequency of 1:500 and allele frequencies for all allele markers calculated from the pedigree using the computer program ILINK (Lathrop et al. 1984).

20

### EXAMPLE 3

#### **Mutations in SCN1A in IGE patients**

Genomic DNA from IGE and normal patients was obtained by conventional methods. Primers used to amplify the genomic  
25 DNA are shown in Figure 2. Following PCR, SSCP analysis was performed and mutations in SCN1A were identified as follows (Figure 3): (1) Glu1238Asp; normal: GCA TTT GAA GAT ATA; patient R10191 who has an idiopathic generalized epilepsy (IGE): GCA TTT GAC GAT ATA (found in 1 of 70 IGE patients). The mutation is thus a conservative aa



change, in the extracellular domain between III-S1 and III-S2. Furthermore, this residue is located at the junction between the TM domain and the extracellular domain. It may thus influence gating activity. The aa change between adult and neonatal isoforms is at a similar juxta-  
5 TM domain position (between I-S3 and I-S4).  
(2) Ser1773Tyr; normal: ATC ATA TcC TTC CTG, patient R9049 (affected with IGE): ATC ATA TmC TTC CTG :(TCC>TAC). This mutation is in the middle of IV-S6 TM domain; found in 1/70 IGE patients, and 0/150 control subjects tested. This mutation is interesting from a biological point of view  
10 for a number of reasons. First, this region of SCN gene (IV-S6) has been found to play a critical role in fast inactivation of the SCN, by mutagenesis experiments in rat SCN (McPhee et al., 1998). This is highly relevant for pathophysiology of epilepsy, since this may increase neuronal hyperexcitability. Moreover, in patients with GEFs, a mutation has been  
15 found in the SCN1 subunit, causing impairment of the fast inactivation of the SCN (Wallace et al, 1999). Finally, many of the antiepileptic drugs (e.g. phenytoin, carbamazepine) primarily act by reducing the repetitive firing of neuron, which also involves fast inactivation of the SCN.

20

#### EXAMPLE 4

##### **Mutations in SCN2A in IGE patients**

Genomic DNA from IGE and normal patients was obtained by conventional methods. Primers used to amplify the genomic DNA are shown in Figure 4. Following PCR, SSCP analysis was  
25 performed and mutations in SCN2A were identified as follows (Figure 5):  
(1) Lys908Arg: normal: TAC AAA GAA for patient numbers always preceded by R; R9782 (Patient with IGE): TAC AGA GAA. The mutation is thus a conservative aa change, located in an extracellular domain

between TM domains IIS5 and IIS6; in 1/70 IGE patients; 0/96 normal controls. The mutation involves an important component of the SCN gene, since the S5 and S6 segments are thought to form the wall of the transmembrane pore which allows the sodium to enter the cell. This may have an influence on the gating control of the pore.

(2) Leu768Val, in individuals R8197, R9062 and R9822 (all IGE patients) (found in 3/70 IGE patients and 0/65 control subjects). The mutations is in the IV-S6 component of the sodium channel, which is important in the inactivation of the channel (see above for more detail).

10

#### EXAMPLE 5

##### **Mutations in SCN3A in IGE patients**

Genomic DNA from IGE and normal patients was obtained by conventional methods. Primers used to amplify the genomic DNA are shown in Figure 6. Following PCR, SSCP analysis was performed and mutations in SCN3A were identified as follows (Figure 7):

15

(1) Asn43DEL: allele 1: CAA GAT AAT GAT GAT GAG ; allele 2: CAA GAT --- GAT GAT GAG ; in open reading frame deletes 1 aa: DNDDEN->QDDDEN, in the cytoplasmic N-terminal segment; in IGE patients, the frequency of allele 1 = 131/146 (0.90); allele 2= 15/146 (0.10); for IGE patients: homozygotes (22): R3958, R9632; heterozygotes (12): R9049, R9152, R9649, R9710, R9896, R10069, R10191, R10213, R9993, R10009, R10256 . Of note, 2 patients are homozygous for the rare allele and all patients have IGE. In controls: allele 1 = 145/154 (0.94); allele 2 = 9/154 (0.06) and no 22 homozygotes were found.

20

(2) normal: tggtgtaaggttag, R10670 (IGE patient): tggtataaggttag, in conserved intron between 5N & 5A exons, significance uncertain.

25

(3) normal: ccccttatatctccaac, R10250 (IGE patient): ccccttatayctccaac; in conserved intron between 5N & 5A exons, significance uncertain.

- (4) Val1035Ile: normal: AAA TAC GTA ATC GAT, R9269 (IGE patient): AAA TAC RTA ATC GAT ; (GTA>ATA = Val>Ile). The mutation is thus a conservative aa change which destroys a SnaBI site (this could thus be used as a polymorphism identifiable by restriction enzyme digestion). In
- 5 SCN1A, this Val is a Ile, therefore probably not a causative mutation. In cytoplasmic domain bw II-S6 & III-S1 TMs; found in 1/70 IGE alleles; and 0/70 controls.

#### **EXAMPLE 6**

10 **SCN1A is involved in idiopathic  
generalized epilepsy**

The assumption that SCN1A gene is involved in idiopathic generalised epilepsy in humans is based on many sets of evidence. First, a mutation has been found in a large Australian family

15 with autosomal dominant epilepsy. The phenotype is idiopathic generalised epilepsy that is associated with febrile seizures (GEFS syndrome). The gene for this family has been previously mapped to the long arm of chromosome 2. The maximum lod score is 6.83 for marker D2S111. The candidate region is very large, spanning 21cM between

20 markers D2S156 and D2S311. However, within this interval, there is a cluster of sodium channel genes, including SCN1A which was hypothesized to be a candidate gene for the disease.

Screening by SSCP of a small panel of three (3) affected patients from the family, and 3 normal controls was carried-out at

25 first. All the exons of the SCN1A gene have been amplified by PCR, and a SSCP variant in exon 4 was found for all of the affected individuals, and none of the controls. By sequencing an affected patient and a control, an A-T substitution at nucleotide 565 was found. This variation destroys a BamHI restriction site, this nzyme was thus used as a diagnostic test to

screen all the affected patients from the family, as well as more control cases. All affected patients from the family have A565T substitution, and none of the unaffected patients in the same kindred. An A565T substitution was not found in more than 400 control chromosomes.

5           The A565T substitution correspond to a non-conservative amino acid change (D188V). This amino acid is conserved in all sodium channels thus far identified, in all species. The only exception is SCN2A identified in rat by Numa et al, where the aspartic acid is replaced by asparagine. However, it is likely that this represents  
10 an error during replication of cDNA, since other investigators have cloned the same gene in rat and found that the aspartic acid is conserved at position 188. Moreover, the same group has shown that D188N has a functional effect on channel activation in oocytes (Escayg et al., *Nature Genetics*. 24(4):343-5, 2000). Of note, this A565T substitution has not  
15 been found in 150 epileptic patients and in 200 control patients. Thus, this substitution has yet to be identified after 700 chromosomes assessments.

          In view of proving that D188V in SCN1A, identified in the large Australian family studied, is a pathogenic mutation, the oligonucleotide mismatch mutagenesis technique was used to introduce  
20 the mutation in rat SCN1A clone. RNA was isolated from mutant and wild-type clones, and injected into oocytes in view of recording sodium currents by the patch-clamp technique. The amplitude of the currents was dramatically reduced for the mutant. Also, a small shift in the inactivation curve was observed for the mutant, as compared to the wild-type. Taken  
25 together, these preliminary results confirm a functional effect of D188V mutation on SCN1A gene. (more detail below).

          The results presented herein are corroborated by studies from other investigators. For example, several other groups have also found linkage to the same locus on chromosome 2 for families with

GEFS or very similar syndromes. Mutations in SCN1A (Thr875Met mutation; Arg1648His) have been found to be the cause of the epileptic syndrome in at least two (2) of these families (Escayg et al., *Nature Genetics*. 24(4):343-5, 2000). Also, GEFS syndrome has been shown to

5 be caused by mutation in SCN1B gene. It is demonstrated that the beta subunits interact with alpha subunits of voltage-gated sodium channels to alter kinetics of sodium currents in cells. These data suggest a common mechanism for generating abnormal neuronal discharges in the brain of patients with idiopathic generalised epilepsy.

10 Finally, in the process of screening patients from the large kindred with GEFS described above, a large cohort of patients with idiopathic generalised epilepsy was also screened by SSCP. Two (2) SSCP variants, that were subsequently sequenced were thereby identified. The variation observed are shown in Table 3:

**Table 3**

exon	DNA variation	IGE alleles	Control alleles
1Ax17	Glu1238Asp; conservative AA change in extracellular domain between III-S1 and III-S2	3/254	0/284
1Ax24.2	Ser1773Tyr; middle of IV-S6 TM domain	1/252	0/334

Previous functional studies have shown that amino acid substitution in the IV-S6 transmembrane domain of SCN2A significantly affects the rate of inactivation of the channel. It is thus likely that Ser1773Tyr will have an effect on the SCN1A gene function. Such functional studies are currently underway.

#### **EXAMPLE 7**

##### **Further validation of the role of SCN1A, SCN2A, SCN3A, and specific mutations thereof in IGE and epilepsy in general**

A number of methods could be used to further validate the role of SCN1A, SCN2A, SCN3A, and specific mutations thereof in IGE. For example, additional patients could be screened for mutations in SCN1A, SCN2A, or SCN3A. Furthermore, additional normal patients could be screened in order to validate that the mutations identified significantly correlate with disease, as opposed to reflecting a polymorphism which is not linked to IGE. Polymorphisms which are not directly linked to IGE, if in linkage disequilibrium with a functional mutation

linked to IGE, could still be useful in diagnosis and/or prognosis assays. In addition, functional studies can be carried. Numerous methods are amenable to the skilled artisan. One particularly preferred functional assay involves the use of *Xenopus* oocytes and recombinant constructs

5 harboring normal or mutant sequence of SCN1A, SCN2A, or SCN3A. *Xenopus* oocytes have been used in functional assays to dissect the structure-function relationship of the cyclic AMP-modulated potassium channel using recombinant KCNQ2 and KCNQ3 (Schroeder et al., 1998). As well, it has been used to dissect the structure-function relationship of

10 the beta subunit of the sodium channel (SCN1B gene; Wallace et al. 1998).

One such example of functional studies was investigated by assessing the effects of mutation D188V in the SCN1A gene on sodium channel function by introducing the mutation into a cDNA

15 encoding the rat ortholog SCN1A gene. This rat gene shares > 95% identity with the human SCN1A gene. The expression of wild type and mutant channels in *Xenopus* oocytes, and the examination of their properties using voltage-clamp electrophysiological recording is amenable to this *Xenopus* system. Wild type sodium channels are closed at

20 hyperpolarized membrane potentials. In response to membrane depolarization the channels open within a few hundred microseconds, resulting in an inward sodium flux, which is terminated within a few milliseconds by channel inactivation. In whole cell recordings, rapid activation and inactivation of thousands of sodium channels distributed

25 throughout the cell membrane results in a transient inward sodium current that rises rapidly to peak amplitude and then decays to baseline within a few milliseconds. Among the channel properties that are likely to be altered by mutations linked to epilepsy are: 1) the voltage-dependence of activation, a measure of the strength of membrane depolarization

necessary to open the channels; 2) the voltage-dependence of steady state inactivation, a measure of the fraction of channels available to open at the resting membrane potential; and 3) the time course of inactivation. Preliminary results indicate that D188V mutant channels are identical to  
5 wild type channels with respect to the voltage-dependence of activation and to inactivation time course. However, steady state inactivation for the mutant channels is shifted to membrane potentials that are slightly more positive than observed in wild type channels. This positive shift should increase the fraction of channels available to open at rest. This could  
10 increase neuronal excitability and contribute to epileptogenesis. Thus, a functional consequence of a naturally occurring mutation in a sodium channel gene has been tentatively identified. Thus, the functional consequence of the D188M mutant could at least in part explain its role in epilepsy. Such a functional consequence is expected to be observed with  
15 other mutations identified above in SCNA1, SCNA2 and SCNA3.

Although the present invention has been described hereinabove by way of preferred embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims.



**REFERENCES:**

- Andermann E (1982) Multifactorial inheritance of generalized and focal epilepsy. In: Anderson VE, Hauser WA, Penry JK, Sing CF (eds) Genetic Basis of the Epilepsies. New York, Raven Press, pp:355-374
- 5 Anderson MA and Gusella JF (1984) Use of cyclosporin A in establishing Epstein Barr virus-transformed human lymphoblastoid cell lines. *In Vitro* 20:856-858
- Anneger JF, Hauser WA, Anderson VE (1982) Risk of seizures among relatives of patients with epilepsy: families in a defined population. In:
- 10 Anderson VE, Hauser WA, Sing L, Porter R (eds) The Genetic Basis of the Epilepsies, Raven Press, New York, pp 151-159
- Barnard EA, Darlison MG, Seeburg P (1987) Molecular biology of the GABAA receptor: the receptor/channel superfamily. *Trends Neurosci* 10:502-509.
- 15 Berkovic SF, et al. Epilepsies in twins: genetics of the major epileptic syndromes. *Ann Neurol*. 43:435-445 (1998).
- Bievert C, Schoeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinlein OK (1998) A potassium channel mutation in neonatal human epilepsy. *Science* 279:403-406
- 20 Bu DF, Tobin AJ (1994) The exon-intron organization of the genes (GAD1 and GAD2) encoding two human glutamate decarboxylases (GAD67 and GAD65) suggests that they derive from a common ancestral GAD. *Genomics* 1:222-228.

Charlier C, et al. A pore mutation in a novel KGT-like potassium channel gene in an idiopathic epilepsy family. *Nat. Genet.* 18:53-55 (1998).

Commission on Classification and Terminology of the International League against Epilepsy (1989) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. *Epilepsia* 22:489-501

Corey LA, Berg K, Pellock JM, Solaas MH, Nance WE, DeLorenzo RJ (1991) The occurrence of epilepsy and febrile seizures in Virginian and Norwegian twins. *Neurology* 41:433-436

10 Elmslie FV, Rees M, Williamson MP, Kerr M, Kjeldsen MJ, Pang KA, Sundqvist A, et al (1997) Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. *Hum Mol Genet* 6:1329-1334

Engel JJ, Pedley TA (1998) What is epilepsy ? In: Engel JJ, Pedley TA (eds) *Epilepsy a Comprehensive Textbook*, Lippincott-Raven Publishers, Philadelphia, pp:1-10.

Escayg et al., *Nature Genetics*. 24(4):343-5, 2000.

Greenberg DA, Delgado-Escueta AV, Wideltz H, Sparkes RS, Treiman L, Maldonado HM, et al (1988) Juvenile myoclonic epilepsy (JME) may be linked to the BF and HLA loci on human chromosome 6. *Am J Hum Genet* 31:185-192

Guipponi M, Rivier F, Vigevano F, Beck C, Crespel A, Echenne B, Lucchini P, et al (1997) Linkage mapping of benign familial infantile seizures (BFIS) to chromosome 19q. *Hum Mol Genet* 6:473-477

- Gyapay G, Morissette J, Vignal A, et al. (1994) The 1993-94 Genethon human genetic linkage map. *Nat Genet* 7:246-339
- Harvald B and Hauge M (1965) Hereditary factors elucidated by twin studies. In: Neel JV, Shaw MW, Schull WJ (eds) *Genetics and the Epidemiology of Chronic Diseases*, Washington Public Health Service Publications 1163:61-76
- 5 Inouye E (1960) Observations on forty twin index cases with chronic epilepsy and their co-twins. *J Nerv Ment Dis* 130: 401-416
- Lathrop GM, Lalouel JM, (1984) Easy calculations of lod scores and genetic risks on small computers. *Am J Hum Genet* 36:460-465
- 10 Lennox WG, Lennox MA (1960) *Epilepsy and related disorders*. Boston, Little Brown.
- Leppert M, Anderson VE, Quattlebaum T, Staufe D, O'Connell P, Nakamura Y, Lalouel JM, et al (1989) Benign familial neonatal convulsions linked to genetic markers on chromosome 20. *Nature* 337:647-648
- 15 Lewis TB, Leach RJ, Ward K, O'Connell P, Ryan SG (1993) Genetic Heterogeneity in benign familial neonatal convulsions: identification of a new locus on chromosome 8q. *Am J Hum Genet* 53:670-675
- 20 McPhee et al., 1998, *J. Biol. Chem.* 273:1121-1129
- Ottman R, Annegers JF, Hauser WA, Kurland LT (1989) Seizure risk in offspring of parents with generalized versus partial epilepsy. *Epilepsia* 30:157-161

- Ottman R, Hauser WA, Barker-Cummings C, Lee JH, Risch N (1997) Segregation analysis of cryptogenic epilepsy and an empirical test of the validity of the results. *Am J Hum Genet* 60:667-675
- 5     Sambrook J, Fritsch EF, Maniatis T (eds) (1989) *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp E.3-E.4
- Scheffer IE and Berkovic SF (1997) Generalised epilepsy with febrile seizures plus: a genetic disorder with heterogeneous clinical phenotypes. *Brain* 120: 479-490.
- 10    Schroeder et al., 1998, *Nature* 396:687-690.
- Silanpaa M, Koskenvuo M, Romanov K, Kaprio J (1991) Genetic factors in epileptic seizures: evidence from a large twin population. *Acta Neurol Scand* 84:523-526
- 15    Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, et al (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. *Nat Genet* 18:25-29
- Steinlein OK, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. *Nat. Genet.* 11:201-203 (1995).
- 20    Wallace RH, Wang DW, Sing R, Scheffer IE, George-Jr AL, Phillips HA, Saar K, et al (1998) Febrile seizures and generalized epilepsy associated with a mutation in the Na<sup>+</sup>-channel (1 subunit gene SCN1B. *Nat Genet* 19:366-370

**WHAT IS CLAIMED IS:**

1. A method of determining an individual's predisposition to epilepsy and/or development of epilepsy, as well as  
5 predicting this individual's response to medication, said method comprising the step of determining the genotype of at least one gene selected from SCN1A, SCN2A and SCN3A of the individual, or of a DNA variant, equivalent, or mutation which shows a linkage disequilibrium therewith, thereby determining an individual's predisposition to epilepsy  
10 and/or development of epilepsy.
2. The method of claim 1, wherein the step of determining the SCN1A, SCN2A or SCN3A genotype comprises restriction endonuclease digestion.
3. The method of claim 1 or 2, wherein the step of  
15 determining the SCN1A, SCN2A or SCN3A genotype comprises hybridizing with allele specific oligonucleotides.
4. The method of claim 1, which further comprises a step, prior to determining the SCN1A, SCN2A or SCN3A genotype, of amplifying a segment of the the SCN1A, SCN2A or SCN3A using  
20 polymerase chain reaction.
5. The method of claim 1, wherein the step of determining the SCN1A, SCN2A or SCN3A genotype comprises a sequencing of SCN1A, SCN2A or SCN3A , or parts thereof.
6. The method of claim 1, wherein the SCN1A,  
25 SCN2A or SCN3A genotype is determined using a polymorphic variant

site in linkage disequilibrium with at least one allelic variant or mutant identified in accordance with the present invention.

7. An assay for screening a test agent and selecting an agent which modulates inactivation of a sodium channel involved in epilepsy comprising:

a) a recombinant SCN1A, SCN2A or SCN3A gene which encodes an alpha subunit of said sodium channel or functional fragment thereof; and

b) assaying a function of said sodium channel;

wherein an agent can be selected when an observable difference is observed between the inactivation of said sodium channel in the presence of said test agent, as compared to in an absence thereof, and wherein a malfunction of said sodium channel is associated with epilepsy.

8. An assay for screening a test agent and selecting an agent which modulates the activity of a sodium channel involved in epilepsy comprising:

a) a recombinant SCN1A, SCN2A or SCN3A gene which encodes an alpha subunit of said sodium channel or functional fragment thereof; and

b) assaying the activity of said sodium channel;

wherein an agent can be selected when an observable difference is observed between the activity of said sodium channel in the presence of said test agent, as compared to in an absence thereof, and wherein a malfunction of said sodium channel is associated with epilepsy.

9. A method of using specific alleles of the SCN1A, SCN2A or SCN3A genes, or a variant, equivalent, or mutation thereof which shows linkage disequilibrium therewith, to set-up a screening assay

for agents destined to modulate sodium channel function for the purpose of identifying agents having an application in epilepsy therapy.

10. A method for identifying, from a library of  
5 compounds, a compound with therapeutic effect on epilepsy or other neurological disorders comprising:

- a) providing a screening assay comprising a measurable biological activity of SCN1A, SCN2A or SCN3A protein or gene;
- 10 b) contacting said screening assay with a test compound; and
- c) detecting if said test compound modulates the biological activity of SCN1A, SCN2A or SCN3A protein or gene;

wherein a test compound which modulates said biological activity is a compound with said therapeutic effect.

15

11. The method of claim 10, wherein the test compound with said therapeutic effect is further modified by combinatorial or medicinal chemistry to provide further analogs of said test compound also having said therapeutic effect.

20

12. A compound having therapeutic effect on epilepsy or other neurological disorders, identified by a method comprising,

- a) providing a screening assay comprising a measurable biological activity of SCN1A, SCN2A or SCN3A protein or gene;
- 25 b) contacting said screening assay with a test compound; and
- c) detecting if said test compound modulates the biological activity of SCN1A, SCN2A or SCN3A protein or gene;

wherein a test compound which modulates said biological activity is a compound with said therapeutic effect.

13. The compound of claim 12, wherein the  
5 compound with said therapeutic effect is further modified by combinatorial or medicinal chemistry to provide analogs of said compound also having said therapeutic effect.



1/21

**Ch 2q23-q31****Centromere**

1cM	<b>D2S142</b>
	<b>D2S284</b>
4cM	
4cM	<b>D2S156/</b>
	<b>D2S354</b>
	<b>D2S111</b>
5cM	
	<b>D2S294</b>
2cM	
	<b>D2S335</b>

**IGE locus**

6cM 29 cM

	<b>D2S324</b>
2cM	
	<b>D2S384</b>
2cM	
	<b>D2S152</b>

8cM

**Telomere****D2S311**FIG - 1

2/21

1Ax00.1

NaC-340 TGTGTTCTGCCCCAGTGAGACT,  
NaC-341 CTTCTGCTCTGCCCAAAGTGAAT  
257 bp 53.4C

1Ax00.2

NaC-342 GGCGATGTAATGTAAGGTGCTGTC,  
NaC-343 GTGCCTTCAGTTGCAATTGTTTCAG  
259 bp 54.5C

1Ax01.1

NaC-268, TTAGGAATTTTCATATGCAGAATAA,  
NaC-269 TGGGCCATTTTTCGTCGTC  
201 bp 50.9C

1Ax01.2

NaC-270 GAAAGACGCATTGCAGAAGAAAAGG,  
NaC-271 CTATTGGCATGTGTTGGTGCTACA  
277 bp 54.4C

1Ax02

NaC-45 GTGCTGGTTTCTCATTTAAGTTTAC,  
NaC-46 TTCCCAACTTAATTTGATATTTAGC  
319 bp 49.9C

1Ax03


NaC-87, GCAGTTTGGGCTTTTCAATGTTAG,  
NaC-88, GACACAGTTTCARAATCCCRAATG  
234 bp 48.9C

1Ax04

NaC-63, TTAGGGCTACGTTTTCATTTGTATG,  
NaC-64, AGCACTGATGGAAAACCAAAGTAT  
338 bp 50.8C

1Ax05

NaC-164 AGCCCATGCAGTAATATAAATCCT,  
NaC-165 TCCAGGCTGATAAGCTATGTCTAA  
488 bp 52.8C



SUBSTITUTE SHEET (RULE 26)

*3/21*

1Ax06

NaC-276, CTGTGGCCTGCCTGAGCGTATT,  
NaC-277 CCAATTCTACTTTTAAAGGAAATG  
248 bp 50.3C

1Ax07

NaC-272, AAATACTTGTGCCTTTGAA,  
NaC-273, GTACATACAATATACACAGATGC  
240 bp 46.7C

1Ax08

NaC-89, AGGCAGCAGAACGACTTGTAATA,  
NaC-90, ATCCGGTTTTAATTTTATACTCA  
267 bp 51.9C

1Ax09.2

NaC-217 GTTGAGCACCCCTTAGTGAATAATA,  
NaC-218 TCACACGCTCTAGACTACTTCTCT  
337 bp 52.7C

1Ax10a NaC-29, TGCAAATACTTCAGCCCTTTCAA,  
NaC-30, TTCCCCACCAGACTGCTCTTTC  
239 bp 55.1C

1Ax10a


NaC-31, GCAGCAGGCAGGCTCTCA,  
NaC-32, TCTCCCATGTTTTAATTTTCAACC  
293 bp 54.5C

1Ax10b

NaC-67, ATAATCTTGCAAAATGAAATCACA,  
NaC-68, ATCCGGGATGACCTACTGG  
307 bp 53.7C

1Ax10b

NaC-65, GATAACGAGAGCCGTAGAGATTCC,  
NaC-66, AGCCAGCCATGCCTGAACTA  
282 bp 56.4C

 *2 (cont'd)*

4/21

1Ax10c

NaC-39, TGTTTGCTTGTCATATTGCTCAA,

NaC-40, TGCACTATTCCCAACTCACAAA

286 bp 50.7C

1Ax11.1

NaC-69 AAGGGTGTCTCTGTAACAAAAATG,

NaC-70, GTGATGGCCAGGTCAACAAA

269 bp 50.8C

1Ax11.2

NaC-71 CTGGGACTGTTCTCCATATTGGTT,

NaC-72, TTTGCAGGGGCCAGGAAG

294 bp 53.3°C

1Ax12

NaC-41 CATTGTGGGAAAATAGCATAAGC,

NaC-42, GCAAGAACCCTGAATGTTAGAAA

334 bp 51.2C

1Ax13.1

NaC-92 TAATGCTTTTAAGAATCATACAAA,

NaC-93, CCAGCGTGGGAGTTGACAATC

256 bp 51.1C

1Ax13.2

NaC-75 CGGCATGCAGCTCTTTGGTA,

NaC-91, ATGTGCCATGCTGGTGTATTTC

277 bp 55.6C

1Ax14.1

NaC-79 CACCCATCTTCTAATCACTATGC,

NaC-80, CAGCAATTTGGAGATTATTCATT


254 bp 50.4C

1Ax14.2

NaC-81 GCAGCCACTGATGATGATAA,

NaC-82, CTGCCAGTTCCTATAACCACTT

269 bp 49.4C

 (cont'd)

SUBSTITUTE SHEET (RULE 26)

5/21

1Ax14.3

NaC-83 TACAGCAGAAATTGGGAAAGAT,  
NaC-84, GTATTCATACCTACCCACACCTAT  
269 bp 50.2C

1Ax15

NaC-202 TTCTTGGCAGGCAACTTATTACC,  
NaC-203 TAAGCTGCACTCCAAATGAAAGAT  
233 bp 53.1C

1Ax16.1

NaC-187, GGCTGAATGTTTCCACAACCT,  
NaC-168 GTTCAACTATTCGGAAACACG  
277 bp 51.4C

1Ax16.2

NaC-188, AGGCAGAGGAAAACAATGG,  
NaC-189, ACAAGGTGGGATAATTAAAAATG  
234 bp 50.3C

1Ax17

NaC-143, GTTTCTCTGCCCTCCTATTCC,  
NaC-144, AAGCTACCTTGAACAGAGACA  
330 bp 48.8C

1Ax18


NaC-139, AATGATGATTCTGTTTATTA,  
NaC-140, AATTGCCATTCCTTTTG  
272 bp 46.1C

1Ax19.1

NaC-219 TTGACATCGAAGACGTGAATAATC,  
NaC-220 CCATCTGGGCTCATAAACTTGTA  
285 bp 49.3C

1Ax20

NaC-338 CCCTTTGAAAATTATATCAGTAA,  
NaC-339 ATTTGGTCGTTTATGCTTTATTC  
230 bp 47.6C

 - 2 (cont'd)

6/21

1Ax21

NaC-252, TCCAGCACTAAAATGTATGGTAAT,  
NaC-253, ATTTGGCAGAGAAAACACTCC  
261 bp 49.8C

1Ax22

NaC-254, TTTTAGCCATCCATTTTCTATTTT,  
NaC-255, TATTTTCCCCCATATCATTTGA  
223 bp 49.1C

1Ax23.1

NaC-256 TTGCAAGAACTAGAAAGTC,  
NaC-257 TTGATGCGTGACAAAATGG  
250 bp 48.3C

1Ax23.2

NaC-258 GACCAGAGTGAATATGTGACTACC,  
NaC-259 CTGGGATGATCTTGAATCTAATC  
246 bp 49.5C

1Ax24.1

NaC-221 GCAACTCAGTTCATGGAATTTGAA,  
NaC-222 CTTGTTTTTCGTTTTAAAGTAGTA  
289 bp 56.1C

1Ax24.2


NaC-213 CAAAGATCACCTGGAAGCTCAGTT,  
NaC-223 TTCAAGCGCAGCTGCAAACCTGAGAT  
277 bp 55.8C

1Ax24.3

NaC-260 ACATCGGCCTCCTACTCTTCCTA,  
NaC-261 ACAGATGGGTTCACACAGTCC  
268 bp 55.3C

1Ax24.4

NaC-262 TAACGCATGATTTCTTCACTGGTT,  
NaC-263 ATCCCAAAGATGGCGTAGATGA  
262 bp 54.9C

 (cont'd)

7/21

1Ax24.5

NaC-308, TGAGAAATAGGCTAAGGACCTCTA,

NaC-309 CCTAGGGGCTGGATTCC

244 bp 53.2C

1Ax24.6

NaC-310, AAGGGGTGCAAACCTGTGATTTT,

NaC-311 AGGGCCATGTGGTTGCCATAC

252 bp 53.4C

1Ax24.7

NaC-312 CTTCCGGTTTATGTTTTTCATTTCT,

NaC-313 TCTTTATTAGTTTTGCACATTTTA

278 bp 48.4C

1Ax24.8

NaC-364 CAATCCTTCCAAGGTCTCCTATC,

NaC-365 TTTCATCTTTGCCTTCTTGCTCAT


326 bp 52.4C

1Ax24.9

NaC-366 CATGTCCACTGCAGCTTGTCCA,

NaC-367 TCCCCTTTACACAGAGTCACAGTT

292 bp 53.1C

 2 (cont'd)

8/21

a. Glu1238Asp:

normal:

GCA TTT GAA GAT ATA;

patient R10191 with IGE:

GCA TTT GAC GAT ATA.

b. Ser1773Tyr:

normal:

ATC ATA TcC TTC CTG;

patient R9049 with IGE:

ATC ATA TmC TTC CTG; TCC&gt;TAC

Fi 3



9/21

2Ax00.1 NaC-235 ATGGGTTGAATGACTTTCTGACAT, NaC-236,  
AGGCATTTCTGTACAGGGACTAC

266 bp 52.7C

2Ax00.2 NaC-237 ACAGGAAATGCCTCTTCTTACTTC, NaC-238,  
TTTCCCCAAGGATTCTACTACTGT

277 bp 50.6C

2Ax01 NaC-100, AGTGCATGTAACTGACACAATCAC, NaC-101,  
CTTGCGTTCCTGTTTGGGTCTCT

241 bp 53.7C

2Ax01 NaC-11 TCCGCTTCTTTACCAGGGAATC, NaC-102,  
AGGCAGTGAAGGCAACTTGACTAA

259 bp 55.1C

2Ax02 NaC-96, CAGGGCAATATTTATAAATAATGG, NaC-97,  
TTTGGAAAATGTGTAGCTCAATAA

289 bp 48.7C

2Ax03 NaC-43, AAGGCATGGTAGTGCATAAAAG, NaC-44,  
ATGAAACATAAAGGGAGGTCAA

201 bp 49.3°C

2Ax04 NaC-47, AATGTGAGCTTGGCTATTGTCTCT, NaC-48,  
ATAGGCTCCCACCAGTGATTTAC

213 bp 50.9°C

2Ax05 NaC-49, AGGCCCTTATATCTCCAAGT, NaC-50,  
CAACAAGGCTTCTGCACAAAAG

241 bp 53.9°C

2Ax05.2 NaC-110, CTTGGTGGCTTGCCTTGAC, NaC-111,  
TCATGAGTGTCGCCATCAGC

223 bp 51.1C

FILE - 4

10/21

2Ax05.3 NaC-112, GGAAAGCTGATGGCGACACT, NaC-113,  
CTGAGACATTGCCCAGGTCC  
329 bp 53.0C

2Ax05.4 NaC-114, TTTTACCCGTTGCTTTCTTTA, NaC-115,  
TATCCCTTGCTCTTTCATTTATCT  
224 bp 50.9C

2Ax06.1 NaC-169, GCCGGTAAAATAGCTGTTGAGTAG, NaC-170,  
GCCATTGCAAACATTTATTTCGTA  
206 bp 53.3C

2Ax06.2 NaC-171, GCGTGTTTGCGCTAATAG, NaC-172,  
CTAAGTCACTTGATTCACATCTAA  
295 bp 48.0C

2Ax07 NaC-196, ACAGGGTGGCTGAAGTGTTTTA, NaC-197,  
GTGGGAGGTGGCAGGTTATT  
199 bp 52.6C

2Ax08 NaC-118, CAATTAGCAGACTTGCCGTTATT, NaC-119,  
TCTCTTGAGTTCGGTGTTTTATGA  
252 bp 52.9C

2Ax09 NaC-120, ACCGAACTCAAGAGAATTGCTGTA, NaC-121,  
AAAGGACCGTATGCTTGTTCACTA  
334 bp 52.9C

2Ax10a.1 NaC-161 TATGAATGCGCATTTTACTCTTTG, NaC-156,  
TGGAGCTCAACTTAGATGCTACTG  
286 bp 52.1C

2Ax10a.2 NaC-13 GGTGCTGGTGGGATAGGAGTTTTT, NaC-162,  
TCCATTAAATTCTGGCATATTCTT  
316 bp 50.9C

2Ax10b.1 NaC-145 TCAGAGGGGTGCTTTCTTCCACAT, NaC-14,  
CTTCGGCTGTCATTGTCCTCAAAG  
298 bp 55.6C

FIG. 4 (cont'd)

SUBSTITUTE SHEET (RULE 26)

*11/21*

2Ax10b.2 NaC-146, GCAAAGGACATTGGCTCTGAGAAT, NaC-147,  
CTGCCTGCACCAAGTCACAACCTCT

324 bp 59.4C

2Ax10c NaC-190, TGGGCTTTGCTGCTTTCAA, NaC-191,  
AGTAACTGTGACGCAGGACTTTTA

218 bp 51.5C

2Ax11.1 NaC-148, CCCTGTTCTCCAGCAGATTA, NaC-70,  
GTGATGGCCAGGTCAACAAA

283 bp 51.5C

2Ax11.2 NaC-149, TTTGATTTGGGACTGTTGTAAAC, NaC-150,  
AAGGCAATTATAAACTCTTTCAAG

233 bp 52.0C

2Ax12 NaC-159, TGGGAGTTAAATTAAGTTGCTCAA, NaC-160,  
ACATTTTATGAACACTCCCAGTTA

285 bp 50.4C

2Ax13.1 NaC-239 ATTAACACTGTTCTTGCTTTTAT, NaC-240,  
GTGCCAGCGTGGGAGTTC

239 bp 51.1C

2Ax13.2 NaC-241 GTGGGGGCTCTAGGAAACCT, NaC-242,  
TTTAATGAAAATGAGGAAAATGTT

324 bp 53.7C

2Ax14.1 NaC-134, GACCAAGCATTTTTATTTCATTC, NaC-135,  
AGTGGCAGCAAGATTGTCA

234 bp 49.6C

2Ax14.2 NaC-136, GGCCTTGCTTTTGAGTTCC, NaC-137,  
GGTCTTTGCCTATTCTATGGTG

257 bp 51.1C

FIG - 4 (cont'd)

12/21

2Ax14.3 NaC-266, TTAAACCGCTTGAAGATCTAAATA, NaC-267,  
TATACACCAAATATCTCCTTAT  
319 bp 48.5C

2Ax15 NaC-314 GGGGCACACCTAATTAATTTTAT, NaC-315,  
AAAGAGGATACTCAAGACCACATA  
(247 bp) 51.5C

2Ax16 NaC-344 CCCACCAACACAAATATACCTAAT, NaC-345,  
TGAAGGGAAAGGGAAAAGATTT  
283 bp 52.2C

2Ax17 NaC-346 TCCAGCCTTAGGCACCTGATAA, NaC-347,  
ATAAAGCAGCAAAGTGCAGCATAC  
310 bp 52.4C

2Ax18 NaC-348 AAGGCTGAACTGTGTAGACATTTT, NaC-349,  
TGACATTTCCATGGTACAAAGTGT  
262 bp 52.2C

2Ax19.1 NaC-350 TTTGTTGTTGGCTTTTCACTTAT, NaC-351,  
CCACCTGGCAGTTTGATTG  
268 bp 51.9C

2Ax19.2 NaC-352 TAAGCGTGGTCAACAACACTACAGT, NaC-353,  
ATTCTTGCCAGCATTTATTGTC  
260 bp 50.2C

2Ax20 NaC-354 CAAACATTGCCCCAAAAG, NaC-355,  
TCAAACATAACAATTTCCCTCTAA  
239 bp 48.1C

2Ax21 NaC-306, GATAATTAAAACTCACTGATGTA, NaC-307,  
GGAGGCTAAAGGAAAGAGTATG  
288 bp 46.6C

2Ax22 NaC-356 ATTTTATAGCCAGCAAAGAACAC, NaC-357,  
CTAGAAATTCGGGCTGTGAA  
230 bp 49.6C

FIG. 4 (cont'd)

SUBSTITUTE SHEET (RULE 26)

13/21

2Ax23.1 NaC-358 CTGCTTTGTGACCTAAGGCAAGTT, NaC-359,  
GTGACCATGTTAAGGCAGATGAGG  
290 bp 51.4C

2Ax23.2 NaC-360 GGAATGGTCTTTGATTTTGTAACC, NaC-361,  
TCCTTAACTGAATAAAAGCACCTC  
290 bp 51.6C

2Ax24.1 NaC-207 TGGAACACCCATCAAAGAAGATACT, NaC-208,  
GTGGGAGTCCTGTTGACACAAAC  
278 bp 52.8C

2Ax24.2 NaC-209 AGCGATTTCATGGCATCAAAC, NaC-210,  
ACGTGGTGGAAGGCGTCATA  
270 bp 52.9C

2Ax24.3 NaC-211 GCGACCCAGTTTATAGAGTTTGCC, NaC-212,  
CTTGTTTGCGTTTCAACGTGGTC  
289 bp 56.1C

2Ax24.4 NaC-213 CAAAGATCACCCCTGGAAGCTCAGTT, NaC-214,  
ATCCAGGGCATCTGCAAAATCAGAA  
277 bp 55.8C

2Ax24.5 NaC-215 TGCCTATGTTAAGAGGGAAGTTGGG, NaC-216,  
ATGACCGCGATGTACATGTTTCAG  
279 bp 55.3C

2Ax24.6 NaC-278 TCAATTGTTTACAGCCCGTGATG, NaC-279,  
TTTATACAAAGGCAGACAACAT  
302 bp 52.0C

2Ax24.7 NaC-280 AGGCGTAATGGCTACTCAGACGA, NaC-281,  
GTAATCCCTCTCCCCGAACATAAAC  
251 bp 53.8C

2Ax24.8 NaC-282 TTTGATTACGGGTTGTTTACTCTTA, NaC-283,  
TTCTATGGAACATTACAGGCACATT  
294 bp 52.1C

14/21

2Ax24.9 NaC-284 TAATGTGCCTGTAAATGTTCCATAGA, NaC-285,  
CAGGCTTCTTAGAAAGGACTGATAGG

264 bp 50.6C

2Ax24.10 NaC-286 GTCCCAGCAGCATGACTATC, NaC-287,  
CCCAGTGGGTAAAATTACTAAC

249 bp 49.4C

2Ax24.11 NaC-288 TAGCCATCTTCTGCTCTTGGT, NaC-289,  
TGGCTTCCCATATTAGACTTCTG

307 bp 51.3C

2Ax24.12 NaC-290 TCTTGCCTATGCTGCTGTATCTTA, NaC-291,  
AGTCGGGCTTTTCATCATTGAG

207 bp 51.8C

2Ax24.13 NaC-292 TTCTTCATGTCATTAAGCAATAGG, NaC-293,  
TTCAATTTAAAAGTGCTAGGAACA

299 bp 49.4C

2Ax24.14 NaC-294 CTTCAGGTGGATGTCACAGTCACTA, NaC-295,  
ATTCAAGCAATGCCAAGAGTATCA

263 bp 51.5C

2Ax24.15 NaC-296 CTTTCAATAGTAATGCCTTATCAT, NaC-297,  
TCCTGCATGCATTTACCAAC

348 bp 49.6C

2Ax24.16 NaC-362 CTGTTACATTTTGTA AAACTAAT, NaC-263,  
ATCCCAAAGATGGCGTAGATGA

309 bp 50.8C

2Ax24.17 NaC-325 CACGCTGCTCTTTGCTTTGA, NaC-363,  
GATCTTTGTCAGGGTACAGTCT

269 bp 54.0C

FIG - 4 (cont'd)

SUBSTITUTE SHEET (RULE 26)

15/21

- a. Lys908Arg:  
normal: TAC AAA GAA;  
9782 (Patient with IGE): TAC AGA GAA;
- b. leu768val, in individuals 8197, 9062 et 9822 (all IGE patients).

FiS 5

16/21

3Ax00a.1 NaC-390 TGTGTCCGCCAGTAGATGG, NaC-391,  
TTTTTGACCACAGAGGTTTACAA  
233 bp 51.4C

3Ax00a.2 NaC-392 GAAGCGGAGGCATAAGCAGA, NaC-393,  
GGTGCAGATAATGAAATGTTTTGT  
253 bp 51.3C

3Ax00b NaC-394 CACCCCTATGCCAAATGTCAAAGA, NaC-395,  
CAAAAACAAACTTATACCCAGAAG  
293 bp 51.6C

3Ax00c NaC-396 CAAATATTGGGCAAACCCTAAT, NaC-397,  
AAGGTGCCATCACAAAATCAT  
225 bp 50.7C

3Ax01.1 NaC-51 ATCGCTTGCTTTCCTAACTCTTGT, NaC-52,  
AAGTCACTATTTGGCTTTGGTTG  
260 bp 53.1C


3Ax01.2 NaC-53 AGAAGCCCCAAAAAGGAACAAGATA, NaC-54,  
GGCCCAGAAAAGTATATTACAGTT  
231 bp 50.8C

3Ax02 NaC-85, TCCTTAAATAAGCCCATGTCTAAT, NaC-86,  
TCTCAAAGAAATTTTACAGATACT  
273 bp 47.3C

3Ax03 NaC-27, AATGGCCATGGTAACCTACTAACA, NaC-28,  
CAGGCTATACCCACAAGGAGATT  
212 bp 51.8C

3Ax04 NaC-94, TGTTAATTTTGGCTTGGATGTT, NaC-95,  
TCACTCCTTTGCGCTTATCAA  
198 bp 50.8C

3Ax05.1 NaC-247, AGGGCTCTATGTGCCAAACC, NaC-248,  
AGGGGCCTACTACCTTACACCAG  
213 bp 52.2C



SUBSTITUTE SHEET (RULE 26)



17/21

3Ax05.2 NaC-249 TGTAATCCCAGGTAAGAAGAAAC, NaC-250,  
TACCGGGATGAACTGTAATAATAA  
304 bp 51.8C

3Ax06.1 NaC-192, TTCTGGCACTCTTCCTCAGGTAAC, NaC-193,  
GTCCCATTTGAATCCATTGTGC  
261 bp 55.4C

3Ax06.2 NaC-194, GGCCCCCAAGCGATTCTG, NaC-195,  
TGTACACCCACAGTCTCAACTATT  
209 bp 50.3C

3Ax07 NaC-204, ACAGCCACCTTTGTAAATAA, NaC-205,  
TTTTTCGCAAAGAGTTCTAT  
220 bp 46.6C

3Ax08 NaC-98, AAAGTGACCCTACCTCCATTTCTC, NaC-99,  
ACTCAGCCTATGCTTTTCATTTCA  
247 bp 53.2C

3Ax09 NaC-37 CAGATATTTATTTGGGGACATTAT, NaC-38,  
AAATCTTTGCKTTTATCACTCAGT  
295 bp 52.0C

3Ax10a.1 NaC-198 TAGTGCCTGGCTTTGTTTTATGAC, NaC-199,  
CGGATTTGGGAAAGCTGTCTCT  
225 bp 54.3C

3Ax10a.2 NaC-200 AGAGCACCTTGAAGGAAACAACAA, NaC-274,  
TCCCTCAACTGAAGTACAGATAGT  
253 bp 51.2C

3Ax10b NaC-33, ATAATTGCGTTCTTCCCCTACCC, NaC-34,  
AAGCCCTGGCACCATCCTG  
301 bp 56.2°C

3Ax10c NaC-35, \_TTTGCAAAGAAATGCTATGT, NaC-36,  
CTGGGTAACAGACTTCAGTAAT  
303 bp 51.4°C

Fi - 6 (cont'd)

SUBSTITUTE SHEET (RULE 26)

18/21

3Ax11.1 NaC-122, ATGGGATTGTCTTCTCAAGTTTCT, NaC-123,  
GATGGCAAGATCAACAAATGGA  
294 bp 50.3C

3Ax11.2 NaC-124, CTTGATCTGGGACTGCTGTGATG, NaC-125,  
AGGATATAATTTTGGTTCAACA  
284 bp 51.5C

3Ax12 NaC-61, TTTTCAGTGCTCTTGATAGTAGTG, NaC-62,  
GTGCCAATGAGCGACAGG  
254 bp 50.7°C

3Ax13.1 NaC-73, CCACGTGTGGTTCTATGATACC, NaC-74,  
ACCGTGGGAGCGTACAGTCA  
298 bp 52.3C

3Ax13.2 NaC-75, CGGCATGCAGCTCTTTGGTA, NaC-76,  
TGGCCACGTTCCTAGCTACTGTC  
291 bp 55.9C


3Ax14.1 NaC-55, GAGTTCCCTTTTTAGGCTGTTATT, NaC-56,  
TCTTATTGCCTTCATGGATTTCTA  
285 bp 50.5C

3Ax14.2 NaC-57, TGAAAAATAAGATGCGGGAGTG, NaC-58,  
GTGAGGCTGGGGTTGTTTATG  
247 bp 51.7C

3Ax14.3 NaC-59, GAGATGGGAATGGAACCACCA, NaC-60,  
TTCGATAATGCATATAAGCACAA  
297 bp 51.7C

3Ax15 NaC-318 AAGGGGGAAAATCACATCTTT, NaC-319,  
TTAAATGAGGCATATTCAGTCTCC  
235 bp 51.8C

3Ax16 NaC-116, GGAAGTGGAGTGGGGAAGG, NaC-117,  
ATTCTTGCCAATATGCATTTCACT  
271 bp 51.1C

 (cont'd)

SUBSTITUTE SHEET (RULE 26)

19/21

3Ax17 NaC-157, TTCTTTTGTACTCACTATTATACTAA, NaC-158,  
AAACTTGCCTCTTTTAAAAACAAT  
317 bp 46.6C

3Ax18 NaC-374 TACCACACCCTATACCTTCAGTCA, NaC-375,  
GAGTATGGCACCCTTTTCTATCTA  
275 bp 51.4C

3Ax19.1 NaC-386 GCTATGTTCCCCTCGCTGTCT, NaC-387,  
TGCTTGCCAAGAGCCTGAC  
231 bp 53.6C

3Ax19.2 NaC-388 GCTGGCAAGTTCTACCACTGTG, NaC-389,  
CAAACGAAGAACATCAGGGAAATA  
247 bp 53.0C

3Ax20 NaC-376 TTCACAATATTGTACAAAAAGTTA, NaC-377,  
ATTACCACCAATATTCACCATAAG  
230 bp 46.4C


3Ax21 NaC-378 TCAGGGTAAGGCAAAAAGTAGCAC, NaC-379,  
GAACCCCAGAATGAAGAAAGGTAA  
294 bp 50.2C

3Ax22 NaC-380 TTTGTGAAAGTACTATTGGAACAC, NaC-381,  
ACGCATGGCTTTGGAACAT  
204 bp 49.6C

3Ax23.1 NaC-382 CCCGTATGTGGAAGGGCTTTAT, NaC-383,  
CTAGGTTGATCCGGGACAAAATA  
246 bp 52.9C

3Ax23.2 NaC-384 AACGGATGACCAGGGCAAATAC, NaC-385,  
CTAGAAGGTCCTGGGGCAACTG  
234 bp 54.8C

3Ax24.1 NaC-317 AAGCCATCATGTAAAGTGAAAAG, NaC-320,  
ATCCCAAAGATGGCATAGATA  
274 bp 52.5C

 (cont'd)

20/21

3Ax24.2 NaC-325 CACGCTGCTCTTTGCTTTGA, NaC-326,  
TGAGCTGCCAGGGTGAATTG  
282 bp 54.9C

3Ax24.3 NaC-327 TTGCTAGCACCTATTCTTAATAGTGC NaC-328,  
CCAGGGCAGCTGCAAAATCAGAG  
318 bp 54.2C

3Ax24.4 NaC-329 CCCGATGCGACCCAGTTTA, NaC-330,  
TGGAGGGGTTTGATGCCATA  
250 bp 55.2C

3Ax24.5 NaC-331 GATGGATGCCCTTCGAATACAGA, NaC-332,  
TTCCCATTTAGTTTGTCATAATC  
258 bp 50.6C

3Ax24.6 NaC-321 AAGGGGAGGATTGACTTACCTAT, NaC-333,  
TTGGCATGGACCTCCTCTTGA  
302 bp 51.5C

FI - 6 (cont'd)

21/21

a. Asn43DEL:

9706 (allele 1; IGE patient): CAA GAT AAT GAT GAT GAG ;

9632 (allele 2; patient has IGE): CAA GAT --- GAT GAT GAG ;

allele 1 = 131/146 (0.90);

allele 2 = 15/146 (0.10);

for IGE patients: homozygotes (22): 3958, 9632; heterozygotes (12): 9049, 9152, 9649, 9710, 9896, 10069, 10191, 10213, 9993, 10009, 10256 (note that 2 patients are homozygous for the rare allele; all patients have IGE); in controls: allele 1 = 45/154 (0.94); allele 2 = 9/154 (0.06) and no 22 homozygotes found.

b. normal: tgggtgaaggtag,

10670 (IGE patient): tgggtataaggtag

c. normal: ccccttatatctccaac;

10250 (IGE patient): ccccttatayctccaac;

d. Val1035Ile:

normal: AAA TAC GTA ATC GAT,

9269 (IGE patient): AAA TAC RTA ATC GAT; GTA&gt;ATA = Val&gt;Ile.

FIG. 7

## SEQUENCE LISTING

&lt;110&gt; McGill University

Rouleau, Guy A.

Lafrenière, Ronald G.

Cossette, Patrick

Ragsdale, David

<120> LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS  
THEREOF AND METHOD USING SAME TO ASSESS, DIAGNOSE,  
PROGNOSE OR OR TREAT EPILEPSY

&lt;130&gt; 13180.17

&lt;140&gt; PCT/CA00/01404

&lt;141&gt; 2000-11-24

&lt;160&gt; 408

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 8378

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

tactgcagag gtctctggtg catgtgtgta tgtgtgcgtt tgtgtgtgtt tgtgtgtctg 60  
tgtgttctgc cccagtgaga ctgcagccct tgtaaatact ttgacacctt ttgcaagaag 120  
gaatctgaac aattgcaact gaaggcacat tgttatcatc tcgtcttttg gtgatgctgt 180  
tcctcactgc agatggataa ttttcctttt aatcaggaat ttcatatgca gaataaatgg 240  
taattaaaat gtgcaggatg acaagatgga gcaaacagtg cttgtaccac caggacctga 300  
cagcttcaac ttcttcacca gagaatctct tgcggctatt gaaagacgca ttgcagaaga 360  
aaaggcaaag aatcccaaac cagacaaaaa agatgacgac gaaaatggcc caaagccaaa 420  
tagtgacttg gaagctggaa agaaccttcc atttatttat ggagacattc ctccagagat 480  
ggtgtcagag cccctggagg acctggaccc ctactatata aataagaaa cttttatagt 540  
attgaataaa gggaaggcca tcttcgggtt cagtgccacc tctgccctgt acattttaac 600  
tcccttcaat cctcttagga aaatagctat taagatttg gtacattcat tattcagcat 660  
gctaattatg tgcactattt tgacaaactg tgtgtttatg acaatgagta accctcctga 720  
ttggacaaag aatgtagaat acaccttcac aggaatatat acttttgaat cacttataaa 780  
aattattgca aggggattct gtttagaaga ttttactttc cttcgggata catggaactg 840  
gctcgatttc actgtcatta catttgcgta cgtcacagag tttgtggacc tgggcaatgt 900  
ctcggcattg agaacattca gagttctccg agcattgaag acgatttcag tcattccagg 960  
cctgaaaacc attgtgggag cctgatcca gtctgtgaag aagctctcag atgtaatgat 1020  
cctgactgtg ttctgtctga gcgtatttgc tctaattggg ctgcagctgt tcatgggcaa 1080  
cctgaggaat aatgtatac aatggcctcc caccaatgct tccttgagg aacatagtat 1140  
agaaaagaat ataactgtga attataatgg tacacttata aatgaaactg tctttgagtt 1200  
tgactggaag tcatatattc aagattcaag atatcattat ttcttgagg gttttttaga 1260

tgcactacta	tgtggaaata	gctctgatgc	aggccaatgt	ccagagggat	atatgtgtgt	1320
gaaagctggg	agaaatccca	attatggcta	cacaagcttt	gataccttca	gttgggcttt	1380
tttgtccttg	tttcgactaa	tgactcagga	cttctgggaa	aatctttatc	aactgacatt	1440
acgtgctgct	gggaaaacgt	acatgatatt	ttttgtattg	gtcattttct	tgggctcatt	1500
ctacctataa	aatttgatcc	tggtctgggt	ggccatggcc	tacgaggaac	agaatcaggc	1560
caccttgga	gaagcagaac	agaaagaggc	cgaatttcag	cagatgattg	aacagcttaa	1620
aaagcaacag	gaggcagctc	agcaggcagc	aacggcaact	gcctcagaac	attccagaga	1680
gcccagtgca	gcaggcaggc	tctcagacag	ctcatctgaa	gcctctaagt	tgagttccaa	1740
gagtgtctaa	gaaagaagaa	atcgaggagaa	gaaaagaaaa	cagaaagagc	agtctgggtg	1800
ggaagagaaa	gatgaggatg	aattccaaaa	atctgaatct	gaggacagca	tcaggaggaa	1860
aggttttcgc	ttctccattg	aagggaaccg	attgacatat	gaaaagaggt	actcctcccc	1920
acaccagtct	ttgttgagca	tccgtggctc	cctattttca	ccaaggcgaa	atagcagaac	1980
aagccttttc	agcttttagag	ggcgagcaaa	ggatgtggga	tctgagaacg	acttcgcaga	2040
tgatgagcac	agcacctttg	aggataacga	gagccgtaga	gattccttgt	ttgtgccccg	2100
acgacacgga	gagagacgca	acagcaacct	gagtcagacc	agtaggtcat	cccggatgct	2160
ggcagtgttt	ccagcgaatg	ggaagatgca	cagcactgtg	gattgcaatg	gtgtgggtttc	2220
cttggttggt	ggaccttcag	ttctacatc	gcctgttgga	cagcttctgc	cagaggtgat	2280
aatagataag	ccagctactg	atgacaatgg	aacaaccact	gaaactgaaa	tgagaaagag	2340
aaggtcaagt	tctttccacg	tttccatgga	ctttctagaa	gatccttccc	aaaggcaacg	2400
agcaatgagt	atagccagca	ttctaacaaa	tacagtagaa	gaacttgaag	aatccaggca	2460
gaaatgccca	cctgttggt	ataaattttc	caacatattc	ttaatctggg	actgtttctc	2520
atattggtta	aaagtgaaac	atgttgtcaa	cctggttgtg	atggacctat	ttgttgacct	2580
ggccatcacc	atctgtattg	tcttaaatac	tcttttcatg	gccatggagc	actatccaat	2640
gacggaccat	ttcaataatg	tgcttacagt	aggaaacttg	gttttctactg	ggatctttac	2700
agcagaaaatg	tttctgaaaa	ttattgccat	ggatccttac	tattatttcc	aagaaggctg	2760
gaatatcttt	gacggtttta	ttgtgacgct	tagcctggta	gaacttgga	tcgccaatgt	2820
ggaaggatta	tctgttctcc	gttcatttctg	attgctgcga	gttttcaagt	tggcaaaatc	2880
ttggccaacg	ttaaataatg	taataaagat	catcggaat	tccgtggggg	ctctgggaaa	2940
tttaaccctc	gtcttgacca	tcacgtctct	catttttgcc	gtggtcggca	tgcagctctt	3000
tggtaaaagc	tacaaagatt	gtgtctgcaa	gatcgccagt	gattgtcaac	tcccacgctg	3060
gcacatgaat	gacttcttcc	actccttctc	gattgtgttc	cgctgtctgt	gtggggagtg	3120
gatagagacc	atgtgggact	gtatggaggt	tgctggtcaa	gccatgtgcc	ttactgtctt	3180
catgatggtc	atggtgattg	gaaacctagt	ggctctgaat	ctctttctgg	ccttgcttct	3240
gagctcattt	agtgcagaca	accttgagc	cactgatgat	gataatgaaa	tgaataatct	3300
ccaaattgct	gtggatagga	tgacaaaagg	agtagcttat	gtgaaaagaa	aaatatatga	3360
atattattcaa	cagtccttca	ttaggaaaca	aaagatttta	gatgaaatta	aaccacttga	3420
tgatctaaac	aacaagaaag	acagttgtat	gtccaatcat	acagcagaaa	ttgggaaaga	3480
tcttgactat	cttaaagatg	taaatggaac	tacaagtgg	ataggaactg	gcagcagtgt	3540
tgaaaaatac	attattgatg	aaagtgatta	catgtcattc	ataaacaacc	ccagtcttac	3600
tgtgactgta	ccaattgctg	taggagaatc	tgactttgaa	aatttaaaca	cggaagactt	3660
tagtagtgaa	tcggatctgg	aagaaagcaa	agagaaactg	aatgaaagca	gtagctcatc	3720
agaaggtagc	actgtggaca	tcggcgaccc	tgtagaagaa	cagcccgtag	tggaaacctga	3780
agaaactctt	gaaccagaag	cttgtttcac	tgaaggctgt	gtacaaagat	tcaagtgttg	3840
tcaaatcaat	gtggaagaag	gcagaggaaa	acaatggtgg	aacctgagaa	ggacgtgttt	3900
ccgaatagtt	gaacataact	ggtttgagac	cttcattgtt	ttcatgattc	tccttagtag	3960
tggtgctcgg	catttgaaaga	tatatatatt	gatcagcgaa	agacgattaa	gacgatgttg	4020
gaatatgctg	acaaggtttt	cacttacatt	ttcattctgg	aaatgcttct	aaaatgggtg	4080
gcatatggct	atcaaacata	tttcaccaat	gcctgggtgt	ggctggactt	cttaattgtt	4140

gatgtttcat tggtcagttt aacagcaaat gccttgggtt actcagaact tggagccatc 4200  
 aaatctctca ggacactaag agctctgaga cctctaagag ccttatctcg atttgaagg 4260  
 atgaggggtg ttgtgaatgc ccttttagga gcaattccat ccatcatgaa tgtgcttctg 4320  
 gtttgtctta tattctggct aattttcagc atcatgggcg taaatttggt tgcctggcaaa 4380  
 ttctaccact gtattaacac cacaactggt gacaggtttg acatcgaaga cgtgaataat 4440  
 catactgatt gcctaaaact aatagaaaaga aatgagactg ctctgatggaa aaatgtgaaa 4500  
 gtaaaacttg ataatgtagg atttgggtat ctctctttgc ttcaagttgc cacattcaaa 4560  
 ggatggatgg atataatgta tgcagcagtt gattccagaa atgtggaact ccagcctaag 4620  
 tatgaagaaa gtctgtacat gtatctttac tttgttattt tcatcatctt tgggtccttc 4680  
 ttcaccttga acctgtttat tgggtgtcatc atagataatt tcaaccagca gaaaaagaag 4740  
 tttggaggtc aagacatctt tatgacagaa gaacagaaga aatactataa tgcaatgaaa 4800  
 aaattaggat cgaaaaaacc gcaaaagcct atacctcgac caggaaacaa atttcaagga 4860  
 atggtctttg acttcgtaac cagacaagtt tttgacataa gcatcatgat tctcatctgt 4920  
 cttaacatgg tcacaatgat ggtggaaaca gatgaccaga gtgaatatgt gactaccatt 4980  
 ttgtcacgca tcaatctggt gttcattgtg ctatttactg gagagtgtgt actgaaactc 5040  
 atctctctac gccattatta ttttaccatt ggatggaata tttttgattt tgtggttgc 5100  
 attctctcca ttgtaggtat gtttcttgcc gagctgatag aaaagtattt cgtgtccct 5160  
 accctgttcc gagtgtaccg tcttgctagg attggccgaa tcctacgtct gatcaaagga 5220  
 gcaaagggga tccgcacgct gctctttgct ttgatgatgt cccttccctgc gttgtttaac 5280  
 atcggcctcc tactcttccct agtcatgttc atctacgcca tctttgggat gtccaacttt 5340  
 gcctatgtta agaggggaagt tgggatcgat gacatgttca actttgagac ctttggcaac 5400  
 agcatgatct gcctattcca aattacaacc tctgtctggt gggatggatt gctagcacc 5460  
 attctcaaca gtaagccacc cgactgtgac cctaataaag ttaaccctgg aagctcagtt 5520  
 aaggagact gtgggaaccc atctgttggg attttctttt ttgtcagtta catcatcata 5580  
 tccttccctg ttgtggtgaa catgtacatc gcggtcatcc tggagaactt cagtgttgc 5640  
 actgaagaaa gtgcagagcc tctgagttag gatgactttg agatgttcta tgaggtttg 5700  
 gagaagtttg atcccgatgc aactcagttc atggaatttg aaaaattatc tcagtttgca 5760  
 gctgcgcttg aaccgcctct caatctgcca caaccaaaaca aactccagct cattgccatg 5820  
 gatttgccca tgggtgagtgg tgaccggatc cactgtcttg atatcttatt tgcttttaca 5880  
 aagcgggttc taggagagag tggagagatg gatgctctac gaatacagat ggaagagcga 5940  
 ttcatggctt ccaatccttc caaggtctcc tatcagccaa tcactactac tttaaaacga 6000  
 aaacaagagg aagtatctgc tgtcattatt cagcgtgctt acagacgcca ctttttaaag 6060  
 cgaactgtaa aacaagcttc ctttacgtac aataaaaaca aaatcaaagg tggggctaat 6120  
 cttcttataa aagaagacat gataattgac agaataaatg aaaactctat tacagaaaaa 6180  
 actgatctga ccatgtccac tgcagcttgt ccaccttct atgaccgggt gacaaaagcca 6240  
 attgtggaaa aacatgagca agaaggcaaa gatgaaaaag ccaaagggaa ataaatgaaa 6300  
 ataaataaaa ataattgggt gacaaattgt ttacagcctg tgaaggatgat gtatttttat 6360  
 caacaggact cctttaggag gtcaatgcca aactgactgt ttttacacaa atctccttaa 6420  
 ggtcagtgcc tacaataaga cagtgacccc ttgtcagcaa actgtgactc tgtgtaaagg 6480  
 ggagatgacc ttgacaggag gttactgttc tcactaccag ctgacactgc tgaagataag 6540  
 atgcacaatg gctagtcaga ctgtagggac cagtttcaag gggtgcaaac ctgtgatttt 6600  
 ggggttgttt aacatgaaac acttttagtgt agtaattgta tccactgttt gcatttcaac 6660  
 tgccacattt gtcacatttt tatggaatct gttagtggat tcatcttttt gttaatccat 6720  
 gtgtttatta tatgtgacta tttttgtaaa cgaagtttct gttgagaaat aggctaagga 6780  
 cctctataac aggtatgcca cctggggggt atggcaacca catggccctc ccagctacac 6840  
 aaagtcgtgg tttgcatgag ggcatgctgc acttagagat catgcatgag aaaaagtcac 6900  
 aagaaaaaca aattcttaaa tttcaccata tttctgggag gggtaattgg gtgataagt 6960  
 gaggtgcttt gttgatcttg ttttgcaaaa tccagccct agaccaagta gattatttgt 7020



```

gggtaggccca gtaaattctta gcaggtgcaa acttcattca aatgtttgga gtcataaatg 7080
ttatgtttct ttttgttgta ttaaaaaaaa aacctgaata gtgaatattg cccctcacc 7140
tccaccgccca gaagactgaa ttgacaaaaa ttactcttta taaatttctg ctttttccctg 7200
cactttgttt agccatcttc ggctctcagc aaggttgaca ctgtatatgt taatgaaatg 7260
ctatttatta tgtaaatagt cattttaccc tgtggtgcac gtttgagcaa acaaataatg 7320
acctaagcac agtattttatt gcatcaaata tgtaccacaa gaaatgtaga gtgcaagctt 7380
tacacaggta ataaaatgta ttctgtacca tttatagata gtttggatgc tatcaatgca 7440
tgtttatatt accatgctgc tgtatctggt ttctctcact gctcagaatc tcatttatga 7500
gaaaccatat gtcagtggta aagtcaagga aattgttcaa cagatctcat ttattttaagt 7560
cattaagcaa tagtttgagc cactttaaca gctttttggt tttttttaca ttttaagtgg 7620
ataacatatg gtatatagcc agactgtaca gacatgttta aaaaaacaca ctgcttaacc 7680
tattaaatat gtgttttaga ttttataagc aaatataaat actgtaaaaa gtcactttat 7740
tttatttttc agcattatgt acataaatat gaagaggaaa ttatcttcag gttgatatca 7800
caatcacttt tcttactttc tgtccatagt actttttcat gaaagaaatt tgctaaataa 7860
gacatgaaaa caagactggg tagttgtaga tttctgcttt ttaaattaca tttgctaatt 7920
ttagattatt tcacaatttt aaggagcaaa ataggttcac gattcatatc caaattatgc 7980
tttgcaattg gaaaagggtt taaaatttta tttatatttc tggtagtacc tgcactaaact 8040
gaattgaagg tagtgcttat gttatttttg ttcttttttt ctgacttcgg tttatgtttt 8100
catttctttg gagtaatgct gctctagttg ttctaaatag aatgtgggct tcataatttt 8160
ttttccaca aaaacagagt agtcaactta tatagtcaat tacatcagga cattttgtgt 8220
ttcttacaga agcaaacat aggtctctct ttctcttaaa actacttaga taaactgtat 8280
tcgtgaactg catgctggaa aatgctacta ttatgctaaa taatgctaac caacatttaa 8340
aatgtgcaaa actaataaag attacatttt ttatttta 8378

```

&lt;210&gt; 2

&lt;211&gt; 8378

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

tactgcagag gtctctggtg catgtgtgta tgtgtgcggt tgtgtgtggt tgtgtgtctg 60
tgtgttctgc cccagtgaga ctgcagccct tgtaaatact ttgacacctt ttgcaagaag 120
gaatctgaac aattgcaact gaaggcacat tgttatcatc tcgtctttgg gtgatgctgt 180
tctcactgc agatggataa ttttctttt aatcaggaat ttcatatgca gaataaatgg 240
taattaaaat gtgcaggatg acaagatgga gcaaacagtg cttgtaccac caggacctga 300
cagcttcaac ttcttcacca gagaatctct tgcggctatt gaaagacgca ttgcagaaga 360
aaaggcaaa aatcccaaac cagacaaaaa agatgacgac gaaaatggcc caaagccaaa 420
tagtgacttg gaagctggaa agaaccttcc atttatttat ggagacattc ctccagagat 480
gggtgcagag cccctggagg acctggaccc ctactatata aataagaaaa cttttatagt 540
attgaataaa gggaaggcca tcttccggtt cagtgcacc tctgccctgt acattttaac 600
tcccttcaat cctcttagga aaatagctat taagattttg gtacattcat tattcagcat 660
gctaattatg tgcactattt tgacaaactg tgtgtttatg acaatgagta accctcctga 720
ttggacaaa aatgtagaat acaccttcac aggaatatat acttttgaat cacttataaa 780
aattattgca aggggattct gtttagaaga ttttactttc ctccgggatc catggaactg 840
gctcgatttc actgtcatta catttgctgt tgaacagaa tttgtaaacc taggcaattt 900
ttcagctctt cgcactttca gagtcttgag agctttgaaa actatttcgg taattccagg 960
cctgaaaacc attgtgggag cctgatcca gtctgtgaag aagctctcag atgtaatgat 1020

```

cctgactgtg ttctgtctga gcgtatttgc tctaattggg ctgcagctgt tcatgggcaa 1080  
 cctgaggaat aaatgtatac aatggcctcc caccaatgct tccttgagg aacatagtat 1140  
 agaaaagaat ataactgtga attataatgg tacacttata aatgaaactg tctttgagtt 1200  
 tgactggaag tcatatatcc aagattcaag atatcattat ttcttgagg gttttttaga 1260  
 tgcactacta tgtggaaata gctctgatgc aggccaatgt ccagagggat atatgtgtgt 1320  
 gaaagctggg agaaatccca attatggcta cacaagcttt gataccttca gttgggcttt 1380  
 tttgtccttg tttcgactaa tgactcagga cttctgggaa aatctttatc aactgacatt 1440  
 acgtgctgct gggaaaacgt acatgatatt ttttgtattg gtcattttct tgggctcatt 1500  
 ctacctataa aatttgatcc tggctgtggt ggccatggcc tacgaggaac agaatacaggc 1560  
 caccttgga aagcagaac agaaagaggc cgaatttcag cagatgattg aacagcttaa 1620  
 aaagcaacag gaggcagctc agcaggcagc aacggcaact gcctcagaac attccagaga 1680  
 gccagtgca gcaggcaggc tctcagacag ctcatctgaa gcctctaagt tgagttccaa 1740  
 gagtgtctaa gaaagaagaa atcggaggaa gaaaagaaaa cagaaagagc agtctggtgg 1800  
 ggaagagaaa gatgaggatg aattccaaaa atctgaatct gaggacagca tcaggaggaa 1860  
 aggttttcgc ttctccattg aagggaaccg attgacatat gaaaagagg actcctcccc 1920  
 acaccagtct ttgttgagca tccgtggctc cctattttca ccaaggcgaa atagcagaac 1980  
 aagccttttc agcttttagag ggcgagcaaa ggatgtggga tctgagaacg acttcgcaga 2040  
 tgatgagcca gcacctttga ggataacgag agccgtagag attccttggt tgtgccccga 2100  
 cgacacggag agagacgcaa cagcaacctg agtcagacca gtaggtcatc ccgatgctg 2160  
 gcagtgtttc cagcgaatgg gaagatgcac agcactgtgg attgcaatgg tgtggtttcc 2220  
 ttggttggtg gaccttcagt tctacatcg cctgttgga agcttctgcc agaggtgata 2280  
 atagataagc cagctactga tgacaatgga acaaccactg aaactgaaat gagaaagaga 2340  
 aggtcaagtt ctttccacgt ttccatggac tttctagaag atccttcca aaggcaacga 2400  
 gcaatgagta tagccagcat tctaacaat acagtagaag aacttgaaga atccaggcag 2460  
 aaatgccac cctgttggtg taaattttcc aacatattct taatctggga ctgttctcca 2520  
 tattggttaa aagtgaacaa tgtgtcaac ctggttggtg tggaccatt tgttgacctg 2580  
 gccatacca tctgtattgt cttaaatact ctttcatgg ccatggagca ctatccaatg 2640  
 acggaccatt tcaataatgt gcttacagta ggaaacttgg ttttactgg gatctttaca 2700  
 gcagaaatgt ttctgaaaat tattgccatg gatccttact attatttcca agaaggctgg 2760  
 aatatctttg acggttttat tgtgacgctt agcctgtag aacttggact cgccaatgtg 2820  
 gaaggattat ctgttctccg ttcatttcga ttgctgcgag ttttcaagtt ggcaaaatct 2880  
 tggccaacgt taaatatgct aataaagatc atcggcaatt ccgtgggggc tctgggaaat 2940  
 ttaaccctcg tcttgccat catcgtcttc atttttgccg tggcggcat gcagctcttt 3000  
 ggtaaaagct acaaagattg tgtctgcaag atcgccagtg attgtcaact cccacgctgg 3060  
 cacatgaatg acttcttcca ctcttctctg attgtgttcc gcgtgctgtg tggggagtgg 3120  
 atagagacca tgtgggactg tatggagggt gctggtcaag ccatgtgcct tactgtcttc 3180  
 atgatggtca tggatgattg aaacctagtg gtctgaatc tctttctggc cttgcttctg 3240  
 agctcattta gtgcagacaa ccttgcagcc actgatgatg ataataaat gaataatctc 3300  
 caaattgctg tggataggat gcacaaagga gtagcttatg tgaaaagaaa aatatatgaa 3360  
 tttattcaac agtccttcat taggaaacaa aagatttttag atgaaattaa accacttgat 3420  
 gatctaataa acaagaaaga cagttgtatg tccaatcata cagcagaaat tgggaaagat 3480  
 cttgactatc ttaaagatgt aaatggaact acaagtggta taggaactgg cagcagtgtt 3540  
 gaaaaataca ttattgatga aagtgttac atgtcattca taaacaaccc cagtcttact 3600  
 gtgactgtac caattgctgt aggagaatct gactttgaaa atttaaacac ggaagacttt 3660  
 agtagtgaat cggatctgga agaaagcaaa gagaaactga atgaaagcag tagctcatca 3720  
 gaaggtagca ctgtggacat cggcgcacct gtagaagaac agcccgtagt ggaacctgaa 3780  
 gaaactcttg aaccagaagc ttgtttcact gaaggctgtg tacaagatt caagtgttgt 3840  
 caaatcaatg tggaagaagg cagaggaaaa caatggtgga acctgagaag gacgtgtttc 3900

cgaatagttg aacataactg gtttgagacc ttcattgttt tcatgattct ccttagtagt 3960  
ggtgctctgg catttgaaga tatatatatt gatcagcgaa agacgattaa gacgatgttg 4020  
gaatatgctg acaagggttt cacttacatt ttcattctgg aaatgcttct aaaatgggtg 4080  
gcatatggct atcaaaatat ttcaccaatg cctgggtgtg gctggacttc ttaattgttg 4140  
atgtttcatt ggtcagttta acagcaaag ccttgggtta ctcagaactt ggagccatca 4200  
aatctctcag gacactaaga gctctgagac ctctaagagc cttatctcga tttgaaggga 4260  
tgagggtggt tgtgaatgcc cttttaggag caattccatc catcatgaat gtgcttctgg 4320  
tttgtcttat attctggcta attttcagca tcatgggcgt aaatttgttt gctggcaaat 4380  
tctaccactg tattaacacc acaactggtg acagggttga catcgaagac gtgaataatc 4440  
atactgattg cctaaaacta atagaaagaa atgagactgc tcgatgaaa aatgtgaaag 4500  
taaactttga taatgtagga tttgggtatc tctctttgct tcaagttgcc acattcaaag 4560  
gatggatgga tataatgtat gcagcagttg attccagaaa tgtggaactc cagcctaagt 4620  
atgaagaaag tctgtacatg tatctttact ttgttatttt catcatcttt gggtccttct 4680  
tcaccttgaa cctgtttatt ggtgtcatca tagataattt caaccagcag aaaaagaagt 4740  
ttggagggtca agacatcttt atgacagaag aacagaagaa atactataat gcaatgaaaa 4800  
aattaggatc gaaaaaaccg caaaagccta tacctcgacc aggaacaaa tttcaaggaa 4860  
tggtctttga cttcgtaacc agacaagttt ttgacataag catcatgatt ctcatctgtc 4920  
ttaacatggt cacaatgatg gtggaacag atgaccagag tgaatatgtg actaccattt 4980  
tgtcacgcat caatctggtg ttcatttgtc tatttactgg agagtgtgta ctgaaactca 5040  
tctctctacg ccattattat tttaccattg gatggaatat ttttgatttt gtggttgtca 5100  
ttctctccat tgtaggtagt tttcttgccg agctgataga aaagtatttc gtgtccccta 5160  
ccctgttccg agtgatccgt cttgctagga ttggccgaat cctacgtctg atcaaaggag 5220  
caaaggggat ccgcacgctg ctctttgctt tgatgatgtc ccttctctgc ttgtttaaca 5280  
tcggcctcct actcttcccta gtcattgtca tctacgcat ctttgggatg tccaactttg 5340  
cctatgttaa gaggggaagt gggatcgatg acatgttcaa ctttgagacc tttggcaaca 5400  
gcatgatctg cctattccaa attacaacct ctgctggctg ggatggattg ctagcaccca 5460  
ttctcaacag taagccaccc gactgtgacc ctaataaagt taaccctgga agctcagtta 5520  
agggagactg tggaaccca tctgttgga ttttctttt tgtcagttac atcatcatat 5580  
ccttctggtg tgtggtgaac atgtacatcg cggtcacct ggagaacttc agtgttgcta 5640  
ctgaagaaag tgcagagcct ctgagttagg atgactttga gatgttctat gaggtttggg 5700  
agaagtttga tcccgatgca actcagttca tggaatttga aaaattatct cagtttgtag 5760  
ctgcgcttga accgcctctc aatctgccac aaccaacaa actccagctc attgccatgg 5820  
atttgcccat ggtgagtggg gaccggatcc actgtcttga tatcttattt gcttttacia 5880  
agcgggttct aggagagagt ggagagatgg atgctctacg aatacagatg gaagagcgat 5940  
tcatggcttc caatccttcc aaggctctct atcagccaat cactactact ttaaaacgaa 6000  
aacaagagga agtatctgct gtcattattc agcgtgctta cagacgccac cttttaaaagc 6060  
gaactgtaaa acaagcttcc tttacgtaca ataaaaacaa aatcaaagggt ggggctaate 6120  
ttcttataaa agaagacatg ataattgaca gaataaatga aaactctatt acagaaaaaa 6180  
ctgatctgac catgtccact gcagcttgct caccttcccta tgaccgggtg acaaagccaa 6240  
ttgtggaaaa acatgagcaa gaaggcaaag atgaaaaagc caaagggaaa taaatgaaaa 6300  
taaataaaaa taattgggtg acaaattgtt tacagcctgt gaagggtgat tatttttatc 6360  
aacaggactc ctttaggagg tcaatgccaa actgactgtt tttacacaaa tctccttaag 6420  
gtcagtgcct acaataagac agtgaccctt tgtcagcaaa ctgtgactct gtgtaaaggg 6480  
gagatgacct tgacaggagg ttactgttct cactaccagc tgacactgct gaagataaga 6540  
tgcacaatgg ctagttagac tgtagggacc agtttcaagg ggtgcaaacc tgtgattttg 6600  
gggttgttta acatgaaaca ctttagtgta gtaattgtat ccactgtttg catttcaact 6660  
gccacatttg tcacattttt atggaatctg ttagtgatt catctttttg ttaatccatg 6720  
tgtttattat atgtgactat ttttgtaaac gaagtttctg ttgagaaata ggctaaggac 6780

```

ctctataaca ggtatgccac ctgggggggta tggcaaccac atggccctcc cagctacaca 6840
aagtcgtggt ttgcatgagg gcatgctgca cttagagatc atgcatgaga aaaagtcaca 6900
agaaaaacaa attcttaaat ttcacccatat ttctgggagg ggtaattggg tgataagtgg 6960
agggtccttg ttgatcttgt tttgcgaaat ccagcccta gaccaagtag attatttgtg 7020
ggtaggccag taaatcttag caggtgcaaa cttcattcaa atgtttggag tcataaatgt 7080
tatgtttctt tttgttgat taaaaaaaaa acctgaatag tgaatattgc ccctcaccct 7140
ccaccgccag aagactgaat tgacccaaat tactctttat aaatttctgc ttttccctgc 7200
actttgttta gccatcttcg gctctcagca aggttgacac tgtatatgtt aatgaaatgc 7260
tatttattat gtaaatagtc attttaccct gtggtgcacg tttgagcaaa caaataatga 7320
cctaagcaca gtatttattg catcaaatat gtaccacaag aaatgtagag tgcaagcttt 7380
acacaggtaa taaatgtat tctgtacat ttatagatag tttggatgct atcaatgcat 7440
gtttatatta ccatgctgct gtatctggtt tctctcactg ctcagaatct catttatgag 7500
aaacccatag tcagtgttaa agtcaaggaa attgttcaac agatctcatt tatttaagtc 7560
attaagcaat agtttgcagc actttaacag ctttttggtt atttttacat ttttaagtga 7620
taacatatgg tatatagcca gactgtacag acatgtttaa aaaaacacac tgcttaacct 7680
attaaatatg tgtttagaat ttataagca aatataaata ctgtaaaaag tcactttatt 7740
ttatttttca gcattatgta cataaatatg aagaggaaat tatcttcagg ttgatatcac 7800
aatcactttt cttactttct gtccatagta ctttttcacg aaagaaattt gctaaataag 7860
acatgaaaac aagactgggt agttgtagat ttctgctttt taaattacat ttgctaattt 7920
tagattattt cacaatttta aggagcaaaa taggttcacg attcatatcc aaattatgct 7980
ttgcaattgg aaaagggttt aaaattttat ttatatttct ggtagtacct gcactaactg 8040
aattgaaggt agtgcttatg ttatttttgt tcttttttct tgacttcggt ttatgttttc 8100
atttcttttg agtaatgctg ctctagattg ttctaaatag aatgtgggct tcataatttt 8160
tttttccaca aaaacagagt agtcaactta tatagtcaat tacatcagga catttttgtg 8220
ttcttacaga agcaaacat aggctcctct tttccttaaa actacttaga taaactgtat 8280
tcgtgaactg catgctggaa aatgctacta ttatgctaaa taatgctaac caacatttaa 8340
aatgtgcaaa actaataaag attacatttt ttatttta 8378

```

&lt;210&gt; 3

&lt;211&gt; 2009

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

```

Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
  1              5              10              15

```

```

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
      20              25              30

```

```

Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
      35              40              45

```

```

Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
      50              55              60

```

```

Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu

```

65		70		75		80									
Asp	Pro	Tyr	Tyr	Ile	Asn	Lys	Lys	Thr	Phe	Ile	Val	Leu	Asn	Lys	Gly
				85					90					95	
Lys	Ala	Ile	Phe	Arg	Phe	Ser	Ala	Thr	Ser	Ala	Leu	Tyr	Ile	Leu	Thr
			100					105					110		
Pro	Phe	Asn	Pro	Leu	Arg	Lys	Ile	Ala	Ile	Lys	Ile	Leu	Val	His	Ser
		115					120					125			
Leu	Phe	Ser	Met	Leu	Ile	Met	Cys	Thr	Ile	Leu	Thr	Asn	Cys	Val	Phe
		130				135					140				
Met	Thr	Met	Ser	Asn	Pro	Pro	Asp	Trp	Thr	Lys	Asn	Val	Glu	Tyr	Thr
145					150					155					160
Phe	Thr	Gly	Ile	Tyr	Thr	Phe	Glu	Ser	Leu	Ile	Lys	Ile	Ile	Ala	Arg
			165						170					175	
Gly	Phe	Cys	Leu	Glu	Asp	Phe	Thr	Phe	Leu	Arg	Asp	Pro	Trp	Asn	Trp
			180					185					190		
Leu	Asp	Phe	Thr	Val	Ile	Thr	Phe	Ala	Tyr	Val	Thr	Glu	Phe	Val	Asp
		195					200					205			
Leu	Gly	Asn	Val	Ser	Ala	Leu	Arg	Thr	Phe	Arg	Val	Leu	Arg	Ala	Leu
		210				215					220				
Lys	Thr	Ile	Ser	Val	Ile	Pro	Gly	Leu	Lys	Thr	Ile	Val	Gly	Ala	Leu
225					230					235					240
Ile	Gln	Ser	Val	Lys	Lys	Leu	Ser	Asp	Val	Met	Ile	Leu	Thr	Val	Phe
			245						250					255	
Cys	Leu	Ser	Val	Phe	Ala	Leu	Ile	Gly	Leu	Gln	Leu	Phe	Met	Gly	Asn
			260					265					270		
Leu	Arg	Asn	Lys	Cys	Ile	Gln	Trp	Pro	Pro	Thr	Asn	Ala	Ser	Leu	Glu
		275					280					285			
Glu	His	Ser	Ile	Glu	Lys	Asn	Ile	Thr	Val	Asn	Tyr	Asn	Gly	Thr	Leu
		290				295					300				
Ile	Asn	Glu	Thr	Val	Phe	Glu	Phe	Asp	Trp	Lys	Ser	Tyr	Ile	Gln	Asp
305					310					315					320
Ser	Arg	Tyr	His	Tyr	Phe	Leu	Glu	Gly	Phe	Leu	Asp	Ala	Leu	Leu	Cys

9  
**SUBSTITUTE SHEET (RULE 26)**

580

585

590

Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu  
 595 600 605

Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln  
 610 615 620

Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys  
 625 630 635 640

Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly  
 645 650 655

Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile  
 660 665 670

Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu  
 675 680 685

Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu  
 690 695 700

Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu  
 705 710 715 720

Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro  
 725 730 735

Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro  
 740 745 750

Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro  
 755 760 765

Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe  
 770 775 780

Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu  
 785 790 795 800

Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe  
 805 810 815

Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp  
 820 825 830

Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly

835		840		845
Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu				
850		855		860
Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile				
865		870		875
				880
Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val				
	885		890	895
Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe				
	900		905	910
Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln				
	915		920	925
Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val				
	930		935	940
Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met				
	945		950	955
				960
Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met				
	965		970	975
Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu				
	980		985	990
Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu				
	995		1000	1005
Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val Ala				
	1010		1015	1020
Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe Ile Arg				
	1025		1030	1035
				1040
Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp Leu Asn Asn				
	1045		1050	1055
Lys Lys Asp Ser Cys Met Ser Asn His Thr Ala Glu Ile Gly Lys Asp				
	1060		1065	1070
Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr Ser Gly Ile Gly Thr				
	1075		1080	1085
Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp Glu Ser Asp Tyr Met Ser				



1090	1095	1100
Phe Ile Asn Asn Pro Ser Leu Thr Val Thr Val Pro Ile Ala Val Gly		
1105	1110	1115 1120
Glu Ser Asp Phe Glu Asn Leu Asn Thr Glu Asp Phe Ser Ser Glu Ser		
1125	1130	1135
Asp Leu Glu Glu Ser Lys Glu Lys Leu Asn Glu Ser Ser Ser Ser Ser		
1140	1145	1150
Glu Gly Ser Thr Val Asp Ile Gly Ala Pro Val Glu Glu Gln Pro Val		
1155	1160	1165
Val Glu Pro Glu Glu Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly		
1170	1175	1180
Cys Val Gln Arg Phe Lys Cys Cys Gln Ile Asn Val Glu Glu Gly Arg		
1185	1190	1195 1200
Gly Lys Gln Trp Trp Asn Leu Arg Arg Thr Cys Phe Arg Ile Val Glu		
1205	1210	1215
His Asn Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu Leu Ser Ser		
1220	1225	1230
Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile Asp Gln Arg Lys Thr Ile		
1235	1240	1245
Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr Ile Phe Ile		
1250	1255	1260
Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Tyr Gln Thr Tyr Phe		
1265	1270	1275 1280
Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp Val Ser Leu		
1285	1290	1295
Val Ser Leu Thr Ala Asn Ala Leu Gly Tyr Ser Glu Leu Gly Ala Ile		
1300	1305	1310
Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser		
1315	1320	1325
Arg Phe Glu Gly Met Arg Val Val Val Asn Ala Leu Leu Gly Ala Ile		
1330	1335	1340
Pro Ser Ile Met Asn Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile		

1345                      1350                      1355                      1360

Phe Ser Ile Met Gly Val Asn Leu Phe Ala Gly Lys Phe Tyr His Cys  
1365                      1370                      1375

Ile Asn Thr Thr Thr Gly Asp Arg Phe Asp Ile Glu Asp Val Asn Asn  
1380                      1385                      1390

His Thr Asp Cys Leu Lys Leu Ile Glu Arg Asn Glu Thr Ala Arg Trp  
1395                      1400                      1405

Lys Asn Val Lys Val Asn Phe Asp Asn Val Gly Phe Gly Tyr Leu Ser  
1410                      1415                      1420

Leu Leu Gln Val Ala Thr Phe Lys Gly Trp Met Asp Ile Met Tyr Ala  
1425                      1430                      1435                      1440

Ala Val Asp Ser Arg Asn Val Glu Leu Gln Pro Lys Tyr Glu Glu Ser  
1445                      1450                      1455

Leu Tyr Met Tyr Leu Tyr Phe Val Ile Phe Ile Ile Phe Gly Ser Phe  
1460                      1465                      1470

Phe Thr Leu Asn Leu Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln  
1475                      1480                      1485

Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln  
1490                      1495                      1500

Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln  
1505                      1510                      1515                      1520

Lys Pro Ile Pro Arg Pro Gly Asn Lys Phe Gln Gly Met Val Phe Asp  
1525                      1530                      1535

Phe Val Thr Arg Gln Val Phe Asp Ile Ser Ile Met Ile Leu Ile Cys  
1540                      1545                      1550

Leu Asn Met Val Thr Met Met Val Glu Thr Asp Asp Gln Ser Glu Tyr  
1555                      1560                      1565

Val Thr Thr Ile Leu Ser Arg Ile Asn Leu Val Phe Ile Val Leu Phe  
1570                      1575                      1580

Thr Gly Glu Cys Val Leu Lys Leu Ile Ser Leu Arg His Tyr Tyr Phe  
1585                      1590                      1595                      1600

Thr Ile Gly Trp Asn Ile Phe Asp Phe Val Val Val Ile Leu Ser Ile

1605	1610	1615
Val Gly Met Phe Leu Ala Glu Leu Ile Glu Lys Tyr Phe Val Ser Pro		
1620	1625	1630
Thr Leu Phe Arg Val Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg		
1635	1640	1645
Leu Ile Lys Gly Ala Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met		
1650	1655	1660
Met Ser Leu Pro Ala Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val		
1665	1670	1675
Met Phe Ile Tyr Ala Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys		
1685	1690	1695
Arg Glu Val Gly Ile Asp Asp Met Phe Asn Phe Glu Thr Phe Gly Asn		
1700	1705	1710
Ser Met Ile Cys Leu Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly		
1715	1720	1725
Leu Leu Ala Pro Ile Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro Asn		
1730	1735	1740
Lys Val Asn Pro Gly Ser Ser Val Lys Gly Asp Cys Gly Asn Pro Ser		
1745	1750	1755
Val Gly Ile Phe Phe Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val		
1765	1770	1775
Val Val Asn Met Tyr Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala		
1780	1785	1790
Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe		
1795	1800	1805
Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp Ala Thr Gln Phe Met Glu		
1810	1815	1820
Phe Glu Lys Leu Ser Gln Phe Ala Ala Ala Leu Glu Pro Pro Leu Asn		
1825	1830	1835
Leu Pro Gln Pro Asn Lys Leu Gln Leu Ile Ala Met Asp Leu Pro Met		
1845	1850	1855
Val Ser Gly Asp Arg Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr		

1860

1865

1870

Lys Arg Val Leu Gly Glu Ser Gly Glu Met Asp Ala Leu Arg Ile Gln  
 1875 1880 1885

Met Glu Glu Arg Phe Met Ala Ser Asn Pro Ser Lys Val Ser Tyr Gln  
 1890 1895 1900

Pro Ile Thr Thr Thr Leu Lys Arg Lys Gln Glu Glu Val Ser Ala Val  
 1905 1910 1915 1920

Ile Ile Gln Arg Ala Tyr Arg Arg His Leu Leu Lys Arg Thr Val Lys  
 1925 1930 1935

Gln Ala Ser Phe Thr Tyr Asn Lys Asn Lys Ile Lys Gly Gly Ala Asn  
 1940 1945 1950

Leu Leu Ile Lys Glu Asp Met Ile Ile Asp Arg Ile Asn Glu Asn Ser  
 1955 1960 1965

Ile Thr Glu Lys Thr Asp Leu Thr Met Ser Thr Ala Ala Cys Pro Pro  
 1970 1975 1980

Ser Tyr Asp Arg Val Thr Lys Pro Ile Val Glu Lys His Glu Gln Glu  
 1985 1990 1995 2000

Gly Lys Asp Glu Lys Ala Lys Gly Lys  
 2005

&lt;210&gt; 4

&lt;211&gt; 1246

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

mtvvvgsntr saarrakakn kdkkdddngk nsdagknygd mvsddyyknk tvnkgkarsa 60  
 tsaytnrkak vhssmmcttn cvmtmsndwt knvyttgyts kargcdtrdw nwdtvtavtv 120  
 ngnsartrvr aktsvgktvg asvkksdvmt vcsvagmgnr nkcwnashs kntvnynngtn 180  
 tvdwksydsr yhygdacgns sdagcgymcv kagrnnnygt sdtswasrmt dwnytraagk 240  
 tymvvgsyna vvamaynata kamkkaaat atashrsaa grsdsssask ssksakrrnr 300  
 rkkrrksggk ddkssdsrrk grsgnrtykr ysshssrgss rrnsrtssrg rakdvgsnda 360  
 ddhstdnsrr dsrrrhgrn snstsrssrm avangkmhst vdcngvvsvg gsvtsvgvdk 420  
 atddngtttt mrkrrssshv smddsrrams astntvsrk cwyksnwdes ywkvkhvvnv 480  
 vmdvdatcvt tmamhymtdh nnvtvgvntg tamkamdyyy gwndgvtsvg anvgsvrsrr 540  
 vkakswtnmk gnsvgagntv avavvgmgks ykdcvckasd crwhmndhsv rvcgwtmwdc 600  
 mvagamctvm mvmvgnvvna sssadnaatd ddnmnnavdr mhkgvayvkr kysrkkdkdd 660  
 nnkkdscmsn htagkddykd vngttsgggtg ssvkydsdym snnstvtvav gsdnntdsss 720

```

dskknsssss gstdvgavvv tactgcvrkc cnvgrgkwwn rrtcrvhnwt vmssgaadyd 780
rktktmyadk vtymkwvayg ytytnawc wdvdsvstana gysgaksrtr arrasrgmrv 840
vvnagasmnv vcwsmgvnag kyhentttgd rddvnnhtdc krntarwknv kvndnvggys 900
vatkgwmdmy aavdsrnvky symyyvgstn gvdnnkkkgg dmtkkyynam kkgskkkrgn 960
kgmvdvtrvd smcnmvtmmv tddsyvttsr nvvtgcvsr hytgwndvv vsvgmakyvs 1020
trvrargrrk gakgrtamms angvmyagms nayvkrvgdd mntgnsmtt sagwdgansk 1080
dcnkvngss vkgdcgnsvg vsysvvvnmv avnsvatsas ddmvwwkdda tmksaaannk 1140
amdmsvsgdrh cdatkrvgsg mdarmmasn skvsytttkr kvsavrayrr hkrtvkasty 1200
nknkkggank dmdrnnstkt dtmstaacsy drvtkvkhgk dkakgk 1246

```

&lt;210&gt; 5

&lt;211&gt; 850

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

```

ctaaaataat gctaaagttt ttcaagtact acttgaaaat agctatatatt actttcaaac 60
cttttctctt ttgagtcatt aggttcattga tattatatag caatagggaa tgaaagagaa 120
gcaaggagaa gcaatactgg gagattacag agaagaaagg aaaaaaggct gagagaaaag 180
aggttgagga agaaatcata aatctggatt gtgagaaagt gtttaatat tagccactag 240
atggcgatgt aatgtaaggt gctgtcttga cttttttttt ttttttttga aacaagctat 300
ttgctgattt gtattaggta ccatagagtg aggcgaggat gaagccgaga agatactgca 360
gaggtctctg gtgcatgtgt gtatgtgtgc gtttgtgtgt gtttgtgtgt ctgtgtgttc 420
tgccccagtg agactgcagc ccttgtaa atcttgacac cttttgcaag aaggaatctg 480
aacaattgca actgaaggca cattgttatc atctcgtctt tgggtgatgc tgttcctcac 540
tgcagatgga taattttcct tttaatcagg taagccatct aattgtttca tcttgatttt 600
aagtttattc attccagtta ttcctttgga aaaagagtcc atggaaattc agtttgggca 660
gagcaggaag tccatttttg tatgtgtatt cagaccaact gtcccccctcc tccctctcct 720
cctcttcttg tccccctccc cgcgcctcc tctctcaacc ttccatgaac tgaaatcagg 780
tttgttttgc agttcagcat tttgatagaa gatgggattc tttggcctga aatagcttgg 840
catctggcca 850

```

&lt;210&gt; 6

&lt;211&gt; 483

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

```

acatctctta gtcctctctt aaatatctgt attcctttta ttttaggaat ttcatatgca 60
gaataaatgg taattaaaaat gtgcaggatg acaagatgga gcaaacagtg cttgtaccac 120
caggacctga cagcttcaac ttcttcacca gagaatctct tgcggctatt gaaagacgca 180
ttgcagaaga aaaggcaaag aatcccaaac cagacaaaaa aagatgacga cgaaaaatgg 240
cccaaagcaa atagtgactt ggaagctgga aagaaccttc cattatttta tggagacatt 300
cctccagaga tgggtgcaga gccctggag gacctggacc cctactatat caataagaaa 360
gtgagtgttt tttttatcag gcatattttt gctgctaatt gcctactgca ttccttggac 420
tggtgtagca ccaacacatg ccaatagcac aaatctagta tctctgttag aatgaacaca 480

```

ttt

483

&lt;210&gt; 7

&lt;211&gt; 497

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

```
taagaagaga tccagtgaca gtttggtttc atggggcact ttaggaaatt gtgattgtgc 60
tggtttctca ttttaacttta caataattta ttatgacaag taacagaaag tagataacag 120
agttaaagtg gtttatactt tcatacttct atgttggtgtt cctgtcttac agacttttat 180
agtattgaat aaaggggaagg ccatcttccg gttcagtgcc acctctgccc tgtacatttt 240
aactcccttc aatcctctta ggaaaatagc tattaagatt ttggtacatt catatccttt 300
ttcaagtgat taatattaac tatttgtaga tgatctgtaa gcactttata gctaaatata 360
aaattaagtt gggaaatgtc catattatat aggtttcatc actctcattt tgcattctttg 420
tcataattagc ctcatcttta aagttcatta atcacataga cattactgaa acatgtactc 480
tttaacattt tatatat 497
```

&lt;210&gt; 8

&lt;211&gt; 501

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

```
tcatatacat tacctcattt aatctataca aatactcagt gaaggtgata ttattaccca 60
cattttacac atgaagaaat tgaaatgtaa ggagattaga agacttgccc acaatgcatt 120
tatccctgaa ttttggtctaa gctgcagttt gggcttttca atgttagctt tttgtaatat 180
aacacttgga ttttgatttt cttttgtgtg ttccttaaca ataacctaca ttattcagca 240
tgctaattat gtgcactatt ttgacaaact gtgtgtttat gacaatgagt aaccctcctg 300
attggacaaa gaatgtagag taagttcaac ttatatattt aataacatat atacattygg 360
gattytgaaa ctgtgtctta atgtagtctt aaaataaaac tgaagagcat tttattaaag 420
tcattcctag acaaaattac gcagcaagag gacaatgctc attggccctc aggccctgctg 480
gcgttatact gattatcact c 501
```

&lt;210&gt; 9

&lt;211&gt; 563

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

```
gctaaataga tttcatatac cttgtatttc tcacactact ctttaagacac tttacgaaac 60
aactctttgt gtttaggaagc tgaatttaaa ttaggggcta cgtttcattt gtatgaaatt 120
aaaatccatc tgcttagttt tcttttttag tatttatcta ttccactgat ggagtataa 180
gaaattggta tgctatgaaa aaacactggt actttatcaa attttttgga tgcttgtttt 240
cagatacacc ttcacaggaa tatatacttt tgaatcactt ataaaaatta ttgcaagggg 300
```

attctgttta gaagatttta ctttccttcg ggatccatgg aactggctcg atttcaactgt 360  
 cattacattt gcgtaagtgc ctttbytga aactttaagag agaacatagt ttgggtttcc 420  
 atcagtgcct atgcttttaa gaatagggtt gctttacctg tagaatattt ttgtgtgatt 480  
 tatacattca aactctggat ttcaatttag cacaacaaag gtctaagtgg aatttcacta 540  
 tagcatgaag gctttgcagt agt 563

<210> 10

<211> 253

<212> DNA

<213> Homo sapiens

<400> 10

cttataagcc catgcagtaa tataaatcct gctaaaatct tgaataattc tgatttaatt 60  
 ctacagggtt gtaacagaat ttgtaaacct aggcaatttt tcagctcttc gcactttcag 120  
 agtcttgaga gctttgaaaa ctatttcggt aattccaggt aagaagtgat tagagtaaag 180  
 gataggctct ttgtacctac agctttttct ttgtgtcctg tttttgtgtt tgtgtgtgaa 240  
 ctcccgtta cag 253

<210> 11

<211> 340

<212> DNA

<213> Homo sapiens

<400> 11

gtaagaagtg attagagtaa aggataggct ctttgtacct acagcttttt ctttgtgtcc 60  
 tgtttttgtg tttgtgtgtg aactcccgct tacaggtagc tcacagagtt tgtggacctg 120  
 ggcaatgtct cggcattgag aacattcaga gttctccgag cattgaagac gatttcagtc 180  
 attccagggt agagcaagg tagataatga gacggaccca tcagtgtatt cagcatcctt 240  
 ctctgcttga cattcagttt tacagaaaat caggaatcat aagactagggt gttcaaagaa 300  
 atgattatta tgtagacat agcttatcag cctggagtta 340

<210> 12

<211> 409

<212> DNA

<213> Homo sapiens

<400> 12

cacgcgtgct tagccctcat agtaatagcc tcctaccttc aggctgaaa accattgtgg 60  
 gagccctgat ccagtctgtg aagaagctct cagatgtaat gatcctgact gtgttctgtc 120  
 tgagcgtatt tgctctaatt gggctgcagc tgttcattgg caacctgagg aataaatgta 180  
 tacaatggcc tcccaccaat gcttccttgg aggaacatag tatagaaaag aatataactg 240  
 tgaattataa tgggtacact ataaatgaaa ctgtctttga gtttgactgg aagtcataata 300  
 ttcaagattc aagtaagaat tattgttatg tacatttcct taaaaagtag aattggattg 360  
 tttgtaacac aaaggataaa tacttgaggg gctggatata ccattttac 409

<210> 13  
 <211> 266  
 <212> DNA  
 <213> Homo sapiens

<400> 13  
 cgcgcaaata cttgtgcctt tgaatgaata atatatttaa aattactcaa taaacttaaa 60  
 agtagaacct gaccttcctg ttctctttga gtgttttttaa caatgcaaat gttcagcata 120  
 cgactttctt ttttcaaaca ggatattcatt atttcctgga gggtttttta gatgcactac 180  
 tatgtggaaa tagctctgat gcagggtaag tcaatattgt gtgcatctgt gtatattgta 240  
 tgtacacaat acatatgtgt atcttt 266

<210> 14  
 <211> 604  
 <212> DNA  
 <213> Homo sapiens

<400> 14  
 aggtgttgaa aatgcaaatt atcaacaaaa attattttgt aaaatattat tagaaatgct 60  
 gcaccatatt ttaatgatga caccaagtag ctaataagac tatatgcagt caaaagttgg 120  
 gaaatagatt agttacttat ttgtcaaact tttattttga aataccaaat ctttctgact 180  
 aggcaatatt atagcatagt atcagagtaa aaaggcagca gaacgacttg taatactttc 240  
 ttttacccca cttgcagcca atgtccagag ggatatatgt gtgtgacagc tggtagaaat 300  
 cccaattatg gctacacaag ctttgatacc ttcagttggg cttttttgtc cttgtttcga 360  
 ctaatgactc aggacttctg ggaaaatctt tatcaactgg tgagaactaa agagccacac 420  
 tctccattta agtaaaaagta tacaagaaaa ccaattgagt tatgaaatta aaaccggatg 480  
 ataatatagt agaaagagca gaacttgaca cgagacttga gttcctctat cctattgatt 540  
 ataacacata ctgagcagag tgatgccaaag gattgcaatt ctctccatt tcttcttggc 600  
 tcaa 604

<210> 15  
 <211> 378  
 <212> DNA  
 <213> Homo sapiens

<400> 15  
 ttatatctga gttttgctag ccacatgagt aaattgaaag ttgagcacco ttagtgaata 60  
 atattgggaa ataattctga tatttttgtt tgcagacatt acgtgctgct gggaaaacgt 120  
 acatgatatt ttttgtattg gtcattttct tgggctcatt ctacctaata aatttgatcc 180  
 tggctgtggt ggccatggcc tacgaggaac agaatcaggc caccttgga gaagcagaac 240  
 agaaagaggc cgaatttcag cagatgattg aacagcttaa aaagcaacag gaggcagctc 300  
 aggtaagctg ccctgctcat ggcactgacc tttatcgtct gatgtactat atgagagaag 360  
 tagtctagag cgtgtgat 378



<210> 16  
 <211> 845  
 <212> DNA  
 <213> Homo sapiens

<400> 16  
 caaccctaata taaataccaa tttttaaaagt aaatcaaata ccaaaaaagta atgaatttat 60  
 tttcttggtg atacatgttg gatatttttg aatacgtggt ctgtggagca ttaacagaga 120  
 cataataaat gttaccatgg agcaaactaa attatctcca aaagccttca ttaggtagaa 180  
 agaaaaaaaa aatctcctct tatacttgca gagaatcttc tctgtgagat gatcttcagt 240  
 cagttcaata tattttttta aagccatgca aatacttcag ccctttcaaa gaaagataca 300  
 gtctcttcag gtgctatgtt aaaatcattt ctcttcaata tagcaggcag caacggcaac 360  
 tgccctcagaa cattccagag agcccagtg agcaggcagg ctctcagaca gctcatctga 420  
 agcctctaag ttgagttcca agagtgctaa ggaaagaaga aatcggagga agaaaagaaa 480  
 acagaaagag cagtctggtg gggaagagaa agatgaggat gaattccaaa aatctgaatc 540  
 tgaggacagc atcaggaggw aagggttttcg cttctccatt gaaggggaacc ggttgacata 600  
 tgaaaagagg tactctctcc cacaccaggt atggcactgc tgagtttact gatgcatggt 660  
 tgaaaattaa aacatgggag agagggggag atttagaaaa tggactcagg aatttttatc 720  
 aactgaatca accactgttg tggtatattt aaacccatcc cttcttcaca tagttatgca 780  
 aaaactttac tccacagata tgtaagtcta cagctcgggtg tagttaagat aacaccaagt 840  
 tgaca 845

<210> 17  
 <211> 965  
 <212> DNA  
 <213> Homo sapiens

<400> 17  
 cattgccata ttctaaggat gtttcccttt gaacttgaga aatggtcggt caggggtgtgt 60  
 gtgtatgtgt gtgtgtgtgt gtttcaatat gttaagggtg caatctatct cctcattctt 120  
 taatcccaag ggctagaaac tttcttttat caaggtaatt taatttaatg tgaatgcaca 180  
 taaaatgaga atgataatca aaaggaatga accatattct gttatgaatg ctgaaatctc 240  
 cttctacata atcttgcaaa atgaaatcac attcaaatgt ccatattaat atgactctat 300  
 ttgtbtgctc tttcaaactt ctagtctttg ttgagcatcc gtggctccct attttcacca 360  
 aggcgaaata gcagaacaag ccttttcagc ttttagagggc gagcaaagga tgtgggatct 420  
 gagaacgact tcgcagatga tgagcacagc acctttgagg ataacgagag ccgtagagat 480  
 tccttggttg tgccccgacg acacggagag agacgcaaca gcaacctgag tcagaccagt 540  
 aggtcatccc ggatgctggc agtgtttcca gcgaatggga agatgcacag cactgtggat 600  
 tgcaatggtg tgggttcctt ggttggtgga ccttcagttc ctacatcgcc tgttgagacg 660  
 cttctgccag aggtgataat agataagcca gctactgatg acaatgtaag gaagtytta 720  
 atagttcagg catggctggc tcactattgc tgcaccagcc agtgtgtcta cagaacggca 780  
 accttgagaa tgattcctgg ttggtcacgc tgtgaatgca cctgcatctt gtaatatctt 840  
 tgatagacta accaactaaa acttaaaacc ttagcagtcg cctgcacaaa cctgaatgca 900  
 tttacttatt aaaagtgcta aggattgatt agacacaata attactgcct ccagttggag 960  
 gattt 965

<210> 18  
 <211> 641  
 <212> DNA  
 <213> Homo sapiens

<400> 18  
 aagagtttta tcaactatat taaaattatt ttgtatttta taaaattatg aaatcaggaa 60  
 gttaacatct tggtttttgc tgtatgacta aatgggtaac agtttgaaca ttccaggcta 120  
 atgatacaat aagtcagaaa tatctgccat caccaattga atatgaaagt gcatgatgca 180  
 tgtgtttcat gaaattcact gtgtcaccat ttggttggtt gcttgtcata ttgctcaaat 240  
 taattgttta atgcattagc attttttttt acaggggaaca accactgaaa ctgaaatgag 300  
 aaagagaagg tcaagttctt tccacgtttc catggacttt ctagaagatc cttcccaag 360  
 gcaacgagca atgagtatag ccagcattct aacaaatata gtagaagggt ggtaacaaat 420  
 tctattttcg tttcaattat tttcaccaaaa cttatattgt ctcatttcaa acaaatatat 480  
 ttgtgagttg ggaatagtgc attctaataa aaagacagtc taattcaaga gctgttattt 540  
 cttatatcta ctcagatatt ctagaagcct taacaattta ttttaaaatg agtgatattg 600  
 ggactaagac tgttttccta actgtgtagc aactctttga a 641

<210> 19  
 <211> 818  
 <212> DNA  
 <213> Homo sapiens

<400> 19  
 gtgaggcggc acatgaaaga ccacccattt aacctgaggc caagtgtgta gccacaatgg 60  
 cagtgcataa gacaaaaaac taccatttgt tacctggggc ctatgtgtgt gtctgatgaa 120  
 ataaccttgg gaggtttaga gtaaactgta atttttttta caagtacaaa aaagggtgtc 180  
 tctgtaacaa aaatgtgttg attactgaaa ataagtttag tggatatgaa ataaatgtgt 240  
 gtgtataaag tawacctttt ggtgggtctt tttttttttt ttcttaatct agaacttgaa 300  
 gaatccaggc agaaatgccc accctgttgg tataaatttt ccaacatatt cttaatctgg 360  
 gactgttctc catattgggt aaaagtgaat catgttgtca acctgggtgt gatggaccca 420  
 tttgttgacc tggccatcac catctgtatt gtcttaataa ctcttttcat ggccatggag 480  
 cactatccaa tgacggacca tttcaataat gtgcttacag taggaaactt ggtaagcata 540  
 ttggaaggta aatgtgttta gtcttcaaat tttctgcttg aaaaactgtt tacatttaat 600  
 tgtgtatagc agtctttcaa ccatacttca tgcttcctgg cccctgcaaa atcgcaatta 660  
 tatttagctg gctatactct acttttttgc caaaaataat cacccttaat gtgctcacia 720  
 aaactgagaa aggcataagg ctacagcact acttgaaaag tcaacagcaa tatttataat 780  
 ttttcaggat ccagaagtag ctcatagatt aagaacat 818

<210> 20  
 <211> 645  
 <212> DNA  
 <213> Homo sapiens

<400> 20  
 caagccattt caccatctg aagacctcag tttccttata tgtaaagtaa taattgtata 60

```

ttatctactt cgcgtttcca caaggataaa attaaataat gtatatgawa gtctttcatc 120.
aactacaaat tgccatacaa atttaagtta gtaatagaat cattgtggga aaatagcata 180
agcattatgt tctaagagca aatcttatgt catgtatgtt attatctggt ggaattagat 240
taattttgtt ttgatcttag gttttcactg ggatctttac agcagaaatg tttctgaaaa 300
ttattgccat ggatccttac tattatttcc aagaaggctg gaatatcttt gacggtttta 360
ttgtgacgct tagcctggta gaacttggac tcgccaatgt ggaagggtta tctgttctcc 420
gttcatttgc attggtaaaa aaaaaaaaaa aaggaaccaa attcaaaaac ctttctaaca 480
ttcagggttc ttgcatagca ttgtcatagt ttttttgcca cacaaccatt aggcattgta 540
agtttttctg taacatttgc attgtcaaaa acttttccta catgggaata attctcaatt 600
attaggttac cttagttcaa gggcwaggtc ggaagggtta cgggtt 645

```

&lt;210&gt; 21

&lt;211&gt; 829

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

```

gaatttcta at gaccatttct aggtaaagct caatatatat aatgctttta agaatcatalc 60
aaatatatat taatctttca ttttccagct gcgagatttc aagttggcaa aatcttggcc 120
aacgttaaat atgctaataa agatcatcgg caattccgtg ggggctctgg gaaatttaac 180
cctcgtcttg gccatcatcg tcttcatttt tgccgtgggc ggcatgcagc tctttggtta 240
aagctacaaa gattgtgtct gcaagatcgc cagtgttgt caactccac gctggcacat 300
gaatgacttc ttccactcck hcctgattgt gttccgcgtg ctgtgtgggg agtggataga 360
gaccatgtgg gactgtatgg aggttgctgg tcaagccatg tgccttactg tcttcatgat 420
ggtcatgggt attggaaacc tagcgggtat taccactta agatgtgat tttggaaata 480
caccagcatg gcacatgtat acatatgtta ctaacctgca cattgtgcac atgtacccta 540
aaacttaag tataataaaa aaaaagagta taatttaatg gtgactgttt tgtcaaaaag 600
aaaaacaaac tatgattatt ggttttaaag tccattacct tggatatatt atcactttta 660
caacacagca atatabcagt gccctgcat tttttatacc aaattctatt ttgtcagtca 720
ctttatcaca ttttttatgt gaattacaat agagtatcat attgagatga gcctaaaagg 780
atgtgctggg accattttat aaattcagag ccaaggaaga gagaagtct 829

```

&lt;210&gt; 22

&lt;211&gt; 909

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

```

gaattctcgt attgtacaca tataaatctg ttttcttcta ctcatacaat tttagagtta 60
acaaaacctt agattagctc attcaatttc actttacgaa tgggagaact tgagagcaac 120
agaaatcatg tctttgtcca aggatgtgct attgagccag tcacaaattc agatcaccca 180
tcttctaate actatgctgt ggtgtttcct tctcatcaag ttttagaact tagagttttt 240
tccacactta aaagaaagaa taagtgttgc taatctgctc ttcctacat tgggtgtaaaa 300
ttataatcat gtttttgttg tttttaaggt cctgaatctc tttctggcct tgcttctgag 360
ctcatttagt gcagacaacc ttgcagccac tgatgatgat aatgaaatga ataacttcca 420
aattgctgtg gataggatgc acaaaggagt agcttatgtg aaaagaaaaa tatatgartt 480

```

```

tattcaacag tccttcatta ggaaacaaaa gatttttagat gaaattaaac cacttgatga 540
tctaaacaac aagaaagaca gttgtatgtc caatcataca gcagaaattg ggaaagatct 600
tgactatctt aaagatgtaa atggaactac aagtggata ggaactggca gcagtgttga 660
aaaatacatt attgatgaaa gtgattacat gtcattcata aacaacccca gtcttactgt 720
gactgtacca attgctgtag gagaatctga ctttgaaaat ttaaacacgg aagacttttag 780
tagtgaatcg gatctggaag aaagcaaaga ggtaagattc tataggtgtg ggtaggtatg 840
aatacatata catatataca tatacacaca tacagatgay cctcagctta atgatgtttt 900
tacttaaga                                     909

```

&lt;210&gt; 23

&lt;211&gt; 516

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

```

aagcttacat tgtgaattat ggtaaaaggg ttagcacaga caatgatttt cttatttctt 60
ccccttattc aatctctctt tttctctaaa aatatctcta cctcaagaag aataaaaaac 120
aaattcatag taataatcct tcttggcagg caacttatta ccaaaattaa ggactttact 180
ttctatgtcc atctcactta cagaaactga atgaaagcag tagctcatca gaaggtagca 240
ctgtggacat cggcgcacct gtagaagaac agcccgtagt ggaacctgaa gaaactcttg 300
aaccggaagc ttgtttcact gaaggtaaag aaaagaatcc taatgttaat ctttcatttg 360
gagtgcagct tatttagctg ttggtcagct aanataaatc acatataata aaatngcact 420
ttgtaataga tataattcaa tcacctctaa tatnttgaca gacaaaaaaa cttaaagtct 480
agtgtcatgc tttgattata tctgcccaat atntgg                                     516

```

&lt;210&gt; 24

&lt;211&gt; 640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

```

ccattttaat gtggctgaat gtttccacaa cttcacacag ctgatgaatg tgctcttact 60
actctaggct tagagagcta tgctagcaag acagagatga gcatagtaat aaaaagacaa 120
gacaaggaca ttgctaaagg atattatgga agcagagaca ctttatctac ttttatttca 180
acactttctg caggctgtgt acaaagattc aagtgttgtc aaatcaatgt ggaagaaggc 240
agaggaaaac aatgggtggaa cctgagaagg acgtgtttcc gaatagttga acataactgg 300
tttgagacct tcattgtttt catgattctc cttagtagtg gtgctctggg gagtgagatt 360
aagaaaaggt gatacagcac taatttttag aacactctaa tactgatgac ttattaatcc 420
tttgtttcat tgtcttagta tccaatgcat ttttaattat cccaccttgt atcttctata 480
gatttactct ataactctat atttctggat taacttttac tatgtatgta aatataattt 540
taagaagcta atcattaatt tttgcttact attaaatagc ccagaaagtg tagcccttca 600
gcttattcat taacaccaaa ggatgtgaat attcaattac                                     640

```

&lt;210&gt; 25

&lt;211&gt; 607

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

```
ccacatcagg atacaacatc aagaactatt tcctgactaa gtcaaattaa ttcattggaa 60
tcatactttt ctttttcttc caccaatagt ctttcccctg attaaataag taaaagacct 120
ttgcgaggaa aaaaaaaaaa taacagtaac tactgtttct ctgccctcct attccaatga 180
aatgtcatat gcatatgatt aattttttaa atagcttatg gagtataatt atttttgaaa 240
gctaataatg tgtaacattt tctttatagg catttgaaga tatatatatt gaycagcgaa 300
agacgattaa gacgatgttg gaatatgctg acaaggtttt cacttacatt ttcattcttg 360
aaatgcttct aaaatgggtg gcatatggct atcaaacata tttcaccaat gcctggagtt 420
ggctggactt ctttaattgtt gatgtaggta tcgttcatat ttttgtctct gttcaaggta 480
gcttgtctta tttatattca aattctacaa tagtgagtct cagaccacta tgttatgttg 540
acagactata atarccacta aacgcatata tgcaatgaga gtgtcatttc tggaagacaa 600
gggctaa 607
```

&lt;210&gt; 26

&lt;211&gt; 336

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

```
aaaaattata cttgtcgtat tatatagcaa ctacacattg aatgatgatt ctgtttatta 60
attgttatta ttcytgtgtg tgcaggtttc attggtcagt ttaacagcaa atgccttggg 120
ttactcagaa cttggagcct atcaatctct caggacacta agagctctga gacctctaag 180
agccttatct cgatttgaag ggatgagggt aagaaaaatg aaagaacctg aagtattgta 240
tatagccaaa attaaactaa attaaattta gaaaaaagga aaaatgtatg catgcaaaag 300
gaatggcaaa ttcttgcaaa atgctcttta ttgttt 336
```

&lt;210&gt; 27

&lt;211&gt; 677

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

```
cttggttata ttgcctatag ttgttttcc t aagtgtattg ctttaagaaaa aaaaatgaat 60
tttaagattt ttttgaacct tgcttttaca t atcctagaa taaatagcat tgatagaaaa 120
aaagaatgga aagaccagag attactaggg gaattttttt tctttattaa cagataagaa 180
ttctgacttt tctttttttc catttgtgta ttaggtgggt gtgaatgcc ttttaggagc 240
aattccatcc atcatgaatg tgcttctggg ttgtcttata ttctggctaa ttttcagcat 300
catgggcgta aatttgtttg ctggcaaatt ctaccactgt attaacacca caactggtga 360
caggtttgac atcgaagacg tgaataatca tactgattgc ctaaaactaa tagaaagaaa 420
tgagactgct cgatggaaaa atgtgaaagt aaactttgat aatgtaggat ttgggtatct 480
ctctttgctt caagttgtaa gtgaacacta ttttctctga atatttttat tgtttggaat 540
aataacaaaa taatgacata catctattat ttagttccta agaaaaagta tatatttctt 600
tctatttaaa aaatttcaat ttgttagtac aagtttatga gccagatgg gtgaaaactt 660
```

tattacatgt aaggact

677.

&lt;210&gt; 28

&lt;211&gt; 457

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

```

aatggccatt ttgttcaata tgtgttctag aaatgaaaag ccatactaaa atactgtctt 60
gggtccaaaat ctgtgtaaaaa tttgttttga aatgtctttc aaaaatattc ctttttgaaa 120
attatatcag taagaatatt tattaacat cagggtctaaa ttatttttac tccaaagtaa 180
aacatgcatg tccttcttaa taggccacat tcaaaggatg gatggatata atgtatgcag 240
cagttgattc cagaaatgta agtattcctt gtattctaag tctttttaca atattgatca 300
ggtggtaaaa ttaatcgaat aaagcataaa cgaccaaag aaatgattct atcttgattt 360
aaaatatttg ggaaaaagtg tgacaggtaa atattcaagc atagcaatgt ttatcagaaa 420
gatcttacta agataattca acacatgaat tattttg 457

```

&lt;210&gt; 29

&lt;211&gt; 379

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

```

cagaaaaaaa aaaaatgctg acatattagt aagaataatt ttntctattg ttatgaaaaa 60
gcaccagtga cgatttccag cactaaaatg tatggtaata ttttacaaaa tattcccctt 120
tggtagggtg aactccagcc taagtatgaa gaaagtctgt acatgtatct ttactttgtt 180
attttcatca tctttgggtc cttcttcacc ttgaacctgt ttattgggtg catcatagat 240
aatttcaacc agcagaaaaa gaagataagt atttctaata ttttctctcc cactgagata 300
gaaaaattat tccttgagtg gttttctctg ccaaatgagt acttgaattt agaacaaatg 360
ggagtatata ttataactg 379

```

&lt;210&gt; 30

&lt;211&gt; 393

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

```

gtcattttga attatttagg gaattaaaat attatcatat ctaaagagta caattttttt 60
tacattttta atcccagata taattatact aatcagttga attttgattt tcttttttta 120
gccatccatt ttctatttta acattgaaaa aaatgtacaa aaggacacag ttttaaccag 180
tttgattttt cttttctata ctttgagggt caagacatct ttatgacaga agaacagaag 240
aaatactata atgcaatgaa aaaattagga tcgaaaaaac cgcaaaagcc tatacctcga 300
ccaggagtaa gaagtatcaa atgatatggg ggaaaataca aaaacaaaaa ctgcatgctt 360
gtctcacaaa aaagaaaagt aagctaaaca ttt 393

```

&lt;210&gt; 31

&lt;211&gt; 539

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

```

ttttaacaat taattatgct ataaattcat tcttacaaaa atcatttgga atgactactt 60
tgcaagaaac tagaaagtca attaatgcag aaagtactta atgctaatgc acatgagaaa 120
aactcctttg ttgttaaaag catttctatt tctctacaga acaaatttca aggaatgggtc 180
tttgacttcg taaccagaca agtttttgac ataagcatca tgattctcat ctgtcttaac 240
atgggtcaca tgatgggtga aacagatgac cagagtgaat atgtgactac ctttttgtca 300
cgcacatcat tgggtgttcat tgtgctatct actggagagt gtgtactgaa actcatctct 360
ctacgccatt attattttac cattggatgg aatatttttg attttgtggt tgtcattctc 420
tccattgtag gtaagaaata tttaaagttc ttaaattcag ttaaataaaa gtgaaagctg 480
aaacaatcaa gattagattc aagatcatcc cagcaatcag agataatcac tgtaaatat 539

```

&lt;210&gt; 32

&lt;211&gt; 3403

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

```

agtatatatt atatatagtt gtcatatatta atataactgg gttcaggact ctgaacctta 60
ccttgagagct ttagaagaaa catatgttta ttttaacgca tgatttcttc actggttggt 120
attctcattg tttattcata ggtatgtttc ttgccgagct gatagaaaag tatttcgtgt 180
cccctacctt gttccgagtg atccgtcttg ctaggattgg ccgaatccta cgtctgatca 240
aaggagcaaa ggggatccgc acgctgctct ttgctttgat gatgtccctt cctgcgttgt 300
ttaacatcgg cctcctactc ttcctagtca tgttcatcta cgccatcttt gggatgtcca 360
actttgccta tgtaagagg gaagttggga tcgatgacat gttcaacttt gagaccttg 420
gcaacagcat gatctgccta ttccaaatta caacctctgc tggctgggat ggattgctag 480
caccattctt caacagtaag ccaccgact gtgacctaa taaagttaac cctggaagct 540
cagttaaggg agactgtggg aacctatctg ttggaatttt cttttttgtc agttacatca 600
tcatatcctt cctggttgtg gtgaacatgt acatcgcggt catcctggag aacttcagt 660
ttgctactga agaaagtga gagcctctga gtgaggatga ctttgagatg ttctatgagg 720
tttgggagaa gtttgatccc gatgcaactc agttcatgga atttgaaaaa ttatctcagt 780
ttgcagtgcg cttgaaccgc ctctcaatct gccacaacca aacaaactcc agtcattgc 840
catggatttg ccatgggtga gtggtgaccg gatccactgt cttgatattt tatttgcttt 900
tacaaagcgg gttctaggag agagtggaga gatggatgct ctacgaatac agatggaaga 960
gcgattcatg gcttccaatc cttccaaggt ctctatcag ccaatcacta ctactttaaa 1020
acgaaaacaa gaggaagtat ctgctgtcat tattcagcgt gcttacagac gccacctttt 1080
aaagcgaact gtaaaacaag cttcctttac gtacaataaa aacaaaatca aaggtggggc 1140
taatcttctt ataaaagaag acatgataat tgacagaata aatgaaaact ctattacaga 1200
aaaaactgat ctgaccatgt ccactgcagc ttgtccacct tcctatgacc ggggtgacaaa 1260
gccaatgtg gaaaaacatg agcaagaagg caaagatgaa aaagccaaag ggaaataaat 1320
gaaaataaat aaaaataatt ggggtgacaaa ttgtttacag cctgtgaagg tgatgtattt 1380
ttatcaacag gactccttta ggaggtcaat gccaaactga ctgtttttac acaaatctcc 1440

```

```

ttaagggtcag tgcctacaat aagacagtga ccccttgta gcaaactgtg actctgtgta 1500
aaggggagat gaccttgaca ggaggttact gttctcacta ccagctgaca ctgctgaaga 1560
taagatgcac aatggctagt cagactgtag ggaccagttt caaggggtgc aaacctgtga 1620
ttttgggggtt gtttaacatg aaacacttta gtgtagtaat tgtatccact gtttgcattt 1680
caactgccac atttgtcaca tttttatgga atctgttagt ggattcatct ttttgttaat 1740
ccatgtgttt attatatgtg actatttttg taaacgaagt ttctgttgag aaataggcta 1800
aggacctcta taacaggtat gccacctggg gggtaggca accacatggc cctcccagct 1860
acacaaagtc gtggtttgca tgagggcagc ctgcacttag agatcatgca tgagaaaaag 1920
tcacaagaaa aacaaattct taaatttcac catatttctg ggaggggtaa ttgggtgata 1980
agtggaggtg ctttgttgat cttgttttgc gaaatccagc ccctagacca agtagattat 2040
ttgtgggtag gccagtaaat cttagcaggt gcaaacttca ttcaaatgtt tggagtcata 2100
aatgttatgt ttctttttgt tgtattaaaa aaaaaacctg aatagtgaat attgcccctc 2160
accctccacc gccagaagac tgaattgacc aaaattactc tttataaatt tctgcttttt 2220
cctgcacttt gtttagccat cttcggtctc cagcaaggtt gacactgtat atgttaatga 2280
aatgctattt attatgtaaa tagtcatttt accctgtggt gcacgtttga gcaaacaaat 2340
aatgacctaa gcacagtatt tattgcatca aatatgtacc acaagaaatg tagagtgcaa 2400
gctttacaca ggtaataaaa tgtattctgt accatttata gatagtttgg atgctatcaa 2460
tgcagtgtta tattaccatg ctgctgtatc tggtttctct cactgctcag aatctcattt 2520
atgagaaacc atatgtcagt ggtaaagtca aggaaattgt tcaacagatc tcatttattt 2580
aagtcattaa gcaatagttt gcagcacttt aacagctttt tggttatttt tacattttta 2640
gtggataaca tatggtatat agccagactg tacagacatg tttaaaaaaa cacactgctt 2700
aacctattaa atatgtgttt agaattttat aagcaaatat aaatactgta aaaagtcact 2760
ttattttatt tttcagcatt atgtacataa atatgaagag gaaattatct tcaggttgat 2820
atcacaatca cttttcttac tttctgtcca tagtactttt tcatgaaaga aatttgctaa 2880
ataagacatg aaaacaagac tgggtagtgt tagatttctg ctttttaaatt tacatttgct 2940
aatttttagat tatttcacaa ttttaaggag caaaataggt tcacgattca tatccaaatt 3000
atgctttgca attggaaaag ggtttaaaat tttatttata tttctggtag tacctgcact 3060
aactgaattg aaggtagtgc ttatgttatt tttgttcttt ttttctgact tcggtttatg 3120
ttttcatttc tttggagtaa tgctgctcta gattgttcta aatagaatgt gggcttcata 3180
attttttttt ccacaaaaac agagtagtca acttatatag tcaattacat caggacattt 3240
tgtgtttctt acagaagcaa accataggct cctcttttcc ttaaaactac ttagataaac 3300
tgtattcgtg aactgcatgc tggaaaatgc tactattatg ctaaataatg ctaaccaaca 3360
tttaaaatgt gcaaaactaa taaagattac attttttatt tta 3403

```

&lt;210&gt; 33

&lt;211&gt; 8349

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 33

```

ttcttggtgc cagcttatca atccaaaact ctgggtgtaa aagattctac agggcacttt 60
cttatgcaag gagctaaaca gtgattaaag gagcaggatg aaaagatggc acagtcaagt 120
ctggtaccgc caggacctga cagcttccgc ttctttacca gggaatccct tgctgctatt 180
gaacaacgca ttgcagaaga gaaagctaag agacccaaac aggaacgcaa ggatgaggat 240
gatgaaaatg gcccaaagcc aaacagtgc ttggaagcag gaaaatctct tccatttatt 300
tatggagaca ttctccaga gatggtgtca gtgcccctgg aggatctgga cccctactat 360
atcaataaga aaacgtttat agtattgaat aaagggaag caatctctcg attcagtgcc 420

```



```

accctgccc ttacatttt aactcccttc aaccctatta gaaaattagc tattaagatt 480.
ttggtacatt ctttattcaa tatgctcatt atgtgcacga ttcttaccaa ctgtgtattt 540
atgaccatga gtaaccctcc agactggaca aagaatgtgg agtatacctt tacaggaatt 600
tatacttttg aatcacttat taaaataactt gcaaggggct tttgtttaga agatttcaca 660
tttttacggg atccatggaa ttggttgat ttcacagtca ttacttttgc atatgtgaca 720
gagtttgtgg acctgggcaa tgtctcagcg ttgagaacat tcagagttct ccgagcattg 780
aaaacaattt cagtcattcc aggcctgaag accattgtgg gggccctgat ccagtcagtg 840
aagaagcttt ctgatgtcat gatcttgact gtgttctgtc taagcgtgtt tgcgctaata 900
ggattgcagt tgttcatggg caacctacga aataaatgtt tgcaatggcc tccagataat 960
tcttcctttg aaataaatat cacttccttc tttaacaatt cattggatgg gaatggtact 1020
actttcaata ggacagtggag catatttaac tgggatgaat atattgagga taaaagtcac 1080
ttttattttt tagagggggca aaatgatgct ctgctttgtg gcaacagctc agatgcaggc 1140
cagtgtcctg aaggatacat ctgtgtgaag gctggtagaa accccaacta tggctacacg 1200
agctttgaca cctttagttg ggcctttttg tcttattttc gtctcatgac tcaagacttc 1260
tgggaaaacc tttatcaact gacactacgt gctgctggga aaacgtacat gatatttttt 1320
gtgctggtca ttttcttggg ctcatcttat ctaataaatt tgatcttggc tgtggtggcc 1380
atggcctatg aggaacagaa tcaggccaca ttggaagagg ctgaacagaa ggaagctgaa 1440
tttcagcaga tgctcgaaca gttgaaaaag caacaagaag aagctcaggc ggcagctgca 1500
gccgatctg ctgaatcaag agacttcagt ggtgctggtg ggataggagt tttttcagag 1560
agttcttcag tagcatctaa gttgagctcc aaaagtgaag aagagctgaa aaacagaaga 1620
aagaaaaaga aacagaaaga acagtctgga gaagaagaga aaaatgacag agtcctaaaa 1680
tcggaatctg aagacagcat aagaagaaaa ggtttccgtt tttccttga aggaagtagg 1740
ctgacatatg aaaagagatt ttcttctcca caccagtcct tactgagcat ccgtggctcc 1800
cttttctctc caagacgcaa cagtagggcg agccttttca gcttcagagg tcgagcaaag 1860
gacattggct ctgagaatga ctttgctgat gatgagcaca gcaccttga ggacaatgac 1920
agccgaagag actctctgtt cgtgccgcac agacatggag aacggcgcca cagcaatgtc 1980
agccaggcca gccgtgcctc caggggtgctc cccatcctgc ccatgaatgg gaagatgcat 2040
agcgtgtgg actgcaatgg tgtggtctcc ctggctgggg gcccttctac cctcacatct 2100
gctgggcagc tctaccaga gggcacaact actgaaacag aaataagaaa gagacggctc 2160
agttcttctc atgtttccat ggatttattg gaagatccta catcaaggca aagagcaatg 2220
agtatagcca gtattttgac caacaccatg gaagaacttg aagaatccag acagaaatgc 2280
ccaccatgct ggtataaatt tgctaatatg tgtttgattt gggactgttg taaaccatgg 2340
ttaaagggtg aacaccttgt caacctggtt gtaatggacc catttggtga cctggccatc 2400
accatctgca ttgtcttaaa tacactcttc atggctatgg agcactatcc catgacggag 2460
cagttcagca gtgtactgtc tgttgaaac ctggtcttca cagggatctt cacagcagaa 2520
atgtttctca agataattgc catggatcca tattattact ttcaagaagg ctggaatatt 2580
tttgatggtt ttattgtgag ccttagttta atggaacttg gtttggcaaa tgtggaagga 2640
ttgtcagttc tccgatcatt ccggtgctc cgagttttca agttggcaaa atcttgcca 2700
actctaaata tgctaattaa gatcattggc aattctgtgg gggctctagg aaacctcacc 2760
ttggtattgg ccatcatcgt cttcattttt gctgtggtcg gcatgcagct ctttggttaag 2820
agctacaaag aatgtgtctg caagatttcc aatgattgtg aactccacg ctggcacatg 2880
catgactttt tccactcctt cctgatcgtg ttccgcgtgc tgtgtggaga gtggatagag 2940
accatgtggg actgtatgga ggtcgctggc caaacatgt gccttactgt cttcatgatg 3000
gtcatggtga ttggaaatct agtggttctg aacctcttct tggccttgc tttgagttcc 3060
ttcagttctg acaatcttgc tgccactgat gatgataacg aaatgaataa tctccagatt 3120
gctgtgggaa ggatgcagaa aggaatcgat tttgttaaaa gaaaaatacg tgaatttatt 3180
cagaaagcct ttgttaggaa gcagaaagct ttagatgaaa ttaaaccgct tgaagatcta 3240
aataataaaa aagacagctg tatttccaac cataccacca tagaaatagg caaagacctc 3300

```

```

aattatctca aagacggaaa tggaaactact agtggcatag gcagcagtgt agaaaaatat 3360
gtcgtggatg aaagtgatta catgtcattt ataaacaacc ctagcctcac tgtgacagta 3420
ccaattgctg ttggagaatc tgactttgaa aatttaaata ctgaagaatt cagcagcgag 3480
tcagatatgg aggaaagcaa agagaagcta aatgcaacta gttcatctga aggcagcacg 3540
gttgatattg gagctcccg caggggagaa cagcctgagg ttgaacctga ggaatccctt 3600
gaacctgaag cctgttttac agaagactgt gtacggaagt tcaagtgttg tcagataagc 3660
atagaagaag gcaaagggaa actctggtgg aatttgagga aaacatgcta taagatagtg 3720
gagcacaatt ggttcgaaac cttcattgtc ttcattgattc tgctgagcag tggggctctg 3780
gcctttgaag atatatacat tgagcagcga aaaaccatta agaccatgtt agaatatgct 3840
gacaaggttt tcacttacat attcattctg gaaatgctgc taaagtgggt tgcatatggt 3900
tttcaagtgt attttaccaa tgcctggtgc tggctagact tcctgattgt tgatgtctca 3960
ctggttagct taactgcaa tgccttggt tactcagaac ttggtgccat caaatccctc 4020
agaacactaa gagctctgag gccactgaga gctttgtccc ggtttgaagg aatgagggct 4080
gttgtaaatg ctcttttagg agccattcca tctatcatga atgtacttct ggtttgtctg 4140
atcttttggc taatattcag tatcatggga gtgaatctct ttgctggcaa gttttaccat 4200
tgtattaatt acaccactgg agagatgttt gatgtaagcg tggtaacaa ctacagttag 4260
tgcaaagctc tcattgagag caatcaaact gccaggtgga aaaatgtgaa agtaaacttt 4320
gataacgtag gacttgagata tctgtctcta cttcaagtag ccacgtttta gggatggatg 4380
gatattatgt atgcagctgt tgattcacga aatgtagaat tacaaccaa gtatgaagac 4440
aacctgtaca tgtatcttta ttttgcctc tttattattt ttggttcatt ctttaccttg 4500
aatcttttca ttggtgtcat catagataac ttcaaccaac agaaaaagaa gtttgagggt 4560
caagacattt ttatgacaga agaacagaag aaatactaca atgcaatgaa aaaactgggt 4620
tcaaagaaac cacaaaaacc cctacctcga cctgctaaca aattccaagg aatgggtctt 4680
gattttgtaa ccaacaagt ctttgatata agcatcatga tcctcatctg ccttaacatg 4740
gtcaccatga tgggtgaaac cgatgaccag agtcaagaaa tgacaaacat tctgtactgg 4800
attaatctgg tgtttattgt tctgttact ggagaatgtg tgctgaaact gatctctctt 4860
cgttactact atttactat tggatggaat atttttgatt ttgtggtggt cattctctcc 4920
attgtaggaa tgtttctggc tgaactgata gaaaagtatt ttgtgtcccc taccctgttc 4980
cgagtgatcc gtcttgccag gattggccga atcctacgtc tgatcaaagg agcaaagggg 5040
atccgcacgc tgctctttgc tttgatgatg tcccttccctg cgttgtttta catcgccctc 5100
cttcttttcc tggatcatgtt catctacgcc atctttggga tgtccaattt tgcctatggt 5160
aagaggggaa ttgggatcga tgacatgttc aactttgaga cctttggcaa cagcatgata 5220
tgccgtgtcc aaattacaac ctctgctggc tgggatggat tgctagcacc tattcttaat 5280
agtggacctc cagactgtga ccctgacaaa gatcacctcg gaagctcagt taaaggagac 5340
tgtgggaacc catctgttgg gattttcttt tttgtcagtt acatcatcat atccttctctg 5400
gttggtgtga acatgtacat cgcggtcatc ctggagaact tcagtgttgc tactgaagaa 5460
agtgcagagc ctctgagtga ggatgacttt gagatgttct atgaggtttg ggagaagttt 5520
gatcccgatg cgaccaggtt tatagagttt gccaaacttt ctgattttgc agatgccctg 5580
gatcctcctc ttctcatagc aaaaccaaac aaagtccagc tcattgccat ggatctgccc 5640
atggtgagtg gtgaccgat ccactgtctt gacatcttat ttgcttttac aaagcgtgtt 5700
ttgggtgaga gtggagagat ggatgccctt cgaatacaga tggagagcg attcatggca 5760
tcaaaccctt ccaaagtctc ttatgagccc attacgacca cgttgaaacg caaacaagag 5820
gaggtgtctg ctattattat ccagaggggt tacagacgct acctcttgaa gcaaaaagtt 5880
aaaaaggtat caagtatata caagaaagac aaaggcaaag aatgtgatgg aacacccatc 5940
aaagaagata ctctcattga taaactgaat gagaattcaa ctccagagaa aaccgatatg 6000
acgccttcca ccacgtctcc accctcgtat gatagtgtga ccaaaccaga aaaagaaaaa 6060
tttgaaaaag acaaatcaga aaaggaagac aaagggaaag atatcaggga aagtaaaaaa 6120
taaaaagaaa ccaagaattt tccattttgt gatcaattgt ttacagcccg tgatggtgat 6180

```

```

gtgtttgtgt caacaggact cccacaggag gtctatgcc aactgactgt ttttaciaaat 6240
gtatacttaa ggtcagtgcc tataacaaga cagagacctc tggtcagcaa actggaactc 6300
agtaaactgg agaaatagta tcgatgggag gtttctatct tcacaaccag ctgacactgc 6360
tgaagagcag aggcgtaatg gctactcaga cgataggaac caatttaaag gggggaggga 6420
agttaaattt ttatgtaaat tcaacatgtg acacttgata atagtaattg tcaccagtgt 6480
ttatgtttta actgccacac ctgccatatt tttacaaaac gtgtgctgtg aatttatcac 6540
ttttcttttt aattcacagg ttgtttacta ttatatgtga ctatttttgt aaatgggttt 6600
gtgtttgggg agagggatta aaggaggga attctacatt tctctattgt attgtataac 6660
tggatatatt ttaaaggag gcatgctgca attctcattc acacataaaa aaatcacatc 6720
acaaaaggga agagtttact tcttgtttca ggatgttttt agatttttga ggtgcttaaa 6780
tagctattcg tatttttaag gtgtctcatc cagaaaaaat ttaatgtgcc tgtaaatgtt 6840
ccatagaatc acaagcatta aagagttgtt ttatttttac ataaccatt aaatgtacat 6900
gtatatatgt atatatgtat atgtgctgt atatacatat atatgtatac acacatgcac 6960
acacagagat atacacatac cattacattg tcattcacag tcccagcagc atgactatca 7020
catttttgat aagtgtcctt tggcataaaa taaaaatata ctatcagtc tttctaagaa 7080
gcctgaattg accaaaaaac atccccacca ccactttata aagttgatcc tgccttatcc 7140
tgcagtattg tttagccatc ttctgctctt ggtaagggtg acatagtata tgtcaattta 7200
aaaaataaaa gtctgctttg taaatagtaa ttttaccag tgggtgcatgt ttgagcaaac 7260
aaaaatgatg atttaagcac actacttatt gcatcaaata tgtaccacag taagtatagt 7320
ttgcaagctt tcaacaggta atatgatgta attgggtcca ttatagtttg aagctgtcac 7380
tgctgcatgt ttatcttgcc tatgtgctg tatcttattc ctccactgt tcagaagtct 7440
aatatgggaa gccatatatc agtggtaaag tgaagcaaat tgttctacca agacctcatt 7500
cttcatgtca ttaagcaata ggttgagca aacaaggag agcttcttgc tttttattct 7560
tccaacctta attgaacact caatgatgaa aagcccgact gtacaaacat gttgcaagct 7620
gcttaaatct gtttaaaata tatggttaga gttttctaag aaaatataaa tactgtaaaa 7680
agttcatttt attttatttt tcagcctttt gtacgtaaaa tgagaaatta aaagtatctt 7740
caggtggatg tcacagtcac tattgttagt ttctgttctt agcactttta aattgaagca 7800
cttcacaaaa taagaagcaa ggactaggat gcagtgtagg tttctgcttt tttattagta 7860
ctgtaaaact gcacacattt caatgtgaaa caaatctcaa actgagttca atgtttattt 7920
gctttcaata gtaatgcctt atcattgaaa gaggttaaa gaaaaaaaaa atcagctgat 7980
actcttgga ttgcttgaat ccaatgtttc cacctagtct ttttattcag taatcatcag 8040
tcttttccaa tgtttgttta cacagataga tcttatigac ccatatggca ctagaactgt 8100
atcagatata atatgggac ccagcttttt ttctctctcc aaaaaccag gtagtgaagt 8160
tatattacca gttacagcaa aatactttgt gtttcacaag caacaataaa tgtagattct 8220
ttatactgaa gctattgact tgtagtgtgt tggatgaatgc atgcaggaag atgctgttac 8280
cataaagaac ggtaaaccac attacaatca agccaaagaa taaaggttcg cttatgtata 8340
tgtatttaa
8349

```

&lt;210&gt; 34

&lt;211&gt; 8349

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 34

```

ttcttggtgc cagcttatca atcccaaact ctgggtgtaa aagattctac agggcacttt 60
cttatgcaag gagctaaaca gtgattaaag gagcaggatg aaaagatggc acagtcagt 120
ctggtagcgc caggacctga cagcttccgc ttctttacca ggaatccct tgctgtatt 180

```

```

gaacaacgca ttgcagaaga gaaagctaag agacccaaac aggaacgcaa ggatgaggat 240
gatgaaaatg gcccaaagcc aaacagtgcac ttggaagcag gaaaatctct tccatttatt 300
tatggagaca ttctccaga gatggtgtca gtgccctgg aggatctgga cccctactat 360
atcaataaga aaacgtttat agtattgaat aaagggaaag caatctctcg attcagtgcc 420
accctgccc ttacatttt aactcccttc aaccctatta gaaaattagc tattaagatt 480
ttggtacatt ctttattcaa tatgctcatt atgtgcacga ttcttaccac ctgtgtattt 540
atgaccatga gtaaccctcc agactggaca aagaatgtgg agtatacctt tacaggaatt 600
tatacttttg aatcacttat taaaatactt gcaaggggct tttgtttaga agatttcaca 660
tttttacggg atccatggaa ttggttgat ttacagtca ttacttttgc atatgtgaca 720
gagtttgtgg acctgggcaa tgtctcagcg ttgagaacat tcagagttct ccgagcattg 780
aaaacaattt cagtcattcc aggcctgaag accattgtgg gggccctgat ccagtcagtg 840
aagaagcttt ctgatgtcat gatcttgact gtgttctgtc taagcgtgtt tgcgctaata 900
ggattgcagt tgttcattgg caacctacga aataaatgtt tgcaatggcc tccagataat 960
tcttcctttg aaataaatat cacttccttc ttaacaatt cattggatgg gaatggtact 1020
actttcaata ggacagtgc catatttaac tgggatgaat atattgagga taaaagtcac 1080
ttttattttt tagaggggca aatgatgct ctgctttgtg gcaacagctc agatgcaggc 1140
cagtgtcctg aaggatacat ctgtgtgaag gctggtagaa accccaacta tggctacacg 1200
agctttgaca cctttagttg ggcctttttg tccttatttc gtctcatgac tcaagacttc 1260
tgggaaaacc ttatcaact gacactacgt gctgctggga aaacgtacat gatatttttt 1320
gtgctggtca tttcttggg ctcatctat ctaataaatt tgatcttggc tgtggtggcc 1380
atggcctatg aggaacagaa tcaggccaca ttggaagagg ctgaacagaa ggaagctgaa 1440
tttcagcaga tgctcgaaca gttgaaaaag caacaagaag aagctcaggc ggcagctgca 1500
gccgcctctg ctgaatcaag agacttcagt ggtgctggtg ggataggagt tttttcagag 1560
agttcttcag tagcatctaa gttgagctcc aaaagtgaag aagagctgaa aaacagaaga 1620
aagaaaaaga aacagaaaga acagtctgga gaagaagaga aaaatgacag agtcctaaaa 1680
tcggaatctg aagacagcat aagaagaaaa ggtttccgtt tttccttggg aggaagtagg 1740
ctgacatatg aaaagagatt ttcttctcca caccagctct tactgagcat ccgtggctcc 1800
cttttctctc caagacgcaa cagtagggcg agccttttca gcttcagagg tcgagcaaag 1860
gacattggct ctgagaatga ctttctgat gatgagcaca gcacctttga ggacaatgac 1920
agccgaagag actctctgtt cgtgccgcac agacatggag aacggcgcca cagcaatgtc 1980
agccaggcca gccgtgctc cagggtgctc cccatcctgc ccatgaatgg gaagatgcat 2040
agcgtgtgg actgcaatgg tgtggtctcc ctggctgggg gcccttctac cctcacatct 2100
gctgggcagc tcctaccaga gggcacaact actgaaacag aaataagaaa gagacggtcc 2160
agttcttacc atgtttccat ggatttattg gaagatccta catcaaggca aagagcaatg 2220
agtatagcca gtattttgac caacaccatg gaagaacttg aagaatccag acagaaatgc 2280
ccaccatgct ggtataaatt tgctaatatg tgtttgattt gggactgttg taaaccatgg 2340
ttaaagggtg aacaccttgt caacctggtt gtaatggacc catttggtga cctggccatc 2400
accatctgca ttgtcttaaa tacactcttc atggctatgg agcactatcc catgacggag 2460
cagttcagca gtgtactgtc tgttggaac ctggtcttca cagggatctt cacagcagaa 2520
atgtttctca agataattgc catggatcca tattattact ttcaagaagg ctggaatatt 2580
tttgatggtt ttattgtgag ccttagttta atggaacttg gtttgcaaaa tgtggaagga 2640
ttgtcagttc tccgatcatt ccggctgctc cgagttttca agttggcaaa atcttgcca 2700
actctaaata tgctaattaa gatcattggc aattctgtgg gggctctagg aaacctcacc 2760
ttggtattgg ccatcatcgt cttcattttt gctgtggtcg gcatgcagct ctttggtgaa 2820
agctacaaag aatgtgtctg caagatttcc aatgattgtg aactcccacg ctggcacatg 2880
catgactttt tccactcctt cctgatcgtg ttccgcgtgc tgtgtggaga gtggatagag 2940
accatgtggg actgtatgga ggctcgctggc caaaccatgt gccttactgt cttcatgatg 3000
gtcatggtga ttggaaatct agtgggtctg aacctcttct tggccttgct tttgagttcc 3060

```

```

ttcagttctg acaatcttgc tgccactgat gatgataacg aaatgaataa tctccagatt 3120
gctgtgggaa ggatgcagaa aggaatcgat tttgttaaaa gaaaaatagc tgaattttatt 3180
cagaaagcct ttgttaggaa gcagaaagct ttagatgaaa ttaaaccgct tgaagatcta 3240
aataataaaa aagacagctg tatttccaac cataccacca tagaaatagg caaagacctc 3300
aattatctca aagacggaaa tggaaactact agtggcatag gcagcagtggt agaaaaatat 3360
gtcgtggatg aaagtgatta catgtcattt ataaacaacc ctagecctcac tgtgacagta 3420
ccaattgctg ttggagaatc tgactttgaa aattttaata ctgaagaatt cagcagcgag 3480
tcagatatgg aggaaagcaa agagaagcta aatgcaacta gttcatctga aggcagcacg 3540
gttgatattg gagctcccgc cgagggagaa cagcctgagg ttgaacctga ggaatccctt 3600
gaacctgaag cctgttttac agaagactgt gtacggaagt tcaagtgttg tcagataagc 3660
atagaagaag gcaaagggaa actctgggtg aatttgagga aaacatgcta taagatagtg 3720
gagcacaatt ggttcgaaac cttcattgtc ttcattgattc tgctgagcag tggggctctg 3780
gcctttgaag atatatacat tgagcagcga aaaaccatta agaccatggt agaatatgct 3840
gacaagggtt tcacttacat attcattctg gaaatgctgc taaagtgggt tgcatatggt 3900
tttcaagtgt attttaccaa tgccctgggtc tggctagact tcctgattgt tgatgtctca 3960
ctgggttagct taactgcaaa tgccctgggt tactcagaac ttggtgccat caaatccctc 4020
agaacactaa gagctctgag gccactgaga gctttgtccc gggttgagg aatgagggtc 4080
gttgtaaagt ctcttttagg agccattcca tctatcatga atgtacttct gggttgctctg 4140
atcttttggc taatattcag tatcatggga gtgaatctct ttgctggcaa gttttaccat 4200
tgtattaatt acaccactgg agagatgttt gatgtaagcg tggccaacaa ctacagttag 4260
tgcaaagctc tcattgagag caatcaaact gccaggtgga aaaatgtgaa agtaaaacttt 4320
gataacgtag gacttgata tctgtctcta cttcaagtag ccacgtttaa gggatggatg 4380
gatattatgt atgcagctgt tgattcacga aatgtagaat tacaacccaa gtatgaagac 4440
aacctgtaca tgtatcttta ttttgtcatc tttattattt ttggttcatt ctttaccttg 4500
aatcttttca ttgggtgtcat catagataac ttcaaccaac agaaaaagaa gtttgagggt 4560
caagacattt ttatgacaga agaacagaag aaatactaca atgcaatgaa aaaactgggt 4620
tcaaagaaac cacaaaaacc catacctcga cctgctaaca aattccaagg aatgggtctt 4680
gattttgtaa ccaaacaagt ctttgatata agcatcatga tcctcatctg ccttaacatg 4740
gtcaccatga tgggtgaaac cgatgaccag agtcaagaaa tgacaaacat tctgtactgg 4800
attaatctgg tgtttattgt tctgttcact ggagaatgtg tgctgaaact gatctctctt 4860
cgttactact atttcactat tggatggaat atttttgatt ttgtgggtgg cattctctcc 4920
attgtaggaa tgtttctggc tgaactgata gaaaagtatt ttgtgtcccc taccctgttc 4980
cgagtgatcc gtcttgccag gattggccga atcctacgtc tgatcaaagg agcaaagggg 5040
atccgcaecg tgetctttgc tttgatgatg tcccttctct cgttgtttta catcggcctc 5100
cttcttttcc tgggtcatgt catctacgcc atctttggga tgtccaattt tgccatgttt 5160
aagagggaag ttgggatcga tgacatgttc aactttgaga cctttggcaa cagcatgata 5220
tgccctgttc aaattacaac ctctgctggc tgggatggat tgctagcacc tattcttaat 5280
agtggacctc cagactgtga ccctgacaaa gatcaccctg gaagctcagt taaaggagac 5340
tgtgggaacc catctgttgg gattttcttt tttgtcagtt acatcatcat atccttctctg 5400
gttggtggga acatgtacat cgcggtcctc ctggagaact tcagtgttgc tactgaagaa 5460
agtgcagagc ctctgagtga ggatgacttt gagatgttct atgaggtttg ggagaagttt 5520
gatcccgatg cgaccaggtt tatagagttt gccaaacttt ctgattttgc agatgccctg 5580
gatcctcctc ttctcatagc aaaacccaac aaagtccagc tcattgccat ggatctgccc 5640
atgggtgagt gtgaccggat ccactgtctt gacatcttat ttgcttttac aaagcgtgtt 5700
ttgggtgaga gtggagagat ggatgccctt cgaatacaga tggaagagcg attcatggca 5760
tcaaaccctt ccaaagtctc ttatgagccc attacgacca cgttgaaacg caaacaagag 5820
gaggtgtctg ctattattat ccagagggct tacagacgct acctcttgaa gcaaaaagtt 5880
aaaaaggtat caagtatata caagaaagac aaaggcaaag aatgtgatgg aacacccatc 5940

```

```

aaagaagata ctctcattga taaactgaat gagaattcaa ctccagagaa aaccgatatg 6000
acgccttcca ccacgtctcc accctcgtat gatagtgtga ccaaaccaga aaaagaaaaa 6060
tttgaaaaag acaaatacaga aaaggaagac aaagggaag atatcaggga aagtaaaaaa 6120
taaaaagaaa ccaagaattt tccattttgt gatcaattgt ttacagcccg tgatggtgat 6180
gtgttttgtt caacaggact cccacaggag gtctatgcca aactgactgt ttttacaat 6240
gtatacttaa ggtcagtgc tataacaaga cagagacctc tggtcagcaa actggaactc 6300
agtaaactgg agaaatagta tcgatgggag gtttctattt tcacaaccag ctgacactgc 6360
tgaagagcag aggcgtaatg gctactcaga cgataggaac caatttaaag gggggaggga 6420
agttaaattt ttatgtaaat tcaacatgtg acacttgata atagtaattg tcaccagtgt 6480
ttatgtttta actgccacac ctgccatatt tttacaaaac gtgtgctgtg aatttatcac 6540
ttttcttttt aattcacagg ttgtttacta ttatatgtga ctatttttgt aaatgggttt 6600
gtgtttgggg agagggatta aaggaggga attctacatt tctctattgt attgtataac 6660
tggatatatt ttaaattggag gcatgctgca attctcattc acacataaaa aaatcacatc 6720
acaaaaggga agagtttact tcttgtttca ggatgttttt agatttttga ggtgcttaaa 6780
tagctattcg tatttttaag gtgtctcacc cagaaaaaat ttaatgtgcc tgtaaatgtt 6840
ccatagaatc acaagcatta aagagttgtt ttatttttac ataaccatt aaatgtacat 6900
gtatatatgt atatatgtat atgtgctgt atatacatat atatgtatac acacatgcac 6960
acacagagat atacacatac cattacattg tcatcacag tcccagcagc atgactatca 7020
catttttgat aagtgtcctt tggcataaaa taaaaatata ctatcagtc tttctaagaa 7080
gcctgaattg accaaaaaac atccccacca ccactttata aagttgattc tgctttatcc 7140
tgcagtattg ttagccatc ttctgctctt ggtaagggtg acatagtata tgtcaattta 7200
aaaaataaaa gtctgctttg taaatagtaa ttttaccag tggtgcatgt ttgagcaaac 7260
aaaaatgatg atttaagcac actacttatt gcatcaaata tgtaccacag taagtatagt 7320
ttgcaagctt tcaacaggta atatgatgta attggttcca ttatagtttg aagctgtcac 7380
tgctgcatgt ttatcttgcc tatgctgctg tatcttattc cttccactgt tcagaagtct 7440
aatatgggaa gccatatatc agtggtaaaag tgaagcaaat tgttctacca agacctcatt 7500
cttcatgtca ttaagcaata ggttgacgca aacaagggaag agcttcttgc tttttattct 7560
tccaacctta attgaacact caatgatgaa aagcccgact gtacaaacat gttgcaagct 7620
gcttaaatct gtttaaaata tatggttaga gttttctaag aaaatataaa tactgtaaaa 7680
agttcatttt attttatttt tcagcctttt gtacgtaaaa tgagaaatta aaagtatctt 7740
caggtggatg tcacagtcac tattgttagt ttctgttctt agcactttta aattgaagca 7800
cttcacaaaa taagaagcaa ggactaggat gcagtgtagg tttctgcttt tttattagta 7860
ctgtaaactt gcacacattt caatgtgaaa caaatctcaa actgagttca atgtttattt 7920
gctttcaata gtaatgcctt atcattgaaa gaggtttaa gaaaaaaa atcagctgat 7980
actcttgga ttgcttgaat ccaatgtttc cacctagtct ttttattcag taatcatcag 8040
tcttttccaa tgtttgttta cacagataga tcttattgac ccatatggca ctagaactgt 8100
atcagatata atatgggatc ccagcttttt ttctctccc acaaaaccag gtagtgaagt 8160
tatattacca gttacagcaa aatactttgt gtttcacaag caacaataaa tgtagattct 8220
ttatactgaa gctattgact tgtagtgtgt tggatgaatgc atgcaggaag atgctgttac 8280
cataaagaac ggtaaaccac attacaatca agccaaagaa taaaggttcg cttatgtata 8340
tgtatttaa 8349

```

&lt;210&gt; 35

&lt;211&gt; 2005

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

Met Ala Gln Ser Val Leu Val Pro Pro Gly Pro Asp Ser Phe Arg Phe  
 1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Gln Arg Ile Ala Glu Glu  
 20 25 30

Lys Ala Lys Arg Pro Lys Gln Glu Arg Lys Asp Glu Asp Asp Glu Asn  
 35 40 45

Gly Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Ser Leu Pro Phe  
 50 55 60

Ile Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Val Pro Leu Glu Asp  
 65 70 75 80

Leu Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys  
 85 90 95

Gly Lys Ala Ile Ser Arg Phe Ser Ala Thr Pro Ala Leu Tyr Ile Leu  
 100 105 110

Thr Pro Phe Asn Pro Ile Arg Lys Leu Ala Ile Lys Ile Leu Val His  
 115 120 125

Ser Leu Phe Asn Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val  
 130 135 140

Phe Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr  
 145 150 155 160

Thr Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala  
 165 170 175

Arg Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn  
 180 185 190

Trp Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val  
 195 200 205

Asp Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala  
 210 215 220

Leu Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala  
 225 230 235 240

Leu Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val  
 245 250 255

Phe Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly  
 260 265 270

Asn Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Asp Asn Ser Ser Phe  
 275 280 285

Glu Ile Asn Ile Thr Ser Phe Phe Asn Asn Ser Leu Asp Gly Asn Gly  
 290 295 300

Thr Thr Phe Asn Arg Thr Val Ser Ile Phe Asn Trp Asp Glu Tyr Ile  
 305 310 315 320

Glu Asp Lys Ser His Phe Tyr Phe Leu Glu Gly Gln Asn Asp Ala Leu  
 325 330 335

Leu Cys Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile  
 340 345 350

Cys Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp  
 355 360 365

Thr Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp  
 370 375 380

Phe Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr  
 385 390 395 400

Tyr Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu  
 405 410 415

Ile Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn  
 420 425 430

Gln Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln  
 435 440 445

Met Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Ala Ala  
 450 455 460

Ala Ala Ala Ser Ala Glu Ser Arg Asp Phe Ser Gly Ala Gly Gly Ile  
 465 470 475 480

Gly Val Phe Ser Glu Ser Ser Ser Val Ala Ser Lys Leu Ser Ser Lys  
 485 490 495

Ser Glu Lys Glu Leu Lys Asn Arg Arg Lys Lys Lys Lys Gln Lys Glu  
 500 505 510



Gln Ser Gly Glu Glu Glu Lys Asn Asp Arg Val Leu Lys Ser Glu Ser  
 515 520 525

Glu Asp Ser Ile Arg Arg Lys Gly Phe Arg Phe Ser Leu Glu Gly Ser  
 530 535 540

Arg Leu Thr Tyr Glu Lys Arg Phe Ser Ser Pro His Gln Ser Leu Leu  
 545 550 555 560

Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Ala Ser  
 565 570 575

Leu Phe Ser Phe Arg Gly Arg Ala Lys Asp Ile Gly Ser Glu Asn Asp  
 580 585 590

Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Asn Asp Ser Arg Arg  
 595 600 605

Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg His Ser Asn  
 610 615 620

Val Ser Gln Ala Ser Arg Ala Ser Arg Val Leu Pro Ile Leu Pro Met  
 625 630 635 640

Asn Gly Lys Met His Ser Ala Val Asp Cys Asn Gly Val Val Ser Leu  
 645 650 655

Val Gly Gly Pro Ser Thr Leu Thr Ser Ala Gly Gln Leu Leu Pro Glu  
 660 665 670

Gly Thr Thr Thr Glu Thr Glu Ile Arg Lys Arg Arg Ser Ser Ser Tyr  
 675 680 685

His Val Ser Met Asp Leu Leu Glu Asp Pro Thr Ser Arg Gln Arg Ala  
 690 695 700

Met Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu  
 705 710 715 720

Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Lys Phe Ala Asn Met Cys  
 725 730 735

Leu Ile Trp Asp Cys Cys Lys Pro Trp Leu Lys Val Lys His Leu Val  
 740 745 750

Asn Leu Val Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys  
 755 760 765

Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr  
 770 775 780

Glu Gln Phe Ser Ser Val Leu Ser Val Gly Asn Leu Val Phe Thr Gly  
 785 790 795 800

Ile Phe Thr Ala Glu Met Phe Leu Lys Ile Ile Ala Met Asp Pro Tyr  
 805 810 815

Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Phe Ile Val Ser  
 820 825 830

Leu Ser Leu Met Glu Leu Gly Leu Ala Asn Val Glu Gly Leu Ser Val  
 835 840 845

Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp  
 850 855 860

Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala  
 865 870 875 880

Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala  
 885 890 895

Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys  
 900 905 910

Lys Ile Ser Asn Asp Cys Glu Leu Pro Arg Trp His Met His Asp Phe  
 915 920 925

Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile  
 930 935 940

Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu  
 945 950 955 960

Thr Val Phe Met Met Val Met Val Ile Gly Asn Leu Val Val Leu Asn  
 965 970 975

Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala  
 980 985 990

Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Leu Gln Ile Ala Val Gly  
 995 1000 1005

Arg Met Gln Lys Gly Ile Asp Phe Val Lys Arg Lys Ile Arg Glu Phe  
 1010 1015 1020

Ile Gln Lys Ala Phe Val Arg Lys Gln Lys Ala Leu Asp Glu Ile Lys  
 1025 1030 1035 1040

Pro Leu Glu Asp Leu Asn Asn Lys Lys Asp Ser Cys Ile Ser Asn His  
 1045 1050 1055

Thr Thr Ile Glu Ile Gly Lys Asp Leu Asn Tyr Leu Lys Asp Gly Asn  
 1060 1065 1070

Gly Thr Thr Ser Gly Ile Gly Ser Ser Val Glu Lys Tyr Val Val Asp  
 1075 1080 1085

Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val Thr  
 1090 1095 1100

Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn Thr Glu  
 1105 1110 1115 1120

Glu Phe Ser Ser Glu Ser Asp Met Glu Glu Ser Lys Glu Lys Leu Asn  
 1125 1130 1135

Ala Thr Ser Ser Ser Glu Gly Ser Thr Val Asp Ile Gly Ala Pro Ala  
 1140 1145 1150

Glu Gly Glu Gln Pro Glu Val Glu Pro Glu Glu Ser Leu Glu Pro Glu  
 1155 1160 1165

Ala Cys Phe Thr Glu Asp Cys Val Arg Lys Phe Lys Cys Cys Gln Ile  
 1170 1175 1180

Ser Ile Glu Glu Gly Lys Gly Lys Leu Trp Trp Asn Leu Arg Lys Thr  
 1185 1190 1195 1200

Cys Tyr Lys Ile Val Glu His Asn Trp Phe Glu Thr Phe Ile Val Phe  
 1205 1210 1215

Met Ile Leu Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile  
 1220 1225 1230

Glu Gln Arg Lys Thr Ile Lys Thr Met Leu Glu Tyr Ala Asp Lys Val  
 1235 1240 1245

Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr  
 1250 1255 1260

Gly Phe Gln Val Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu  
 1265 1270 1275 1280

Ile Val Asp Val Ser Leu Val Ser Leu Thr Ala Asn Ala Leu Gly Tyr  
 1285 1290 1295

Ser Glu Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg  
 1300 1305 1310

Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met Arg Ala Val Val Asn  
 1315 1320 1325

Ala Leu Leu Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val Cys  
 1330 1335 1340

Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu Phe Ala  
 1345 1350 1355 1360

Gly Lys Phe Tyr His Cys Ile Asn Tyr Thr Thr Gly Glu Met Phe Asp  
 1365 1370 1375

Val Ser Val Val Asn Asn Tyr Ser Glu Cys Lys Ala Leu Ile Glu Ser  
 1380 1385 1390

Asn Gln Thr Ala Arg Trp Lys Asn Val Lys Val Asn Phe Asp Asn Val  
 1395 1400 1405

Gly Leu Gly Tyr Leu Ser Leu Leu Gln Val Ala Thr Phe Lys Gly Trp  
 1410 1415 1420

Met Asp Ile Met Tyr Ala Ala Val Asp Ser Arg Asn Val Glu Leu Gln  
 1425 1430 1435 1440

Pro Lys Tyr Glu Asp Asn Leu Tyr Met Tyr Leu Tyr Phe Val Ile Phe  
 1445 1450 1455

Ile Ile Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe Ile Gly Val Ile  
 1460 1465 1470

Ile Asp Asn Phe Asn Gln Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile  
 1475 1480 1485

Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu  
 1490 1495 1500

Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg Pro Ala Asn Lys Phe  
 1505 1510 1515 1520

Gln Gly Met Val Phe Asp Phe Val Thr Lys Gln Val Phe Asp Ile Ser  
 1525 1530 1535

Ile Met Ile Leu Ile Cys Leu Asn Met Val Thr Met Met Val Glu Thr  
 1540 1545 1550

Asp Asp Gln Ser Gln Glu Met Thr Asn Ile Leu Tyr Trp Ile Asn Leu  
 1555 1560 1565

Val Phe Ile Val Leu Phe Thr Gly Glu Cys Val Leu Lys Leu Ile Ser  
 1570 1575 1580

Leu Arg Tyr Tyr Tyr Phe Thr Ile Gly Trp Asn Ile Phe Asp Phe Val  
 1585 1590 1595 1600

Val Val Ile Leu Ser Ile Val Gly Met Phe Leu Ala Glu Leu Ile Glu  
 1605 1610 1615

Lys Tyr Phe Val Ser Pro Thr Leu Phe Arg Val Ile Arg Leu Ala Arg  
 1620 1625 1630

Ile Gly Arg Ile Leu Arg Leu Ile Lys Gly Ala Lys Gly Ile Arg Thr  
 1635 1640 1645

Leu Leu Phe Ala Leu Met Met Ser Leu Pro Ala Leu Phe Asn Ile Gly  
 1650 1655 1660

Leu Leu Leu Phe Leu Val Met Phe Ile Tyr Ala Ile Phe Gly Met Ser  
 1665 1670 1675 1680

Asn Phe Ala Tyr Val Lys Arg Glu Val Gly Ile Asp Asp Met Phe Asn  
 1685 1690 1695

Phe Glu Thr Phe Gly Asn Ser Met Ile Cys Leu Phe Gln Ile Thr Thr  
 1700 1705 1710

Ser Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile Leu Asn Ser Gly Pro  
 1715 1720 1725

Pro Asp Cys Asp Pro Asp Lys Asp His Pro Gly Ser Ser Val Lys Gly  
 1730 1735 1740

Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Phe Phe Val Ser Tyr Ile  
 1745 1750 1755 1760

Ile Ile Ser Phe Leu Val Val Val Asn Met Tyr Ile Ala Val Ile Leu  
 1765 1770 1775

Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu  
 1780 1785 1790

Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp  
 1795 1800 1805

Ala Thr Gln Phe Ile Glu Phe Ala Lys Leu Ser Asp Phe Ala Asp Ala  
 1810 1815 1820

Leu Asp Pro Pro Leu Leu Ile Ala Lys Pro Asn Lys Val Gln Leu Ile  
 1825 1830 1835 1840

Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg Ile His Cys Leu Asp  
 1845 1850 1855

Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly Glu Ser Gly Glu Met  
 1860 1865 1870

Asp Ala Leu Arg Ile Gln Met Glu Glu Arg Phe Met Ala Ser Asn Pro  
 1875 1880 1885

Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr Leu Lys Arg Lys Gln  
 1890 1895 1900

Glu Glu Val Ser Ala Ile Ile Ile Gln Arg Ala Tyr Arg Arg Tyr Leu  
 1905 1910 1915 1920

Leu Lys Gln Lys Val Lys Lys Val Ser Ser Ile Tyr Lys Lys Asp Lys  
 1925 1930 1935

Gly Lys Glu Cys Asp Gly Thr Pro Ile Lys Glu Asp Thr Leu Ile Asp  
 1940 1945 1950

Lys Leu Asn Glu Asn Ser Thr Pro Glu Lys Thr Asp Met Thr Pro Ser  
 1955 1960 1965

Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys Pro Glu Lys Glu  
 1970 1975 1980

Lys Phe Glu Lys Asp Lys Ser Glu Lys Glu Asp Lys Gly Lys Asp Ile  
 1985 1990 1995 2000

Arg Glu Ser Lys Lys  
 2005

<210> 36

<211> 2005

<212> PRT

<213> Homo sapiens

&lt;400&gt; 36

Met Ala Gln Ser Val Leu Val Pro Pro Gly Pro Asp Ser Phe Arg Phe  
 1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Gln Arg Ile Ala Glu Glu  
 20 25 30

Lys Ala Lys Arg Pro Lys Gln Glu Arg Lys Asp Glu Asp Asp Glu Asn  
 35 40 45

Gly Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Ser Leu Pro Phe  
 50 55 60

Ile Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Val Pro Leu Glu Asp  
 65 70 75 80

Leu Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys  
 85 90 95

Gly Lys Ala Ile Ser Arg Phe Ser Ala Thr Pro Ala Leu Tyr Ile Leu  
 100 105 110

Thr Pro Phe Asn Pro Ile Arg Lys Leu Ala Ile Lys Ile Leu Val His  
 115 120 125

Ser Leu Phe Asn Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val  
 130 135 140

Phe Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr  
 145 150 155 160

Thr Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala  
 165 170 175

Arg Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn  
 180 185 190

Trp Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val  
 195 200 205

Asn Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala  
 210 215 220

Leu Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala  
 225 230 235 240

Leu Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val

245	250	255
Phe Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly		
260	265	270
Asn Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Asp Asn Ser Ser Phe		
275	280	285
Glu Ile Asn Ile Thr Ser Phe Phe Asn Asn Ser Leu Asp Gly Asn Gly		
290	295	300
Thr Thr Phe Asn Arg Thr Val Ser Ile Phe Asn Trp Asp Glu Tyr Ile		
305	310	315 320
Glu Asp Lys Ser His Phe Tyr Phe Leu Glu Gly Gln Asn Asp Ala Leu		
325	330	335
Leu Cys Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile		
340	345	350
Cys Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp		
355	360	365
Thr Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp		
370	375	380
Phe Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr		
385	390	395 400
Tyr Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu		
405	410	415
Ile Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn		
420	425	430
Gln Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln		
435	440	445
Met Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Ala Ala		
450	455	460
Ala Ala Ala Ser Ala Glu Ser Arg Asp Phe Ser Gly Ala Gly Gly Ile		
465	470	475 480
Gly Val Phe Ser Glu Ser Ser Ser Val Ala Ser Lys Leu Ser Ser Lys		
485	490	495
Ser Glu Lys Glu Leu Lys Asn Arg Arg Lys Lys Lys Lys Gln Lys Glu		



500	505	510
Gln Ser Gly Glu Glu Glu Lys Asn Asp Arg Val Leu Lys Ser Glu Ser		
515	520	525
Glu Asp Ser Ile Arg Arg Lys Gly Phe Arg Phe Ser Leu Glu Gly Ser		
530	535	540
Arg Leu Thr Tyr Glu Lys Arg Phe Ser Ser Pro His Gln Ser Leu Leu		
545	550	555 560
Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Ala Ser		
565	570	575
Leu Phe Ser Phe Arg Gly Arg Ala Lys Asp Ile Gly Ser Glu Asn Asp		
580	585	590
Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Asn Asp Ser Arg Arg		
595	600	605
Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg His Ser Asn		
610	615	620
Val Ser Gln Ala Ser Arg Ala Ser Arg Val Leu Pro Ile Leu Pro Met		
625	630	635 640
Asn Gly Lys Met His Ser Ala Val Asp Cys Asn Gly Val Val Ser Leu		
645	650	655
Val Gly Gly Pro Ser Thr Leu Thr Ser Ala Gly Gln Leu Leu Pro Glu		
660	665	670
Gly Thr Thr Thr Glu Thr Glu Ile Arg Lys Arg Arg Ser Ser Ser Tyr		
675	680	685
His Val Ser Met Asp Leu Leu Glu Asp Pro Thr Ser Arg Gln Arg Ala		
690	695	700
Met Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu		
705	710	715 720
Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Lys Phe Ala Asn Met Cys		
725	730	735
Leu Ile Trp Asp Cys Cys Lys Pro Trp Leu Lys Val Lys His Leu Val		
740	745	750
Asn Leu Val Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys		

755	760	765
Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr		
770	775	780
Glu Gln Phe Ser Ser Val Leu Ser Val Gly Asn Leu Val Phe Thr Gly		
785	790	795 800
Ile Phe Thr Ala Glu Met Phe Leu Lys Ile Ile Ala Met Asp Pro Tyr		
805	810	815
Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Phe Ile Val Ser		
820	825	830
Leu Ser Leu Met Glu Leu Gly Leu Ala Asn Val Glu Gly Leu Ser Val		
835	840	845
Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp		
850	855	860
Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala		
865	870	875 880
Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala		
885	890	895
Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys		
900	905	910
Lys Ile Ser Asn Asp Cys Glu Leu Pro Arg Trp His Met His Asp Phe		
915	920	925
Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile		
930	935	940
Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu		
945	950	955 960
Thr Val Phe Met Met Val Met Val Ile Gly Asn Leu Val Val Leu Asn		
965	970	975
Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala		
980	985	990
Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Leu Gln Ile Ala Val Gly		
995	1000	1005
Arg Met Gln Lys Gly Ile Asp Phe Val Lys Arg Lys Ile Arg Glu Phe		

1010	1015	1020
Ile Gln Lys Ala Phe Val Arg Lys Gln Lys Ala Leu Asp Glu Ile Lys		
1025	1030	1035 1040
Pro Leu Glu Asp Leu Asn Asn Lys Lys Asp Ser Cys Ile Ser Asn His		
1045	1050	1055
Thr Thr Ile Glu Ile Gly Lys Asp Leu Asn Tyr Leu Lys Asp Gly Asn		
1060	1065	1070
Gly Thr Thr Ser Gly Ile Gly Ser Ser Val Glu Lys Tyr Val Val Asp		
1075	1080	1085
Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val Thr		
1090	1095	1100
Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn Thr Glu		
1105	1110	1115 1120
Glu Phe Ser Ser Glu Ser Asp Met Glu Glu Ser Lys Glu Lys Leu Asn		
1125	1130	1135
Ala Thr Ser Ser Ser Glu Gly Ser Thr Val Asp Ile Gly Ala Pro Ala		
1140	1145	1150
Glu Gly Glu Gln Pro Glu Val Glu Pro Glu Glu Ser Leu Glu Pro Glu		
1155	1160	1165
Ala Cys Phe Thr Glu Asp Cys Val Arg Lys Phe Lys Cys Cys Gln Ile		
1170	1175	1180
Ser Ile Glu Glu Gly Lys Gly Lys Leu Trp Trp Asn Leu Arg Lys Thr		
1185	1190	1195 1200
Cys Tyr Lys Ile Val Glu His Asn Trp Phe Glu Thr Phe Ile Val Phe		
1205	1210	1215
Met Ile Leu Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile		
1220	1225	1230
Glu Gln Arg Lys Thr Ile Lys Thr Met Leu Glu Tyr Ala Asp Lys Val		
1235	1240	1245
Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr		
1250	1255	1260
Gly Phe Gln Val Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu		

1265	1270	1275	1280
Ile Val Asp Val Ser Leu Val Ser Leu Thr Ala Asn Ala Leu Gly Tyr	1285	1290	1295
Ser Glu Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg	1300	1305	1310
Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met Arg Ala Val Val Asn	1315	1320	1325
Ala Leu Leu Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val Cys	1330	1335	1340
Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu Phe Ala	1345	1350	1355
Gly Lys Phe Tyr His Cys Ile Asn Tyr Thr Thr Gly Glu Met Phe Asp	1365	1370	1375
Val Ser Val Val Asn Asn Tyr Ser Glu Cys Lys Ala Leu Ile Glu Ser	1380	1385	1390
Asn Gln Thr Ala Arg Trp Lys Asn Val Lys Val Asn Phe Asp Asn Val	1395	1400	1405
Gly Leu Gly Tyr Leu Ser Leu Leu Gln Val Ala Thr Phe Lys Gly Trp	1410	1415	1420
Met Asp Ile Met Tyr Ala Ala Val Asp Ser Arg Asn Val Glu Leu Gln	1425	1430	1435
Pro Lys Tyr Glu Asp Asn Leu Tyr Met Tyr Leu Tyr Phe Val Ile Phe	1445	1450	1455
Ile Ile Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe Ile Gly Val Ile	1460	1465	1470
Ile Asp Asn Phe Asn Gln Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile	1475	1480	1485
Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu	1490	1495	1500
Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg Pro Ala Asn Lys Phe	1505	1510	1515
Gln Gly Met Val Phe Asp Phe Val Thr Lys Gln Val Phe Asp Ile Ser			

1525	1530	1535
Ile Met Ile Leu Ile Cys Leu Asn Met Val Thr Met Met Val Glu Thr		
1540	1545	1550
Asp Asp Gln Ser Gln Glu Met Thr Asn Ile Leu Tyr Trp Ile Asn Leu		
1555	1560	1565
Val Phe Ile Val Leu Phe Thr Gly Glu Cys Val Leu Lys Leu Ile Ser		
1570	1575	1580
Leu Arg Tyr Tyr Tyr Phe Thr Ile Gly Trp Asn Ile Phe Asp Phe Val		
1585	1590	1595
Val Val Ile Leu Ser Ile Val Gly Met Phe Leu Ala Glu Leu Ile Glu		
1605	1610	1615
Lys Tyr Phe Val Ser Pro Thr Leu Phe Arg Val Ile Arg Leu Ala Arg		
1620	1625	1630
Ile Gly Arg Ile Leu Arg Leu Ile Lys Gly Ala Lys Gly Ile Arg Thr		
1635	1640	1645
Leu Leu Phe Ala Leu Met Met Ser Leu Pro Ala Leu Phe Asn Ile Gly		
1650	1655	1660
Leu Leu Leu Phe Leu Val Met Phe Ile Tyr Ala Ile Phe Gly Met Ser		
1665	1670	1675
Asn Phe Ala Tyr Val Lys Arg Glu Val Gly Ile Asp Asp Met Phe Asn		
1685	1690	1695
Phe Glu Thr Phe Gly Asn Ser Met Ile Cys Leu Phe Gln Ile Thr Thr		
1700	1705	1710
Ser Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile Leu Asn Ser Gly Pro		
1715	1720	1725
Pro Asp Cys Asp Pro Asp Lys Asp His Pro Gly Ser Ser Val Lys Gly		
1730	1735	1740
Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Phe Phe Val Ser Tyr Ile		
1745	1750	1755
Ile Ile Ser Phe Leu Val Val Val Asn Met Tyr Ile Ala Val Ile Leu		
1765	1770	1775
Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu		

1780	1785	1790
Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp		
1795	1800	1805
Ala Thr Gln Phe Ile Glu Phe Ala Lys Leu Ser Asp Phe Ala Asp Ala		
1810	1815	1820
Leu Asp Pro Pro Leu Leu Ile Ala Lys Pro Asn Lys Val Gln Leu Ile		
1825	1830	1835
Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg Ile His Cys Leu Asp		
1845	1850	1855
Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly Glu Ser Gly Glu Met		
1860	1865	1870
Asp Ala Leu Arg Ile Gln Met Glu Glu Arg Phe Met Ala Ser Asn Pro		
1875	1880	1885
Ser Lys Val Ser Tyr Glu Pro Ile Thr Thr Thr Leu Lys Arg Lys Gln		
1890	1895	1900
Glu Glu Val Ser Ala Ile Ile Ile Gln Arg Ala Tyr Arg Arg Tyr Leu		
1905	1910	1915
Leu Lys Gln Lys Val Lys Lys Val Ser Ser Ile Tyr Lys Lys Asp Lys		
1925	1930	1935
Gly Lys Glu Cys Asp Gly Thr Pro Ile Lys Glu Asp Thr Leu Ile Asp		
1940	1945	1950
Lys Leu Asn Glu Asn Ser Thr Pro Glu Lys Thr Asp Met Thr Pro Ser		
1955	1960	1965
Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys Pro Glu Lys Glu		
1970	1975	1980
Lys Phe Glu Lys Asp Lys Ser Glu Lys Glu Asp Lys Gly Lys Asp Ile		
1985	1990	1995
Arg Glu Ser Lys Lys		
2005		

<210> 37  
 <211> 912  
 <212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

```
gaattccttta tatgggttga atgactttct gacatagcaa ataaaaagca tgaggagaag 60
cattatctgt taacaaaatt aacacttaaa atcaacaaag ttttaatggt tcgttccaag 120
aaaagcctgt ggaagatcag ttccacaact gagagctttg ggctgcttca gacatatgtc 180
tgtgtgtacg ctgtgaaggt gtttctcttc acagttcccc gccctctagt ggtagttaca 240
ataatgccat tttgtagtcc ctgtacagga aatgcctctt cttacttcag ttaccagaat 300
ccttttacag gaagttaggt gtggtccttg aaggagaatt aaaaaaaaaa aaaaaaaaaa 360
aaaaaagatt tttttttttt taaagcatga tgggaatttta gctgcagtct tcttggggcc 420
agcttatcaa tcccaaactc tgggggtaaa agattctaca ggggtaatgt tttattattc 480
ttattatgct tattctctgt gatgcttctc tacctttaca gtagtagaat ccttggggaa 540
atctgcagag ggaccacttt cattttgaag ctgctggctg catgttttag catgtctctt 600
ctattagaga atccaggcat ggcagtttcc tccccagtg tgcaaggacc atcttcatgc 660
ctatgtctgt cgctaggcat gaggtctct aggaatgggt gaaaaaaatg agggatgttt 720
tgagggcact ataatactgg ggagggcagt ctgctagctg gtagctgaaa ggtcctgggt 780
tacttcaaca ttttttttaa ataaaactgt gcagtagttt ttgttatttt agggttccct 840
ctgttttatc tgggtgatgc tgcagaagtg aactgcataa cacatttcac tcttagaaat 900
gcattccata ta 912
```

&lt;210&gt; 38

&lt;211&gt; 722

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

```
ctcagtgcat gtaactgaca caatcacctc tatctaattg tcatgcttct tacctcctgt 60
tctgtagcac tttcttatgc aaggagctaa acagtgatta aaggagcagg atgaaaagat 120
ggcacagtca gtgctggtac cgccaggacc tgacagcttc cgcttcttta ccagggaatc 180
ccttgctgct attgaacaac gcattgcaga agagaaagct aagagacca aacaggaacg 240
caaggatgag gatgatgaaa atggcccaaa gccaaacagt gacttgggaag cagsaaaatc 300
tcttccattt atttatggag acattcctcc agagatggtg tcagtgtccc tggaggatct 360
ggacccctac tatatcaata agaaagtgag ttcttagtca agttgccttc actgcctatt 420
tactaattgg ttctgggcta gtcccaggga tgatggtgaa gaaggctggc ctcttccct 480
ctgtctaaag tatcactaag atgctggatg ggcctgaccg tgtaatggac caatgatcct 540
agaagtcttt tggaagcact catttgaacc tgcatttgtg agacaggcag agaactggtg 600
aggcatcctc cagcgcggga attaaggaag gacaaaagcc tattcacctt cttgaatata 660
aattatatgc ttaaacaggt gtaaattgac cctgattccc taataatgtt gagaagcaaa 720
aa 722
```

&lt;210&gt; 39

&lt;211&gt; 561

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

```

cctatggcat tgatcacaaa ttttcttaat aatcctcatg tcatttatca aatttaggaa 60...
agtttatagt gtcagaaaaa aaaaagcatc tatcttcacg tcatatgatg gtaattatta 120
tggtatacac tattttacag ggcaatattt ataaataatg gttttacttt tctcttaaaa 180
tattcttaat atatattcta agttttgttt tatgtgttgt gttttctttt tcagacgttt 240
atagtattga ataaagggaa agcaatctct cgattcagtg ccacccctgc cctttacatt 300
ttaactccct tcaaccctat tagaaaatta gctattaaga ttttggtaca ttcataccct 360
ttttcaaadc gtcacttaat atgattttct tcttgacca agttattgag ctacacattt 420
tccaaaatat ctgtggttgg caatgttatg tgttctttct ttttctttcc ttttactcaa 480
tcgttagcat gttgcaaaat gagatcacag gtaagtgaat tactttcccc cgtcttctaa 540
gtgtttcttc tctaccaac t 561

```

&lt;210&gt; 40

&lt;211&gt; 510

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

```

acctaaatag cctcaaaaata gttgatggct tggcctgaag acaagatcta aatatgaggt 60
tgctgagtta tagaaatggc aaaaaaaagg gtcaataata gaataataag caacaaaata 120
atagtaagca ctaaagtttt aaacttcacg gtggtgaagg catggtagtg cataaaagta 180
agatttttcc attgaacttt gtcttccttg acgatattct actttattca atatgctcat 240
tatgtgcacg attcttacca actgtgtatt tatgaccatg agtaaccctc cagactggac 300
aaagaatgtg gagtaagtat aaatattttt caatattgac ctccctttat gtttcatatt 360
gtgcttttaa caccttgaga cctcctcaat ttctttaaca aatcatgcta gctactgtta 420
accagaccct gattcaaat catttctgtc actaaatgtc ttctaggaca aagcttgtag 480
tgggctcact tagttgtgta aattactgca 510

```

&lt;210&gt; 41

&lt;211&gt; 370

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

```

taagatatgt acttgtaaata taaccactag atttttaatg tgagcttggc tattgtctct 60
caggtatacc ttacaggaa tttatacttt tgaatcactt attaaaatac ttgcaagggg 120
cttttgttta gaagatttca catttttacg ggatccatgg aattggttgg atttcacagt 180
cattactttt gcgtaagtat cttaatacat tttctatcct ggaagagtaa atcactggtg 240
ggagcctata ctatattttc cttggtggct tgccttgaca gaccaagcat ttntcttagt 300
aatcatagtt ttcttccaat caaatatcc agtttgagga aattaggaac tatcatagta 360
aattacatgg 370

```

&lt;210&gt; 42

&lt;211&gt; 370

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens



&lt;400&gt; 42

```

caattagcac tgtaaagtaa taaagtttcc caaataacag agattatgat tgatgacaat 60
gccattttcc tcttaattgg gaaagctgat ggcgacactc atgaaattaa aaaggctctg 120
atgaaagacc aangaagacg tagattttccc taaattctga ataactctga ttttaattcta 180
caggtatgta acagaatttg taaacctagg caatgtttca gctcttcgaa ctttcagagt 240
cttgagagct ttgaaaacta tttctgtaat tccaggtaag aagaaaatgg tataagggtgg 300
taggccctt atatctccaa ctgtttcttg tgttctgtca ttgtgtttgt gtgtgaaccc 360
cctattacag                                     420

```

&lt;210&gt; 43

&lt;211&gt; 410

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

```

gtaagaagaa aatgggtataa ggtggtaggc ccttatatc tccaactgtt tcttgtgttc 60
tgtcattgtg tttgtgtgtg aacccccctat tacagatatg tgacagagtt tgtggacctg 120
ggcaatgtct cagcgttgag aacattcaga gttctccgag cattgaaaac aatttcagtc 180
attccagggtg agagctaggt taaacaccga ggctgacttt agctacagtg gtgctacaat 240
cacagctttt gtgcagaagc cttgttgcta gttgcatatt gcaaataaat atgtaaaaaa 300
gcaagaattg gtacatcatt ttttggtatg atttgattct ttgcttttta cccgttgctt 360
tctttaaaac tattctaaat cagcctttga gtttaacaag tgttgcata 410

```

&lt;210&gt; 44

&lt;211&gt; 1066

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

```

aaagagtgtt tggaaataca catttggttc atttccattc acagttttct aatgaacata 60
caagttctgc tttcattcat tttcaccagc tagtaggctt ttcataaaaa tgttattcaa 120
tcacaaacat taaactaata ttgttggtcat tctgcatgac atttttattt tccaggccaa 180
gctcatgata tttttgccgg taaaatagct gttgagtagt atatttaant tcccccttct 240
gattttgttt gtaggcctga agaccattgt gggggccctg atccagtcag tgaagaagct 300
ttctgatgtc atgatcttga ctgtgttctg tctaagcgtg tttgcgctaa taggattgca 360
gttgttcatg ggcaacctac gaaataaatg tttgcaatgg cctccagata attcttcctt 420
tgaaataaat atcacttcct tctttaacaa ttcattggat gggaatggtg ctactttcaa 480
taggacagtg agcatattta actgggatga atatattgag gataaaaagta agatatactc 540
tataaaccat taagttgttt agttctctaa atattaaata ttatatataa tggaaattat 600
ctcaatttag atgtgaatca agtgacttag actaatttaa gatgatttaa tacatataaa 660
agagatatca aaggatacct tattctatct tttttatctg tccattgata tagtaaaagt 720
tctcatttga aaatgtgttg tcttatactc atgttgaaag taatttcata ttatgccata 780
ttaaaaaagg tttatttggg agacattaat caggtttttc agtcatttta ataaataagt 840
cagtagtttg aactattcmg cgtattccac tgaaatgtcg ttaagaagac tgaggggaaa 900
taatttggcc ctatttgggt gatgcaacat atgtattgag tacatatgct atatctgaaa 960

```

ctagagaaac catttatcaa gatgaaataa gaatttgtgt gtcctcaga aggttaagta 1020  
accctgattt agccattcac ttcattcata ttctaattag tccctt 1066

<210> 45  
<211> 385  
<212> DNA  
<213> Homo sapiens

<400> 45  
gttcaattat tgtgaaaaat cttcttttagc catatatatt tattagttta tccatctcat 60  
tatgattgaa aacatttgtg agctttgcc aataaacagg gtggctgaag tgttttacag 120  
gatttttaatg attctttcta ttcctttctc tttaaatagg tcacttttat tttttacagg 180  
ggcaaaatga tgctctgctt tgtggcaaca gctcagatgc agggtaagtg tatgcttctc 240  
actgagtttc agtccacact gctccatcag tgtcaataac ctgccacctc ccactcatcc 300  
agtcccacca ctctcactc aaaacctcc ataaattcta cttcacgggtg actctcagaa 360  
tgaccaggat aagtgtagat tctca 385

<210> 46  
<211> 430  
<212> DNA  
<213> Homo sapiens

<400> 46  
tataataatg acaattatga atcacagagg aatccacaaa gtagacctta tagattctgt 60  
cattatataa atcagtcac ttagtgctga gttaagtact gggtaagggtg agagaaatcg 120  
gcttttttct agtgccctga taaaacagac attggcatat attaaaacag gaaaaccaat 180  
tagcagactt gccgttattg actycctctc tttcctctaa cctaattaca gccagtgtcc 240  
tgaaggatac atctgtgtga aggctggtag aaaccccaac tatggctaca cgagctttga 300  
caccttttagt tgggcctttt tgccttatt tgcctcatg actcaagact tctgggaaaa 360  
cctttatcaa ctggtgagaa cagataaaat catttttctg agaatcataa aacaccgaac 420  
tcaagagaat 430

<210> 47  
<211> 646  
<212> DNA  
<213> Homo sapiens

<400> 47  
tgctgtagaa tattttatta cttagagtgt aagtttgtaa catcctatat aaaatttatt 60  
aaaatctctc ttccattttg cagacactac gtgctgctgg gaaaacgtac atgatatttt 120  
ttgtgctggt cattttcttg ggctcattct atctaataaa tttgatcttg gctgtggtgg 180  
ccatggccta tgaggaacag aatcaggcca cattggaaga ggctgaacag aaggaagctg 240  
aatttcagca gatgctcgaa cagttgaaaa agcaacaaga agaagctcag gtatagttaa 300  
caagcatacg gtcctttgtt tttctgtatc taaattcttt aacctaaatg ttgaggtcag 360  
tggcaaggta gttgacatta gaaataggctc atatgtgttt ggtaagtgtc aggagcctgt 420

```

ttggttatta agaagttatt actttattgc aatgatctct gtcaatagtg tcaatagtaa 480..
tggcatcaaa aaatggataa ttataattgc tttactgaca tttttttctc ccttggtgact 540
ccttgaggaa attaattgatt aacaaaggcc tcatgtactc aaacttgcag agtagataaa 600
cctacatgtc ctcagttgaa gtattttctt aggggaagag gaattc 646

```

&lt;210&gt; 48

&lt;211&gt; 711

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 48

```

tatgtatcat cttccatatg aatgcgcatt ttactctttg attggtctaa taacagtgtg 60
ctgtgttcta aaacacagaa taaaatggag aattgttttt caagattatc ttcattgat 120
tgaagctcaa ttaagcagta acatgataat tatttttttaa gatnatatgc aacttcccac 180
atactttgcg cccttctagg cggcagctgc agccgcattc gctgaatcaa gagacttcag 240
tggtgctggt gggataggag ttttttcaga gagttcttca gtagcatcta agttgagctc 300
caaaagtga aaagagctga aaaacagaag aaagaaaaag aaacagaaag aacagtctgg 360
agaagaagag aaaaatgaca gagtcctaaa atcggaatct gaagacagca taagaagaaa 420
aggtttccgt ttttccttgg aaggaagtag gctgacatat gaaaagagat tttcttctcc 480
acaccaggtt aaaatattaa attacatgaa ttgtgttctc ataaattttt taaaagaata 540
tgccagaatt taatggagag aaaaccgcct tccacctgga tggcacaatg ctttcagagt 600
agtgatgatt atcaagtgtt ttggctatca cttcagagaa tttgtgagtt ttgcaacttt 660
ttggaatccc aggaaggaaa ttttagatcc ctctgggttt ggaaaaattt g 711

```

&lt;210&gt; 49

&lt;211&gt; 1026

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

```

ttatggggac acttctgact atgttgaggt gtgggttaaag taggagaaaa gagagcagaa 60
gatggaaaat gga'ggaagga gaaaaagcga gagtgaata gaaaaggatga accttgtaga 120
aagtgccaaa atgccaccag cagtcattcag aggggtgctt tcttccacat gtccaatgac 180
ttatccttga gtaagtcaat gactatgaca caatgaatca aattctgttt ttcagaatgc 240
cagctcttaa ctctcttcat ctcatTTTTTg tttcttttct tgttattcat agtccttact 300
gagcatccgt ggctcccttt tctctccaag acgcaacagt agggcgagcc ttttcagctt 360
cagaggtcga gcaaaggaca ttggctctga gaatgacttt gctgatgatg agcacagcac 420
ctttgaggac aatgacagcc gaagagactc tctgttctgt cgcacagac atggagaacg 480
gcccacagc aatgtcagcc aggccagccg tgctccagg gtgtcccca tctgtcccat 540
gaatgggaag atgcatagcg ctgtggactg caatgggtgt gtctccctgg tcgggggccc 600
ttctaccctc acatctgctg ggcagctcct accagaggtg aggccaaacy magattgcag 660
ctgatgtgaa gagagttgtg actggtgcag gcaggagtgy ttttccattt mcacatctaa 720
gaatttkttg agtttsttgc ccaaaggctg ggagtttgtt caatcaagct gttaactgtc 780
ttgtgaaact sttctattca gacttitycta caaagtaatt aaaaacctag gttggctgtc 840
agagaatata attagamgtm atctttcatc ayyattacta tggatatgaa ctgcgcaaaa 900
agcaaagcaa caatttatca agcataatgt tygaytaata tagttaaatt aaatccaag 960

```

aaattaatgc tcacaaatta aataaatact taaggatttt gtgattgttg ttcatttaaa 1020  
aggaga 1026

<210> 50  
<211> 601  
<212> DNA  
<213> Homo sapiens

<400> 50  
ataggaaagc ccaccttgac aaaccaggg ctccccaaaa gctgaaaatc tgacagactt 60  
taaacaaccc ccaaataatt atcattccaa caatatctta gtgagctttt tacatctgag 120  
aaagcatggt gtatatttag tttaaataaca cctgttgtag gaatgctttg ggctttgctg 180  
ctttcaaaaa tagtggttat ttcattctgaa attctacttc tagggcacia ctactgaaac 240  
agaaataaga aagagacggt ccagttctta tcatgtttcc atggatttat tggaagatcc 300  
tacatcaagg caaagagcaa tgagtatagc cagtattttg accaacacca tggaaggtat 360  
gttaaaagtc ctgctgcaca gttacttggt gctttcctaa tgatgaaaaa cacttcataa 420  
atttcaataa aatacttctt gacttgatat tgtatcatta ttacacattt tactaaataa 480  
cagtaaaatc cgtgcataac tcatggattc atatattcca cagatttttt ttttttatat 540  
ttagcctgta gaaagctgct gcaaagttaa ggtatatttg aacaccactt tcataactta 600  
a 601

<210> 51  
<211> 645  
<212> DNA  
<213> Homo sapiens

<400> 51  
gcttactagc ctttctgtac tgatcctttc tatgacagca aaccatttgt aaaattttcc 60  
ctgttcctcc agcagattaa ccataatat cttttaacaa ctttagattt tttaaattcc 120  
ttttaattta aaccaaactc gcttaataga aagtaagcag ttttcatgag gattctaact 180  
ttttttcttc cagaacttga agaattccaga cagaaatgcc caccatgctg gtataaattt 240  
gctaatatgt gtttgatttg ggactgttgt aaaccatggt taaagggtgaa acaccttgct 300  
aacctggttg taatggaccc atttggtgac ctggccatca ccatctgcat tgtcttaaat 360  
acactcttca tggctatgga gcaactatccc atgacggagc agttcagcag tgtactgtct 420  
gttggaacc tggtaagcct cactgagagt ttctcttctt cttgaaagag tttataattg 480  
ccttagtgaa ttttacctat tgctctcaaa ttaaataatca actaattggc catgtatatc 540  
ttgacatcaa atgttttagca tcccttttaa ataacaaaaa aatgttgcta ccatagtgca 600  
aaagagtcaa agaatttatg tacaatttga tttagaattg aattt 645

<210> 52  
<211> 485  
<212> DNA  
<213> Homo sapiens

<400> 52

```

tggcccaaac caatttttaa atcaggaatt taatttwtat attggtggga gttaaattaa 60...
gttgctcaat aattattcgt gtttcaakas tatttgctca tataatgaac tacacttctc 120
atttaggtct tcacagggat cttcacagca gaaatgttcc tcaagataat tgccatggat 180
ccatattatt actttcaaga aggctggaat atttttgatg gttttattgt gagccttagt 240
ttaatggaac ttggtttggc aaatgtggaa ggattgtcag ttctccgac attccggctg 300
gtaaattaaac tgggagtgtt cataaaatgt actttttaat taattagtct tcattctcat 360
ctagtaaaaaa tggcaagatt tcccatcatt ataatatatt tgaatacctt ctaaaacaga 420
ttggattgcc ataccaccaa atggtagttt cttcttcac atagctttaa taaagttcac 480
ttaaa 485

```

&lt;210&gt; 53

&lt;211&gt; 602

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 53

```

acagatttcc tctgtgtcc atgtgactaa cccattgtgc acatgtaccc taaaaattag 60
tatataataa taaaataaaa taaaataaaa aataaaaaaa taaaataaaa ataaaattgc 120
agattttttt agaaatgcag agattaacac tgttcttgct tttatttcca gctccgagtt 180
ttcaagttgg caaaatcttg gccaaactcta aatatgctaa ttaagatcat tggcaattct 240
gtgggggctc taggaaacct caccttggtt ttggccatca tctgttccat tttgtctgtg 300
gtcggcatgc agctctttgg taagagctac aaagaatgtg tctgcaagat ttccaatgat 360
tgtgaactcc cacgctggca catgcatgac tttttccact ccttctctgat cgtgttccgc 420
gtgctgtgtg gagagtggat agagaccatg tgggactgta tggaggtcgc tggccaaacc 480
atgtgcctta ctgtcttcat gatggtcatg gtgattggaa atctagtggg atgtagcaaa 540
aacattttcc tcattttcat taaaataaat gtaatcatta aaaagtgttc aactgaagaa 600
ta 602

```

&lt;210&gt; 54

&lt;211&gt; 803

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

```

gtttcattta gcaatgattt cagtattttc tgcaatgact aataagcaaa tagtgataat 60
agtattattt tatattgacc aagcattttt atttcattca ctttttttca gaatagtgtg 120
tcatgaatta gcagaaatgc atgttagaat aaaataaggt gtcaagaaca atcttagaaa 180
actaatgatg gaaagcaatt gaagcaatag aatgttttga tcacctgttt ttctgtctgt 240
gtttcagggt ctgaacctct tcttggcctt gcttttgagt tcttccagtt ctgacaatct 300
tgctgccact gatgatgata acgaaatgaa taatctccag attgctgtgg gaaggatgca 360
gaaaggaatc gattttgtta aaagaaaaat acgtgaattt attcagaaag cttttgttag 420
gaagcagaaa gcttttagatg aaattaaacc gcttgaagat cttaaataa aaaaagacag 480
ctgtatttcc aaccatacca ccatagaaat aggcaaagac ctcaattatc tcaaagacgg 540
aaatggaact actagtggca taggcagcag tgtagaaaaa tatgtcgtgg atgaaagtga 600
ttacatgtca tttataaaca accctagcct cactgtgaca gtaccaattg ctgttggaga 660
atctgacttt gaaaatttaa atactgaaga attcagcagc gagtcagata tggaggaaag 720

```

caaagaggta aaatgttaaa taaggagata ttttggtgta tataatctgt gttaaataac 780  
 aggtgttttaa tgcgtgtctc tgt 803

<210> 55  
 <211> 615  
 <212> DNA  
 <213> Homo sapiens

<400> 55  
 atctctatatac taggctcaaa cagaagttat ttccgttggt agcaccatat ttttaaaaga 60  
 aaaaaaata ctatggtggt gtatctaata ttgtgacccc tgacctttac caaagcggat 120  
 tggcattatg ttttaagttct taattacaga tcaagaaaaa tgcatacaga agatgggggg 180  
 gggcacacct aattaatttt tatatttaga ttaaagaaaa taattaaatg tgtttttttg 240  
 tgggattgat tttcagaagc taaatgcaac tagttcatct gaaggcagca cggttgatat 300  
 tggagctccc gccgaggag aacagcctga ggttgaacct gaggaatccc ttgaacctga 360  
 agcctgtttt acagaagnnn nnnnnnaagc aaaacaataa catatgtggt cttgagtatc 420  
 ctcttttcta cccatttttt cctattttatt taaatgtctg tttatttgtc taccatctag 480  
 ttcattctatc tatctgtatc tatctatcta tctatctatc tagtaatcat ctatacctat 540  
 ccaacaactg tacattttatt tgtttttttt ttttgcatct gctgtttgaa aaaaaatgca 600  
 acgtttttaa ggcaa 615

<210> 56  
 <211> 400  
 <212> DNA  
 <213> Homo sapiens

<400> 56  
 gatagctttt gtaagcggaa gctatcttaa aaattaatgt tatttacaat gtattatcag 60  
 gtaataatgt aaatgaatct cccaccaaca caaatatacc taatcaaaga gtaatttttt 120  
 gtcttcattt ttttccca tatttttagac tgtgtacgga agttcaagtg ttgtcagata 180  
 agcatagaag aaggcaaaag gaaactctgg tggaatttga ggaaaacatg ctataagata 240  
 gtggagcaca attggttcga aaccttcatt gtcttcatga ttctgctgag cagtggggct 300  
 ctggtagggt atgcatgatc cactccttca cctttcatct gaaatctttt ccctttccct 360  
 tcaatcaact catattaccc acttttaaat taagggtgtt 400

<210> 57  
 <211> 560  
 <212> DNA  
 <213> Homo sapiens

<400> 57  
 aaattactga aacccttggt tgactgaaat gccagtcag cagtcattta tgatcagata 60  
 atgataaagt aaaattcagc catgggaaac attaaacctt ccagccttag gcacctgata 120  
 agagcttgca tcgttttctt ttttaagaaa tcatcaatta gagactgttt ctgatcataa 180  
 aatttaatat aattttttga cttacaggcc ttgaagata tatacattga gcagcgaaaa 240

accattaaga ccatggttaga atatgctgac aagggttttca cttacatatt cattctggaa 300.  
atgctgctaa agtgggttgc atatggtttt caagtgtatt ttaccaatgc ctgggtgctgg 360  
ctagacttcc tgattgttga tgtgagtatg ctgcactttg ctgctttatt cattggcata 420  
tatgtaatag ttctagcaat ggtgcctgac acagtgtagg cactcagtaa cactgtatca 480  
gccccaaatat aaattatgtt tctcattttca cagtgaagagg atgcctcaaa acatttttta 540  
ccaatttaaa tacatatata 560

&lt;210&gt; 58

&lt;211&gt; 480

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

aaattcttag gcctttcccc aaacttacta agtcagactc tgctattggt gtttttaaca 60  
agacccttgg gtgattttga aactcatgaa agttcgagaa ttactgattc attgcataga 120  
gcaaggctga actgtgtaga cttttttata tgtaaataag aaaattgtgt tgctttttct 180  
gtataggtct cactgggttag cttaactgca aatgccttgg gttactcaga acttgggtgcc 240  
atcaaatccc tcagaacact aagagctctg aggccactga gagctttgtc ccggtttgaa 300  
ggaatgaggg taagactgaa tgccttagag tttgtcagaa ttattattga gagcagactg 360  
acactttgta ccatggaaat gtcaaattta tggagaattt gtgtcttaca cattcatact 420  
gacatagcta atcaatcaaa aataatattt accagatgcc cataatactt ggcactgctg 480

&lt;210&gt; 59

&lt;211&gt; 640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 59

taatttttaa attcttagtt ggagctacca gagtctagtt tctacccaat attcaacttt 60  
gaaacagatt tttttaatca ttgactgtt cttttaataa tgtttaaaaa taagtaaata 120  
tttggtgttg gcttttctact tatttttcct tctcatctctg tgccaggttg ttgtaaatagc 180  
tcttttagga gccattccat ctatcatgaa tgtacttctg gtttgtctga tcttttggt 240  
aatattcagt atcatgggag tgaatctctt tgctggcaag ttttaccatt gtattaatta 300  
caccactgga gagatgtttg atgtaagcgt ggtcaacaac tacagtgagt gcaaagctct 360  
cattgagagc aatcaaaactg ccaggtggaa aaatgtgaaa gtaaactttg ataacgtagg 420  
acttgatat ctgtctctac ttcaagtagt aagtaatcac tttattattt tccatgatgt 480  
gtaattaaaa tgagtctaaa gtttttcttc ctcataatga gatatccacc tgtagaatg 540  
gctattatca aacagataaa tgacaataaa tgctggcaag aatgtgaaga aaaggggaacc 600  
cttgtagatt gttggcaggg atgtaaatta gtatagcttt 640

&lt;210&gt; 60

&lt;211&gt; 480

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

atttgaagta ttttcaatgc atatcgcaaa acattgcccc aaaagtgaat acaaatttca 60  
 agcttatttta tatgcctgta ttgaatacat gtcaaataga attttgatca attattcaat 120  
 ttatttttcta aaattataat tttgggaaaa aagaaaatga tatgactttt cttacaggcc 180  
 acgtttaagg gatggatgga tattatgtat gcagctgttg attcacgaaa tgtaagtcta 240  
 gttagaggga aattgttttag tttgattaaa tgtatatttc tacaatattg taatttagtg 300  
 atattgtcaa taaaataaaa ttatgtgctt aatttataaa acccatctat attataagga 360  
 taaaatattt aatcatacta tttctttcaa aattatcata ggatgatttt ctctaatacac 420  
 tctgtatctt ttaacatata ttttctagta tttagcaagg cacctgacac aaaactttat 480

&lt;210&gt; 61

&lt;211&gt; 366

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 61

taaaacatgc ttagataatt aaaaactcac tgatgtactt tttgtgaaac aagtactaga 60  
 tataatgggtt acaattcttc atattcttta ggtagaatta caacccaagt atgaagacaa 120  
 cctgtacatg tatctttatt ttgtcatctt tattattttt gggtcattct ttaccttgaa 180  
 tcttttcatc ggtgtcatca tagataactt caaccaacag aaaaagaaga taagtatatt 240  
 aaaacttcat ccttgctctg aaatatgaac taaatatttc atactcttct ctttagcctc 300  
 caaaatgcaa tcaccaaaaa aagaatataa aattcagaaa ttattttgag acatttgata 360  
 atcgat 366

&lt;210&gt; 62

&lt;211&gt; 560

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 62

tcgataagct tttaagcaat taataattca gatagcatgt ttttgatatt tttagtctag 60  
 aaatatgact aatatggcat aatttatata ttgaataaag gcatctctat aaatacagat 120  
 attagtaaca atagaatgaa atgtgggagc caattttcac atgattacta aggtggattt 180  
 tatagccagc aaagaacaca attttaacaa gtgttgcttt catttcttta ctttgagggt 240  
 caagacattt ttatgacaga agaacagaag aaatactaca atgcaatgaa aaaactgggt 300  
 tcaaagaaac cacaaaaacc catacctcga cctgctgtaa gaataacata ttttcattgc 360  
 ctgttaaaac tatattacct aaccgtttca cagcccgaat ttctagaac tagttatttt 420  
 tgtggatttg taacacaaag ttttttacct taacaatggg actagctagc ctaaaatagct 480  
 tgaaaaatgt actttacata tataatatgt ataaattata taatgcataa catattttat 540  
 atgtaaacat ataaaatata 560

&lt;210&gt; 63

&lt;211&gt; 650

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens



&lt;400&gt; 63

gttttgcaag gaattttttt ttttgtaaaa tgttgtagg attaaagatg tgtttttata 60  
aaagctacat tttttgttgc tttcttaaaa tcagaagaat tgaattcgat tttttttaag 120  
gtttctaag gaacttttac atattatttg ttccagaaca aattccaagg aatgggtctt 180  
gattttgtaa ccaaacaagt ctttgatata agcatcatga tcctcatctg ccttaacatg 240  
gtcaccatga tgggtggaac cgatgaccag agtcaagaaa tgacaaacat tctgtactgg 300  
attaatctgg tgtttattgt tctgttcaact ggagaatgtg tgctgaaact gatctctctt 360  
cgttactact atttcactat tggatggaat atttttgatt ttgtggtggt cattctctcc 420  
attgtaggta agaagagggtg cttttattca gtttaaggaat atagtggtaa aaatatgtgt 480  
tttaaaactt tagagggtgtt tttcactaat ctttctcatt catcccaaac tcccaaataa 540  
aaatctaata gtccattgtt ttagtttttag tttgccattt ctctaattgc atgctgtgct 600  
tgaaatgatg agtggaatac aaggaattta tattttcagc tttcatttat 650

&lt;210&gt; 64

&lt;211&gt; 3700

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 64

aatgttataa caccaaaccat accagtttca ttttgctcaa caaacattgc agattatttg 60  
catatatata tgtacctaac tgtcctgttc acattttgta aaactaatgt acttatgtaa 120  
actttcattt gctactatta agtataacaa tatttttggt atttgttgat tttctacagg 180  
aatgtttctg gctgaactga tagaaaagta ttttggtgcc cctaccctgt tccgagtgat 240  
ccgtcttgcc aggattggcc gaatcctacg tctgatcaaa ggagcaaagg ggatccgcac 300  
gctgctcttt gctttgatga tgtcccttcc tgcgttggtt aacatcggcc tccttctttt 360  
cctggctcatg ttcactacg ccatctttgg gatgtccaat tttgcctatg ttaagaggga 420  
agttgggac gatgacatgt tcaactttga gacctttggc aacagcatga tctgcctgtt 480  
ccaaattaca acctctgctg gctgggatgg attgctagca cctattctta atagtggacc 540  
tccagactgt gaccctgaca aagatcacc tgggaagctca gttaaaggag actgtgggaa 600  
cccatctgtt gggattttct ttttgctcag ttacatcatc atatccttcc tggttgtggt 660  
gaacatgtac atcgcggtca tcctggagaa cttcagtgtt gctactgaag aaagtgcaga 720  
gcctctgagt gaggatgact ttgagatgtt ctatgaggtt tgggagaagt ttgatcccg 780  
tgcgaccag tttatagagt ttgccaaact ttctgatttt gcagatgcc tggatcctcc 840  
tcttctcata gcaaaacca acaaagctca gctcattgcc atggatctgc ccatgggtgag 900  
tgggtgaccg atccactgtc ttgacatctt atttgctttt acaaagcgtg ttttgggtga 960  
gagtggagag atggatgccc ttcgaatata gatggaagag cgattcatgg catcaaacc 1020  
ctccaaagtc tcttatgagc ccattacgac cacgttgaaa cgcaaacaag aggaggtgtc 1080  
tgctattatt atccagaggg cttacagacg ctacctcttg aagcaaaaag ttaaaaagg 1140  
atcaagtata tacaagaaag acaaaggcaa agaattgtgat ggaacaccca tcaaagaaga 1200  
tactctcatt gataaactga atgagaattc aactccagag aaaaccgata tgacgccttc 1260  
caccacgtct ccaccctcgt atgatagtgt gaccaaacca gaaaaagaaa aatttgaaaa 1320  
agacaaatca gaaaaggga acaaaggga agatatcagg gaaagtaaaa agtaaaaaga 1380  
aaccaagaat tttccatttt gtgatcaatt gtttacagcc cgtgatggtg atgtgtttgt 1440  
gtcaacagga ctcccacagg aggtctatgc caaactgact gtttttacia atgtatactt 1500  
aaggtcagt cctataacaa gacagagacc tctggctcagc aaactggaac tcagtaaact 1560  
ggagaaatag tatcgatggg aggtttctat tttcacaacc agctgacact gctgaagagc 1620

```

agaggcgtaa tggctactca gacgatagga accaatttaa aggggggagg gaagttaa 1680
ttttatgtaa attcaacatg tgacacttga taatagtaat tgtcaccagt gtttatgttt 1740
taactgccac acctgccata tttttacaaa acgtgtgctg tgaattttatc acttttcttt 1800
ttaattcaca ggttggtttac tattatatgt gactattttt gttaaagggt ttgtgttttg 1860
ggagagggat taaagggagg gaattctaca tttctctatt gtattgtata actggatata 1920
ttttaaatgg aggcattgctg caattctcat tcacacataa aaaaatcaca tcacaaaagg 1980
gaagagttta cttcttggtt caggatgttt ttagattttt gaggtgctta aatagctatt 2040
cgtattttta aggtgtctca tccagaaaaa atttaatgtg cctgtaaag ttccatagaa 2100
tcacaagcat taaagagttg ttttattttt acataaccca ttaaagtac atgtatatat 2160
gtatatatgt atatgtgcgt gtatatacat atatatgtat acacacatgc acacacagag 2220
atatacacat accattacat tgtcattcac agtcccagca gcatgactat cacatttttg 2280
ataagtgtcc tttggcataa aataaaaaata tcctatcagt cttttctaag aagcctgaat 2340
tgacaaaaaa acatccccac caccacttta taaagttgat tctgctttat cctgcagtat 2400
tgtttagcca tcttctgctc ttggttaagg tgacatagta tatgtcaatt taaaaataa 2460
aagtctgctt tgtaaagatg aattttaccc agtgggtgcat gtttgagcaa acaaaaatga 2520
tgatttaagc aactacttta ttgcatcaaa tatgtaccac agtaagtata gtttgcaagc 2580
tttcaacagg taatatgatg taattggttc cattatagtt tgaagctgct actgctgcat 2640
gtttatcttg cctatgctgc tgtatcttat tcttccact gttcagaagt ctaatatggg 2700
aagccatata tcagtggtaa agtgaagcaa attgttctac caagacctca ttcttcattg 2760
cattaagcaa taggttgtag caaacaagga agagcttctt gctttttatt cttccaacct 2820
taattgaaca ctcaatgatg aaaagcccga ctgtacaaac atgttgcaag ctgcttaaat 2880
ctgtttaaaa tatatgggta gagttttcta agaaaatata aatactgtaa aaagttcatt 2940
ttattttatt tttcagcctt ttgtacgtaa aatgagaaat taaaagtatc ttcagggtga 3000
tgtcacagtc actattgtta gtttctgttc ctagcacttt taaattgaag cacttcacaa 3060
aataagaagc aaggactagg atgcagtgtg ggtttctgct tttttattag tactgtaaac 3120
ttgcacacat ttcaatgtga aacaaatctc aaactgagtt caatgtttat ttgctttcaa 3180
tagtaatgcc ttatcattga aagaggctta aagaaaaaaa aaatcagctg atactcttg 3240
cattgcttga atccaatgtt tccacctagt ctttttattc agtaatcatc agtcttttcc 3300
aatgtttgtt tacacagata gatcttattg acccatatgg cactagaact gtatcagata 3360
taatatggga tcccagcttt ttttctctc ccacaaaacc aggtagtga gttatattac 3420
cagttacagc aaaatacttt gtgtttcaca agcaacaata aatgtagatt ctttatactg 3480
aagctattga cttgtagtgt gttggtgaat gcatgcagga agatgctgtt accataaaga 3540
acggtaaacc acattacaat caagccaaag aataaagggt cgcttatgta tatgtattta 3600
attgttgtct ttgtttctat ctttgaaatg ccatttaaag gtagatttct atcatgtaa 3660
aataatctat ctgaaaaaca aatgtaaaga acacacatta 3700

```

&lt;210&gt; 65

&lt;211&gt; 9112

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 65

```

accatagagt gaatctcaga acaggaagcg gaggcataag cagagaggat tctggaaagg 60
tctctttgtt ttcttatcca cagagaaaga aagaaaaaaa attgtaacta atttgtaaac 120
ctctgtggtc aaaaaaaaaa aaaaaaaaaa aagctgaaca gctgcagagg aagacacgtt 180
ataccctaac catcttgatg gctgggcttt gttatgctgt aattcataag gctctgtttt 240
atcagagatt atggagcaag aaaactgaag ccaagccaca tcaaggtttg acagggatga 300

```

gatacctgtc aaggattcat agtagagtgg cttactggga aaggagcaaa gaatctcttc 360  
tagggatatt gtaagaataa atgagataat tcacagaagg gacctggagc ttttccggaa 420  
aaaggtgctg tgactatcta aggggaaaag ctgagagtct ggaactagcc tatcttccga 480  
ggacttagag acaacagtat gggaatttca acgagacgtt ttactttct tttgaccaag 540  
attcaaatc tttattccag cccttgataa gtaaataaga aggtaattcg tatgcaagaa 600  
gctacacgta attaaatgtg caggatgaaa agatggcaca ggcactgttg gtaccccgag 660  
gacctgaaag cttccgcctt ttactagag aatctcttgc tgctatcgaa aaacgtgctg 720  
cagaagagaa agccaagaag cccaaaaagg aacaagataa tgatgatgag aacaaaccaa 780  
agccaaatag tgacttgga gctggaaaga accttccatt tatttatgga gacattcctc 840  
cagagatggt gtcagagccc ctggaggacc tggatcccta ctatatcaat aagaaaactt 900  
ttatagtaat gaataaagga aaggcaattt cccgattcag tgccacctct gccttgata 960  
ttttaactcc actaaaccct gttaggaaaa ttgctabsaa gattttggtg cattctttat 1020  
tcagcatgct tatcatgtgc actattttga ccaactgtgt atttatgacc ttgagcaacc 1080  
ctcctgactg gacaaagaat gtagagtaca cattcactgg aatctatacc tttgagtcac 1140  
ttataaaaaat cttggcaaga gggttttgct tagaagattt tacgtttctt cgtgatccat 1200  
ggaactggct ggatttcagt gtcattgtga tggcatatgt gacagagttt gtggacctgg 1260  
gcaatgtctc agcgttgaga acattcagag ttctccgagc actgaaaaca atttcagtca 1320  
ttccaggttt aaagaccatt gtggggggccc tgatccagtc ggtaaagaag ctttctgatg 1380  
tgatgatect gactgtgttc tgtctgagcg tgtttgctct cattgggctg cagctgttca 1440  
tgggcaatct gaggaataaa tgtttgcagt ggcccccaag cgattctgct tttgaaacca 1500  
acaccacttc ctactttaat ggcacaatgg attcaaatgg gacatttgtt aatgtaacaa 1560  
tgagcacatt taactggaag gattacattg gagatgacag tcacttttat gttttggatg 1620  
ggcaaaaaga ccctttactc tgtggaaatg gctcagatgc aggccagtgt ccagaaggat 1680  
acatctgtgt gaaggctggt cgaaacccca actatggcta cacaagcttt gacaccttta 1740  
gctgggcttt cctgtctcta ttctgactca tgactcaaga ctactgggaa aatctttacc 1800  
agttgacatt acgtgctgct gggaaaacat acatgatatt ttttgtctg gtcattttct 1860  
tgggctcatt ttatttggtg aatttgatcc tggctgtggt ggccatggcc tatgaggggc 1920  
agaatcaggc caccttgga gaagcagaac aaaaagaggc cgaatttcag cagatgctcg 1980  
aacagcttaa aaagcaacag gaagaagctc aggcagttgc ggcagcatca gctgcttcaa 2040  
gagatttcag tggaataggt gggtaggag agctgttgga aagttcttca gaagcatcaa 2100  
agttgagttc caaaagtgt aaagaatgga ggaaccgaag gaagaaaaga agacagagag 2160  
agcacctga aggaacaac aaaggagaga gagacagctt tcccaaatcc gaatctgaag 2220  
acagcgtcaa aagaagcagc ttcttttct ccatggatgg aaacagactg accagtgaac 2280  
aaaaattctg ctccctcat cagtctctct tgagtatccg tggctccctg ttttcccaa 2340  
gacgcaatag caaaacaagc attttcagtt tcagaggtcg ggcaaaggat gttggatctg 2400  
aaaatgactt tgctgatgat gaacacagca catttgaaga cagcgaaagc aggagagact 2460  
cactgtttgt gccgcacaga catggagagc gacgcaacag taacggcacc accactgaaa 2520  
cggaagtcag aaagagaagg ttaagctctt accagatttc aatggagatg ctggaggatt 2580  
cctctggaag gcaaagagcc gtgagcatag ccagcattct gaccaacaca atggaagaac 2640  
ttgaagaatc tagacagaaa tgctcgccat gctggtatag atttgccaat gtgttcttga 2700  
tctgggactg ctgtgatgca tggttaaaag taaaacatct tgtgaattta attgttatgg 2760  
atccatttgt tgatcttgcc atcactatct gcattgtctt aaataccctc tttatggcca 2820  
tggagcacta ccccatgact gagcaattca gtagtgtgtt gactgtagga aacctggtct 2880  
ttactgggat ttttacagca gaaatggttc tcaagatcat tgccatggat ccttattact 2940  
atttccaaga aggctggaat atctttgatg gaattattgt cagcctcagt ttaatggagc 3000  
ttggtctgtc aaatgtggag ggattgtctg tactgcatc attcagactg cttagagttt 3060  
tcaagttggc aaaatcctgg cccacactaa atatgcta taagatcatt ggcaattctg 3120  
tgggggctct aggaaacctc accttgggtg tggccatcat cgtcttcatt tttgctgtgg 3180

```

tcggcatgca gctctttggt aagagctaca aagaatgtgt ctgcaagatc aatgatgact 3240
gtacgctccc acggtggcac atgaacgact tcttccactc cttcctgatt gtgttccgcg 3300
tgctgtgtgg agagtggata gagaccatgt gggactgtat ggaggtcgct ggccaaacca 3360
tgtgccttat tgttttcatt ttggtcatgg tcattggaaa ccttgtgggt ctgaacctct 3420
ttctggcctt attgttgagt tcatttagct cagacaacct tgctgctact gatgatgaca 3480
atgaaatgaa taatctgcag attgcagtag gaagaatgca aaaggggaatt gattatgtga 3540
aaaataagat gcgggagtggt ttccaaaaag ctttttttag aaagccaaaa gttatagaaa 3600
tccatgaagg caataagata gacagctgca tgtccaataa tactggaatt gaaataagca 3660
aagagcttaa ttatcttaga gatgggaatg gaaccaccag tgggttaggt actggaagca 3720
gtgttgaaaa atacgtaatc gatgaaaatg attatatgtc attcataaac aaccccagcc 3780
tcaccgtcac agtgccaatt gctgttgagg agtctgactt tgaaaactta aatactgaag 3840
agttcagcag tgagtcagaa ctagaagaaa gcaaggagaa attaaatgca accagctcat 3900
ctgaaggaag cacagttgat gttgttctac cccgagaagg tgaacaagct gaaactgaac 3960
ccgaagaaga ccttaaaccg gaagcttggt ttactgaagg atgtattaaa aagtttccat 4020
tctgtcaagt aagtacagaa gaaggcaaag ggaagatctg gtggaatctt cgaaaaacct 4080
gctacagtat tgttgagcac aactggtttg agactttcat tgtgttcatt atccttctca 4140
gtagtggtgc attggccttt gaagatatat acattgaaca gcgaaagact atcaaaacca 4200
tgctagaata tgctgacaaa gtctttacct atatattcat tctggaaatg cttctcaaat 4260
gggttgctta tggatttcaa acatatttca ctaatgcctg gtgctggcta gatttcttga 4320
tcgttgatgt ttctttggtt agcctggtag ccaatgctct tggctactca gaactcggtg 4380
ccatcaaate attacggaca ttaagagctt taagacctct aagagcctta tcccggttg 4440
aaggcatgag ggtggttggt aatgctcttg ttggagcaat tccctctatc atgaatgtgc 4500
tggttggtctg tctcatcttc tggttgatct ttagcatcat ggggtggaat ttgtttgctg 4560
gcaagttcta ccactgtgtt aacatgacaa cgggtaacat gtttgacatt agtgatgtta 4620
acaatttgag tgactgtcag gctcttggca agcaagctcg gtggaaaaac gtgaaagtaa 4680
actttgataa tgttggcgct ggctatcttg cactgcttca agtgccaca tttaaaggct 4740
ggatggatat tatgtatgca gctgttgatt cacgagatgt taaacttcag cctgtatatg 4800
aagaaaatct gtacatgtat ttatactttg tcatctttat catctttggg tcattcttca 4860
ctctgaatct attcattggt gtcatcatag ataacttcaa ccagcagaaa aagaagtttg 4920
gaggtcaaga catctttatg acagaggaac agaaaaaata ttacaatgca atgaagaaac 4980
ttggatccaa gaaacctcag aaaccatac ctgcgccagc aaacaaattc caaggaatgg 5040
tctttgattt tgtaaccaga caagtctttg atatcagcat catgatcctc atctgcctca 5100
acatggtcac catgatgggtg gaaacggatg accagggcaa atacatgacc ctagttttgt 5160
cccggatcaa cctagtgttc attgttctgt tcaactggaga atttgtgctg aagctcgtct 5220
ccctcagaca ctactacttc actataggct ggaacatctt tgacttttggt gtggtgattc 5280
tctccattgt aggtatgttt ctggctgaga tgatagaaaa gtatttttggt tcccctacct 5340
tggtccgagt gatccgtctt gccaggattg gccgaatcct acgtctgac aaaggagcaa 5400
aggggatccg cacgctgctc tttgctttga tgatgtccct tcctgcgttg tttaacatcg 5460
gcctcctgct cttectgggt atgtttatct atgccatctt tgggatgtcc aactttgcct 5520
atgttaaaaa ggaagctgga attgatgaca tgttcaactt tgagaccttt ggcaacagca 5580
tgatctgctt gttccaaatt acaacctctg ctggatggga tggattgcta gcacctattc 5640
ttaatagtgc accaccgac tgtgaccctg acacaattca cctggcagc tcagttaagg 5700
gagactgtgg gaacctatct gttgggattt tcttttttgt cagttacatc atcatatcct 5760
tcctgggtgt ggtgaacagt tacatcgcgg tcactctgga gaacttcagt gttgctactg 5820
aagaaagtgc agagccctg agtgaggatg actttgagat gttctatgag gtttgggaaa 5880
agtttgatcc cgatgcgacc cagtttatag agttctctaa actctctgat tttgcagctg 5940
ccctggatcc tcctcttctc atagcaaaac ccaacaaagt ccagcttatt gccatggatc 6000
tgcccatggt cagtgggtgac cggatccact gtcttgatat tttatttgcc tttacaaagc 6060

```

```

gtgttttggg tgagagtgga gagatggatg cccttcgaat acagatggaa gacaggttta 6120
tggtcatcaaa cccctccaaa gtctcttatg agcctattac aaccactttg aaacgtaaac 6180
aagaggagggt gtctgccgct atcattcagc gtaatttcag atgttatctt ttaaagcaaa 6240
ggttaaaaaa tatatcaagt aactataaca aagaggcaat aaaggggagg attgacttac 6300
ctataaaaca agacatgatt attgacaaac tgaatgggaa ctccactcca gaaaaaacag 6360
atgggagttc ctctaccacc tctctctctt cctatgatag tgtaacaaaa ccagacaagg 6420
aaaagtttga gaaagacaaa ccagaaaaag aaagcaaagg aaaagagggtc agagaaaatc 6480
aaaagtaaaa agaaacaaag aattatcttt gtgatcaatt gtttacagcc tatgaaggta 6540
aagtatatgt gtcaactgga cttcaagagg aggtccatgc caaactgact gttttaacaa 6600
atactcatag tcagtgccta tacaagacag tgaagtgacc tctctgtcac tgcaactctg 6660
tgaagcaggg tatcaacatt gacaagaggt tgctgttttt attaccagct gacactgctg 6720
aggagaaacc caatggctac ctagactata gggatagttg tgcaaagtga acattgtaac 6780
tacaccaaac acctttagta cagtccttgc atccattcta tttttaactt ccatactctg 6840
catattttta caaaatttgt tctagtgcac ttccatgggtc cccaattcat agttttattca 6900
taatgctatg tcaactatttt tgtaaagtga gtttacgttg aagaaacagt atacaagaac 6960
cctgtctctc aaatgatcag acaaagggtg tttgccagag agataaaatt tttgctcaaa 7020
accagaaaaa gaattgtaat ggctacagtt tcagttactt ccattttcta gatggcttta 7080
atthtgaag tatthtagtc tghtatgttt gthtctatct gaacagttat gtgcctgtaa 7140
agtctctctt aatattttaa ggattattht tatgcaaagt attctgtttc agcaagtgca 7200
aattthtatt taagtttcag agctctatat ttaatttagg tcaaagtctt tccaaaaagt 7260
aatctaataa atccattcta gaaaaatata tctaaagtat tgctthtaga tagttgttcc 7320
actthtctgt gcagtattgc tttgccatct tctgtctctc gcaaagctga tagtctatgt 7380
caattaaata ccctatgtta tgtaaatagt tatthtattc tgtggtgcat gtttgggcaa 7440
atatatatat agcctgataa acaacttcta ttaaatacaa tatgtaccac agtgtatgtg 7500
tctthtgcaa gcttccaaca gggatgtatc ctgtatcatt cattaaacat agthttaaagg 7560
ctatcactaa tgcatgttaa tattgcctat gctgtcttat thtactcaat ccattcttca 7620
caagtcttgg ttaaagaatg tcacatattg gtgatagaat gaattcaacc tgctctgtcc 7680
attatgtcaa gcagaataat ttgaagctat ttacaaacac cthtacttht gcactthttaa 7740
ttcaacatga gtatcatatg gtatctctct agatttcaag gaaacacact ggatactgcc 7800
tactgacaaa acctattctt catatttttg taaaaatatg tctaaaactt gcgcaaatat 7860
aaataatgta aaaatataat caactthtatt tgtcagcatt ttgtacataa gaaaattatt 7920
ttcaggttga tgacatcaca atthatttht cthtatgtct ttgctthtga thtthtaatca 7980
caattccaaa cthtthgaatc cataagattt ttcaatggat aattthccta aataaaagt 8040
agataatggg thtthtggtat thtthtgtha taatatattt tctaccattc caataggaga 8100
tacattgggtc aaacactcaa acctagatca thtthtacc aactatgggt cctcaatata 8160
acctthtatt catagatgtt thtththtatt caactthtgt agtattthacg tatgcagact 8220
agtctthtth thtthattcc tgctgcacta aagctattac aaatataaca tggactthgt 8280
tctththtagc catgaacaaa gtggcaaagt tgtgcaatta cctaacatga tataaattth 8340
tgtththtgc acaaaccaa agthttaatgt taattcttht taaaaacta thtactgtag 8400
tgtattgaag aactgcatgc agggaaattg tattgtctaa aagaatgggt agctacgtca 8460
ttattgagcc aaaagaataa atthcattth ttattgcatt tcacttattg gcctctgggg 8520
thtthtgtht ttgtththtg ctgttggcag thtaaaatat atataattaa taaaacctgt 8580
gcttgatctg acatttgat acataaaagt ttacatgaat thtacaacag actagtgcac 8640
gattcaccaa gcagtactac agaacaaagg caaatgaaaa gcagctthgt gcactthtat 8700
gtgtgcaaag gatcaagttc acatgttcca actthcaggt ttgataataa tagtagtaac 8760
cacctacaat agctthcaat ttcaattaac tcccttgggt ataagcatct aaactcatct 8820
tctthcaata taattgatgc tatctcttaa thacttgggt gctaataaat gttacattct 8880
ttgttactta aatgcattat ataaactcct atgtatacat aaggtattaa tgatatagtt 8940

```

attgagaatt tatattaact tttttttcaa gaacccttgg atttatgtga ggtcaaaacc 9000  
 aaactcttat tctcagtga aaactccagt tgtaatgcat atttttaag acaatttga 9060  
 tctaaatatg tatttcataa ttctcccata ataaattata taaggtggct aa 9112

<210> 66  
 <211> 9112  
 <212> DNA  
 <213> Homo sapiens

<400> 66  
 accatagagt gaatctcaga acaggaagcg gaggcataag cagagaggat tctggaaagg 60  
 tctctttgtt ttcttatcca cagagaaaga aagaaaaaaa attgtaacta atttgtaaac 120  
 ctctgtggtc aaaaaaaaaa aaaaaaaaaa aagctgaaca gctgcagagg aagacacgtt 180  
 ataccctaac catcttggat gctgggcttt gttatgctgt aattcataag gctctgtttt 240  
 atcagagatt atggagcaag aaaactgaag ccaagccaca tcaaggtttg acagggatga 300  
 gatacctgtc aaggattcat agtagagtgg cttactggga aaggagcaaa gaatctcttc 360  
 tagggatatt gtaagaataa atgagataat tcacagaagg gacctggagc ttttccggaa 420  
 aaaggtgctg tgactatcta aggggaaaag ctgagagtct ggaactagcc tatcttccga 480  
 ggacttagag acaacagtat gggaatttca acgagacgtt tttactttct tttgaccaag 540  
 attcaaattc tttattccag cccttgataa gtaaataaga aggtaattcg tatgcaagaa 600  
 gctacacgta attaaatgtg caggatgaaa agatggcaca ggcactgttg gtacccccag 660  
 gacctgaaag cttccgcctt tttactagag aatctcttgc tgctatcgaa aaacgtgctg 720  
 cagaagagaa agccaagaag cccaaaaagg aacaagataa tgatgatgag aacaaacca 780  
 agccaaatag tgacttggaa gctggaaaaga accttccatt tatttatgga gacattcctc 840  
 cagagatggt gtcagagccc ctggaggacc tggatcccta ctatatcaat aagaaaactt 900  
 ttatagtaat gaataaagga aaggcaattt cccgattcag tgccacctct gccttgtata 960  
 ttttaactcc actaaacctt gttaggaaaa ttgctabsaa gattttggta cattctttat 1020  
 tcagcatgct tatcatgtgc actattttga ccaactgtgt atttatgacc ttgagcaacc 1080  
 ctctgactg gacaaagaat gtagagtaca cattcactgg aatctatacc tttgagtcac 1140  
 ttataaaaaat cttggcaaga gggttttgct tagaagattt tacgtttctt cgtgatccat 1200  
 ggaactggct ggatttcagt gtcattgtga tggcgtatgt aacagaattt gtaagcctag 1260  
 gcaatgtttc agcccttcga actttcagag tcttgagagc tctgaaaact atttctgtaa 1320  
 tcccaggttt aaagaccatt gtggggggccc tgatccagtc ggtaaagaag ctttctgatg 1380  
 tgatgatcct gactgtgttc tgtctgagcg tgtttgctct cattgggctg cagctgttca 1440  
 tgggcaatct gaggaataaa tgtttgcagt ggcccccaag cgattctgct tttgaaacca 1500  
 acaccacttc ctactttaat ggcacaatgg attcaaatgg gacatttgtt aatgtaacaa 1560  
 tgagcacatt taactggaag gattacattg gagatgacag tcacttttat gttttggatg 1620  
 ggcaaaaaga ccctttactc tgtggaaatg gctcagatgc aggccagtgt ccagaaggat 1680  
 acatctgtgt gaaggctggt cgaaacccca actatggcta cacaagcttt gacaccttta 1740  
 gctgggcttt cctgtctcta tttcgactca tgactcaaga ctactgggaa aatctttacc 1800  
 agttgacatt acgtgctgct gggaaaacat acatgatatt ttttgcctg gtcattttct 1860  
 tgggctcatt ttatttgggt aatttgatcc tggctgtggt ggccatggcc tatgaggggc 1920  
 agaatcaggc caccttgga gaagcagaac aaaaagaggc cgaatttcag cagatgctcg 1980  
 aacagcttaa aaagcaacag gaagaagctc aggcagttgc ggcagcatca gctgcttcaa 2040  
 gagatttcag tggaataggt gggttaggag agctgttgga aagttcttca gaagcatcaa 2100  
 agttgagttc caaaagtgt aaagaatgga ggaaccgaag gaagaaaaga agacagagag 2160  
 agcaccttga aggaaacaac aaaggagaga gagacagctt tcccaaatcc gaatctgaag 2220

```

acagcgtcaa aagaagcagc ttccttttct ccatggatgg aaacagactg accagtgcaca 2280
aaaaattctg ctccctcat cagtctctct tgagtatccg tggctccctg ttttcccaa 2340
gacgcaatag caaaacaagc attttcagtt tcagaggtcg ggcaaaggat gttggatctg 2400
aaaatgactt tgctgatgat gaacacagca catttgaaga cagcgaaagc aggagagact 2460
cactgtttgt gccgcacaga catggagagc gacgcaacag taacggcacc accactgaaa 2520
cggaagttag aaagagaagg ttaagctctt accagatttc aatggagatg ctggaggatt 2580
cctctggaag gcaaagagcc gtgagcatag ccagcattct gaccaacaca atggaagaac 2640
ttgaagaatc tagacagaaa tgccgccat gctggtatag atttgccaat gtgttcttga 2700
tctgggactg ctgtgatgca tggttaaaag taaaacatct tgtgaattta attgttatgg 2760
atccatttgt tgatcttgcc atcactatct gcattgtctt aaataccctc tttatggcca 2820
tggagcacta ccccatgact gagcaattca gtagtgtgtt gactgtagga aacctggtct 2880
ttactgggat ttttacagca gaaatgggtc tcaagatcat tgccatggat ccttattact 2940
atttccaaga aggctggaat atctttgatg gaattattgt cagcctcagt ttaatggagc 3000
ttggtctgtc aaatgtggag ggattgtctg tactgcatc attcagactg cttagagttt 3060
tcaagttggc aaaatcctgg ccacactaa atatgctaata taagatcatt ggcaattctg 3120
tgggggctct aggaacctc accttgggtg tggccatcat cgtcttcatt tttgctgtgg 3180
tcggcatgca gctcttttgt aagagctaca aagaatgtgt ctgcaagatc aatgatgact 3240
gtacgctccc acggtggcac atgaacgact tcttccactc cttcctgatt gtgttccgcg 3300
tgctgtgtgg agagtggata gagaccatgt gggactgtat ggaggtcgct ggccaaacca 3360
tgtgccttat tgttttcatg ttggtcatgg tcattggaaa ccttgtggtt ctgaacctct 3420
ttctggcctt attgttgagt tcatttagct cagacaacct tgctgctact gatgatgaca 3480
atgaaatgaa taatctgcag attgcagtag gaagaatgca aaagggaatt gattatgtga 3540
aaaataagat gcgggagtgt ttccaaaaag ctttttttag aaagccaaaa gttatagaaa 3600
tccatgaagg caataagata gacagctgca tgtccaataa tactggaatt gaaataagca 3660
aagagcttaa ttatcttaga gatgggaatg gaaccaccag tgggtgtaggt actggaagca 3720
gtgttgaaaa atacgtaatc gatgaaaatg attatatgtc attcataaac aaccccagcc 3780
tcaccgtcac agtgccaatt gctgttggag agtctgactt tgaaaactta aatactgaag 3840
agttcagcag tgagtcagaa ctagaagaaa gcaaggagaa attaaatgca accagctcat 3900
ctgaaggaag cacagttgat gttgttctac cccgagaagg tgaacaagct gaaactgaac 3960
ccgaagaaga ccttaaaccg gaagcttgtt ttactgaagg atgtattaaa aagtttccat 4020
tctgtcaagt aagtacagaa gaaggcaaag ggaagatctg gtggaatctt cgaaaaacct 4080
gctacagtat tgttgagcac aactggtttg agactttcat tgtgttcatg atccttctca 4140
gtagtgggtc attggccttt gaagatatat acattgaaca gcgaaagact atcaaaaacca 4200
tgctagaata tgctgacaaa gtctttacct atatattcat tctggaaatg cttctcaaat 4260
gggttgctta tggatttcaa acatatttca ctaatgcctg gtgctggcta gatttcttga 4320
tcgttgatgt ttctttggtt agcctggtag ccaatgctct tggctactca gaactcgggt 4380
ccatcaaate attacggaca ttaagagctt taagacctct aagagcetta tcccggtttg 4440
aaggcatgag ggtggttggt aatgctcttg ttggagcaat tccctctatc atgaatgtgc 4500
tgttggtctg tctcatcttc tggttgatct ttagcatcat ggggtgtgaat ttgtttgctg 4560
gcaagttcta ccactgtgtt aacatgacaa cgggtaacat gtttgacatt agtgatgtta 4620
acaatttgag tgactgtcag gctcttggca agcaagctcg gtggaaaaac gtgaaagtaa 4680
actttgataa tgttggcgct ggctatcttg cactgcttca agtggccaca tttaaaggct 4740
ggatggatat tatgtatgca gctgttgatt cacgagatgt taaacttcag cctgtatatg 4800
aagaaaatct gtacatgtat ttatactttg tcatctttat catctttggg tcattcttca 4860
ctctgaatct attcattggg gtcacatag ataacttcaa ccagcagaaa aagaagtttg 4920
gaggtcaaga catctttatg acagaggaac agaaaaaata ttacaatgca atgaagaaac 4980
ttggatccaa gaaacctcag aaaccatac ctcgcccagc aaacaaattc caaggaatgg 5040
tctttgattt tgtaaccaga caagtctttg atatcagcat catgatcctc atctgcctca 5100

```

acatgggtcac catgatgggtg gaaacggatg accagggcaa atacatgacc ctagttttgt 5160  
 cccggatcaa cctagtgttc attgttctgt tcaactggaga atttgtgctg aagctcgtct 5220  
 ccctcagaca ctactacttc actataggct ggaacatctt tgactttgtg gtgggtgattc 5280  
 tctccattgt aggtatgttt ctggctgaga tgatagaaaa gtattttgtg tccccacct 5340  
 tgttccgagt gatccgtctt gccaggattg gccgaatcct acgtctgac aaaggagcaa 5400  
 aggggatccg cacgctgctc tttgctttga tgatgtccct tcctgcgttg tttaacatcg 5460  
 gcctcctgct cttcctggctc atgtttatct atgccatctt tgggatgtcc aactttgcct 5520  
 atgttaaaaa ggaagctgga attgatgaca tgttcaactt tgagaccttt ggcaacagca 5580  
 tgatctgctt gttccaaatt acaacctctg ctggatggga tggattgcta gcacctattc 5640  
 ttaatagtgc accaccgcac tgtgacctg acacaattca ccctggcagc tcagttaagg 5700  
 gagactgtgg gaacccatct gttgggattt tctttttgt cagttacatc atcatatcct 5760  
 tcctgggtgt ggtgaacagt tacatcgcgg tcatcctgga gaacttcagt gttgctactg 5820  
 aagaaagtgc agagcccctg agtgaggatg actttgagat gttctatgag gtttgggaaa 5880  
 agtttgatcc cgatgcgacc cagtttatag agttctctaa actctctgat tttgcagctg 5940  
 ccctggatcc tcctcttctc atagcaaaac ccaacaaagt ccagcttatt gccatggatc 6000  
 tgcccatggt cagtggtgac cggatccact gtcttgatat tttatttgcc tttacaaagc 6060  
 gtgttttggg tgagagtgga gagatggatg cccttcgaat acagatggaa gacagggtta 6120  
 tggcatcaaa cccctccaaa gtctcttatg agcctattac aaccactttg aaacgtaaac 6180  
 aagaggaggt gtctgccgct atcattcagc gtaatttcag atgttatctt ttaaagcaaa 6240  
 ggtaaaaaaa tatatcaagt aactataaca aagaggcaat aaaggggagg attgacttac 6300  
 ctataaaaaca agacatgatt attgacaaac tgaatgggaa ctccactcca gaaaaaacag 6360  
 atgggagttc ctctaccacc tctctctctt cctatgatag tgtaacaaaa ccagacaagg 6420  
 aaaagtttga gaaagacaaa ccagaaaaag aaagcaaagg aaaagaggtc agagaaaatc 6480  
 aaaagtaaaa agaaacaaag aattatcttt gtgatcaatt gtttacagcc tatgaaggta 6540  
 aagtatatgt gtcaactgga cttcaagagg aggtccatgc caaactgact gttttaacaa 6600  
 atactcatag tcagtgccta tacaagacag tgaagtgacc tctctgtcac tgcaactctg 6660  
 tgaagcaggg tatcaacatt gacaagagg tgctgttttt attaccagct gacactgctg 6720  
 aggagaaacc caatggctac ctgactata gggatagttg tgcaaagtga acattgtaac 6780  
 tacaccaaac acctttagta cagtccttgc atccattcta tttttaactt ccatactctg 6840  
 catattttta caaaatttgt tctagtgcac ttccatggct cccaattcat agtttattca 6900  
 taatgctatg tcaactattt tgtaaatgag gtttacgttg aagaaacagt atacaagaac 6960  
 cctgtctctc aaatgatcag acaaagggtg tttgccagag agataaaatt tttgctcaaa 7020  
 accagaaaaa gaattgtaat ggctacagtt tcagttactt ccattttcta gatggcttta 7080  
 attttgaaag tatttttagt tggtatgttt gtttctatct gaacagttat gtgcctgtaa 7140  
 agtctcctct aatatttaaa ggattatttt tatgcaaagt attctgtttc agcaagtgca 7200  
 aattttattc taagtttcag agctctatat ttaatttagg tcaaattgct tccaaaaagt 7260  
 aatctaataa atccattcta gaaaaatata tctaaagtat tgcttttaga tagttgttcc 7320  
 actttctgct gcagtattgc tttgccatct tctgctctca gcaaagctga tagtctatgt 7380  
 caattaaata ccctatgtta tgtaaatagt tattttatcc tgtgggtgcat gtttgggcaa 7440  
 atatatatat agcctgataa acaacttcta ttaaatacaa tatgtaccac agtgatgtg 7500  
 tcttttgcaa gcttccaaca gggatgtatc ctgtatcatt cattaaacat agtttaaagg 7560  
 ctatcactaa tgcatgttaa tattgccat gctgctctat tttactcaat ccattcttca 7620  
 caagtcttgg ttaaagaatg tcacatattg gtgatagaat gaattcaacc tgctctgtcc 7680  
 attatgtcaa gcagaataat ttgaagctat ttacaaacac ctttactttt gcacttttaa 7740  
 ttcaacatga gtatcatatg gtatctctct agatttcaag gaaacacact ggatactgcc 7800  
 tactgacaaa acctattctt catattttgc taaaaatatg tctaaaactt gcgcaaatat 7860  
 aaataatgta aaaatataat caactttatt tgtcagcatt ttgtacataa gaaaattatt 7920  
 ttcagggtga tgacatcaca atttatttta ctttatgctt ttgcttttga ttttaataca 7980



```

caattccaaa cttttgaatc cataagattt ttcaatggat aatttcctaa aataaaagtt 8040
agataatggg ttttatggat ttctttgtta taatatattt tctaccattc caataggaga 8100
tacattgggtc aaacactcaa acctagatca ttttctacca actatgggtg cctcaatata 8160
accttttatt catagatggt tttttttatt caacttttgt agtatttacg tatgcagact 8220
agtcttattt ttttaattcc tgctgcacta aagctattac aaatataaca tggactttgt 8280
tcttttttagc catgaacaaa gtggcaaagt tgtgcaatta cctaacaatga tataaatttt 8340
tgttttttgc acaaaccaaa agtttaatgt taattctttt tacaaaacta tttactgtag 8400
tgtattgaag aactgcatgc agggaattgc tattgctaaa aagaatgggtg agctacgtca 8460
ttattgagcc aaaagaataa atttcatttt ttattgcatt tcaactattg gcctctgggg 8520
ttttttgttt ttgttttttg ctgttggcag tttaaaatat atataattaa taaaacctgt 8580
gcttgatctg acatttgtat acataaaagt ttacatgaat ttacaacag actagtgcac 8640
gattcaccaa gcagtactac agaacaaagg caaatgaaaa gcagctttgt gcacttttat 8700
gtgtgcaaag gatcaagttc acatgttcca actttcaggt ttgataataa tagtagtaac 8760
cacctacaat agctttcaat ttcaattaac tcccttggct ataagcatct aaactcatct 8820
tctttcaata taattgatgc tatctcctaa ttacttggtg gctaataaat gttacattct 8880
ttgttactta aatgcattat ataaactcct atgtatacat aaggatttaa tgatatagtt 8940
attgagaatt tatattaact tttttttcaa gaacccttgg atttatgtga ggtcaaaacc 9000
aaactcttat tctcagtgga aaactccagt tgtaatgcat attttttaaag acaatttgga 9060
tctaaatatg tatttcataa ttctcccata ataaattata taagggtggct aa 9112

```

&lt;210&gt; 67

&lt;211&gt; 1951

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 67

```

Met Ala Gln Ala Leu Leu Val Pro Pro Gly Pro Glu Ser Phe Arg Leu
  1             5             10             15

```

```

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Lys Arg Ala Ala Glu Glu
      20             25             30

```

```

Lys Ala Lys Lys Pro Lys Lys Glu Gln Asp Asn Asp Asp Glu Asn Lys
      35             40             45

```

```

Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
      50             55             60

```

```

Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
      65             70             75             80

```

```

Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Met Asn Lys Gly
      85             90             95

```

```

Lys Ala Ile Ser Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
      100            105            110

```

Pro Leu Asn Pro Val Arg Lys Ile Ala Xaa Lys Ile Leu Val His Ser  
 115 120 125

Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe  
 130 135 140

Met Thr Leu Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr  
 145 150 155 160

Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala Arg  
 165 170 175

Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp  
 180 185 190

Leu Asp Phe Ser Val Ile Val Met Ala Tyr Val Thr Glu Phe Val Asp  
 195 200 205

Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu  
 210 215 220

Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu  
 225 230 235 240

Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe  
 245 250 255

Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn  
 260 265 270

Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Ser Asp Ser Ala Phe Glu  
 275 280 285

Thr Asn Thr Thr Ser Tyr Phe Asn Gly Thr Met Asp Ser Asn Gly Thr  
 290 295 300

Phe Val Asn Val Thr Met Ser Thr Phe Asn Trp Lys Asp Tyr Ile Gly  
 305 310 315 320

Asp Asp Ser His Phe Tyr Val Leu Asp Gly Gln Lys Asp Pro Leu Leu  
 325 330 335

Cys Gly Asn Gly Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile Cys  
 340 345 350

Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr  
 355 360 365

Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Tyr  
 370 375 380

Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr Tyr  
 385 390 395 400

Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Val  
 405 410 415

Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Gly Gln Asn Gln  
 420 425 430

Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met  
 435 440 445

Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Val Ala Ala  
 450 455 460

Ala Ser Ala Ala Ser Arg Asp Phe Ser Gly Ile Gly Gly Leu Gly Glu  
 465 470 475 480

Leu Leu Glu Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala  
 485 490 495

Lys Glu Trp Arg Asn Arg Arg Lys Lys Arg Arg Gln Arg Glu His Leu  
 500 505 510

Glu Gly Asn Asn Lys Gly Glu Arg Asp Ser Phe Pro Lys Ser Glu Ser  
 515 520 525

Glu Asp Ser Val Lys Arg Ser Ser Phe Leu Phe Ser Met Asp Gly Asn  
 530 535 540

Arg Leu Thr Ser Asp Lys Lys Phe Cys Ser Pro His Gln Ser Leu Leu  
 545 550 555 560

Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Lys Thr Ser  
 565 570 575

Ile Phe Ser Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp  
 580 585 590

Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Ser Glu Ser Arg Arg  
 595 600 605

Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg Asn Ser Asn  
 610 615 620

Gly Thr Thr Thr Glu Thr Glu Val Arg Lys Arg Arg Leu Ser Ser Tyr  
625 630 635 640

Gln Ile Ser Met Glu Met Leu Glu Asp Ser Ser Gly Arg Gln Arg Ala  
645 650 655

Val Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu  
660 665 670

Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Arg Phe Ala Asn Val Phe  
675 680 685

Leu Ile Trp Asp Cys Cys Asp Ala Trp Leu Lys Val Lys His Leu Val  
690 695 700

Asn Leu Ile Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys  
705 710 715 720

Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr  
725 730 735

Glu Gln Phe Ser Ser Val Leu Thr Val Gly Asn Leu Val Phe Thr Gly  
740 745 750

Ile Phe Thr Ala Glu Met Val Leu Lys Ile Ile Ala Met Asp Pro Tyr  
755 760 765

Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Ile Ile Val Ser  
770 775 780

Leu Ser Leu Met Glu Leu Gly Leu Ser Asn Val Glu Gly Leu Ser Val  
785 790 795 800

Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp  
805 810 815

Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala  
820 825 830

Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala  
835 840 845

Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys  
850 855 860

Lys Ile Asn Asp Asp Cys Thr Leu Pro Arg Trp His Met Asn Asp Phe  
865 870 875 880

Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile  
 885 890 895

Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu  
 900 905 910

Ile Val Phe Met Leu Val Met Val Ile Gly Asn Leu Val Val Leu Asn  
 915 920 925

Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala  
 930 935 940

Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Leu Gln Ile Ala Val Gly  
 945 950 955 960

Arg Met Gln Lys Gly Ile Asp Tyr Val Lys Asn Lys Met Arg Glu Cys  
 965 970 975

Phe Gln Lys Ala Phe Phe Arg Lys Pro Lys Val Ile Glu Ile His Glu  
 980 985 990

Gly Asn Lys Ile Asp Ser Cys Met Ser Asn Asn Thr Gly Ile Glu Ile  
 995 1000 1005

Ser Lys Glu Leu Asn Tyr Leu Arg Asp Gly Asn Gly Thr Thr Ser Gly  
 1010 1015 1020

Val Gly Thr Gly Ser Ser Val Glu Lys Tyr Val Ile Asp Glu Asn Asp  
 1025 1030 1035 1040

Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val Thr Val Pro Ile  
 1045 1050 1055

Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn Thr Glu Glu Phe Ser  
 1060 1065 1070

Ser Glu Ser Glu Leu Glu Glu Ser Lys Glu Lys Leu Asn Ala Thr Ser  
 1075 1080 1085

Ser Ser Glu Gly Ser Thr Val Asp Val Val Leu Pro Arg Glu Gly Glu  
 1090 1095 1100

Gln Ala Glu Thr Glu Pro Glu Glu Asp Leu Lys Pro Glu Ala Cys Phe  
 1105 1110 1115 1120

Thr Glu Gly Cys Ile Lys Lys Phe Pro Phe Cys Gln Val Ser Thr Glu  
 1125 1130 1135

Glu Gly Lys Gly Lys Ile Trp Trp Asn Leu Arg Lys Thr Cys Tyr Ser  
 1140 1145 1150

Ile Val Glu His Asn Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu  
 1155 1160 1165

Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile Glu Gln Arg  
 1170 1175 1180

Lys Thr Ile Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr  
 1185 1190 1195 1200

Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Phe Gln  
 1205 1210 1215

Thr Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp  
 1220 1225 1230

Val Ser Leu Val Ser Leu Val Ala Asn Ala Leu Gly Tyr Ser Glu Leu  
 1235 1240 1245

Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro Leu Arg  
 1250 1255 1260

Ala Leu Ser Arg Phe Glu Gly Met Arg Val Val Val Asn Ala Leu Val  
 1265 1270 1275 1280

Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val Cys Leu Ile Phe  
 1285 1290 1295

Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu Phe Ala Gly Lys Phe  
 1300 1305 1310

Tyr His Cys Val Asn Met Thr Thr Gly Asn Met Phe Asp Ile Ser Asp  
 1315 1320 1325

Val Asn Asn Leu Ser Asp Cys Gln Ala Leu Gly Lys Gln Ala Arg Trp  
 1330 1335 1340

Lys Asn Val Lys Val Asn Phe Asp Asn Val Gly Ala Gly Tyr Leu Ala  
 1345 1350 1355 1360

Leu Leu Gln Val Ala Thr Phe Lys Gly Trp Met Asp Ile Met Tyr Ala  
 1365 1370 1375

Ala Val Asp Ser Arg Asp Val Lys Leu Gln Pro Val Tyr Glu Glu Asn  
 1380 1385 1390

Leu Tyr Met Tyr Leu Tyr Phe Val Ile Phe Ile Ile Phe Gly Ser Phe  
1395 1400 1405

Phe Thr Leu Asn Leu Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln  
1410 1415 1420

Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln  
1425 1430 1435 1440

Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln  
1445 1450 1455

Lys Pro Ile Pro Arg Pro Ala Asn Lys Phe Gln Gly Met Val Phe Asp  
1460 1465 1470

Phe Val Thr Arg Gln Val Phe Asp Ile Ser Ile Met Ile Leu Ile Cys  
1475 1480 1485

Leu Asn Met Val Thr Met Met Val Glu Thr Asp Asp Gln Gly Lys Tyr  
1490 1495 1500

Met Thr Leu Val Leu Ser Arg Ile Asn Leu Val Phe Ile Val Leu Phe  
1505 1510 1515 1520

Thr Gly Glu Phe Val Leu Lys Leu Val Ser Leu Arg His Tyr Tyr Phe  
1525 1530 1535

Thr Ile Gly Trp Asn Ile Phe Asp Phe Val Val Val Ile Leu Ser Ile  
1540 1545 1550

Val Gly Met Phe Leu Ala Glu Met Ile Glu Lys Tyr Phe Val Ser Pro  
1555 1560 1565

Thr Leu Phe Arg Val Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg  
1570 1575 1580

Leu Ile Lys Gly Ala Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met  
1585 1590 1595 1600

Met Ser Leu Pro Ala Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val  
1605 1610 1615

Met Phe Ile Tyr Ala Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys  
1620 1625 1630

Lys Glu Ala Gly Ile Asp Asp Met Phe Asn Phe Glu Thr Phe Gly Asn  
1635 1640 1645

Ser Met Ile Cys Leu Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly  
 1650 1655 1660

Leu Leu Ala Pro Ile Leu Asn Ser Ala Pro Pro Asp Cys Asp Pro Asp  
 1665 1670 1675 1680

Thr Ile His Pro Gly Ser Ser Val Lys Gly Asp Cys Gly Asn Pro Ser  
 1685 1690 1695

Val Gly Ile Phe Phe Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val  
 1700 1705 1710

Val Val Asn Ser Tyr Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala  
 1715 1720 1725

Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe  
 1730 1735 1740

Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu  
 1745 1750 1755 1760

Phe Ser Lys Leu Ser Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Leu  
 1765 1770 1775

Ile Ala Lys Pro Asn Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met  
 1780 1785 1790

Val Ser Gly Asp Arg Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr  
 1795 1800 1805

Lys Arg Val Leu Gly Glu Ser Gly Glu Met Asp Ala Leu Arg Ile Gln  
 1810 1815 1820

Met Glu Asp Arg Phe Met Ala Ser Asn Pro Ser Lys Val Ser Tyr Glu  
 1825 1830 1835 1840

Pro Ile Thr Thr Thr Leu Lys Arg Lys Gln Glu Glu Val Ser Ala Ala  
 1845 1850 1855

Ile Ile Gln Arg Asn Phe Arg Cys Tyr Leu Leu Lys Gln Arg Leu Lys  
 1860 1865 1870

Asn Ile Ser Ser Asn Tyr Asn Lys Glu Ala Ile Lys Gly Arg Ile Asp  
 1875 1880 1885

Leu Pro Ile Lys Gln Asp Met Ile Ile Asp Lys Leu Asn Gly Asn Ser  
 1890 1895 1900



Thr Pro Glu Lys Thr Asp Gly Ser Ser Ser Thr Thr Ser Pro Pro Ser  
 1905 1910 1915 1920

Tyr Asp Ser Val Thr Lys Pro Asp Lys Glu Lys Phe Glu Lys Asp Lys  
 1925 1930 1935

Pro Glu Lys Glu Ser Lys Gly Lys Glu Val Arg Glu Asn Gln Lys  
 1940 1945 1950

<210> 68

<211> 1951

<212> PRT

<213> Homo sapiens

<400> 68

Met Ala Gln Ala Leu Leu Val Pro Pro Gly Pro Glu Ser Phe Arg Leu  
 1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Lys Arg Ala Ala Glu Glu  
 20 25 30

Lys Ala Lys Lys Pro Lys Lys Glu Gln Asp Asn Asp Asp Glu Asn Lys  
 35 40 45

Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile  
 50 55 60

Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu  
 65 70 75 80

Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Met Asn Lys Gly  
 85 90 95

Lys Ala Ile Ser Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr  
 100 105 110

Pro Leu Asn Pro Val Arg Lys Ile Ala Xaa Lys Ile Leu Val His Ser  
 115 120 125

Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe  
 130 135 140

Met Thr Leu Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr  
 145 150 155 160

Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala Arg  
 165 170 175

Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp  
 180 185 190

Leu Asp Phe Ser Val Ile Val Met Ala Tyr Val Thr Glu Phe Val Ser  
 195 200 205

Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu  
 210 215 220

Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu  
 225 230 235 240

Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe  
 245 250 255

Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn  
 260 265 270

Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Ser Asp Ser Ala Phe Glu  
 275 280 285

Thr Asn Thr Thr Ser Tyr Phe Asn Gly Thr Met Asp Ser Asn Gly Thr  
 290 295 300

Phe Val Asn Val Thr Met Ser Thr Phe Asn Trp Lys Asp Tyr Ile Gly  
 305 310 315 320

Asp Asp Ser His Phe Tyr Val Leu Asp Gly Gln Lys Asp Pro Leu Leu  
 325 330 335

Cys Gly Asn Gly Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile Cys  
 340 345 350

Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr  
 355 360 365

Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Tyr  
 370 375 380

Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr Tyr  
 385 390 395 400

Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Val  
 405 410 415

Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Gly Gln Asn Gln  
 420 425 430

Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met  
435 440 445

Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Val Ala Ala  
450 455 460

Ala Ser Ala Ala Ser Arg Asp Phe Ser Gly Ile Gly Gly Leu Gly Glu  
465 470 475 480

Leu Leu Glu Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala  
485 490 495

Lys Glu Trp Arg Asn Arg Arg Lys Lys Arg Arg Gln Arg Glu His Leu  
500 505 510

Glu Gly Asn Asn Lys Gly Glu Arg Asp Ser Phe Pro Lys Ser Glu Ser  
515 520 525

Glu Asp Ser Val Lys Arg Ser Ser Phe Leu Phe Ser Met Asp Gly Asn  
530 535 540

Arg Leu Thr Ser Asp Lys Lys Phe Cys Ser Pro His Gln Ser Leu Leu  
545 550 555 560

Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Lys Thr Ser  
565 570 575

Ile Phe Ser Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp  
580 585 590

Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Ser Glu Ser Arg Arg  
595 600 605

Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg Asn Ser Asn  
610 615 620

Gly Thr Thr Thr Glu Thr Glu Val Arg Lys Arg Arg Leu Ser Ser Tyr  
625 630 635 640

Gln Ile Ser Met Glu Met Leu Glu Asp Ser Ser Gly Arg Gln Arg Ala  
645 650 655

Val Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu  
660 665 670

Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Arg Phe Ala Asn Val Phe  
675 680 685

Leu Ile Trp Asp Cys Cys Asp Ala Trp Leu Lys Val Lys His Leu Val  
 690 695 700

Asn Leu Ile Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys  
 705 710 715 720

Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr  
 725 730 735

Glu Gln Phe Ser Ser Val Leu Thr Val Gly Asn Leu Val Phe Thr Gly  
 740 745 750

Ile Phe Thr Ala Glu Met Val Leu Lys Ile Ile Ala Met Asp Pro Tyr  
 755 760 765

Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Ile Ile Val Ser  
 770 775 780

Leu Ser Leu Met Glu Leu Gly Leu Ser Asn Val Glu Gly Leu Ser Val  
 785 790 795 800

Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp  
 805 810 815

Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala  
 820 825 830

Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala  
 835 840 845

Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys  
 850 855 860

Lys Ile Asn Asp Asp Cys Thr Leu Pro Arg Trp His Met Asn Asp Phe  
 865 870 875 880

Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile  
 885 890 895

Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu  
 900 905 910

Ile Val Phe Met Leu Val Met Val Ile Gly Asn Leu Val Val Leu Asn  
 915 920 925

Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala  
 930 935 940

Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Leu Gln Ile Ala Val Gly  
 945 950 955 960

Arg Met Gln Lys Gly Ile Asp Tyr Val Lys Asn Lys Met Arg Glu Cys  
 965 970 975

Phe Gln Lys Ala Phe Phe Arg Lys Pro Lys Val Ile Glu Ile His Glu  
 980 985 990

Gly Asn Lys Ile Asp Ser Cys Met Ser Asn Asn Thr Gly Ile Glu Ile  
 995 1000 1005

Ser Lys Glu Leu Asn Tyr Leu Arg Asp Gly Asn Gly Thr Thr Ser Gly  
 1010 1015 1020

Val Gly Thr Gly Ser Ser Val Glu Lys Tyr Val Ile Asp Glu Asn Asp  
 1025 1030 1035 1040

Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val Thr Val Pro Ile  
 1045 1050 1055

Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn Thr Glu Glu Phe Ser  
 1060 1065 1070

Ser Glu Ser Glu Leu Glu Glu Ser Lys Glu Lys Leu Asn Ala Thr Ser  
 1075 1080 1085

Ser Ser Glu Gly Ser Thr Val Asp Val Val Leu Pro Arg Glu Gly Glu  
 1090 1095 1100

Gln Ala Glu Thr Glu Pro Glu Glu Asp Leu Lys Pro Glu Ala Cys Phe  
 1105 1110 1115 1120

Thr Glu Gly Cys Ile Lys Lys Phe Pro Phe Cys Gln Val Ser Thr Glu  
 1125 1130 1135

Glu Gly Lys Gly Lys Ile Trp Trp Asn Leu Arg Lys Thr Cys Tyr Ser  
 1140 1145 1150

Ile Val Glu His Asn Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu  
 1155 1160 1165

Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile Glu Gln Arg  
 1170 1175 1180

Lys Thr Ile Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr  
 1185 1190 1195 1200

Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Phe Gln  
 1205 1210 1215

Thr Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp  
 1220 1225 1230

Val Ser Leu Val Ser Leu Val Ala Asn Ala Leu Gly Tyr Ser Glu Leu  
 1235 1240 1245

Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro Leu Arg  
 1250 1255 1260

Ala Leu Ser Arg Phe Glu Gly Met Arg Val Val Val Asn Ala Leu Val  
 1265 1270 1275 1280

Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val Cys Leu Ile Phe  
 1285 1290 1295

Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu Phe Ala Gly Lys Phe  
 1300 1305 1310

Tyr His Cys Val Asn Met Thr Thr Gly Asn Met Phe Asp Ile Ser Asp  
 1315 1320 1325

Val Asn Asn Leu Ser Asp Cys Gln Ala Leu Gly Lys Gln Ala Arg Trp  
 1330 1335 1340

Lys Asn Val Lys Val Asn Phe Asp Asn Val Gly Ala Gly Tyr Leu Ala  
 1345 1350 1355 1360

Leu Leu Gln Val Ala Thr Phe Lys Gly Trp Met Asp Ile Met Tyr Ala  
 1365 1370 1375

Ala Val Asp Ser Arg Asp Val Lys Leu Gln Pro Val Tyr Glu Glu Asn  
 1380 1385 1390

Leu Tyr Met Tyr Leu Tyr Phe Val Ile Phe Ile Ile Phe Gly Ser Phe  
 1395 1400 1405

Phe Thr Leu Asn Leu Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln  
 1410 1415 1420

Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln  
 1425 1430 1435 1440

Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu Gly Ser Lys Lys Pro Gln  
 1445 1450 1455

Lys Pro Ile Pro Arg Pro Ala Asn Lys Phe Gln Gly Met Val Phe Asp  
 1460 1465 1470

Phe Val Thr Arg Gln Val Phe Asp Ile Ser Ile Met Ile Leu Ile Cys  
 1475 1480 1485

Leu Asn Met Val Thr Met Met Val Glu Thr Asp Asp Gln Gly Lys Tyr  
 1490 1495 1500

Met Thr Leu Val Leu Ser Arg Ile Asn Leu Val Phe Ile Val Leu Phe  
 1505 1510 1515 1520

Thr Gly Glu Phe Val Leu Lys Leu Val Ser Leu Arg His Tyr Tyr Phe  
 1525 1530 1535

Thr Ile Gly Trp Asn Ile Phe Asp Phe Val Val Val Ile Leu Ser Ile  
 1540 1545 1550

Val Gly Met Phe Leu Ala Glu Met Ile Glu Lys Tyr Phe Val Ser Pro  
 1555 1560 1565

Thr Leu Phe Arg Val Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg  
 1570 1575 1580

Leu Ile Lys Gly Ala Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met  
 1585 1590 1595 1600

Met Ser Leu Pro Ala Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val  
 1605 1610 1615

Met Phe Ile Tyr Ala Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys  
 1620 1625 1630

Lys Glu Ala Gly Ile Asp Asp Met Phe Asn Phe Glu Thr Phe Gly Asn  
 1635 1640 1645

Ser Met Ile Cys Leu Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly  
 1650 1655 1660

Leu Leu Ala Pro Ile Leu Asn Ser Ala Pro Pro Asp Cys Asp Pro Asp  
 1665 1670 1675 1680

Thr Ile His Pro Gly Ser Ser Val Lys Gly Asp Cys Gly Asn Pro Ser  
 1685 1690 1695

Val Gly Ile Phe Phe Phe Val Ser Tyr Ile Ile Ile Ser Phe Leu Val  
 1700 1705 1710

Val Val Asn Ser Tyr Ile Ala Val Ile Leu Glu Asn Phe Ser Val Ala  
1715 1720 1725

Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu Asp Asp Phe Glu Met Phe  
1730 1735 1740

Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu  
1745 1750 1755 1760

Phe Ser Lys Leu Ser Asp Phe Ala Ala Ala Leu Asp Pro Pro Leu Leu  
1765 1770 1775

Ile Ala Lys Pro Asn Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met  
1780 1785 1790

Val Ser Gly Asp Arg Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr  
1795 1800 1805

Lys Arg Val Leu Gly Glu Ser Gly Glu Met Asp Ala Leu Arg Ile Gln  
1810 1815 1820

Met Glu Asp Arg Phe Met Ala Ser Asn Pro Ser Lys Val Ser Tyr Glu  
1825 1830 1835 1840

Pro Ile Thr Thr Thr Leu Lys Arg Lys Gln Glu Glu Val Ser Ala Ala  
1845 1850 1855

Ile Ile Gln Arg Asn Phe Arg Cys Tyr Leu Leu Lys Gln Arg Leu Lys  
1860 1865 1870

Asn Ile Ser Ser Asn Tyr Asn Lys Glu Ala Ile Lys Gly Arg Ile Asp  
1875 1880 1885

Leu Pro Ile Lys Gln Asp Met Ile Ile Asp Lys Leu Asn Gly Asn Ser  
1890 1895 1900

Thr Pro Glu Lys Thr Asp Gly Ser Ser Ser Thr Thr Ser Pro Pro Ser  
1905 1910 1915 1920

Tyr Asp Ser Val Thr Lys Pro Asp Lys Glu Lys Phe Glu Lys Asp Lys  
1925 1930 1935

Pro Glu Lys Glu Ser Lys Gly Lys Glu Val Arg Glu Asn Gln Lys  
1940 1945 1950

<210> 69



&lt;211&gt; 1380

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 69

```

aatgtattta ttttaattgat gataaactgt aataaaatca tagttgtttg ctctaaagta 60
gatatgaaag gtcagatgaa acaataacat acatctggat tgagaaatat ctttaataact 120
gatggattat ttttattttc tttatgtatt gtgtgcttca atatcctaata aaataatatt 180
agctagggtc actgatgtat agaatctttt tctacattta gatatttctt gcaaagtgtt 240
taccagaaag caacacaaaa atactatcag tgagtatgtg tttacactgt tctctaagga 300
gtcaaattcc tcaccttgaa aataattcat cccaggaaga gaaaagggtt tcaaaagact 360
agagcaggcc acaaggggagc tttcgcaaaa ctctacacgt aaagggtaat gtaaacttaa 420
aacctatttt tcaaacagta atttatatat cttttaattt tagtagttta tgtgtgaaac 480
aatcatgcaa aacaacaaag tgataaaatt ttttaaaaaa attagtgaga tgcaataaac 540
tgaatatgta aaaggctcctac tacatattta tatgtagtag ataagttaca tttttttagt 600
gtgttgaggaa attttagctc acatcacctc tctactgtca tcttggggca ctttcatgac 660
taccatgct tcatgcagggt ttacttttct cctgtgaca gaggataatg ggaatgtttt 720
ttctttggct caattttgtg tgtgtccgcc agtagatggc gtaccacttt gagtgcgac 780
ggcctttttt tctttctttt ttttttttct caaagctgtt ttctgatata tgttggttac 840
catagagtga atctcagaac aggaagcggg ggcataagca gagaggattc tggaaagggtc 900
tctttgtttt cttatccaca gagaaagaaa gaaaaaaat tgtaactaat ttgtaaacct 960
ctgtggtcaa aaaaaaaaaa aaaaaaaaaa gctgaacagc tgcagaggaa gacacgttat 1020
accctaacca tcttggtatgc tgggctttgt tatgtgttaa ttcataaggc tctgttttat 1080
caggtaagct gacaaaacat ttcattatct gcaccataga acctagctac caggtcattt 1140
tccttacttt aaaatcatct tcatgctgct atttttaacc cagtgttggt taaatgtaaa 1200
ttacaggaac caaaggcatc gtttgatgtg taaactgctt actatttctt tatctttcaa 1260
agaaaataga gcctgtctgg aaatggtgat ttatggtaca tactaggcat caatggtctt 1320
gtgtttttgt agatgcttat gattaattgt attcagaaaa aatatttttt attatactta 1380

```

&lt;210&gt; 70

&lt;211&gt; 840

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 70

```

agggagaagac agaaggatgc tcaggagtgc cagcatgcct tcagaaagac taatggatc 60
aaggctgcc aagaagggg agcaccctg tccaaccct aggatcctg cagtggttcc 120
tgggtccatt cttcctaaat catgctaggg catgctttta acaagggtca aatatcttgc 180
tttgcatcat ctttgccttc tcgatccagg gccataaaaa aaaaagggaat aaaaccaga 240
cacagagcca gagcaccct atgcaaagt tcaaagatta taggctaatt tcacctgtat 300
tctctttcta cagagattat ggagcaagaa aactgaagcc aagccacatc aaggtttgac 360
agggatgaga tacctgtcaa ggattcatag tagagtggct tactgggaaa ggagcaaga 420
atctcttcta gggatattgt aagaataaat gagataattc acagaaggga cctggagctt 480
ttccgaaaaa aggtgctgtg actatctaag gtaactaac aacttctgg tataagttg 540
tttttgtgga aaataaacta aaatctctac tatttaacaa ggacagctgt atcaggacca 600
aaagaaggca gagggtgtt ttcttcttc ctctaccagt ttgttcttcc aaaggaggca 660
atacatagc ggagacatag cacagatgac cttagggaat ggaatgatgc caaaggctgt 720

```

tgatgtaaga aagagagatt aactcagttt tttttttgtt tttgtttttt tgttggtggt 780.  
gttggtggtt tgagacagag tctctctctg tcgccaggc tggagtgcag tggcatgaac 840

<210> 71

<211> 780

<212> DNA

<213> Homo sapiens

<400> 71

gatatattaa attttatgta ttttaataaa ttataatgtg catataatca ttaataatat 60  
atatattcca caccaaggca tcagtaagaa ttaattttta aagtctgctc taatgtgaat 120  
ataaaattat gtaagaactc tgtataataa gctcacagag tacaagaaag gagaggaaaa 180  
aagtaaaaga gaactgcgaa agaactatga gggattttcca aacagcaaaa ttgtcattga 240  
agccatgaga aactctactc actaaattct ttaattttctc agcctaccca aatattgggc 300  
aaaccctaatt tctcttgagc gggaaaagct gagagtctgg aactagccta tcttccgagg 360  
acttagagac aacagtatgg gaatttcaac gagacgtttt tactttcttt tgaccaagat 420  
tcaaattctt tattccagcc ctgataagt aaataagaag gtaaaggact atttatttgt 480  
aaaaagttt tcatgatttt gtgatggcag ctgtgtccat atcatctcag ataaatcaga 540  
ataattttgtg aaaattactc ggtgatttcc acattagata ttttaaacct aatgttattt 600  
ctaaaacaaa aaccaaccag gagaatccaa ttaagtaaaa tgtatgtatt aatataaatt 660  
agctattccc atctggaaaa gggcagccat ttctgtgttg aggtgcctca atgatactga 720  
ggctgagaca ggtagatga tacaggcata ccattagcag cagactcaat actaaccag 780

<210> 72

<211> 1025

<212> DNA

<213> Homo sapiens

<400> 72

acaaagttat gaaaaggcgg ggggcaggat gcagaataat taagcaattt tattgacaaa 60  
ctthactggc attactcttt tgctgaaagt atactatatt ttggcttaca gtgtcaaaac 120  
agaatttttt aaatgctttt aaaaaatgga caaaattata gatattcttg agtttaaata 180  
taatgtttat atattatata tactgtacat tgtagaatgg ctaaatacaa ctaattaaca 240  
ttaagtacag acttttgata gatttatgaa ctgtgcttat tgagaatgag gttgaatgat 300  
gatgttttca agttcaaatg tgtagtgcag tactaaaagc atgacttaat gtttatagct 360  
ttaaaaagtt actaaagaat gacatttttg ttgatgttct tatgccaat cgcttgcttt 420  
cctaactctt gtgcaatttt tctttttatt gcaggtaatt cgtatgcaag aagctacacg 480  
taattaaatg tgcaggatga aaagatggca caggcactgt tggtaacccc aggacctgaa 540  
agcttccgcc tttttactag agaattctct gctgctatcg aaaaacgtgc tgcagaagag 600  
aaagccaaga agcccaaaaa ggaacaagat aatgatgatg agaacaaacc aaagccaaat 660  
agtgacttgg aagctggaaa gaaccttcca tttatttatg gagacattcc tccagagatg 720  
gtgtcagagc ccctggagga cctggatccc tactatatca ataagaaagt gagtattgat 780  
tttagacttc taataaatct ttaatgaaac tcttaactgt aatatacttt tctgggcctt 840  
atatacagca tcacaatttt tcttctgtta aagattttat aatactcttc actgtcactt 900  
atttttatca caatataata aaacaaacat ttataagaaa tgaagtcaag agttggttac 960  
agtcaggaaa tatgaataga tgaatgatt ctacaatttc acagtgataa ttcagatagt 1020

caaaa

1025

&lt;210&gt; 73

&lt;211&gt; 433

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 73

tgtaacyata tgtaattta aacatctaac atgtttgtag ttatgatata tcaactgggt 60  
 taaacaaacc agtttgaaca aacaaattcy attttttaaa aaggtcctca tgtatgtaag 120  
 ctcttaaat aagcccatgt ctaatttagt aattttactc gtattttctg tttcagactt 180  
 ttatagtaat gaataaagga aaggcaattt cccgattcag tgccacctct gccttgata 240  
 ttttaactcc actaaaccct gttaggaaaa ttgctabsaa gattttggta cattcatatc 300  
 cttttaatgt gaattgccta aatgctattt ctaacagttg attttaaaga aaatgtcagt 360  
 tatattttca agtatctgta aaatttcttt gagattaatg gtaacattgt tagtttaatt 420  
 catttatttg cat 433

&lt;210&gt; 74

&lt;211&gt; 450

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 74

gagtgcacca aggccatata acaggctttg aagtttctta ttattttatc attgttttaa 60  
 aacaaataat attaatttca cagtttttgc atcgataaac ttttttggtg gttttggatc 120  
 atttataaat ggccatggta acctactaac atttattcct taactataat ctactttatt 180  
 cagcatgctt atcatgtgca ctattttgac caactgtgta tttatgacct tgagcaaccc 240  
 tcctgactgg acaagaatg tagagtaagt aggaataact tctgggaatg agaaatgcac 300  
 actcaaattc tctagcaatc tccttggtgg tatagcctga cttatggttt ccacttctgt 360  
 ctaagaaaag ttattttcat aatatgcagc cggttaaggga ggtctttcgg gggagctatt 420  
 cttctacgag gtaagtattt tcccacaaaa 450

&lt;210&gt; 75

&lt;211&gt; 701

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 75

aaaatttacc atttgyggtt ttccattaca tttctatcag ataactctgc gctagtaggt 60  
 caaactagat gattatccat aagatacatg aaactattat tctaaaaccc aaatagttaa 120  
 accagattag attcctaaag aatatatttt ctcttcagtt taactctttg ctcaggcttg 180  
 taaaactaac taaatgaata gattatttgg taaatagaag taaggaacaa tattttaatg 240  
 aattgaaaaa ccacaaaagg ataggatttg ctatgattga aaacatttat tttacagtt 300  
 caagcaaaat tgtaattttt ggcttggatg tttttcctag gtacacattc actggaatct 360  
 atacctttga gtcacttata aaaatcttgg caagagggtt ttgcttagaa gattttacgt 420

```

ttcttcgtga tccatggaac tggctggatt tcagtgtcat tgtgatggcg tgagtaactt 480.
tgaaaatttg ataagcgcaa aggagtgaag atagtcatag tacaaacaag gtctttgtgt 540
catatattaa atgtagagct ttcttggttag tcaagttaac tatatgggtt gtgtattttc 600
agaatacata ttagaatata tattgcaatg taaatatatc cagtaaatga tcaataaatg 660
gggttatctt catgtcatat agtctttctc ttcataaaaa t 701

```

<210> 76  
 <211> 286  
 <212> DNA  
 <213> Homo sapiens

```

<400> 76
atttggtaaa ctcacagggc tctatgtgcc aaaccagca ttaagtcctt atttagtata 60
aactttgcca aaactatcag taactctgat ttaattctgc aggtatgtaa cagaatttgt 120
aagcctaggg aatgtttcag cccttcgaac tttcagagtc ttgagagctc tgaaaactat 180
ttctgtaatc ccaggtaaga agaaactggg gtaaggtagt aggccctta tatctccaac 240
ttttcttgtg tgttattgtg tttgtgtgtg aactcccta ttacag 286

```

<210> 77  
 <211> 515  
 <212> DNA  
 <213> Homo sapiens

```

<400> 77
gtaagaagaa actggtgtaa ggtagtaggc cccttatatc tccaactttt cttgtgtgtt 60
attgtgtttg tgtgtgaact cccctattac agatatgtga cagagtttgt ggacctgggc 120
aatgtctcag cgttgagaac attcagagtt ctccgagcac tgaaaacaat ttcagtcatt 180
ccaggtgaga gctagggttaa acaccgaggt tgactttaat tattgagttt gaaatcaatt 240
tatatgactt acagcattag ccttggttgc tattattaca gttcatcccg gtaaataatg 300
ccaaatgatg tttcaatgtc agtttagctc ctaaaatttt ataaattaca tgcgtattta 360
taaagtcagc ctttgagttt aacagaaaat tgcagagac atcttcaaaa aatgctaatt 420
tgggcctctt gcgctctctc tctctctttt tcaactaccat ggctttacta acagatttgg 480
athttaccat tcgctgcaga tgtagttcaa aaatg 515

```

<210> 78  
 <211> 564  
 <212> DNA  
 <213> Homo sapiens

```

<400> 78
aaacttcctg actagatatt taaaccttca tattgaattt ccagcaagca cactgttcat 60
gtgtaaaatc tgctgttcat ctatttccca aatcatcagg ctatccatac agctttggtg 120
tctaaatagt caagcaatca tttatggggg aaagagaatg tgtgtgacta ttaagaaatc 180
atgattttctg gcactcttcc tcaggtaacc tatagttctc tctctgcagg tttaaagacc 240
attgtggggg ccctgatcca gtcggtaaag aagctttctg atgtgatgat cctgactgtg 300

```

ttctgtctga gcgtgtttgc tctcattggg ctgcagctgt tcatgggcaa tctgaggaat 360.  
aaatgtttgc agtggccccc aagcgattct gcttttgaaa ccaacaccac ttcctacttt 420  
aatggcaciaa tggattcaaa tgggacattt gttaatgtaa caatgagcac atttaactgg 480  
aaggataaca ttggagatga cagtaagaag tattacatta tgtaaacctt agtggttgctg 540  
aatgaatttt caactataaa tagt 564

<210> 79

<211> 497

<212> DNA

<213> Homo sapiens

<400> 79

tgagactgtg ggtgtacagc cacctttgta aataactgaa atagtccaac tctgatttat 60  
tactaataact aatgtgaata ggattaatat gaaataaaat gggttttttt ttgtattaac 120  
aggtcacttt tatgttttgg atgggcaaaa agacccttta ctctgtggaa atgggttcaga 180  
tgcagggttaa gaaacataat atatattttt aagatataga actctttgctg aaaaaaaaaa 240  
gtaggtagga aaacaactac atgggtatat gtgtagcctt accatgtatg caataaagag 300  
cagtgtctgt cccctagga gtgccttgct tgccttaccg gattgccact ggtcctaaac 360  
tcacagcaat taaaaattat ccctttgtga agacccttcc ccaaaatttc acagttaaga 420  
tgttcttaaa ttgatgtctc aatgtgtgaa ggcccagagt ctgtctttgc tgtacatcta 480  
tcagagctgt taggaaa 497

<210> 80

<211> 501

<212> DNA

<213> Homo sapiens

<400> 80

aaagagtaaa aatatggtaa ggtcagagcc aaaagtgtgt ggttgctagc tttctgccat 60  
tctaaatgtc trwaaawatt tatttgcac taaattttct atcggctctc ctagtgaatt 120  
tcatctgata agtttcacgg tgggcaatca cctaaagtgt tctggaaatt aaagcaagat 180  
aattcgtcac agatagcagc tttgggtttt gaaaattcct ataagtcaaa taaattgaaa 240  
ttgctgtaat ttctaaactg accctacctc catttctctc tcttatagcc agtgtccaga 300  
aggatacatc tgtgtgaagg ctggtcgaaa cccaactat ggctacacaa gctttgacac 360  
cttttagctgg gctttcctgt ctctatttcg actcatgact caagactact gggaaaatct 420  
ttaccagttg gtaagggtcca aatgagcatg cataacattt atttttatag acatgtatga 480  
aatgaaaagc ataggctgag t 501

<210> 81

<211> 432

<212> DNA

<213> Homo sapiens

<400> 81

agctaattag tctactgact atctaactgt ggtaatcaga tattttatttg gggacattat 60

actaaaatac tgatggaatt atccccatt tcccctagac attacgtgct gctgggaaaa 120.  
 catacatgat attttttgtc ctgggtcattt tcttgggctc attttatttg gtgaatttga 180  
 tcctggctgt ggtggccatg gcctatgagg ggcagaatca ggccaccttg gaagaagcag 240  
 aacaaaaaga ggccgaattt cagcagatgc tcgaacagct taaaaagcaa caggaagaag 300  
 ctcaggtact gagtgataaa mgcaaagatt tatcattatt attmttagtt tctaagtaga 360  
 aatagtgtta tactatagag ggtagattgg aactgctttt tcattttata tatmggcatt 420  
 gtcattagac ac 432

&lt;210&gt; 82

&lt;211&gt; 489

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 82

tgcaaactgt tttcaaagct ctgtgttcta aatagtgcct ggctttgttt tatgacaggc 60  
 agttgcgga gcatcagctg cttcaagaga tttcagtga ataggtgggt taggagagct 120  
 gttggaaagt tcttcagaag catcaaagtt gagttccaaa agtgctaaag aatggaggaa 180  
 ccgaaggaag aaaagaagac agagagagca cttgaagga aacaacaaag gagagagaga 240  
 cagctttccc aaatccgaat ctgaagacag cgtcaaaaga agcagcttcc ttttctccat 300  
 ggatggaaac agactgacca gtgacaaaaa attctgtctc cctcatcagg tatgattttc 360  
 tactaagtgc tctggtttct ttgtcattgc tattgctttt tagtttttgt attttgtttt 420  
 ggtacacttt tgtactatct gtacttcagt tgagggacag ggaactaaca tttaatatag 480  
 ttgttttaa 489

&lt;210&gt; 83

&lt;211&gt; 653

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 83

gtgaagacta aatgaagtgg ttgtatactt agtaaattgc aaatcagtat tgtagtcag 60  
 aaaaacactc tttgtactta aatttgcttt aataaaaata tcaaaatata tgtgtcctct 120  
 ataaatttga ttatccatgt ttaagggaag gagtatacta actccaaaga aaacagatcc 180  
 tttaatatta atatttatta aataattgag ttcttccct acccccatcc cattcctttc 240  
 ctttttgctt tctctgcagt ctctcttgag taccgtggc tccctgtttt cccaagacg 300  
 caatagcaaa acaagcattt tcagtttcag aggtcgggca aaggatgttg gatctgaaaa 360  
 tgactttgct gatgatgaac acagcacatt tgaagacagc gaaagcagga gagactcact 420  
 gtttgtgccg cacagacatg gagagcgacg caacagtaac gttagtcagg ccagtatgtc 480  
 atccaggatg gtgccagggc ttccagcaaa tggggaagat gcacagcact gtggattgca 540  
 atggtgtggt ttcttggtg ggtggacctt cagctctaac gtcacctact gggcaacttc 600  
 cccagagggtg ataatagatg acctagctgc tactgacatt attcaccaat ttg 653

&lt;210&gt; 84

&lt;211&gt; 566

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 84

```

gaattctctt aaaggtacta cctgtgatac tttttttaaa aaaaaactgt ttataactta 60
gcaataattc aatattttat tottgaaatt cttacctgga aaattgcatg tagcatgatt 120
tgcaaagaaa tgctatgttg tgttgtatta cttattggga agagtgggtt gagccatcag 180
tatttggttt gcagggcacc accactgaaa cggaagtcag aaagagaagg ttaagctctt 240
accagatttc aatggagatg ctggaggatt cctctggaag gcaaagagcc gtgagcatag 300
ccagcattct gaccaacaca atggaaggta agagcaggtc atggaacagc caactttctg 360
tgattatgtg ctttgtgaac tattccttct tttcatagaa ttactgaagt ctgttaccct 420
gatcgaacta tatattagac ctaagaatgt gatatatggt gtacattatc acattgntta 480
caaaactaat attggcctta ttctttttga cttgggtcct taccttactt gcagagtgat 540
atttcaacac ttgatattat atcaat 566

```

&lt;210&gt; 85

&lt;211&gt; 748

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 85

```

tagtcatttt aaaagcaaaa tattaaattc aaagtgccta ttttctgtat tcaaaagaga 60
aaaaagtcga tctatatgac attttaatta acattttctg aaaatattta atgggattgt 120
cttctcaagt ttcttaagta atatgaactt ctattttcaa atataagcat caattttggt 180
aaataatgta aaatctacta gcaataataa ctcatttttg ttgttattta ctactcttcc 240
ttgttattgt cctccagaa cttgaagaat ctagacagaa atgtccgcca tgctgggtata 300
gatttgccaa tgtgttcttg atctgggact gctgtgatgc atggttaaaa gtaaaacatc 360
ttgtgaattt aattgttatg gatccatttg ttgatcttgc catcactatt tgcattgtct 420
taaataccct ctttatggcc atggagcact accccatgac tgagcaattc agtagtgtgt 480
tgactgtagg aaacctggtg agtacatttg aagtttactt atttactttg gtagatgtgg 540
gagagataga ccaaagggaa agatgtattt gtgctgtggt gaacccaaaa attatatcct 600
ctttcctcat agaaagaaat atctaaggaa tattacaggg aatctcagag atacagccta 660
aaactcaact ggtatgaatg ctgattgttt aggccaatgt ctgtgctgat tgatcatggt 720
gtcttaccag ttgtaaacgt ctcaaaat 748

```

&lt;210&gt; 86

&lt;211&gt; 664

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 86

```

ctaagacttg aattgatttg tcactattct ctcactttaa attttagata tttttattcc 60
tgtctaattg tcttctttat aaattcgtgt agcatcagtg ttttcagtg tcttgatagt 120
agtgtgatc tctaattttt taggtcttta ctgggatttt tacagcagaa atggttctca 180
agatcattgc catggatcct tattactatt tccaagaagg ctggaatatc tttgatggaa 240
ttattgtcag cctcagttta atggagcttg gtctgtcaaa tgtggaggga ttgtctgtac 300
tgcgatcatt cagactggta tctatttata tatatccctg tcgctcattg gcacaacatt 360

```

tattttgaaa ttgaatcaat gtatatttat ataattatta attttaattt taaatttaca 420  
 tcaatatgtg acatttctaag aaaacatgta aacatccyct ttaaagctaa accattttct 480  
 aagaatgatg aaagcattca aaatactcta taatgattag gtatgtaggg cacattagaa 540  
 aacctacaag tacttttctaa aactgtgttt taagtttatg aagctttttt ggccttacag 600  
 tctgtaaaga tacgcaaata aaaatttaga cccaggttaa ttttagcttt ttattaaccc 660  
 tact 664

&lt;210&gt; 87

&lt;211&gt; 750

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 87

tatttttatt ttgcaactta aatgatatta tgaccagatt tacaattcta atattgttaa 60  
 cactattttt tctggatttg aaattgaatc agttcagtat attttgagtt ttacatcta 120  
 ccacgtgtgg ttctatgata ccacatacta ataaaataat gtctaaaatt atattatgat 180  
 tactactaac agcatctttt cacttgatta cagcttagag ttttcaagtt ggcaaatcc 240  
 tggcccacac taaatatgct aattaagatc attggcaatt ctgtgggggc tctaggaaac 300  
 ctacacctgg tgttggccat catcgtcttc atttttgctg tggtcggcat gcagctctt 360  
 ggtaagagct acaaagaatg tgtctgcaag atcaatgatg actgtacgct cccacggtgg 420  
 cacatgaacg acttcttcca ctcttctctg attgtgttcc gcgtgctgtg tggagagtgg 480  
 atagagacca tgtgggactg tatggaggtc gctggccaaa ccattgtgct tattgttttc 540  
 atgttggtca tgggtcattgg aaacctgtg gtatgtatgt agtataaatg ctcataaatt 600  
 agaacaagag cagacagtag ctaggaacgt ggccagatgt agtaaacata tctctggttt 660  
 atagtaagtg gcctagactg aaatccccct attagcactc agagaataag caagttattt 720  
 aacttctcct gggctctggt ttcccathtt 750

&lt;210&gt; 88

&lt;211&gt; 768

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 88

ccttagagca ggatattagg tcctttaaag agtgtgtgac ttagacatgg catctgaaat 60  
 atagtaagca ttcaataaac attgttgaa ataattttag caaagatcta tgagttccct 120  
 ttttaggctg ttatttaaatt gcatatttca atattaarat aggcattttt ctttttttct 180  
 ttttaggttct gaacctcttt ctggccttat tgttgagttc atttagctca gacaaccttg 240  
 ctgctactga tgatgacaat gaaatgaata atctgcagat tgcagtagga agaatgcaaa 300  
 agggaattga ttatgtgaaa aataagatgc gggagtgttt ccaaaaagcc ttttttagaa 360  
 agccaaaagt tatagaaatc catgaaggca ataagataga cagctgcatg tccaataata 420  
 ctggaattga aataagcaaa gagcttaatt atcttagaga tgggaatgga accaccagt 480  
 gtgtaggtac tggaaagcagt gttgaaaaat acgtaatcga tgaaaatgat tatatgtcat 540  
 tcataaacia cccagacctc accgtcacag tgccaattgc tgttggagag tctgactttg 600  
 aaaacttaaa tactgaagag ttcagcagt agtcagaact agaagaaagc aaggaggtaa 660  
 ggaatgcttt taaatttttt gttccatttc ctatgataac catgtactac agttattttac 720  
 tattttcatt gtgcttatat gcattatcga aaagcaatga ttgtaagt 768



<210> 89  
 <211> 471  
 <212> DNA  
 <213> Homo sapiens

<400> 89  
 taattatttag tacataatga tcagtaatgc taatagagtt aaatgctatc actacatttt 60  
 ttttcacaca atgacacagt atttcccgagt tagttaaata aaaggggggaa aatcacatct 120  
 ttgaaatggg attttgtttc cagaaattaa atgcaaccag ctcatctgaa ggaagcacag 180  
 ttgatgttgt tctaccccgga gaaggtgaac aagctgaaac tgaacccgaa gaagacctta 240  
 aaccggaagc ttgttttact gaaggtaaac aagctctgat gtgattaaat acaatctccc 300  
 cttgttcttt acgggagactg aatatgcctc atttaaaaaa aaaaatttag caaacgaggt 360  
 gtggtggctt atgcctgtaa ccccaaaatt ttgggagggt acggtaggag gattgcttga 420  
 cccagagagt ttgagaccac cctgggaaat gtagtaaggc tttgcctcta c 471

<210> 90  
 <211> 623  
 <212> DNA  
 <213> Homo sapiens

<400> 90  
 gaattctaag tagctggctg agtatataag tctgagaata attcattata caggagggat 60  
 gctgacgata actaggaaat gaaggagatg gttaccctat gaaatgatta cctggaagtg 120  
 gagtggggaa ggggcaagaa agtttatttt ttctatttta agattaaaat atatttttta 180  
 attaaactata ttttsattttt aggatgtatt aaaaagtttc cattctgtca agtaagtaca 240  
 gaagaaggca aagggaagat ctggtggaat cttcgaaaaa cctgctacag tattgttgag 300  
 cacaactggt ttgagacttt cattgtgttc atgacccctc tcagtagtgg tgcattggta 360  
 agtgaaatgc atattggcaa gaatcagatt ctggtgaaat agtttattct ccaaaattac 420  
 cagatgcaaa cactgagctt cagaatcaaa agaaaaggca tatctgtgtc ttgcagagct 480  
 tggcacccaa ggtttaacga tgcaaaattc agttctgaac aaatcagcac catgaaacag 540  
 ccagatggaa tttctcatct ggtgtttatc taacagatgt tttcctcact gagacaacca 600  
 tttgcagaga cattctgtaa cca 623

<210> 91  
 <211> 520  
 <212> DNA  
 <213> Homo sapiens

<400> 91  
 ctagttagtc tttagatttg tctcatgttc aatgtttatg taaaatatca ataataaaaa 60  
 ttattctttt gtactcacta ttataactaag caattttttc aaatatttag aagaagcaag 120  
 ccatttaagt aaaataaaat atttttgatt cataggcctt tgaagatata tacattgaac 180  
 agcgaaagac tatcaaaacc atgctagaat atgctgacaa agtctttacc tatatatcca 240  
 ttctggaaat gcttctcaaa tgggttgctt atggatttca aacatatttc actaatgcct 300

```

ggtgctggct agatttcc atcgttgatg taagtatttt aagtgatttt tataaaattg 360
tttttaaaag aggcaagttt gacatttcat atgtttctgt tattaaaact ttcactaata 420
atgacataat tatgcagtta tttaaacaaa actgtaacat atgcaacaat gaggaatatc 480
tcatgggaaa gagtagagga ggtcctaaac atgggcagtg 520

```

```

<210> 92
<211> 595
<212> DNA
<213> Homo sapiens

```

```

<400> 92
ctaactaata atttaagcac acatccatga aggatctggc attgaactca atcctgaatt 60
atcagtggta tatgcacaag ttgaaaaggg gtccatggta taaaatatct aactggagat 120
attgacacgt gttgataaat atgggcaagt attctggttt cattgggtta aaaaaagcaa 180
tagtatgaga tgagactggc aatataagat gacccacta tgtggaagat gaaagttgcc 240
aagggtatgtc caaattagta tttagtctgc attaaataga taccacaccc tataccttca 300
gtcaacagtt tatttcttgg tgaactaatt aatttttttt tccttttgta ggtttctttg 360
gttagcctgg tagccaatgc tcttggtac tcagaactcg gtgccatcaa atcattacgg 420
acattaagag cttaagacc tctaagagcc ttatcccggt ttgaaggcat gagggtaaga 480
agaatagaca ctctaattat tcatgtcaaa aattacatgt aggtaatgat ttagatagaa 540
aagggtgcca tactcttctg atatttattt caatagaaat tacagaatta gaagc 595

```

```

<210> 93
<211> 787
<212> DNA
<213> Homo sapiens

```

```

<400> 93
ccagcataca aacattttct gactccatct tactatacca ggtttttaat gatttctttt 60
catactgtag catattttgc tttccttaaa acctagctc tttagtgtg tcattgtttg 120
ttttccttca aatatgtgct agaaaaatta gaagaaacaa cttgtccacc tagattttta 180
tttaactcct ttcaagcaca tattaatact aaacaaatac attgaaggaa tggtttccat 240
tcaaaagggt tgtaagctat gttccctcgc ctgtctcttc taggtgggtg tgaatgctct 300
tgttggagca attccctcta tcatgaatgt gctgttggc tgtctcatct tctggttgat 360
ctttagcatc atgggtgtga atttgtttgc tggcaagttc taccactgtg ttaacatgac 420
aacgggtaac atgtttgaca ttagtgatgt taacaatttg agtgactgtc aggctcttgg 480
caagcaagct cgggtgaaaa acgtgaaagt aaactttgat aatgttggcg ctggctatct 540
tgactgctt caagtggtaa gtggctactg tacgagtttt gaaaaagttt tcaagatgtt 600
tcaaggaaga ttatttcctt gatgttcttc gtttgaatga ctaacatttg acagcatgaa 660
aaaaagttta tgataacacc tataatatca gcttgaattg atcataaaaa agatgtttaca 720
attattttat aatgtatttt ccttagtggt aagcttttag tatgttttaa tgtgatttta 780
tatttct 787

```

```

<210> 94
<211> 438

```

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 94

```

aaaggaaaca agttccagac tttaaataca aatgtttttc tatttcaatt ttatttcaat 60
ctcttgatat gaaatttcac aatattgtac aaaaagttat ttgttataat actgtcagat 120
tttcatctgg tttaatgtca ttgttaggtg aaatttttat gaacaattca aatatatgtt 180
atttacaggc cacatttaaa ggctggatgg atattatgta tgcagctgtt gattcacgag 240
atgtaagtat cactcaaata ttatttatag gttctagatt tcttatgggtg aatattgggtg 300
gtaatttaaa cactgataca tccaaaattc tatattagaa catttaatat tgcataataa 360
aatgaacag tctgcttcaa tatagatgat gcttgattaa tgtgtgccta atatacaata 420
tgtagcta atgaaacg
438

```

&lt;210&gt; 95

&lt;211&gt; 637

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 95

```

gtaaggcaca atgggaaaag agaatcaaga acaatcataa aacttgcaaa ccttcatttt 60
actagatcat actagtttta aaaaattgtt tttgtagaac aatatctcag ggtaaggcaa 120
aagtagcact gtattaagta acagcactca ataaattact gatttagtgt aagtatttat 180
agtatttttc atattattta atattttcaa tatcatttag gttaaacttc agcctgtata 240
tgaagaaaat ctgtacatgt atttatactt tgtcatcttt atcatctttg ggtcattctt 300
cactctgaat ctattcattg gtgtcatcat agataacttc aaccagcaga aaaagaagat 360
aagtattctt tagcttttac ctttcttcat tctgggggttc tgtctgttaa tacagccaaa 420
taaccagaat acctgtgggtc atgacagact taaatcatgt ttatattatt ttcagttgcc 480
catgtgggta tttaagctgc agggattcca gcctctagtc agtggctcct ctcaaagttt 540
atctattgga tagctttctg acccaaaaat gtgtccactc ctteggaccc atccaacggg 600
tctccagtgc tttagcttgg cttacagagc ctttcag
637

```

&lt;210&gt; 96

&lt;211&gt; 637

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 96

```

acccttgtgc ctacttttaa acatagtata atcaaattag gatcctgtag cgatcagagt 60
tttatgtacg taaggatttt gcataatatt aagatattca gaatttcaca taaatgggaa 120
aagcaggata aatgtatatg taggaggata atatccactt aaaaattaga aaagattaaa 180
ggaaagacaa atattttttg tgaaagtact attggaacac agaattgtaa ccagttttat 240
actatgtctt tactttggag gtcaagacat ctttatgaca gaggaacaga aaaaatatta 300
caatgcaatg aagaaacttg gatccaagaa acctcagaaa cccatacctc gccagcagt 360
aagaattact tgtctccttt aatgttccaa agccatgcgt ccatatgggtc aaattgagca 420
atgctctgga gcagaacata ttaggtgata tcaccaatat tgagccctaa ttataaagtt 480
catattttgc atcataattc acaacttctg cactcattag gagttaccac attccaaaaa 540

```

aaggaggtaa tgttctttat aatttgtgag ttgaaaactt ctagctcagg gttcctaata 600  
 aatacttcca aagcaagggt cactttcctg ctaccaa 637

<210> 97

<211> 759

<212> DNA

<213> Homo sapiens

<400> 97

tatataaacc aaatatgctt tgttttagcta tataaatttt ttttccattt tttttaacat 60  
 gaagagaaaa aaagcacaca aaattgtttg gggtaatatg aggaggggtgc acatccatcc 120  
 cgtatgtgga agggctttat ctacaatttt actgcattat tctttatgaa atatatatag 180  
 taaccttatt tctcttctct cactttctag aacaaattcc aaggaatggg ctttgatttt 240  
 gtaaccagac aagtctttga tatcagcatc atgatcctca tctgcctcaa catgggcacc 300  
 atgatgggtg aaacggatga ccagggcaaa tacatgacct tagttttgtc ccggatcaac 360  
 ctagtgttca ttgttctgtt cactggagaa tttgtgctga agctcgtctc cctcagacac 420  
 tactacttca ctataggctg gaacatcttt gactttgtgg tgggtgattct ctccattgta 480  
 ggtaagaaca gcttaattac caagagggtat agttacagag aaacagttgc cccaggacct 540  
 tctagctgat taacatggaa attaggtctg agaataataa tgcataataga tgtaaagttc 600  
 aacactagca tatttgaata aaaactctga aacctgggtt tattcacaaa gctaactagt 660  
 tagaaaccat gttaggaata ccagatttgg gaaagagggtg aagaagacag gaaataaaca 720  
 ttatcaggta ctctcctaatt cttaaaccac ggtcacagg 759

<210> 98

<211> 3975

<212> DNA

<213> Homo sapiens

<400> 98

aatctgtaat gctaattgcag ggagtggatc caaatattta ataaaggctc atattcataa 60  
 caagtttggt gtgttcatag accttaaaaa agataaagcc atcatgtaaa gtgaaaagat 120  
 attatctgtt tagctgtgtt ctatgttttc cataggtatg tttctggctg agatgataga 180  
 aaagtatttt gtgtcccta ccttggtccg agtgatccgt cttgccagga ttggccgaat 240  
 cctacgtctg atcaaaggag caaaggggat ccgcacgctg ctctttgctt tgatgatgtc 300  
 ccttcctgcg ttgtttaaca tcggcctcct gctcttcctg gtcattgtta tctatgccat 360  
 ctttgggatg tccaactttg cctatgttaa aaaggaagct ggaattgatg acatgttcaa 420  
 ctttgagacc tttggcaaca gcatgatctg cttgttccaa attacaacct ctgctggatg 480  
 ggatggattg ctagcaccta ttcttaatag tgcaccaccc gactgtgacc ctgacacaat 540  
 tcacctggc agctcagtta agggagactg tgggaaccca tctgttggga ttttcttttt 600  
 tgtcagttac atcatcatat ccttcctggg ggtggtgaac agttacatcg cggtcacatc 660  
 ggagaacttc agtgttgcta ctgaagaaag tgcagagccc ctgagtgagg atgactttga 720  
 gatgttctat gaggtttggg aaaagtgtga tcccgatgcg acccagttta tagagttctc 780  
 taaactctct gattttgcag ctgccctgga tctctctct ctcatagcaa aaccaacaa 840  
 agtccagctt attgccatgg atctgcccac ggtcagtggt gaccggatcc actgtcttga 900  
 tattttattt gcctttacaa agcgtgtttt gggtagaggt ggagagatgg atgcccttcg 960  
 aatacagatg gaagacaggt ttatggcatc aaacccctcc aaagtctctt atgagcctat 1020

tacaaccact ttgaaacgta aacaagagga ggtgtctgcc gctatcattc agcgtaattt 1080  
cagatgttat cttttaagc aaagggttaa aaatatatca agtaactata acaaagaggc 1140  
aataaagggg aggattgact tacctataaa acaagacatg attattgaca aactgaatgg 1200  
gaactccact ccagaaaaaa cagatgggag ttcctctacc acctctcctc cttcctatga 1260  
tagtgtaaca aaaccagaca agggaaaagt tgagaaagac aaaccagaaa aagaaagcaa 1320  
aggaaaagag gtcagagaaa atcaaaagta aaaagaaaca aagaattatc tttgtgatca 1380  
attgtttaca gcctatgaag gtaaagtata tgtgtcaact ggacttcaag aggaggtcca 1440  
tgccaaactg actgttttaa caaatactca tagtcagtgc ctatacaaga cagtgaagtg 1500  
acctctctgt cactgcaact ctgtgaagca gggatatcaac attgacaaga ggttgctgtt 1560  
tttattacca gctgacactg ctgaggagaa acccaatggc tacctagact atagggatag 1620  
ttgtgcaaag tgaacattgt aactacacca aacaccttta gtacagtcct tgcattccatt 1680  
ctatttttaa cttccatatt tgccatattt ttacaaaatt tgttctagt ctttccatg 1740  
gtccccaatt catagtttat tcataatgct atgtcactat ttttgtaaat gaggtttacg 1800  
ttgaagaaac agtatacaag aacctgtct ctcaaagtat cagacaaagg tgttttgcca 1860  
gagagataaa atttttgctc aaaaccagaa aaagaattgt aatggctaca gtttcagtta 1920  
cttccatttt ctagatggct ttaattttga aagtatttta gtctgttatg tttgtttcta 1980  
tctgaacagt tatgtgcctg taaagtctcc tctaataatt aaaggattat ttttatgcaa 2040  
agtattctgt ttcagcaagt gcaaatttta ttctaagttt cagagctcta tatttaattt 2100  
aggctcaaat ctttccaaaa agtaatctaa taaatccatt ctagaaaaat atatctaaag 2160  
tattgcttta gaatagttgt tccactttct gctgcagtat tgctttgcca tcttctgctc 2220  
tcagcaaagc tgatagtcta tgtcaattaa atacctatg ttatgtaaat agttatttta 2280  
tcctgtgggt catgtttggg caaatatata tatagcctga taaacaactt ctattaaatc 2340  
aaatatgtac cacagtgtat gtgtcttttg caagcttcca acagggatgt atcctgtatc 2400  
attcattaaa catagtttaa aggctatcac taatgcatgt taatattgcc tatgctgctc 2460  
tattttactc aatccattct tcacaagtct tggttaaaga atgtcacata ttgggtgatag 2520  
aatgaattca acctgctctg tccattatgt caagcagaat aatttgaagc tatttacaaa 2580  
cacctttact tttgcacttt taattcaaca tgagtatcat atgggtatctc tctagatttc 2640  
aaggaaacac actggatact gcctactgac aaaacctatt cttcatattt tgctaaaaat 2700  
atgtctaaaa cttgcgcaaa tataaataat gtaaaaaatat aatcaacttt attgtcagc 2760  
attttgtaca taagaaaatt attttcaggt tgatgacatc acaatttatt ttactttatg 2820  
cttttgcttt tgatttttaa tcacaattcc aaacttttga atccataaga tttttcaatg 2880  
gataatttcc taaaataaaa gttagataat gggttttatg gatttctttg ttataatata 2940  
ttttctacca ttccaatagg agatacattg gtcaaacact caaacctaga tcattttcta 3000  
ccaactatgg ttgcctcaat ataacctttt attcatagat gttttttttt attcaacttt 3060  
tgtagtattt acgtatgcag actagtctta tttttttaat tcctgctgca ctaaagctat 3120  
tacaaatata acatggactt tgttcttttt agccatgaac aaagtggcaa agttgtgcaa 3180  
ttacctaaca tgatataaat ttttgttttt tgcacaaacc aaaagttaa tgtaattct 3240  
ttttacaaaa ctatttactg tagtgattg aagaactgca tgcagggaat tgctattgct 3300  
aaaaagaatg gtgagctacg tcattattga gccaaaagaa taaatttcat tttttattgc 3360  
atttcactta ttggcctctg gggttttttg ttttgtttt ttgctgttg cagtttaaaa 3420  
tatatataat taataaaacc tgtgcttgat ctgacatttg tatacataaa agtttacatg 3480  
aattttacaa cagactagtg catgattcac caagcagtac tacagaacaa aggcaaata 3540  
aaagcagctt tgtgcacttt tatgtgtgca aaggatcaag ttcacatgtt ccaactttca 3600  
ggtttgataa taatagtagt aaccacctac aatagctttc aatttcaatt aactccctg 3660  
gctataagca tctaaactca tcttctttca atataattga tgctatctcc taattacttg 3720  
gtggctaata aatgttacat tcttgttac ttaaagcat tatataaact cctatgtata 3780  
cataaggtat taatgatata gttattgaga atttatatta actttttttt caagaacct 3840  
tggatttatg tgaggtaaaa accaaaactct tattctcagt ggaaaactcc agttgtaatg 3900

catattttta aagacaattt ggatctaaat atgtatttca taattctccc ataataaatt 3960  
atataagggtg gctaa 3975

<210> 99

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 99

tgtgttctgc cccagtgaga ct

22

<210> 100

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 100

cttcttgctc tgcccaaact gaat

24

<210> 101

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 101

ggcgatgtaa tgtaagggtgc tgtc

24

<210> 102

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 102

gtgccttcag ttgcaattgt tcag

24

<210> 103

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 103

ttaggaattt catatgcaga ataa

24

<210> 104

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 104

tgggccattt ttcgtcgtc

19

<210> 105

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 105

gaaagacgca ttgcagaaga aaagg

25

<210> 106

<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 106  
ctattggcat gtgttggtgc taca

24

<210> 107  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 107  
gtgctggttt ctcatTTaac ttTac

25

<210> 108  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 108  
ttcccaactt aatttgatat ttagc

25

<210> 109  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 109.



gcagtttggg cttttcaatg ttag

24.

<210> 110

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 110

gacacagttt caraatcccr aatg

24

<210> 111

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 111

ttagggctac gtttcatttg tatg

24

<210> 112

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 112

agcactgatg gaaaacaaa ctat

24

<210> 113

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 113

agcccatgca gtaatatataa tcct

24

<210> 114

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 114

tccaggctga taagctatgt ctaa

24

<210> 115

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 115

ctgtggcctg cctgagcgta tt

22

<210> 116

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 116

ccaattctac tttttaagga aatg

24

<210> 117

<211> 19

<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 117  
aaatacttgt gcctttgaa

19

<210> 118  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 118  
gtacatacaa tatacacaga tgc

23

<210> 119  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 119  
aggcagcaga acgacttgta ata

23

<210> 120  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 120  
atccggtttt aatttcataa ctca

24

<210> 121

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 121

gttgagcacc cttagtgaat aata

24

<210> 122

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 122

tcacacgctc tagactactt ctct

24

<210> 123

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 123

tgcaaatact tcagcccttt caaa

24

<210> 124

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

## oligonucleotide

&lt;400&gt; 124

ttccccacca gactgctctt tc

22

&lt;210&gt; 125

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 125

gcagcaggca ggctctca

18

&lt;210&gt; 126

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 126

tctcccatgt ttttaattttc aacc

24

&lt;210&gt; 127

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 127

ataatcttgc aaaatgaaat caca

24

&lt;210&gt; 128

&lt;211&gt; 19

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 128

atccgggatg acctactgg

19

<210> 129

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 129

gataacgaga gccgtagaga ttcc

24

<210> 130

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 130

agccagccat gcctgaacta

20

<210> 131

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 131

tgtttgcttg tcatattgct caa

23

<210> 132

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 132

tgcactattc ccaactcaca aa

22

<210> 133

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 133

aagggtgtct ctgtaacaaa aatg

24

<210> 134

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 134

gtgatggcca ggtcaacaaa

20

<210> 135

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 135  
ctgggactgt tctccatatt gggt

24

<210> 136  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 136  
tttgcagggg ccaggaag

18

<210> 137  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 137  
cattgtggga aaatagcata agc

23

<210> 138  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 138  
gcaagaaccc tgaatgtag aaa

23

<210> 139  
<211> 24  
<212> DNA  
<213> Artificial Sequence



&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 139

taatgctttt aagaatcata caaa

24

&lt;210&gt; 140

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 140

ccagcgtggg agttgacaat c

21

&lt;210&gt; 141

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 141

cggcatgcag ctcttttgta

20

&lt;210&gt; 142

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 142

atgtgccatg ctggtgtatt tc

22

<210> 143  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 143  
cacccatctt ctaatcacta tgc

23

<210> 144  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 144  
cagcaatttg gagattattc att

23

<210> 145  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 145  
gcagccactg atgatgataa

20

<210> 146  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 146  
ctgccagttc ctataccact t

21

<210> 147  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 147  
tacagcagaa attgggaaag at

22

<210> 148  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 148  
gtattcatac ctaccacac ctat

24

<210> 149  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 149  
ttcttggcag gcaacttatt acc

23

<210> 150  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 150

taagctgcac tccaaatgaa agat

24

<210> 151

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 151

ggctgaatgt ttccacaact

20

<210> 152

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 152

gttcaactat tcggaacac g

21

<210> 153

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 153

aggcagagga aaacaatgg

19

<210> 154

<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 154  
acaaggtggg ataattaaaa atg

23

<210> 155  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 155  
gtttctctgc cctcctattc c

21

<210> 156  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 156  
aagctacctt gaacagagac a

21

<210> 157  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 157

aatgatgatt ctgtttatta

20

<210> 158

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 158

aatttgccat tccttttg

18

<210> 159

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 159

ttgacatcga agacgtgaat aatc

24

<210> 160

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 160

ccatctgggc tcataaactt gta

23

<210> 161

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 161

ccctttgaaa attatatcag taa

23

<210> 162

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 162

atttggtcgt ttatgcttta ttc

23

<210> 163

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 163

tccagcacta aaatgtatgg taat

24

<210> 164

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 164

atttggcaga gaaaacactc c

21

<210> 165

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 165

tttttagccat ccatttttcta tttt

24

<210> 166

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 166

tatttttcccc catatcattt ga

22

<210> 167

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 167

tttgcaagaa actagaaagt c

21

<210> 168

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 168

ttgatgcgtg acaaaatgg

19



<210> 169  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 169  
gaccagagtg aatatgtgac tacc

24

<210> 170  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 170  
ctgggatgat cttgaatcta atc

23

<210> 171  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 171  
gcaactcagt tcatggaatt tgaa

24

<210> 172  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

## oligonucleotide

&lt;400&gt; 172

cttggttttcg ttttaaagta gta

23

&lt;210&gt; 173

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 173

caaagatcac cctggaagct cagtt

25

&lt;210&gt; 174

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 174

ttcaagcgca gctgcaaact gagat

25

&lt;210&gt; 175

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 175

acatcggcct cctactcttc cta

23

&lt;210&gt; 176

&lt;211&gt; 21

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 176

acagatgggt tcccacagtc c

21

<210> 177

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 177

taacgcatga tttcttcact gggt

24

<210> 178

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 178

atcccaaaga tggcgtagat ga

22

<210> 179

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 179

tgagaaatag gctaaggacc tcta

24

<210> 180

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 180

cctaggggct ggattcc

17

<210> 181

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 181

aaggggtgca aacctgtgat ttt

23

<210> 182

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 182

agggccatgt ggttgccata c

21

<210> 183

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 183  
cttcggttt atgttttcat ttct

24

<210> 184  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 184  
tctttattag ttttgacat tta

24

<210> 185  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 185  
caatccttc aaggtctcct atc

23

<210> 186  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 186  
tttcatcttt gccttcttgc tcat

24

<210> 187  
<211> 22  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 187

catgtccact gcagcttgtc ca

22

&lt;210&gt; 188

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 188

tcccctttac acagagtcac agtt

24

&lt;210&gt; 189

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 189

gcatttgaag atata

15

&lt;210&gt; 190

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 190

gcatttgacg atata

15

&lt;210&gt; 191

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 191

atcatatcct tcctg

15

<210> 192

<211> 15

<212> DNA

<213> Homo sapiens

<400> 192

atcatatmct tcctg

15

<210> 193

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 193

atgggttgaa tgactttctg acat

24

<210> 194

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 194

aggcatttcc tgtacagga ctac

24

<210> 195

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 195

acaggaaatg cctcttctta cttc

24

<210> 196

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 196

tttccccaag gattctacta ctgt

24

<210> 197

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 197

agtgcattga actgacacaa tcac

24

<210> 198

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 198

cttgcgttcc tgtttgggtc tct

23

<210> 199

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide



&lt;400&gt; 199

tccgcttctt taccagggaa tc

22

&lt;210&gt; 200

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 200

aggcagtga ggcaacttga ctaa

24

&lt;210&gt; 201

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 201

cagggcaata tttataaata atgg

24

&lt;210&gt; 202

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 202

tttgaaaaat gtgtagctca ataa

24

&lt;210&gt; 203

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 203

aaggcatggt agtcataaa ag

22

&lt;210&gt; 204

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 204

atgaaacata aagggaggtc aa

22

&lt;210&gt; 205

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 205

aatgtgagct tggctattgt ctct

24

&lt;210&gt; 206

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 206

ataggctccc accagtgatt tac

23

<210> 207  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 207  
aggcccctta tatctccaac tg .

22

<210> 208  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 208  
caacaaggct tctgcacaaa ag

22

<210> 209  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 209  
cttggtggct tgccttgac

19

<210> 210  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 210

tcatgagtgt cgccatcagc

20

&lt;210&gt; 211

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 211

ggaaagctga tggcgacact

20

&lt;210&gt; 212

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 212

ctgagacatt gcccaggtcc

20

&lt;210&gt; 213

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 213

tttttaccgcg ttgctttctt ta

22

&lt;210&gt; 214

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 214

tatcccttgc tctttcattt atct

24

&lt;210&gt; 215

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 215

gccggtaaaa tagctgttga gtag

24

&lt;210&gt; 216

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 216

gccattgcaa acattttattt cgta

24

&lt;210&gt; 217

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 217

gcgtgtttgc gctaataag

18

&lt;210&gt; 218

<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 218  
ctaagtcact tgattcacat ctaa

24

<210> 219  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 219  
acagggtggc tgaagtgttt ta

22

<210> 220  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 220  
gtgggaggtg gcaggttatt

20

<210> 221  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 221

caattagcag acttgccggtt att

23.

<210> 222

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 222

tctcttgagt tcggtgtttt atga

24

<210> 223

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 223

accgaactca agagaattgc tgta

24

<210> 224

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 224

aaaggaccgt atgcttggtc acta

24

<210> 225

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 225

tatgaatgcg cattttactc ttg

24

<210> 226

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 226

tggagctcaa cttagatgct actg

24

<210> 227

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 227

ggtgctggtg ggataggagt tttt

24

<210> 228

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 228

tccattaaat tctggcatat tctt

24

<210> 229

<211> 24



<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 229  
tcagaggggt gctttcttcc acat

24

<210> 230  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 230  
cttcggctgt cattgtcctc aaag

24

<210> 231  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 231  
gcaaaggaca ttggctctga gaat

24

<210> 232  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 232  
ctgcctgcac cagtcacaac tct

23

<210> 233

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 233

tgggctttgc tgctttcaa

19

<210> 234

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 234

agtaactgtg acgcaggact ttta

24

<210> 235

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 235

ccctgttcct ccagcagatt a

21

<210> 236

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

## oligonucleotide

&lt;400&gt; 236

gtgatggcca ggtcaacaaa

20

&lt;210&gt; 237

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 237

tttgatttgg gactgttgta aac

23

&lt;210&gt; 238

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 238

aaggcaatta taaactcttt caag

24

&lt;210&gt; 239

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 239

tgggagttaa attaagttgc tcaa

24

&lt;210&gt; 240

&lt;211&gt; 24

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 240

acattttatg aacactccca gtta

24

<210> 241

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 241

attaacactg ttcttgcttt tat

23

<210> 242

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 242

gtgccagcgt gggagttc

18

<210> 243

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 243

gtgggggctc taggaaacct

20

<210> 244  
<211> 24  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 244  
tttaatgaaa atgaggaaaa tggt

24

<210> 245  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 245  
gaccaagcat ttttatttca ttc

23

<210> 246  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 246  
agtggcagca agattgtca

19

<210> 247  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 247

ggccttgctt ttgagttcc

19

&lt;210&gt; 248

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 248

ggtctttgcc tatttctatg gtg

23

&lt;210&gt; 249

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 249

ttaaaccgct tgaagatcta aata

24

&lt;210&gt; 250

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 250

tatacaccaa aatatctcct tat

23

&lt;210&gt; 251

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 251

ggggcacacc taattaattt ttat

24

&lt;210&gt; 252

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 252

aaagaggata ctcaagacca cata

24

&lt;210&gt; 253

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 253

cccaccaaca caaatatacc taat

24

&lt;210&gt; 254

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 254

tgaagggaaa gggaaaagat tt

22

<210> 255  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 255  
tccagcctta ggcacctgat aa

22

<210> 256  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 256  
ataaagcagc aaagtgcagc atac

24

<210> 257  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 257  
aaggctgaac tgtgtagaca tttt

24

<210> 258  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide



&lt;400&gt; 258

tgacatttcc atggtacaaa gtgt

24

&lt;210&gt; 259

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 259

tttggttggtg gcttttcact tat

23

&lt;210&gt; 260

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 260

ccacctggca gtttgattg

19

&lt;210&gt; 261

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 261

taagcgtggt caacaactac agt

23

&lt;210&gt; 262

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 262

attcttgcca gcatttattg tc

22

<210> 263

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 263

caaaacattg ccccaaaag

19

<210> 264

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 264

tcaaactaaa caatttcct ctaa

24

<210> 265

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 265

gataattaa aactcactga tgta

24

<210> 266

<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 266  
ggaggctaaa ggaaagagta tg

22

<210> 267  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 267  
attttatagc cagcaaagaa cac

23

<210> 268  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 268  
ctagaaattc gggctgtgaa

20

<210> 269  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 269

ctgctttgtg acctaaggca agtt

24.

<210> 270

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 270

gtgaccatgt taaggcagat gagg

24

<210> 271

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 271

ggaatgtct ttgattttgt aacc

24

<210> 272

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 272

tccttaactg aataaaaagca cctc

24

<210> 273

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 273

tggaacaccc atcaaagaag atact

25

<210> 274

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 274

gtgggagtcc tgttgacaca aac

23

<210> 275

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 275

agcgattcat ggcatacaac

20

<210> 276

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 276

acgtggtgga aggcgtcata

20

<210> 277

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 277

gcgacccagt ttatagagtt tgcc

24

<210> 278

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 278

cttgtttgcg tttcaacgtg gtc

23

<210> 279

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 279

caaagatcac cctggaagct cagtt

25

<210> 280

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 280

atccagggca tctgcaaaat cagaa

25

<210> 281  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 281  
tgcctatggtt aagaggggaag ttggg

25

<210> 282  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 282  
atgaccgcga tgtacatggtt cag

23

<210> 283  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 283  
tcaattgttt acagcccgtg atg

23

<210> 284  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

## oligonucleotide

&lt;400&gt; 284

tttatacaaa ggcagacaac at

22

&lt;210&gt; 285

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 285

aggcgtaatg gctactcaga cga

23

&lt;210&gt; 286

&lt;211&gt; 25

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 286

gtaatccctc tccccgaaca taaac

25

&lt;210&gt; 287

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 287

tttgattcac gggttggtta ctctta

26

&lt;210&gt; 288

&lt;211&gt; 26

&lt;212&gt; DNA



<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 288

ttctatggaa catttacagg cacatt

26

<210> 289

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 289

taatgtgcct gtaaattgttc cataga

26

<210> 290

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 290

caggcttctt agaaaggact gatagg

26

<210> 291

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 291

gtcccagcag catgactatc

20

<210> 292

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 292

cccactgggt aaaattacta ac

22

<210> 293

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 293

tagccatctt ctgctcttgg t

21

<210> 294

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 294

tggcttccca tattagactt ctg

23

<210> 295

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 295  
tcttgccctat gctgctgtat cttta

24

<210> 296  
<211> 22  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 296  
agtcgggctt ttcattcattg ag

22

<210> 297  
<211> 24  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 297  
ttcttcatgt cattaagcaa tagg

24

<210> 298  
<211> 24  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 298  
ttcaatttaa aagtgctagg aaca

24

<210> 299  
<211> 25  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 299

cttcaggtgg atgtcacagt cacta

25

&lt;210&gt; 300

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 300

attcaagcaa tgccaagagt atca

24

&lt;210&gt; 301

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 301

ctttcaatag taatgcctta tcat

24

&lt;210&gt; 302

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 302

tcctgcatgc atttcaccaa c

21

<210> 303  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 303  
ctgttcacat tttgtaaaac taat

24

<210> 304  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 304  
atcccaaaga tggcgtagat ga

22

<210> 305  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 305  
cacgctgctc tttgctttga

20

<210> 306  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 306  
gatctttgtc agggtcacag tct

23

<210> 307  
<211> 9  
<212> DNA  
<213> Homo sapiens

<400> 307  
tacaaagaa

9

<210> 308  
<211> 9  
<212> DNA  
<213> Homo sapiens

<400> 308  
tacagagaa

9

<210> 309  
<211> 9  
<212> DNA  
<213> Homo sapiens

<400> 309  
tacagagaa

9

<210> 310  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 310  
tgtgtccgcc agtagatgg

19

<210> 311  
<211> 23  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 311

tttttgacca cagaggttta caa

23

&lt;210&gt; 312

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 312

gaagcggagg cataagcaga

20

&lt;210&gt; 313

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 313

ggtgcagata atgaaatggt ttgt

24

&lt;210&gt; 314

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 314

caccctatg ccaaattgtca aaga

24

<210> 315  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 315  
caaaaacaaa cttataccca gaag

24

<210> 316  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 316  
caaatatgg gcaaacccta at

22

<210> 317  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 317  
aaggtgccat cacaaaatca t

21

<210> 318  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide



&lt;400&gt; 318

atcgcttgct ttctaactc ttgt

24

&lt;210&gt; 319

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 319

aagtcactat ttggctttgg ttg

23

&lt;210&gt; 320

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 320

agaagcccaa aaaggaacaa gata

24

&lt;210&gt; 321

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 321

ggcccagaaa agtatattac agtt

24

&lt;210&gt; 322

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 322

tccttaaata agcccatgtc taat

24

<210> 323

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 323

tctcaaagaa attttacaga tact

24

<210> 324

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 324

aatggccatg gtaacctact aaca

24

<210> 325

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 325

caggctatac ccacaaggag att

23

<210> 326

<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 326  
tgttaatttt ggcttgatg tt

22

<210> 327  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 327  
tcactccttt gcgcttatca a

21

<210> 328  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 328  
agggctctat gtgccaaacc

20

<210> 329  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 329

aggggcctac taccttacac cag

23.

<210> 330

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 330

tgtaatccca ggtaagaaga aac

23

<210> 331

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 331

taccgggatg aactgtaata ataa

24

<210> 332

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 332

ttctggcact cttcctcagg taac

24

<210> 333

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 333

gtcccatttg aatccattgt gc

22

<210> 334

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 334

ggcccccaag cgattctg

18

<210> 335

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 335

tgtacacca cagtctcaac tatt

24

<210> 336

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 336

acagccacct ttgtaaataa

20

<210> 337

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 337

tttttcgcaa agagttctat

20

<210> 338

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 338

aaactgaccc tacctccatt tctc

24

<210> 339

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 339

actcagccta tgcttttcat ttca

24

<210> 340

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 340

cagatattta tttggggaca ttat

24

<210> 341  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 341  
aaatctttgc ktttatcact cagt

24

<210> 342  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 342  
tagtgcctgg ctttgtttta tgac

24

<210> 343  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 343  
cggatttggg aaagctgtct ct

22

<210> 344  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic

## oligonucleotide

&lt;400&gt; 344

agagcacctt gaaggaaaca acaa

24

&lt;210&gt; 345

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 345

tccctcaact gaagtacaga tagt

24

&lt;210&gt; 346

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 346

ataattgcgt tcttccccta ccc

23

&lt;210&gt; 347

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 347

aagccctggc accatcctg

19

&lt;210&gt; 348

&lt;211&gt; 20

&lt;212&gt; DNA



<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 348

tttgcaaaga aatgctatgt

20

<210> 349

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 349

ctgggtaaca gacttcagta at

22

<210> 350

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 350

atgggattgt cttctcaagt ttct

24

<210> 351

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 351

gatggcaaga tcaacaaatg ga

22

<210> 352

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 352

cttgatctgg gactgctgtg atg

23

<210> 353

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 353

aggatataat ttttggttca aca

23

<210> 354

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 354

ttttcagtgc tcttgatagt agtg

24

<210> 355

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 355

gtgccaatga gcgacagg

18

&lt;210&gt; 356

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 356

ccacgtgtgg ttctatgata cc

22

&lt;210&gt; 357

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 357

accgtgggag cgtacagtca

20

&lt;210&gt; 358

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 358

cggcatgcag ctcttttgga

20

&lt;210&gt; 359

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 359

tgccacgtt cctagctact gtc

23

&lt;210&gt; 360

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 360

gagttccctt ttaggctgt tatt

24

&lt;210&gt; 361

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 361

tcttattgcc ttcattgatt tcta

24

&lt;210&gt; 362

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 362

tgaaaaataa gatgcgggag tg

22

<210> 363  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 363  
gtgaggctgg gggtgtttat g

21

<210> 364  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 364  
gagatgggaa tggaaccacc a

21

<210> 365  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 365  
ttcgataatg catataagca caa

23

<210> 366  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 366

aagggggaaa atcacatctt t

21

&lt;210&gt; 367

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 367

ttaaagtggg catatttcagt ctcc

24

&lt;210&gt; 368

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 368

ggaagtggag tggggaagg

19

&lt;210&gt; 369

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 369

attcttgcca atatgcattt cact

24

&lt;210&gt; 370

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 370

ttcttttgta ctcactatta tactaa

26

<210> 371

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 371

aaacttgcct cttttaaaaa caat

24

<210> 372

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 372

taccacaccc tataccttca gtca

24

<210> 373

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 373

gagtatggca cccttttcta tcta

24

<210> 374

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 374  
gctatgttcc cctcgctgtc t

21

<210> 375  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 375  
tgcttgccaa gagcctgac

19

<210> 376  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 376  
gctggcaagt tctaccactg tg

22

<210> 377  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 377



caaacgaaga acatcagggga aata

24

<210> 378

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 378

ttcacaaatat tgtacaaaaa gtta

24

<210> 379

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 379

attaccacca atattcacca taag

24

<210> 380

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 380

tcagggttag gcaaaagtag cac

23

<210> 381

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 381

gaacccccaga atgaagaaag gtaa

24

<210> 382

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 382

tttgtgaaag tactattgga acac

24

<210> 383

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 383

acgcatggct ttggaacat

19

<210> 384

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 384

cccgatatgtg gaagggtttt at

22

<210> 385

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 385

ctaggttgat ccgggacaaa acta

24

<210> 386

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 386

aacggatgac cagggcaaat ac

22

<210> 387

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 387

ctagaaggtc ctggggcaac tg

22

<210> 388

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 388

aagccatcat gtaaagtgaag aag

23

<210> 389

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 389

atcccaaaga tggcatagat a

21

<210> 390

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 390

cacgctgctc tttgctttga

20

<210> 391

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 391

tgagctgcca gggatgaattg

20

<210> 392

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

## oligonucleotide

&lt;400&gt; 392

ttgctagcac ctattcttaa tagtgc

26

&lt;210&gt; 393

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 393

ccagggcagc tgcaaaatca gag

23

&lt;210&gt; 394

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 394

cccgatgcga cccagttta

19

&lt;210&gt; 395

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

&lt;400&gt; 395

tggaggggtt tgatgccata

20

&lt;210&gt; 396

&lt;211&gt; 23

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 396

gatggatgcc cttcgaatac aga

23

<210> 397

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 397

ttcccatтта gtttgtcaat aatc

24

<210> 398

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 398

aaggggagga ttgacttacc tat

23

<210> 399

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 399

ttggcatgga cctcctcttg a

21

<210> 400  
<211> 18  
<212> DNA  
<213> Homo sapiens  
<400> 400  
caagataatg atgatgag

18

<210> 401  
<211> 15  
<212> DNA  
<213> Homo sapiens  
<400> 401  
caagatgatg atgag

15

<210> 402  
<211> 13  
<212> DNA  
<213> Homo sapiens  
<400> 402  
tggtgtaagg tag

13

<210> 403  
<211> 13  
<212> DNA  
<213> Homo sapiens  
<400> 403  
tggtataagg tag

13

<210> 404  
<211> 17  
<212> DNA  
<213> Homo sapiens  
<400> 404  
ccccttatat ctccaac

17

<210> 405  
<211> 17

<212> DNA

<213> Homo sapiens

<400> 405

ccccttatay ctccaac

17

<210> 406

<211> 15

<212> DNA

<213> Homo sapiens

<400> 406

aaatacgtaa tcgat

15

<210> 407

<211> 15

<212> DNA

<213> Homo sapiens

<400> 407

aaatacataa tcgat

15

<210> 408

<211> 15

<212> DNA

<213> Homo sapiens

<400> 408

aaatacrtaa tcgat

15